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Abstract 
COPD is a debilitating chronic respiratory disease with a systemic footprint. COPD is a highly 
heterogeneous disease but invariably its management involves a one-size fits all approach. This 
fails to address individual variations in disease progression, symptom burden and functional 
decline. There remains a need for sensitive monitoring tools that could provide personalised 
care based on patients’ particular phenotypes and informative self-management.  
 
This thesis has standardised collection protocols and processing for saliva, a complex body-
fluid which is readily accessible and user-friendly for near-patient testing.  I have modified 
immunoassays to work in saliva with demonstrable reproducible results for quantification of 
C-reactive protein, Procalcitonin and Neutrophil Elastase. Symptom assessment is crucial in 
longitudinal self-monitoring of COPD. I designed a novel patient wellbeing scale incorporated 
into an electronic self-assessment diary, which was embraced by patients as improving 
symptom change recognition, education and self-management. Using sophisticated analytical 
tools, I have attempted to cluster/phenotype disease trajectory paths driven by a compilation of 
symptom scores, spirometric volumes and saliva biomarker levels and produced novel patient-
specific multidimensional composite scores with significant correlation to COPD disease 
severity. Prodromal changes in FEV1, salivary biomarkers and self-assessment scores were 
reproducibly demonstrated, with potential to predict exacerbation onset.  
 
These results could be exploited for the development of a much-needed personalised COPD 
monitoring eco-system, which isolates early deteriorations and prompts timely interventions, 
leading to beneficial disease outcomes. Patient-researcher iterative co-design has been key 
throughout this thesis. One outcome of this relationship is the design and production of a 
III 
 
bespoke integral saliva collector prototype which could substitute laboratory-based processing 
of saliva samples in readiness for analyte testing.  
 
In conclusion, this thesis has created the necessary tools to improve the classification and 
monitoring of COPD, opening new avenues for proactive patient self-management and 
providing the basis for future personalised and stratified care. 
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1.1. Definition of Chronic obstructive pulmonary disease 
Chronic obstructive pulmonary disease (COPD) is a common, complex disease with an 
insidious onset, involving debilitating breathlessness, with a progressive decline in the patient’s 
ability to perform essential activities of daily living. It is characterised by airway obstruction 
that has little or no reversibility to bronchodilator agents for example, salbutamol. The airflow 
obstruction is due to a combination of small airways disease and parenchymal damage 
(emphysema); the relative contributions of these factors vary within individuals. COPD is 
associated with chronic inflammation due to an abnormal inflammatory response in the lung, 
most likely caused by noxious particles such as tobacco smoking. This causes progressive 
airway remodelling and destruction of the lung parenchyma (GOLD, 2016).  
 
1.1.1. Development of the term COPD 
Interest in bronchitis developed in the early 1950's when chest physicians who had traditionally 
focused their time on tuberculosis were freed with the advent of treatment for the disease. It 
was in 1952 that the Association of Physicians of Great Britain held a symposium on chronic 
bronchitis at which a definition in terms of expectoration was first considered (Fletcher, 1959). 
The Medical Research Council (MRC) established a Committee for Research into Chronic 
Bronchitis under the chairmanship of Professor R.V. Christie. When the Committee first met 
it was unable to agree on any definition of chronic bronchitis or the criteria required for its 
diagnosis. At the time there was considerable confusion between the diagnosis of emphysema 
and chronic bronchitis with emphysema assumed to present in every patient with persistent 
airflow obstruction even when no pathology had been found on autopsy (Cope, 1951). 
Mortality statistics in the 1950's revealed that the greatest mortality from bronchitis and 
emphysema was in the United Kingdom (UK) (Reid and Rose, 1964). This was due to a 
classification bias as a traditional belief among American clinicians that bronchitis was an 
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unimportant and trivial condition. Emphysema tended to be defined as an increase in the 
Residual Volume (RV)/ Total Lung Capacity (TLC) ratio; also since patients with asthma 
usually shared this abnormality they were often concomitantly diagnosed as having 
emphysema. 
 
Two landmark meetings took place: The Company for Chemical Industry Basel (CIBA) Guest 
Symposium 1959, and the American Thoracic Society (ATS) Committee on Diagnostic 
Standards 1962; both described the components of the modern day definition. The CIBA Guest 
Symposium defined emphysema on a morbid anatomical basis as the enlargement of the size 
of air spaces in the lung peripheral to terminal bronchioles. It was suggested that a general term 
was needed to encompass emphysema, asthma and bronchitis and thus a term of “chronic non-
specific lung-disease” was accepted. The ATS Committee on Diagnostic Standards defined 
chronic bronchitis in clinical terms including a chronic cough of at least three months over a 
minimum of two years. Emphysema was described anatomically in terms of enlarged alveolar 
spaces and loss of alveolar walls. Neither definition used any physiological criteria. Asthmatic 
bronchitis was considered an overlapping condition. Many other attempts to clarify this 
complex disease, whilst not significantly improving on these basic definitions did progress to 
include reference to functionality. As disease understanding evolved, several new terms were 
introduced to give greater emphasis to the cause of disability; the most widely adopted became 
chronic obstructive pulmonary disease, and William Briscoe is believed to be the first person 
to use the term COPD in discussions at the 9th Aspen Emphysema Conference 1966 (Petty, 
2006).  
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1.2. Epidemiology of COPD 
COPD poses a major public health burden worldwide with approximately 44 million confirmed 
cases and 160 million undiagnosed cases (Fletcher et al., 2011). It now ranks 3rd in global 
mortality surpassed only by ischaemic heart disease and stroke. In 2010, 2.9 million deaths 
were attributed to COPD (although this is a fall from 3.1 million in 1990) which represents 
5.5% of all-cause mortality (Lozano et al., 2012). COPD represents 27% of deaths related to 
smoking, surpassed only by cancer and cardiovascular disease (Soriano and Rodriguez-Roisin, 
2011).  
 
1.2.1. Impact on the UK 
An estimated 3 million people are affected in the UK, with approximately 835,000 having been 
diagnosed, and 2.2 million people undiagnosed which equates to 13% of the population of 
England over 35 years of age (Shahab et al., 2006). COPD is closely associated with 
socioeconomic status, with higher rates observed in lower status communities (Yin et al., 2011, 
Kanervisto et al., 2011). COPD ranks 5th in mortality in the UK and is the 3rd largest cause of 
respiratory death, accounting for 23%. This equates to approximately 30,000 deaths each year 
which is one of the highest rates in the European Union (EU), with more than 90% occurring 
in the over 65 age group in 2004. COPD accounted for 4.8% of all deaths in England between 
2007 to 2009 (Health, 2011). The rate of mortality for respiratory disease in the UK is almost 
double the European average, although this was on a downward trend between 1994 to 2010 
(Lopez-Campos et al., 2014). The Health Development Agency estimated in 2004 that around 
85% of COPD-related deaths could be attributed to smoking (Hubbard, 2006). Five-year 
survival from diagnosis is 78% in men and 72% in women with clinically mild disease defined 
as not requiring continuous drug therapy, but falls to 30% in men and 24% in women with 
severe disease defined as requiring oxygen or nebulised therapy. Objectively-measured 
Chapter 1:  Introduction 
5 
physical activity is the strongest predictor of all-cause mortality in patients with COPD 
(Waschki et al., 2011, Hallin et al., 2011). 
 
1.2.2. Impact on the National Health Service 
Although only a small proportion of people with COPD are admitted to hospital each year, it 
accounts for approximately 12% (130,000) of all emergency admissions. This makes COPD 
the 2nd largest cause of admissions in the UK, and one of the most-costly inpatient conditions 
treated by the National Health Service (NHS). One million bed days per year, nearly 2% of 
total capacity, are used for its treatment (Halpin and Miravitlles, 2006).  
 
Admission rates have risen in all age groups since 1994 except in the under 45s; with the 
highest rise in the over 85s where rates have almost doubled from 1994 to 2005. (NICE, 2010). 
The National COPD Audit 2013 to 2016 released results from the organisational and clinical 
secondary care audit in November 2014. This document revealed that since the previous audit 
(2008) the median number of COPD admissions had further increased by 13%. It should be 
noted that this audit reports data from just England and Wales; previous audits encompassed 
the whole of the UK. Thus results for previous audits have been reworked for just England and 
Wales to allow for direct comparisons (Royal College of Physicians, 2014). With respects to 
readmissions there are no results at present from the current National COPD Audit. Previous 
national audits (2003 and 2008) revealed a reduction in length of stay by one day to five days 
between the two time frames (George et al., 2011).  This reduction continues with a recent 
longitudinal study conducted in London over four years between 2006 to 2010 also 
demonstrating a reduction by one day (Harries et al., 2015). George et al., in the 2008 data also 
documented an increase from 26% to 34% in the proportion of patients having a shorter stay 
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of at most three days compared to 2003. However, the readmission rates had risen between 
2003 to 2008 from 30 to 33% with the median time to readmission being 38 days. 
 
Health economics on COPD suggest an average annual per patient cost to the UK of £781 to 
£1,154 with an overall annual cost (both direct and indirect) of between £800 to £1500 million 
pounds (Halpin, 2006). Costs increase with disease severity and exacerbation frequency. 
Patients with severe disease (Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
Stage 3 and 4) and an exacerbation frequency of two or more per annum have a per patient 
annual expense of £3,499 (Punekar et al., 2014). A breakdown of direct costs reveals that 54% 
are related to in-patient hospitalisations (Britton, 2003). The indirect costs of COPD are 
substantial with an impact on annual productivity amounting to an estimated 24 million lost 
working days per annum in sick leave and £3.8 billion pounds in direct costs from lost 
productivity (NICE, 2010). Overall a reduced patient requirement for hospital care could 
potentially ease the economic burden on the UK healthcare system. 
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1.3. Risk factors for COPD 
1.3.1. Genetic risk factors 
There is strong evidence that genetic factors can influence COPD development in response to 
smoking, although these genetic differences are mostly unknown. Overall, twin and familial 
aggregation studies suggest that genetic factors likely influence variation in pulmonary 
function in non-smokers, but these results do not necessarily indicate that genetic factors 
increase the risk of developing a clinical diagnosis of COPD (Silverman, 2006).  
 SERPINA-1: This is the only gene with direct causality encoding α1-antitrypsin (AAT), 
a serine protease inhibitor which protects the lungs from oxidative stress (Nakamura, 2011). A 
deficiency in this enzyme results in an accelerated development of emphysema. 
 Cutis laxa: A genetic disease related to irregular elastin fibre processing, which can 
result in emphysema in childhood and adolescence (Turner-Stokes et al., 1983). 
 Gender: Female gender is associated with lung function reduction and more severe 
disease in patients with early onset of COPD or low smoking exposure (Sorheim et al., 2010). 
Smoking has a greater impact on female lung function and after adjustment for smoking 
females experience a higher risk of being admitted to hospital for COPD (Prescott et al., 1997).  
 Pre-existing Asthma: Asthma and COPD are thought to share a common background, 
with the differentiation into one disease or the other being modulated by environmental and 
host factors. Airway inflammation and airflow obstruction seen in asthmatics with increased 
airway hyper reactivity may lead to subsequent lung remodelling due to airway wall thickening 
and sub-epithelial fibrosis (Vignola et al., 2000). There is sufficient evidence of an association 
between chronic asthma and both chronic airway obstruction and accelerated loss of pulmonary 
function. As airway obstruction can lead directly to COPD, it is likely that asthma, with or 
without additional risk factors, can predispose a person to develop COPD. Studies 
demonstrating radiographic evidence of emphysema among life-long non-smokers with asthma 
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also support the possible role of chronic asthma in the genesis of COPD (Silva et al., 2004, 
Eisner et al., 2010). 
 
1.3.2. Acquired risk factors 
There are numerous acquired risk factors that can increase the risk of developing COPD. 
 Cigarette smoking: The primary risk factor for COPD is chronic tobacco smoking, with 
a body of evidence stretching back for over 40 years. Approximately 80 to 90% of cases are 
due to smoking: however, the majority of population-attributable fraction estimates are less 
than 80%, and COPD only affects 10 to 20% of smokers indicating that other risk factors, 
besides cigarette smoking, are important (Eisner et al., 2010). Numerous cross-sectional and 
cohort studies since 2000, using different definitions, have consistently demonstrated an 
association between smoking and COPD. Moreover, there is a consistent exposure–response 
relationship with cohort studies supporting the causal criterion of temporality, in which the 
exposure precedes the onset of disease (Sampsonas et al., 2006). 
 Air pollution: Longitudinal cohort studies provide strong evidence of an association 
between outdoor pollution and decreased lung function growth during childhood and 
adolescence (Allain et al., 2010). Furthermore, decreased lung function growth early in life 
translates into a greater incidence of COPD in later adulthood and thus a higher likelihood of 
a true association between air pollution and COPD. Higher rates of COPD are also observed in 
large cities compared to rural communities. Supplementary studies are needed to confirm the 
exact effect of each component of air pollution on the lungs (Eisner et al., 2010).  
 Second hand cigarette smoke: Second hand smoke exposure appears to cause asthma 
in children and adults, although its role in causing COPD has received limited attention in 
epidemiological studies. Cumulative home and workplace exposure is associated with a greater 
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risk of COPD, and a body of literature now supports an association between exposure and the 
development of COPD independent of personal cigarette smoking (Eisner et al., 2005). 
 Biomass fuels: Biomass is a material derived from living or recently deceased 
organisms which are then used for combustion. Over half the world is exposed daily to the 
smoke from combustion of biomass fuels. In numerous developing countries, indoor air 
pollution from biomass smoke is a common cause of COPD especially in women. Amongst 
the different types of biomass, exposure to wood smoke presents the greatest risk (Kurmi et al., 
2010). 
 Occupational exposure: Intense and prolonged exposure to workplace dusts found in 
coal mining, gold mining, and the cotton textile industry and chemicals such as cadmium, 
isocyanates and fumes from welding have been implicated in the development of airflow 
obstruction, even in non-smokers (Santo Tomas, 2011). There is sufficient evidence from 
multiple epidemiological studies to infer a causal relationship between occupational exposures 
and development of COPD. The population attributable risk percentage for work-related 
COPD is at least 15% and emerging data also indicates that occupational exposures, at a 
minimum, are additive to the smoking associated risk of COPD (Blanc, 2011). 
 Nutrition: Nutrition may affect the development and maintenance of lung function and 
could modulate pulmonary responses to injury. It has been demonstrated that patients with 
coeliac disease appear to be at a moderately increased risk of COPD (Ludvigsson et al., 2011). 
Currently there is little evidence of an association between antioxidant intake and pulmonary 
function. As there are fewer studies that evaluated COPD as a specific end-point, there is 
limited/suggestive evidence of an association between diet and COPD (Eisner et al., 2010). 
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 Microorganisms: An association between mycobacterium tuberculosis and COPD has 
been demonstrated in studies mostly undertaken in Africa, Asia and South America (Menezes 
et al., 2007).  
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1.4. Pathogenesis of COPD 
1.4.1. Pulmonary inflammation 
Inflammation is present in the lungs of all smokers and is thought to be a normal protective 
response to inhaled toxins. An enhanced or abnormal response is believed to be a characteristic 
feature of patients who develop COPD. The precise mechanisms of this response is not fully 
understood, but this abnormal inflammatory response leads to tissue destruction, consequent 
on an impairment of defence and repair mechanisms which would normally limit such 
destruction. In general, the inflammatory and structural changes in the airways increase with 
disease severity and persist even after smoking cessation (Rutgers et al., 2000a). Two other 
processes are also central to COPD pathogenesis: an imbalance between proteases/anti-
proteases, and oxidants/antioxidants termed oxidative stress (Figure 1.1).
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Figure 1.1: COPD pathogenesis.  
This figure (adapted from Chung and Adcock, 2008) summaries key inflammatory and cellular 
interactions and associated amplification signals linking chronic cigarette exposure to COPD. 
 
Studies of bronchial biopsy specimens from patients with mild to moderate COPD show 
increased inflammatory cell infiltrates in the central airways, compared with non-smokers or 
smokers who have not yet developed the disease (Di Stefano et al., 2004). The predominant 
cells are macrophages (greater than 80%), and T-lymphocytes (mainly CD8+ cells) which 
release pro-inflammatory mediators into the lungs (Finkelstein et al., 1995). Increased numbers 
of neutrophils are also present, particularly in the glands, which become even more prominent 
as the disease progresses; in some patients an increased number of eosinophils have been 
observed (Thompson et al., 1989). It has been hypothesised that the presence of increased 
CD8+ T-lymphocytes could identify those smokers who go on to develop COPD; with a 
correlation between T-lymphocyte numbers, alveolar destruction and airflow limitation 
severity (Di Stefano et al., 1998). Smokers with normal lung function also show, albeit to a 
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lesser extent, increased numbers of T-lymphocytes compared with non-smokers (Di Stefano et 
al., 2002). The mechanism which leads to CD8+ T-lymphocyte accumulation in the lungs is 
not fully understood. It has been shown that at least a proportion of disease-specific 
lymphocytes that are part of the inflammatory cascade in the lungs and regional lymph nodes, 
are recruited from the lymphatic and blood circulations (Lehmann et al., 2001). Studies of 
peripheral blood T-lymphocytes in patients with COPD have shown peripheral T-lymphocytes 
(particularly CD8+) are more frequently activated with increased production of various 
mediators; many of these T-lymphocyte abnormalities are highly correlated with disease 
severity (Gadgil and Duncan, 2008). CD8+ cells have also been shown to be associated with 
alveolar cell apoptosis in patients with emphysema (Majo et al., 2001). 
 
Neutrophils contain the only cell products that have been shown to directly cause the 
pathological features of COPD. These include serum proteinases, including Neutrophil 
Elastase (NE), cathepsin G, proteinase-3, matrix metalloproteinase (MMP)-8 and MMP-9, 
which contribute to alveolar destruction (Stockley, 2002) and are also potent stimuli of mucus 
secretion (Kim and Nadel, 2012). A positive correlation has been demonstrated between 
induced sputum MMP-8 and 9 activities and the degree of airflow obstruction (Vernooy et al., 
2004). The direct role neutrophils play in COPD pathogenesis is unclear. Increased numbers 
of neutrophils, recruited from the circulation, have been demonstrated in the bronchial tissues 
of some patients with COPD and have been shown to relate to airflow obstruction (Di Stefano 
et al., 1998). These neutrophils have a unique protein profile compared to neutrophils from 
healthy age-matched controls (Langereis et al., 2011). Neutrophils can migrate to the 
respiratory tract under the control of chemotactic factors (Traves et al., 2002), for example, 
leukotriene (LK)-B4 has been shown to be increased in the airways of patients with COPD (Di 
Stefano et al., 2009). The percentage of neutrophils in sputum is increased in COPD patients, 
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and further enhanced during an exacerbation (Papi et al., 2006). Relationships have been 
demonstrated between increased levels of neutrophils in bronchial biopsies and sputum and the 
decline in forced expiratory volume in one second (FEV1) (Singh et al., 2010). 
 
Macrophages demonstrate a five to ten-fold increase in the lungs of patients with COPD and 
are localised to sites of alveolar destruction with macrophage numbers correlating to disease 
severity (Vlahos and Bozinovski, 2014). Cigarette smoking activates macrophages to release 
inflammatory mediators, as well as promoting the secretion of proteases in a variety of 
pulmonary diseases (Thomas, 2001). Compared with macrophages from normal smokers those 
from patients with COPD are more activated, secrete more inflammatory proteins, and have 
greater elastolytic activity which is further enhanced by exposure to cigarette smoke (Hiemstra, 
2013). Increased macrophage numbers may result through increased recruitment from the 
circulation in response to monocytic chemokines such as monocyte chemotactic peptide 
(MCP)-1, which is increased in sputum and bronchoalveolar lavage (BAL) of COPD patients 
(Barczyk et al., 2001). Cysteine X Cysteine (CXC) chemokines also act as chemo-attractants 
to monocytes. Many of the inflammatory mediators that are expressed in COPD are controlled 
by the transcription factor nuclear factor ĸB, which is up-regulated in sputum alveolar 
macrophages in COPD patients compared to control non-smokers (Caramori et al., 2003). This 
up-regulation may be a key molecular mechanism involved in the on-going and evolving 
inflammatory process found in COPD airways. 
 
Dendritic cells (DC) are antigen-presenting cells responsible for immune homeostasis. They 
initiate and orchestrate innate and adaptive immunity in responses to tissue damage or 
infection. DC circulate in the blood and localise to mucosal surfaces in immature form where 
they act as sentinels, sampling constituents of the external environment that breach the 
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epithelium. With internalisation of the antigen, they become activated, mature, and migrate to 
draining lymph nodes to induce cellular proliferation and to regulate the balance of Th1/Th2 
T-lymphocytes. There is evidence in humans to show that cigarette smoking induces the 
recruitment of large numbers of immature DC into the small airways of COPD patients (Givi 
et al., 2012). It is hypothesised that chronic exposure to cigarette smoking impairs the normal 
maturation process of DC and subsequently alters/suppresses their normal function and 
interaction with naive lymphocytes, resulting in an imbalance of immunity that may increase 
susceptibility of patients with COPD to respiratory infections (Tsoumakidou et al., 2008). 
 
Eosinophil levels are frequently elevated in COPD, especially during exacerbations (Vedel-
Krogh et al., 2015). Eosinophils are similar to neutrophils, containing high concentrations of 
reactive oxygen species (ROS) and proteases both of which contribute to host defence and 
collateral damage to the host epithelium (Crotty Alexander et al., 2015). Recent work has 
revealed that blood eosinophil levels in COPD subjects correlate with elevated eosinophil 
levels in the bronchial submucosa as well as an increased thickness of the basement membrane 
(Eltboli et al., 2015). Eosinophilic airway inflammation in COPD may also be predictive of 
corticosteroid responsiveness during clinical stability and exacerbations (Singh et al., 2014). 
 
Once activated these inflammatory cells release a wide variety of cytokines and inflammatory 
mediators that propagate/amplify the inflammatory events by modulating the behaviour of 
airway wall-forming cells, including epithelial cells, ﬁbroblasts and airway smooth muscle 
cells (Figure 1.1). The combination and interaction of mediators attract and activate 
inflammatory cells and proteinases, which cause elastolysis and mucus hypersecretion 
culminating, in the typical pathophysiological features of COPD (Chung and Adcock, 2008). 
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Overall a wide range of inflammatory mediators have been demonstrated to be elevated in 
COPD and to amplify the inflammatory process (Figure 1.1). These include lipid mediators 
such as LTB4, which is chemoattractant for neutrophils (Griffiths et al., 1995). Chemokines 
MCP-1 (Deshmane et al., 2009) and macrophage inflammatory protein (MIP)-1α which attract 
monocytes (Menten et al., 2002). Interleukin (IL)-8 (Mukaida, 2003) and GRO-α (growth 
related-oncogene) (Bechara et al., 2007), which attracts both neutrophils and monocytes. 
Interferon inducible protein (IP)-10 (Taub et al., 1993), which attracts CD8+ cells, ROS and 
nitric oxide (NO) (Domej et al., 2014); granulocyte-macrophage colony-stimulating factor 
(GM-CSF) (Shi et al., 2006), which prolongs neutrophils’ survival; tumour necrosis factor 
(TNF)-α (Ferrarotti et al., 2003), which amplifies inflammation by switching on multiple 
inflammatory genes and may also account for some of the systemic effects of the disease; 
endothelin (Spiropoulos et al., 2003) and transforming growth factor (TGF)-β (Konigshoff et 
al., 2009), which induce development of fibrosis.  
 
The pro-inflammatory factors released by activated immune cells stimulate the resident cells 
to produce and secrete additional pro-inflammatory factors, thereby attracting more immune 
cells to the site of inflammation, thus leading to vicious circle which sustains the inflammatory 
process (Agusti, 2005). Yet despite the significant role played by inflammation in COPD, anti-
inflammatory treatments do not appear to modulate disease progression, or decrease 
inflammatory markers in induced sputum (Culpitt et al., 1999). Although lung function 
improves, or at least the rate of decline decreases, after patients with COPD cease smoking, 
airway inflammation persists despite the removal of the assumed stimulus (Rutgers et al., 
2000a). An explanation for this may be the failure to excrete particular components of cigarette 
smoke, or that damaged tissues cannot be repaired back to normal (Hogg, 2006). This is 
highlighted by the different healing responses in cells and structures. For example, epithelial 
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cell layers and goblet cells appear to regenerate towards their distribution and function in non-
smokers; however, there is no evidence that the increased mass of smooth muscle in the 
bronchiolar airways shows the same pattern (Thorley and Tetley, 2007). 
 
1.4.2. Protease/anti-protease imbalance 
In the simplest sense, emphysema is caused by the imbalance between proteases and anti-
proteases that results in parenchymal lung destruction (Churg and Wright, 2005). Cigarette 
smoking-induced inflammation is also linked to an increased expression of proteases that 
degrade the extracellular matrix particularly elastin and enhance lung tissue remodelling in 
COPD (Shapiro, 2002). Important to understanding this aspect of COPD pathogenesis were the 
observations of an association between AAT and the development of early onset emphysema 
(Fischer et al., 2011). These observations form the basis of the protease/anti-protease 
hypothesis, which describe that under normal circumstances the release of proteolytic enzymes 
from inflammatory cells migrating to the lungs to fight infection does not cause lung damage 
because of inactivation of these proteolytic enzymes by an excess of inhibitors. However, in 
conditions of excessive enzyme load, or where there is an absolute or a functional deficiency 
of anti-proteases, an imbalance develops between proteases and anti-proteases in favour of 
proteases, leading to uncontrolled enzyme activity and degradation of lung connective tissue 
in alveolar walls, resulting in emphysema (MacNee, 2005). 
 
Elastin along with microfibrils are the two main components of elastic fibres which are major 
extracellular matrix assemblies. Elastin is formed following the assembly and cross-linking of 
its soluble precursor tropoelastin (Wise and Weiss, 2009). The cross-links known as 
desmosines are unique to elastin and they can be used as a marker of elastin degradation 
(Luisetti et al., 2008). The quantification of desmosines in sputum, along with increases in 
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plasma and an elevated free component in urine provide indexes that characterise patients with 
COPD and can be monitored during the course of the disease and treatments (Ma et al., 2007). 
After deposition, tropoelastin production is substantially reduced and there is minimal turnover 
of the mature, cross-linked form of the eventual elastin. The majority of elastin formation in 
mammals occurs during late foetal and in early neonatal periods, and at maturity the production 
of new elastin ceases (Swee et al., 1995). In the event of injury, the production of tropoelastin 
can be rapidly restarted. Production is influenced by exogenous factors such as TNF-α, IL-1β, 
insulin-like growth factor-1 and TGF-β (Pierce et al., 2006). A specific set of proteases, broadly 
grouped under the name elastases are responsible for the remodelling of elastin. The MMPs 
are particularly important in breakdown of elastin with MMP-2, -3, -9 and 12 explicitly shown 
to degrade elastin (Antonicelli et al., 2007). Interconnecting elastic fibre cables facilitate 
coordinated expansion and relaxation of alveoli during respiration, and emphysema 
progression is linked to destruction of these alveolar elastic fibres by elastolytic proteases 
associated with an anti-protease deficiency such as in AAT, and impaired extracellular matrix 
regeneration and maintenance by lung fibroblasts (Zhang et al., 2011). It has been shown that 
in asthma and chronic bronchitis patients, the levels of active and total elastase are inversely 
correlated with the degree of airway obstruction as assessed by FEV1 (Vignola et al., 1998). 
Hamster lungs exposed to elastase have shown that although elastin synthesis after injury 
restores elastin content (Lucey et al., 1998), it does not restore normal lung architecture (Kuhn 
et al., 1976). Together with destruction of elastin plus the abnormality in elastin synthesis, 
inactivation or reduction of anti-proteases and elevation of proteases is central to the 
protease/anti-protease hypothesis. 
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1.4.3. Oxidative stress 
Tobacco smoke contains high concentrations of free radicals and other oxidants. Oxidants 
generated in the biological fluids are efficiently scavenged by antioxidants. Sources of 
oxidative stress arise from inflammatory cells, such as neutrophils and macrophages, which 
generate reactive oxygen species (ROS) when activated. There is now considerable evidence 
for the increased generation of ROS in COPD (MacNee, 2001). Together with inhaled ROS 
and reactive nitrogen species (RNS), these endogenous and exogenous oxidants may constitute 
a major oxidative burden to the lung. ROS and RNS are thought to be critical in amplifying the 
normal inflammatory response to cigarette smoke/environmental oxidants, through the up-
regulation of redox-sensitive transcription factors, and hence pro-inflammatory gene 
expression (Montuschi et al., 2000). 
 
1.4.4. Systemic manifestations of COPD 
Studies have shown that some of the above-described events and consequent mediators of 
COPD inflammation are also reflected systemically and expressed as well-documented clinical 
non-pulmonary manifestations of the disease (Barbu et al., 2011). Adding to the complexity of 
the COPD journey, major systemic consequences and co-morbidities are now recognised 
including: deconditioning, exercise intolerance, skeletal muscle dysfunction, osteoporosis, 
metabolic impact (Posluszna and Doboszynska, 2011), anxiety and depression (Yohannes and 
Alexopoulos, 2014), cardiovascular disease and lung carcinoma (Yang et al., 2011, King, 
2015). It is unclear however whether non-pulmonary manifestations of COPD are the results 
of: (1) inflammatory processes in the lung parenchyma that “spill-over” into the systemic 
circulation; (2) tobacco smoking although sustained inflammation persists even on smoking 
cessation; (3) pathophysiological changes within COPD lungs leading to systemic effects for 
example, hypoxia, hyperinflation (Bailey et al., 2012).  
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1.5. Diagnosis of COPD 
In the majority of cases COPD commences decades before the onset of symptoms and runs an 
insidious undiagnosed course over years. Globally, determinants of COPD under-diagnosis are 
male sex (except in Spain), younger age, never and current smoking, lower level of education, 
absence of reported symptoms, lack of previous spirometry, and milder severity of airflow 
limitation (Lamprecht et al., 2015). Identification of this undiagnosed (preclinical phase) and 
thus early recognition of cases may therefore have the potential to reduce the future burden of 
morbidity and mortality for COPD for example, by providing support for early smoking 
cessation initiatives (Soriano et al., 2009). The diagnosis of COPD is frequently at a relatively 
late stage of the disease; most patients are not diagnosed until they are over 50 years of age. 
Patients suffering from more severe COPD have substantial limitations in activities of daily 
living (ADL), leading to poor health related quality of life and disability (Gore et al., 2000).  
 
Several studies have attempted to generate algorithms to identify populations that would be 
suitable for spirometry in an attempt to identify undiagnosed COPD. It has been demonstrated 
that early detection can be achieved by offering spirometry to adults with tobacco or relevant 
occupational exposure and at least one respiratory symptom such as exertional breathlessness, 
chronic cough, regular sputum production, frequent winter bronchitis or wheeze (Ulrik et al., 
2011). Age, smoking intensity and smoking status among patients with any kinds of acute 
respiratory infections attending urgent primary care have also been demonstrated to be a 
feasible and effective way to triage those who need spirometry testing to confirm the presence 
of underlying COPD (Sandelowsky et al., 2011). 
 
Overall there remains an unmet need for screening programmes to identify preclinical and 
clinical COPD in an attempt to improve burden of the disease. Presently however, no consensus 
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exists on how, when and where spirometry should be offered to screen for COPD despite the 
obvious advantages an earlier diagnosis would provide (Soriano et al., 2009). A recent 
systematic review and meta-analysis looking at the effectiveness of case finding strategies for 
COPD concurs with Soriano et al. This review suggests that well-conducted randomised 
control trials comparing case finding strategies are needed to identify the most effective target 
population, recruitment strategy and screening tests to identify individuals with COPD (Haroon 
et al., 2015). 
 
In conclusion a diagnosis of COPD is confirmed when a patient who experiences the above 
symptoms is found to have non-reversible airﬂow obstruction on spirometry. This is defined 
as a post bronchodilator FEV1/ Forced vital capacity (FVC) ratio of less than 0.70, in the 
absence of an alternative explanation for the symptoms for example, left ventricular failure, or 
other diseases that cause airﬂow obstruction for example, asthma (Qaseem et al., 2011). 
 
1.5.1. Spirometry 
As discussed above spirometry is required to confirm a diagnosis of COPD. Severity of the 
disease is then stratified according to FEV1 (Postma et al., 2011), which is the best single 
correlate of mortality in COPD (Celli, 2000). FEV1 however is not predictive of disease 
progression (Man et al., 2006) with the rate of decline of FEV1 demonstrating variability in 
different COPD patients for example, COPD patients with persistent lower airway bacterial 
colonisation and frequent exacerbator status (greater than 3 per annum) (Donaldson et al., 
2005). 
 
Spirometry as a test requires large resources and is impractical to monitor patients at more than 
3 monthly intervals. Also as the patient's condition deteriorates the ability to perform the test 
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becomes more difficult. Evidence suggests that spirometry should be used to assess for COPD 
in patients with respiratory symptoms but not those who are asymptomatic (Qaseem et al., 
2011). 
 
1.5.1.1. Severity of COPD 
Consensus on a working classification for severity stratification of COPD patients has taken 
many years to achieve. Initially there was disagreement between the European Respiratory 
Society (ERS), ATS and British Thoracic Society (BTS) on whether spirometry should be 
performed post bronchodilatation; the ratio of FEV1/FVC that defines airway obstruction and 
the FEV1 thresholds for different stages of the disease (Siafakas et al., 1995, BTS., 1997, ATS., 
1995). 
 
In 1997, in an effort to streamline global approach to COPD, its management and prevention 
the United States National Heart, Lung, and Blood Institute, together with the World Health 
Organization formed the Global Initiative for Chronic Obstructive Lung Disease (GOLD). The 
first step in the GOLD programme was to prepare a consensus report, Global Strategy for the 
Diagnosis, Management, and Prevention of COPD; this drove the evolution of the GOLD 
classification of COPD severity and was published in 2001 (Table 1.1). All spirometric 
measurements were performed post bronchodilator therapy (Pauwels et al., 2001). 
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Table 1.1: 2001 GOLD classification of COPD severity.  
 Stage 
0  
(at risk) 
I  
(mild) 
II  
(moderate) 
III 
(severe) 
FEV1/FVC 
(ratio) 
normal <0.70 <0.70 <0.70 
FEV1 
(% 
predicted) 
normal ≥ 80% 30% ≤ FEV1 < 
80%  
 
(IIA: 50% ≤ FEV1 
< 80%), 
 
(IIB: 30% ≤ FEV1 
< 50%) 
FEV1 < 30% 
or 
FEV1 < 50% and 
respiratory 
failure* or 
clinical signs of 
heart failure 
Symptoms Chronic 
symptoms 
(cough and 
sputum 
production) 
With or without 
chronic 
symptoms 
(cough and 
sputum) 
With or without 
chronic symptoms 
(cough, sputum, 
dyspnoea) 
 
 
*Respiratory failure: arterial partial pressure of oxygen (PaO2) less than 8.0kPa (60mmHg) 
with or without arterial partial pressure of CO2 (PaCO2) greater than 6.7kPa (50mHg) while 
breathing air at sea level 
 
The GOLD Science Committee aimed to post a yearly update to the consensus report and revise 
the entire document every five years. The 2003 update maintained the framework of the 
original classifications but the stages of severity were adjusted (Table 1.2). This was in line 
with recommendations that were being proposed by the COPD Guidelines Committee 
nominated jointly by the ERS and ATS (Fabbri and Hurd, 2003). 
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Table 1.2: Updated COPD severity classification GOLD 2003.  
 Stage  
0  
(at risk) 
I 
(mild) 
II 
(moderate) 
III 
(severe) 
IV 
(very 
severe) 
FEV1/FVC 
(ratio) 
normal <0.70 <0.70 <0.70 <0.70 
FEV1 
(% 
predicted) 
normal ≥ 80 % 
predicted 
50% ≤ FEV1 
< 80% 
30% ≤ 
FEV1 < 
50% 
FEV1 < 
30% or 
FEV1 < 
50% 
predicted 
and 
chronic 
respiratory 
failure* 
Symptoms Chronic 
symptoms 
(cough and 
sputum 
production) 
With or 
without 
chronic 
symptoms 
(cough and 
sputum) 
With or 
without 
chronic 
symptoms 
(cough and 
sputum) 
With or 
without 
chronic 
symptoms 
(cough and 
sputum) 
 
 
*Respiratory failure is defined as an arterial partial pressure of oxygen (PaO2) less than 8.0kPa, 
with or without an arterial partial pressure of CO2 (PaCO2) greater than 6.7kPa whilst breathing 
at sea level. 
 
Accordingly, in 2004, both the ATS and the ERS updated their original classification published 
in 1995 (Celli and MacNee, 2004). The classification now based on post-bronchodilator values 
mirrored GOLD although they did not incorporate an FEV1 less than 50% predicated with 
respiratory failure as Stage 4 disease. In the same year the BTS guidelines (BTS, 1997) were 
superseded by the National Institute for Health and Clinical Excellence (NICE) published 
guidelines (NICE, 2004). The NICE criteria for COPD diagnosis using spirometry remained 
the same and the FEV1 thresholds for staging were brought into line with GOLD, however the 
definition for each severity stage was different.  
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In 2006 GOLD released its revised consensus report (in line with its 5-year cycle) (Rabe et al., 
2007). The only change to spirometric classification of COPD disease severity was the removal 
of Stage 0. This was in recognition that there was incomplete evidence that the individuals who 
met this definition were at an increased risk of progressing to Stage I of the disease (Vestbo 
and Hogg, 2006). 
 
Eventually, NICE-revised guidelines on COPD stages in 2010 mirrored the GOLD 
classification, albeit with the emphasis that symptoms had to be present in Stage 1 to make a 
confident diagnosis of COPD (NICE, 2010). This guideline remains unchanged although a 
review decision with regards to an update (July 2014) is awaited (NICE, 2010).  
 
GOLD released another revised consensus report in 2011 with no change in the spirometric 
classification of severity; however, to better reflect the complexity of COPD a 
multidimensional mode of classification was incorporated. The “Combined COPD 
Assessment” combined symptom burden based on either modified MRC score or COPD 
Assessment Test (CAT), exacerbation frequency per annum and spirometric classification of 
severity to assign patients into 4 risk groups (Figure 1.2) (GOLD, 2016).  
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Figure 1.2: Combined COPD Assessment. 
A multidimensional risk staging assessment (adapted from GOLD, 2016). A = Low risk, less 
symptoms, B = low risk, more symptoms, C = high risk, less symptoms, D = High risk, more 
symptoms. CAT = COPD assessment tool, MRC = Medical Research Council. 
 
The most recent GOLD update 2015 maintains the spirometric severity staging, however the 
Combined COPD assessment (Figure 1.2) has been amended and places COPD subjects in 
category “D” if they have suffered with at least one exacerbation in the preceding 12 months 
leading to hospitalisation (GOLD, 2016). Comparison of the two classification systems reveals 
that spirometry alone accurately reflects prognosis whereas the Combined COPD assessment 
provides better diagnostic separation regarding predicting exacerbations (Lange et al., 2012). 
G
O
L
D
 C
O
P
D
 S
ev
er
it
y
 C
la
ss
if
ic
at
io
n
 
A
n
n
u
al E
x
acerb
atio
n
 F
req
u
en
cy
 
Total Symptom Score 
Chapter 1:  Introduction 
27 
It has also been demonstrated that classification of COPD by either the modified MRC or CAT 
scores is not identical and thus care should be taken when using the Combined COPD 
assessment to stratify patients (Kim et al., 2013). In conclusion the Combined COPD 
assessment appears to have a role in risk stratifying exacerbations but its role in prognosis has 
yet to be determined. 
 
FEV1 as described above remains the main index for diagnosis, disease stratification and 
mortality prediction. Yet it has been observed that other pulmonary and extra-pulmonary 
variables for example, MRC score, also predict mortality and this has led to the development 
of various multimodal dimensional indices (van Dijk et al., 2011). BODE (Body mass index, 
airflow obstruction (FEV1 % predicted), dyspnoea (modified MRC score) and exercise capacity 
(6-minute walking distance)) at present is the most validated and has been shown to predict 
survival in COPD (Marin et al., 2013). BODE was developed in the late 1990’s and was found 
to better than FEV1 at predicting the risk of death from any cause and from respiratory causes 
in COPD patients (Celli et al., 2004). Marin et al., conducted a pooled analysis on the individual 
data of 3633 patients from 11 COPD cohorts which revealed that whilst no COPD 
multicomponent index predicts short term survival up to 12 months accurately however the 
most valid multicomponent index to predict time of death in all COPD patients is BODE (Marin 
et al., 2013). 
 
1.5.2. Patient reported outcomes 
It is increasingly recognised that the frequent assessment of symptoms is a necessity in the 
stratification and prognostication of COPD (Vestbo et al., 2013). Spirometry (FEV1) is a 
relatively poor correlate of symptoms such as breathlessness and the impact of COPD on 
quality of life. Furthermore, many consequences of COPD, including anxiety, depression and 
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the ability to perform ADL, can only be described and reported reliably by the patient (Jones 
et al., 2012). Patient reported outcomes (PRO) thus have an ability to provide an estimate the 
of all the effects of a disease on a patient (Jones et al., 2012). 
 
Dyspnoea (breathlessness) is one of the predominant symptoms and is often the reason a patient 
will seek medical attention. In the 1950's when research was being undertaken to define COPD, 
a standardised questionnaire on respiratory symptoms was developed to help aid diagnosis. Its 
validity and reproducibility was tested in a survey of Post Office workers in London, although 
observer and subject error were present, bias could be reduced to a degree which made the 
method suitable for epidemiological comparison (Fairbairn et al., 1959). The questionnaire was 
later accepted and published by the MRC’s Bronchitis Research Committee, with subsequent 
widespread international recognition (Fletcher, 1978). The widely used modified MRC 
dyspnoea score (Table 1.3) was adopted from the questionnaire’s “Breathlessness” section.  
 
Table 1.3: Modified MRC dyspnoea score. 
 Degree of breathlessness related to activities 
Grade 1 Not troubled by breathlessness except on strenuous exercise  
Grade 2 Short of breath when hurrying or walking up a slight hill  
Grade 3 Walks slower than contemporaries on level ground because of breathlessness, 
or has to stop for breath when walking at own pace  
Grade 4 Stops for breath after walking about 100 metres or after a few minutes on level 
ground  
Grade 5 Too breathless to leave the house, or breathless when dressing or undressing 
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The development of the MRC score has helped to quantify symptoms and it has been 
demonstrated to be a simple and valid method of categorising COPD patients in terms of their 
disability; although no association has been demonstrated with FEV1 (Bestall et al., 1999). The 
modified MRC score (herein described as MRC score) quantifies the disability associated with 
breathlessness and correlates well with direct measurements of disability such as walking 
distance. Its main disadvantage over other more complex scales for example, St George’s 
Respiratory Questionnaire (SGRQ) is its relative insensitivity to change (Stenton, 2008). This 
provides an insight between disability and physiological parameters and confirms that the 
phenotyping of COPD is complex. MRC score is related to 3-year mortality after 
hospitalisation for an acute exacerbation of COPD and has been shown to be an independent 
determinant of length of stay (Tsimogianni et al., 2009). More recently a study has tried to 
investigate whether a symptom-based case finding questionnaire and MRC score can be used 
to identify “at risk” individuals. In adults with known risk factors, the likelihood of having 
moderate to severe COPD is increased in those who report an MRC score of 3 or more common 
respiratory symptoms or a score of 4 or 5. However, selecting individuals for spirometry based 
on symptoms alone only identified less than half of those with moderate to severe COPD (Hill 
et al., 2011). 
 
In conjunction with the MRC score a variety of other PRO questionnaires have been developed. 
Presently the clinical COPD questionnaire (CCQ), Exacerbation of Chronic Pulmonary 
Disease Tool (EXACT) and CAT have demonstrated some validity and responsiveness to 
treatment in various studies (Cazzola et al., 2015). CCQ has similar psychometric properties to 
CAT and exhibits reliability, validity and high reproducibility (Tsiligianni et al., 2012). 
EXACT appears to be an effective method at assessing the severity of acute exacerbations of 
COPD however doubts remain about the ability of EXACT to accurately detect exacerbations 
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(Mackay et al., 2014). CAT has been developed as a short, simple questionnaire that has been 
demonstrated to be an effective tool to measure health status in patients with COPD (Minov et 
al., 2015). These PRO scoring systems are summarised in Table 1.4. 
 
Table 1.4. Summary of COPD scoring systems. 
Score Variables Pros Cons 
MRC Breathlessness 
Simple and valid score for 
catergorising disability 
No association with FEV1. 
CAT 
Cough, 
Phlegm, 
Chest tightness, 
Breathlessness,  
Activities of daily living, 
Confidence, 
Sleep, 
Lethargy 
Reliable, 
valid, 
high reproducibility for 
measuring health status. 
Not validated for determining the 
severity of an exacerbation 
EXACT 
Breathlessness, 
Cough 
Sputum 
Chest symptoms. 
Reliable and valid for 
monitoring respiratory 
symptoms. 
Not validated for the detection of 
an exacerbation. 
BODE 
Body mass index, 
Airflow obstruction 
(FEV1) 
Dyspnoea 
Exercise capacity 
Better than FEV1 for predicting 
all-cause mortality. 
Not designed to be used as a 
daily scoring system. 
CCQ 
Breathlessness, 
Activities of daily living, 
Cough 
Phlegm. 
Similar to CAT. 
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1.5.3. Ancillary investigative tools  
In an attempt to improve the understanding of COPD pathogenesis diagnosis and staging of the 
disease research has also focused on the role of lung-focused tools. These include radiology to 
directly image the lungs and the analysis of lung-exposed body-fluids for example, BAL and 
sputum. 
 
1.5.3.1. Imaging Techniques 
It is increasingly clear that spirometric measures of lung function alone are inadequate for a 
complete understanding of impact of COPD and are insufficient for the complete categorisation 
of COPD severity. As discussed, (Section 1.5.2, Page 27) PROs attempt to provide the patient’s 
perspective and accompany objective spirometry in the classification and monitoring of COPD. 
To further characterise COPD, techniques in chest imaging and quantitative image analysis 
have advanced to a point where they can now provide novel in-vivo insights into the disease 
and potentially the response to its treatment (Washko, 2012). High resolution computer 
tomography (HRCT) is useful in determining emphysema in patients who are diagnostically 
challenging and can also reveal associated disease processes for example, bronchiectasis which 
are not picked up on conventional imaging (Patel et al., 2004, Nakano et al., 2000). HRCT can 
also better characterise the extent of emphysema which is known to be a primary cause of 
symptom-related burden and increased mortality (Haruna et al., 2010). Additionally, greater 
lung emphysema and airway wall thickness assessed by HRCT are associated with 
exacerbation frequency (Han et al., 2011).  
 
Presently radiological modalities are not used routinely in the diagnosis or monitoring of COPD 
but as discussed they can play a vital role in cases that are complex and where concomitant 
pathologies are present. Radiology also has a place in diagnostically challenging COPD 
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individuals and identification of pneumonia (defined as new consolidation on chest X-ray)-
driven acute exacerbations especially as the presence of pneumonia in COPD acute episodes is 
likely to be underestimated (Finney et al., 2015).  
 
1.5.3.2. Bronchoalveolar lavage  
BAL is used as a tool for direct sampling from the lung to explore the pathogenesis of COPD 
(Zheng et al., 2000, Molet et al., 2005). Importantly BAL has been shown to sample a different 
compartment of the lungs compared to sputum (Tsoumakidou et al., 2003). Several biomarkers 
have been measured in BAL, primarily eosinophil cationic protein, myeloperoxidase, TNF-α 
and IL-8 which have been demonstrated to be increased in COPD and healthy smokers 
compared with healthy non-smokers. IL-8 levels are increased in patients with frequent 
exacerbations (Tumkaya et al., 2007). Surfactant protein A has been suggested as a potential 
diagnostic biomarker with BAL results correlating to levels in induced sputum (Ohlmeler et 
al., 2008). BAL however cannot be widely adopted in clinical practice as it requires concurrent 
bronchoscopy which many COPD patients irrespective of disease state find difficult to tolerate. 
 
1.5.3.3. Sputum  
Sputum is a widely sampled body fluid in COPD as it is produced directly in the lungs and 
expectorated daily by the majority of patients. The analysis of sputum has improved the 
understanding of airway inflammation in COPD; however as not all COPD patients produce 
sputum, induction of sputum by hypertonic saline is also utilised (Rutgers et al., 2000b). 
Induced sputum has been shown to demonstrate the same inflammatory profile as spontaneous 
sputum (Tsoumakidou et al., 2003). Sputum induction however is not tolerated by all and 
questions remain about repeatability (Djukanovic, 2000). In COPD patients with chronic 
sputum production are found elevated levels of eosinophils, neutrophils, eotaxin (an eosinophil 
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chemoattractant), IL-6, MCP-1 and TNF-α compared to non-sputum producers (Khurana et al., 
2014). Key exacerbation-related sputum biomarkers have also been identified including 
sputum IL-1β for bacterial-driven exacerbations (Bafadhel et al., 2011b), with IL-6 appearing 
to be raised in patients who have respiratory viruses isolated by nasal lavage (Rohde et al., 
2008).  
 
The assessment of sputum in clinical practice can be split into subjective observations of 
colour, volume and texture and direct culture of sputum to identify respiratory pathogens. 
Changes in sputum colour can reflect an acute exacerbation of COPD with the presence of 
green being highly sensitive (95%) for the presence of a bacterial exacerbation (Stockley et al., 
2000). An increase in sputum volume (Wedzicha and Donaldson, 2003) and increased sputum 
viscosity (texture) (Bhowmik et al., 2009) have also been is also associated with acute 
exacerbations. COPD patients who have potentially pathogenic microorganisms in the sputum 
demonstrate an exaggerated airway inflammatory response and poor health status compared to 
those who have non-potentially pathogenic sputum even in the stable phase of their disease. 
These COPD patients may represent the frequent exacerbator sub-group (Banerjee et al., 2004). 
Interestingly however NICE does not recommend the routine screening of sputum in COPD 
patients who are stable or undergoing an acute exacerbation in primary care and only 
recommend purulent sputum microscopy and culture for COPD patients referred to hospital 
(NICE, 2010).  
 
In summary, the current available tools for COPD monitoring provide meaningful clinically 
relevant information but the numerous modalities and frequency of testing places a large 
burden on COPD patients and consequently NHS resources. Additionally, some tests for 
example, sputum, cannot be performed by all patients and others for example, spirometry, are 
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not sensitive enough for routine monitoring and not performed in practice frequently enough 
other than on a 6 months to annual basis. The implications of this on COPD disease surveillance 
and patient self-management provides support to the argument of the need to develop more 
encompassing tests or at least to determine the positioning of currently available tools 
(spirometry, PROs and biomarkers) in the COPD process and care pathway (Agusti et al., 
2011). This needs to be done in conjunction with the utilisation of minimally invasive and 
intrusive methodologies; recognising the increasing shift change in patient care away from 
hospital bed-side towards patient self-management programmes and treatments within the 
comfort of patients’ homes. 
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1.6. Acute exacerbations of COPD 
The natural course of COPD is characterised by a chronic progressively declining disease state 
punctuated with episodes of sudden worsening in symptoms called acute exacerbations. These 
exacerbations reflect a more severe, disruptive and limiting phase in the patient's illness; a 
period often associated with high-cost medical and support interventions as well an increased 
risk of death (Toy et al., 2010). Prevention, early detection, and prompt treatment would have 
an important impact on clinical progression and improving quality of life in patients (Wilkinson 
et al., 2004). COPD exacerbations are difficult to define precisely due to two main issues: 
fluctuating symptoms and possible presence of co-morbid conditions. Patients experience a 
day to day variability in their symptoms (Kessler et al., 2011) and thus to characterise an 
exacerbation purely based on PRO, it is necessary to pinpoint when a sustainable decline in 
any of these continuous measurements is worse than expected. Presence of co-morbidities such 
as cardiovascular disease could potentially bias interpretation as they share common symptoms 
such as dyspnoea and acutely can also precipitate respiratory dysfunction. 
 
1.6.1. Definition of an exacerbation  
The current definition follows on discussions of the workshop, “COPD: Working Towards a 
Greater Understanding” (Rodriguez-Roisin, 2000). It was agreed that an exacerbation of COPD 
is “a sustained worsening of the patient’s condition, from the stable state and beyond normal 
day-to-day variations, that is acute in onset and necessitates a change in regular medication in 
a patient with underlying COPD”. 
 
This general description however poses operational challenges for detailed phenotypic 
characterisation of COPD exacerbations. The definition lacks particular clarity in regards of 
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whether the reported changes should be quantitative and/or qualitative. Indeed the duration of 
symptom change that qualifies as an exacerbation varies within studies (Han et al., 2010).  
 
Rodriguez-Roisin et al., proposed a further generalised sub-classification based on healthcare 
utilisation but this has not been widely accepted. Healthcare utilisation is recognised as an 
inadequate substitute for episode severity, as it depends on many social and co-morbidity 
factors, and is now considered an outcome in its own right (Burge and Wedzicha, 2003).  
 
Consequently, in clinical practice it is now more generally accepted that a COPD exacerbation 
identifies an episode where the patient seeks medical intervention rather than a predefined 
change in one or more symptoms (Rodriguez-Roisin, 2000, Calverley, 2005). Attempts have 
been made to create a more comprehensive definition and sub-classification of COPD 
exacerbations, with limited significant progress (Caramori et al., 2009). New approaches 
continue to be explored in an attempt to identify key body-fluid biomarkers that can be used as 
diagnostic tools to enable better stratification of the exacerbations and to determine underlying 
aetiology and guide treatment (Pauwels et al., 2004, Barnes et al., 2006, Thomsen et al., 2013).  
 
1.6.2. Aetiology of an exacerbation 
COPD exacerbations are often triggered by airway infection either with bacterial or viral 
pathogens (Wedzicha and Seemungal, 2007) and pollution (Ling and van Eeden, 2009) 
(Chapter 1, Page 37). During acute COPD exacerbations there is increased bronchial wall 
inflammation with an influx of eosinophils, neutrophils and lymphocytes (Bathoorn et al., 
2008).  
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 Bacterial Infections: The majority 50 to 69% of acute exacerbations of COPD are the result 
of a bacterial infection (Butorac-Petanjek et al., 2010). The most commonly isolated 
organism is Haemophilus influenzae (De Serres et al., 2009) accounting for 50% of all 
sputum isolates (King 2012) alongisde Klebsiella pneumonia, and Pseudomonas 
aeruginosa (Ma et al., 2015). 
 Viral Infections: Approximately one third of acute exacerbations of COPD are associated 
with viruses and recent work suggests that a more severe inflammatory response is 
associated with viral compared to bacterial exacerbations (Clark et al., 2015). Viral 
pathogens are also thought to be partially related to the increased influx of eosinophils as 
described above (Rohde et al., 2008). The commonest viral pathogen is human rhinovirus 
(Wilkinson et al., 2006). 
 Co-existing viral and bacterial infections: It has been demonstrated that in a sub-group of 
COPD exacerbations there is co-existing bacterial and viral pathogens with a corresponding 
increase in exacerbation severity and inflammatory response compared to single pathogen 
exacerbations (Wark et al., 2013). 
 Air pollution: It has been estimated that up to 9% of admissions for acute exacerbations of 
COPD may be due to atmospheric pollution (Li et al., 1996). The main irritants include 
particulate matter, sulphur dioxide, ozone, and nitrogen oxides with evidence indicating an 
adverse effect of air-pollution on symptom burden and acute exacerbations of COPD 
(Peacock et al., 2011).  
 Unknown origin: Approximately 30% of acute exacerbations of COPD are non-specific 
where no cause can be identified (Sapey and Stockley, 2006). Pulmonary embolisms have 
been implicated in a third of these cases (Wang et al., 2012). 
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In view of the mixed aetiology of acute exacerbations of COPD and the importance of pathogen 
interaction further work has looked to phenotype exacerbations. Using this approach four 
distinct clusters of exacerbations have been identified: Bacterial (55%), Viral (29%), 
Eosinophilic (28%) and pauci-inflammatory related to minimal changes in the inflammatory 
profile (Bafadhel et al., 2011b). Interestingly although increased eosinophil numbers are 
believed to be in response to viral pathogens as described above they also appear to have a 
separate cluster to viral exacerbations. This study highlights the importance of more advanced 
statistical techniques (such as cluster analysis) to understand the heterogeneity of COPD 
exacerbations and thus identify distinct exacerbation phenotypes, which appear in some COPD 
patients not to be driven solely by an offending pathogen. 
 
1.6.3. Burden of an exacerbations  
Acute exacerbations of COPD resulting in hospitalisation are associated with a higher mortality 
and morbidity than patients that can be managed at home (Steinmetz et al., 2006). They account 
for up to 70% of the cost of medical care for these patients, and thus identification of factors 
that may be associated with acute COPD exacerbations and managing them proactively could 
result in avoidance of hospital admission and a reduction in healthcare costs (Niewoehner, 
2006). In-hospital mortality is approximately 8% (Fruchter and Yigla, 2008), with COPD 
patients presenting with hypercapnic respiratory failure at increased risk (11%) (Anzueto, 
2010). Overall 6-month post-hospitalisation mortality is 24%; with 1-, 2- and 3-year mortality 
rates of 33%, 39% and 49%, respectively (Gunen et al., 2005).  Importantly, however there is 
evidence to suggest that delays of greater than 24 hours in the initiation of treatment for an 
acute exacerbation of COPD in patients who subsequently present to an Accident & Emergency 
(A&E) department results in a higher risk of hospitalisation (Chandra et al., 2009). 
Hospitalisations are more frequent in winter, and weekend admissions have a higher mortality 
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(Jenkins et al., 2011, Barba et al., 2011). A large retrospective study looking at winter weekend 
admissions has shown that the opening of a dedicated medical admissions unit reduces 
mortality (Brims et al., 2011). Frequent acute exacerbations of COPD result in an accelerated 
decline in lung function (FEV1); additionally, exacerbation frequency also increases as the 
disease becomes more severe (Tashkin, 2011). This results in an impaired quality of life and 
restricted daily activities of living. 
 
Overall the burden of acute exacerbations needs to be improved with earlier identification and 
the prompt initiation of treatment (antibiotics and steroids or other as appropriate). This 
requires intuitive monitoring tools so that COPD patients can effectively self-manage and 
identify changes in their condition and initiate an appropriate course of action taken either by 
contacting community-based respiratory specialists or starting stand-by treatment. Indeed, 
NICE advocates that COPD patients at risk of exacerbations should be given self-management 
advice that encourages them to respond promptly to the symptoms of an exacerbation. In 
conjunction to this, COPD patients should be given a course of treatment (antibiotics and 
steroids) to keep at home for use as part of a self-management strategy (NICE, 2010). However, 
the majority of patient remain unclear as to when they should ideally start treatment and often 
delay taking action. 
  
Chapter 1:  Introduction 
40 
1.7. Development of COPD monitoring tools 
 
Presently there remains an unmet need to develop reliable, sensitive and easily accessible 
monitoring tools for health status in COPD patients. These tools would ideally help with COPD 
patient self-management in the stable phase of their disease to predict and thus facilitate/guide 
the early initiation of treatment for acute exacerbations. This would greatly improve COPD 
outcomes with consequent socio-economic benefit. The concept of point-of-care (POC) 
diagnostics in medicine is rapidly expanding as technologies increasingly rely on minimally 
invasive sampling of body fluids which are not reliant on laboratory infrastructure for 
processing and analysis. Technological advances in POC testing, primarily miniaturisation and 
reduction in user operator variables, have also increased their practical utility (Loubiere and 
Moatti, 2010). POC tests have been successfully deployed in patient self-monitoring and 
community testing for example, hand-held glucose (Newman and Turner, 2005), International 
Normalised Ratio monitors (Garcia-Alamino et al., 2010), pregnancy testing (Posthuma-
Trumpie et al., 2008) and urine dipsticks which can test for a wide variety of analytes (Wilson 
and Gaido, 2004). Within the field of respiratory medicine peak flow meters were one of the 
first POC tests to monitor asthma (Lockhart et al., 1960). Recent developments of POC tests 
in respiratory medicine are focused on viral and bacterial respiratory pathogen diagnostics 
(Zumla et al., 2014). Overall it is equally vital to recognise that adoption of POC technologies 
is not sufficient to achieve improved clinical outcomes unless there is also innovation in the 
process of delivering care (St John, 2010). 
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1.7.1. Novel monitoring approaches in COPD  
One concept of developing novel POC monitoring tools is to utilise easily accessible patient-
produced samples to identify disease-specific biomarkers and enable near-patient testing to 
determine health status. Presently within the field of COPD several patient-derived sample 
approaches have been undertaken in an attempt to develop the ideal POC test to monitor disease 
progress and identify acute episodes. 
 
1.7.1.1. Electronic nose breath analysis 
An electronic nose functions by chemically analysing vapour, using a nano-composite array 
with polymer sensors. When exposed to a gas mixture the sensors swell, thereby changing the 
electrical resistance, resulting in a unique “smell-print” of differential electrical resistances. 
Electronic nose technology has been shown to identify AAT deficiency in a population of 
COPD patients (Hattesohl et al., 2011), as well as discriminating patients with lung cancer from 
COPD and healthy controls (Dragonieri et al., 2009), and distinguishing between asthma and 
COPD (Hattesohl et al., 2011, Fens et al., 2011, Dragonieri et al., 2009). It has been shown to 
have acceptable within-day and between-day repeatability in patients with stable COPD and 
can be used to identify sub-phenotypes of mild-to-moderate COPD (Bofan et al., 2013, Fens et 
al., 2013b). A recent study has demonstrated that electronic nose technology can identify the 
presence of bacterial colonisation in clinically stable COPD (Sibila et al., 2014) and identify 
acute COPD exacerbations with evidence of bacterial infection (Shafiek et al., 2015). Overall 
electronic nose breath analysis utilises pattern recognition, without analysing individual 
molecular components, which has shown promise for diagnostic objectives (Dragonieri et al., 
2009). However, the inability to detect specific target analytes leads to the possibility that other 
substances may produce similar “smell-prints” thus reducing the sensitivity of the technology 
(Röck et al., 2008). A high degree of variability between repeated samples has also been 
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demonstrated, in addition to other methodological factors such as breath exertion factor, which 
still need to be standardised before breath analysis can be reliably used for widespread POC 
testing (Phillips et al., 2014, Fens et al., 2013a). 
 
1.7.1.2. Exhaled breath condensate 
Exhaled breath condensate (EBC) is collected by cooling or freezing exhaled air. This body-
fluid has several qualities which are useful when testing for target analytes; it is simple to 
perform, non-invasive and makes repeated sampling possible (Mutlu et al., 2001). The 
composition of EBC is mainly water vapour but hundreds of different compounds at trace 
concentrations can be found from small inorganic ions through large organic molecules to 
peptides, proteins, surfactants, macromolecules and volatile organic compounds (Peralbo-
Molina et al., 2015). The collection procedure has been standardised (Horvath et al., 2005) and 
there is strong evidence that abnormalities in EBC composition may reflect biochemical 
changes of airway lining fluid (Bajaj and Ishmael, 2013). Multiple biomarkers have been 
identified as elevated in EBC of smokers and COPD patients both during stable and acute 
exacerbations for example, LK-β4 and 8-isoprostane (Biernacki et al., 2003), hydrogen 
peroxide (Dekhuijzen et al., 1996), prostaglandins (Montuschi et al., 2003) and AAT (Koczulla 
et al., 2011). A lower pH has also been observed in COPD (Kostikas et al., 2002, Papaioannou 
et al., 2011); whilst earlier studies showed no change in pH during an acute exacerbation (Antus 
et al., 2010), recent work has demonstrated a further decrease in pH during an acute 
exacerbation of COPD when pH testing is performed immediately after exhaled breath 
sampling. Interestingly by contrast, same samples tested after storage demonstrated a rise in 
pH (Warwick et al., 2013). Levels of AAT and eicosanoids have also been demonstrated to rise 
during acute COPD exacerbations (Antczak et al., 2012, Koczulla et al., 2011). Unfortunately, 
despite numerous studies, analysis of EBC has limitations regarding optimisation and 
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validation of quantitative analytical procedures; thus it is not possible to make direct 
comparisons between different laboratories (Dodig and Čepelak, 2013). This between-
instrument variation is currently a major limitation in the application of EBC to a POC 
instrument.  
 
1.7.1.3. Urine 
Urine testing is a non-invasive and widely used POC test sample with over-the-counter tests 
for pregnancy. Urine test strips can quantify ascorbic acid, glucose, bilirubin, ketones, specific 
gravity, blood, pH, protein, urobilinogen, nitrates and leukocytes (Siemens, 2016). Urine based 
POC testing has also been developed for drugs of abuse for example, cocaine (Beck et al., 
2014). 
 
With respects to COPD the focus has been on detection of desmosine and isodesmosine, both 
by-products of elastin degradation, in urine. It has been shown that both active smoking and 
presence of COPD are significantly and independently associated with higher urinary excretion 
of elastin degradation products (Stone et al., 1995). Levels of both products are also elevated 
in the urine of COPD patients experiencing a more rapid decline in their FEV1 (Gottlieb et al., 
1996).  A small but significant increase in desmosine has been observed during an acute 
exacerbation of COPD (Fiorenza et al., 2002), and a recent abstract has also identified a panel 
of urinary biomarkers for example, IL-6 that can detect acute exacerbations of COPD (Gita et 
al., 2014). Recent work has explored the metabolic signature of urine by using proton nuclear 
magnetic resonance and identified several biomarkers for example, acetate, which were found 
to be enhanced in COPD patients (Wang et al., 2013). Interestingly within this aforementioned 
study metabolic differences between COPD and healthy subjects were more pronounced in 
urine than serum counterparts. Urine appears to be an ideal sample for incorporating into a 
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POC test due to ease of collection. However, urine as a POC test is limited in the accuracy of 
quantifiable levels of analytes and there is no serum-urinary biomarker overlap in COPD. Thus 
well validated serum-based biomarkers for example, CRP shows no correlation to urinary CRP 
levels and it is hypothesised that CRP is an unlikely constituent of urine (Chuang et al., 2010). 
This positions urine as a potential bio-sample significantly behind serum-based testing for valid 
biomarkers in COPD. 
 
1.7.1.4. Dried blood spot  
Dried blood spot (DBS) samples are formed by drops of whole blood collected on filter paper 
from a simple finger prick. DBS testing is mainly used for large population screening of viral 
diseases for example, Human Immunodeficiency virus (Lehmann et al., 2013). The availability 
of DBS samples has also been useful for medical researchers, especially those working in 
remote, isolated communities with several advantages over traditional methods. DBS can be 
stored, packaged and even mailed without the logistical challenges that are present with whole 
blood, urine or saliva samples (Benyshek, 2010). However, one major disadvantage presently 
is consistency of storage and handling of dried samples, for example humidity and temperature 
which can affect the target analyte (Denniff & Spooner 2010). DBS samples for C-Reactive 
protein (CRP) quantification have been shown to be stable for up to 21 days prior to analysis 
(Cordon et al., 1991). Initial small studies have shown correlations in CRP levels between 
paired DBS and serum samples (Cordon et al., 1991, McDade et al., 2004). However, DBS 
levels of CRP are consistently lower than serum values possibly due to inaccurate sample 
volume estimate or CRP adhering to the testing paper (Brindle et al., 2010). These points are 
technical limitations that need to be overcome.  
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Although blood spot testing could be employed as an alternative to the dried spot method and 
is well established for glucose monitoring, one potential disadvantage is that patients would 
have to self-prick. Consequences of prolonged self-pricking include scar formation, the loss of 
perception and pain (Heinemann, 2008). This is not ideal for the COPD patients who are often 
elderly and who are frequently exposed to courses of systemic steroids with consequent 
thinning of their skin. Additionally, finger prick anxiety has been observed in 30% of patients 
with the subsequent avoidance of testing (Shlomowitz and Feher, 2014). 
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1.8. Saliva 
Saliva possesses several functions involved in oral health and homeostasis. It originates from 
three pairs of major salivary glands (parotid 20%, submandibular 65 to 70% and sublingual 
5%) and from a large number of minor salivary glands between 600 to 1000, which exist as 
small discrete aggregates of secretory tissue present in the submucosa throughout most of the 
oral cavity (Carranza et al., 2005) (Figure 1.3).  
 
 
Figure 1.3: Location of major and minor salivary glands 
Figure A demonstrates the anatomical location of the major saliva glands contributing 95% to 
total saliva flow. Parotid = 20%, Sub-mandibular = 65 to 70% and sublingual = 5%. Figure B 
illustrates the location of the minor salivary glands located in the oral cavity. These minor 
glands secrete different types of saliva: serous, mucous and mixed sero-mucous. 
 
Saliva composition also has a non-glandular origin, with possible constituents coming from the 
oropharyngeal mucosa, the gingival crevice epithelia and blood with derived compounds both 
actively and passively transferred. With increasing emphasis on near-patient and non-invasive 
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diagnostics, saliva is being increasingly promoted as a suitable alternative diagnostic bio-
sample to blood, providing useful information on health status and disease (Wong, 2008).  
 
Saliva has numerous practical advantages including: non-invasive access, simple self- and POC 
sampling; minimal training for collection; capability and cost effectiveness for multiple 
sampling and large population screening (Denny et al., 2008). Saliva has been widely and 
reliably used to identify infectious agents (Gallo et al., 1997, Thieme et al., 1992, Li et al., 
1996, Ikuta et al., 2000, Blackbourn et al., 1998), steroid hormones (Trilck et al., 2005), drug 
monitoring (Mandel, 1993) and disease presence (Tishler et al., 1996, Hanemaaijer et al., 1998, 
Kaufman and Lamster, 2002, Hu et al., 2008, Miller et al., 2010, Sugimoto et al., 2010, Xiao 
et al., 2012, Zhang et al., 2012).  
 
Saliva is not just a passive “ultra-filtrate” of serum but a complex multi-factorial body fluid. 
Saliva contains a variety of molecules; inorganic compounds, organic non-proteins, lipids, 
proteins, polypeptide compounds and hormones that reflect important pathophysiological 
activities. The complete proteome of saliva contains approximately 2340 proteins. Major 
compositional differences between serum and saliva have been demonstrated with 
approximately 20% of whole saliva proteins found in plasma (Topkas et al., 2012) (Figure 1.4). 
  
Chapter 1:  Introduction 
48 
 
Figure 1.4: Saliva functions and composition. 
This figure (adapted from A. Bardow, 2008) illustrates the main functions of saliva its 
multifactorial role within the oral cavity and the constituent components that drive specific 
functions. 
 
However, despite these differences, the distribution found across key categories, such as 
molecular function, biological processes and cellular components, shows significant 
similarities. The major constituents of human serum are immunoglobulins and albumins which 
account for 60 to 80% of the total weight (Bjorhall et al., 2005). Overall 99% of total protein 
content is represented by 22 proteins. This makes the identification of the remaining 1%, which 
includes inflammatory markers for example, CRP, Procalcitonin (PCT) and NE challenging. 
However, in whole saliva the 20 most abundant proteins in serum represent only approximately 
40% of the entire salivary proteome (Loo et al., 2010: unpublished observations) Whole saliva 
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has also approximately 15% less proteins than serum (Loo et al., 2010). Thus based on the 
premise that saliva has a comparatively lower content of “overpowering” serum high abundant 
proteins, identification and measurement of serum low abundant proteins such as CRP, PCT 
and NE should be technically feasible in saliva. The possible use of saliva as a body fluid that 
reflects the systemic characteristics of an individual as does blood is due to its exchange with 
substances that compose the plasmatic liquid (Lima et al., 2010). This is due to the presence of 
a thin layer of epithelial cells separating the salivary ducts from the systemic circulation, 
making it possible for proteins to be transferred into saliva via active carriage, ultra-filtration 
or passive diffusion via a concentration gradient (Catalan et al., 2009). 
 
1.8.1. Gland specific or whole saliva sampling 
A sample of saliva for protein analysis can be either a gland-specific or a heterogeneous sample 
made up from the individual glands (whole saliva) (Wong, 2008). Gland-specific saliva 
requires the direct cannulation of the target salivary gland. This is an invasive procedure and 
used only when there is a specific necessity to test a particular gland's function or a clinical 
interest in particular analytes. For example, salivary secretory-IgA and α-amylase, do show 
differences from one salivary gland to another (Crawford et al., 1975, Veerman et al., 1996). 
Whilst there is the potential to use less invasive absorbent devices to sample specific glandular 
or mixed rather than whole saliva, this approach would prove difficult to adopt within clinical 
environments such as for repeated self-sampling in patients at POC or as a method to obtain 
repeated samples from patients in the community. Absorbent devices can introduce bias if not 
correctly positioned and may also cause interference in immunoassays (Shirtcliff et al., 2001). 
Levels of CRP appear to be reduced in glandular compared to unstimulated whole saliva 
(Topkas et al., 2012); PCT and NE have not yet been explored widely in saliva. Overall whole 
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unfractionated saliva would appear to be more practical, expeditious and simpler to provide 
(Nunes et al., 2015). 
 
Although whole saliva can be collected easily, the standardisation of pre-collection parameters 
(of which there are a number of different factors) need to be considered. These include the type 
of whole saliva to be sampled, stimulated or unstimulated; time of day of sampling; oral micro-
trauma caused by for example, tooth brushing; the particular medications patients may be 
taking. In addition to these factors food and/or fluid intake prior to sampling may affect 
composition and flux of salivary components (Chiappin et al., 2007). Storage of fresh saliva 
samples at room temperature needs to be considered as a rapid protein degradation, has been 
found to start on sample collection. This can be negated by immediately collecting saliva in 
ice-cooled containers and also storing freshly collected saliva samples at 4oC (Esser et al., 
2008); however long term storage at -80oC is required to maintain protein stability (Schipper 
et al., 2007). Provided that standardisation of saliva sampling, storage and processing can be 
optimised, saliva offers a readily available means for quantification of changes of specific 
biomarkers with potential clinical implications for the diagnosis and management of both oral 
and systemic diseases. It is important to recognise however that saliva contains lower 
concentrations of analytes that are found in blood (100 to 1000-fold lower) (Pfaffe et al., 2011). 
This reduced analyte concentration hinders widespread use of saliva for target analyte 
quantification as most analysing technology is not sensitive enough (or not available) to detect 
the lower salivary concentrations of many analytes compared to serum (Hart et al., 2011). 
Initial challenges in saliva-based analyte quantification have been met with the development 
of laboratory-based high sensitivity Enzyme-Linked immunosorbent assay (ELISA)s and 
polymerase chain reaction techniques (Malamud and Rodriguez-Chavez, 2011). Salivary POC 
diagnostics however are further complicated by the high viscosity and heterogeneous properties 
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associated with saliva (Christodoulides et al., 2005). Some of these limitations can be overcome 
as discussed below with for example, paramagnetic particle analyte capture (Section 1.8.3.3.1, 
Page 59).  
 
The heterogeneous properties of saliva therefore require standardised collection and processing 
protocols that require training and education. Interestingly, studies exploring patient 
compliance with saliva collection protocols have demonstrated “low” adherence at 26 to 28% 
of the study population (Hall et al., 2011, Kudielka et al., 2003). It is unclear from these studies 
whether patients were involved in the practical design of said protocols to ensure maximal 
patient compliance. 
 
Thus the argument for collection of whole unfractionated saliva for biomarker analysis has 
been made, however what type of whole unfractionated saliva to obtain needs specific 
consideration. 
 
1.8.2. Differences between stimulated and unstimulated saliva 
The production of whole unfractionated saliva can be split into two separate methods. A 
stimulated sample can be produced mechanically by mastication on an inert substance for 
example: paraffin wax, cotton, cellulose acetate, or chemically with a gustatory stimulus for 
example: citric acid on the tongue. An unstimulated sample can be provided either by passive 
drool thus allowing saliva to drain off the lower lip into a plastic vial (Nurkka et al., 2003, 
Hodinka et al., 1998), spit or absorbed via a swab placed in the oral cavity. Whilst spitting 
directly into a collector vial is possible, specimens collected by this method contain up to 
fourteen times more bacteria than those collected by passive drool; this affects storage and 
analysis of several compounds (Nurkka et al., 2003). 
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The rate of flow for unstimulated whole saliva has been demonstrated to be lower than 
mechanically stimulated methods (Bergdahl, 2000, Topkas et al., 2012). However, one study 
in asthmatic children compared to non-asthmatic controls demonstrated no significant 
difference in unstimulated and stimulated salivary flow rates between the two groups (Al-
Dlaigan et al., 2002).  
 
The composition of a whole saliva sample can be affected by which sampling method is chosen.  
No difference has been demonstrated in the total protein content between stimulated and 
unstimulated submandibular saliva (Dawes, 1975). Other work has also confirmed that there is 
no difference in total protein content between stimulated and unstimulated whole saliva 
collected by varying methods (Topkas et al., 2012). More recently unstimulated whole saliva 
has been found to have higher amino acid concentrations when compared to citric acid 
stimulated saliva (Rad et al., 2014). Importantly, citric acid stimulated saliva may affect 
immunoassay performance by creating interference with antibody binding (Bourbeau et al., 
2003). With respects to salivary CRP no difference in concentrations has been demonstrated 
between unstimulated whole saliva via passive drool and mechanically stimulated saliva 
samples (Mohamed et al., 2012). Presently, no comparative studies between different forms of 
whole saliva have been conducted for either salivary PCT or NE. 
 
Studies on therapeutic drug monitoring in saliva have revealed higher mean concentrations of 
theophylline in the unstimulated whole saliva of children taking the medication for asthma 
compared to stimulated (citric acid) whole saliva. Importantly, although both demonstrated 
statistically significant strong correlations with total serum values, unstimulated whole saliva 
was stronger (r = 0.98 in comparison to r = 0.90 respectively) (Siegel et al., 1990).  Mixed 
unstimulated saliva collected via passive absorbance showed a recovery of greater than 90% 
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for a panel of anti-epileptic medications, caffeine and theophylline (Groschl et al., 2008). 
Recent work has also confirmed the benefits of unstimulated whole saliva therapeutic drug 
monitoring for a panel of anti-epileptic medications (Patsalos and Berry, 2013). 
 
Absorbance of unstimulated saliva via polyester swabs has been demonstrated to produce better 
yields for salivary steroids compared to using cotton swabs (Groschl and Rauh, 2006). Cotton 
swab retrieval of saliva, compared to passive drool collection, appears to reduce the 
concentrations of cortisol, s-IgA (Strazdins et al., 2005) and CRP (Topkas et al., 2012).  
Furthermore, stimulated or unstimulated saliva collected via an oral swab can cause end-user 
anxiety, with subjects appearing apprehensive about having to place “foreign 
objects/materials” into their mouths. A study investigating cotinine levels in both stimulated 
and unstimulated saliva documented that 9% of participants found collection of stimulated 
saliva via chewing on cotton wool “not at all acceptable” compared to 1% for passive collection 
of unstimulated saliva (Binnie et al., 2004).  
 
Overall unstimulated compared to stimulated saliva provides a higher total protein content in 
the sample, for example, higher CRP concentrations. Whilst a reduction in saliva flow is noted 
during unstimulated-sampling, the case for not using oral stimulants or passive absorbance with 
oral swabs when collecting saliva samples is well made; furthermore, current immunoassays 
are generally designed to work with small sample volumes which do not prove to be a problem 
for most patients to produce. Importantly, as previously described saliva stimulants may also 
cause immunoassay interference or alteration of levels of some analytes (Granger et al., 2007b).  
  
Chapter 1:  Introduction 
54 
1.8.3. Technological approaches to salivary analysis 
Currently there is a wide variety of technological approaches to saliva-based testing; all of 
which seek to produce a sensitive and reproducible diagnostic that can efficiently and 
repeatedly be used to provide meaningful clinical information. 
 
1.8.3.1. Mass spectrometry 
The first step is to categorise the entire saliva proteome. Mass spectrometry (MS) has been 
used to analyse salivary proteins in minute detail and thus generate a comprehensive proteome 
(Denny et al., 2008). This technique is extremely sensitive for high accuracy measurements of 
proteins and peptides, with unbiased results as no prior knowledge of protein composition is 
required (Gillette and Carr, 2013). There are four different MS techniques used in salivary 
biomarker screening and identification. These include: 2-dimensional gel electrophoresis, 2-
dimensional liquid chromatography-MS, matrix assisted laser desorption ionisation-time of 
flight-MS and surface enhanced laser absorption/ionisation time-of-flight-MS. It should be 
noted that different yields of total proteins have been identified with the various MS techniques. 
(Al-Tarawneh et al., 2011). Initial biomarker fractionation is required for MS-based techniques 
(Esser et al., 2008). Each fractionation is then subject to the MS techniques as described above 
of which the resulting data is then used to search protein databases for identification. As an 
example from a list of 1058 proteins reported as potential cancer biomarkers, 34% are found 
in the whole saliva proteome and 12% are found in both unstimulated whole saliva and serum 
proteomes (Anderson, 2010). Saliva has a lower composition of over-powering serum 
abundant proteins (Section 1.8, Page 49). Thus saliva-based testing for these proteins should 
be more fruitful than serum (Loo et al., 2010). Overall the completion of the saliva proteome 
by MS will help to establish saliva as a validated diagnostic fluid. However, the adoption of 
MS techniques as a POC test is hindered by sample preparation (fractionation). Newer 
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techniques for example, paper spray MS, have been shown to be effective in the analysis of 
complex biological fluids and allows for a reduced sample volume and minimal sample pre-
treatment compared to traditional MS. This approach coupled with a bio-fluid sampler could 
provide for an effective POC test in the future (Wang et al., 2013). 
 
1.8.3.2. Lateral flow assays 
Early saliva-based POC involved lateral flow assays (Figure 1.5) which had the advantage of 
simplicity, but lacked the capability for carrying out complicated operations for example, 
nucleic acid diagnostics. Lateral flow tests are routinely used to detect: pregnancy, infectious 
diseases, myocardial infarction and substances of abuse. Samples may include urine, saliva, 
blood, and stool. Typical lateral flow tests however lack signal amplification, and thus, 
sensitivity falls short of ELISA-based methodologies. Several engineering solutions have been 
developed to overcome problems with autonomously transporting liquids, controlling fluid 
flow in small devices, facilitating mixing, thermal control, dry store reagents for prolonged 
periods of time (greater than 1 year) and means for biomarker quantification (Hart et al., 2011).  
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Figure 1.5: Lateral flow assay architecture. 
This diagram (adapted from Cytodiagnostics, Canada) represents a typical lateral flow assay 
test-strip. (A) Sample containing target analyte is deposited onto the sample pad which by 
capillary flow migrates through the test strip. (B) It initially encounters the conjugate pad where 
target analyte binds to a target antibody. The remaining antibodies in the conjugate pad which 
are unbound continue to migrate with the antigen-antibody complexes. (C) At the test line the 
analyte-antibody complexes attach to an analyte specific “capture” antibody to create a 
coloured line. Antibodies that contain no analyte continue to migrate to the control line where 
they bind to create a control line.  
 
Lateral flow test strips have been developed to semi-quantitatively determine nitrous oxide and 
uric acid in saliva by using chromatography paper impregnated with nitrous oxide and uric acid 
detection chemistries. Brief emersion of the test strip in saliva produces a change in colour, 
which is proportional to the levels of the target biomarkers. These test strips have been shown 
to accurately monitor nitrous oxide and uric acid concentrations in patients undergoing dialysis 
A 
B 
C 
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(Walt et al., 2007). Quantum dots which have superior signal brightness and higher 
photostability compared to organic fluorophores when combined with a lateral flow test strip 
can result in a test that is capable of rapid, sensitive and quantitative detection of nitrated 
ceruloplasmin, a significant biomarker for cardiovascular disease, lung carcinoma and stress 
response to smoking (Li et al., 2010). A recent study demonstrated that a gold nano-particle-
based immunochromatographic test strip could detect organophosphate exposure, providing a 
simple, accurate and qualitative tool that may be adapted to test for other biomarkers (Zhang 
et al., 2013). Presently however, lateral flow assays are limited when highly quantitative and 
reproducible results are demanded (Sajid et al., 2015). 
 
Research continues on the integration of a lateral flow strip combined with a microfluidic 
cassette, which for sample processing would significantly expand the range of applications and 
tasks that could be performed by immunochromatographic methods. Recent advances in 
microfluidics make it possible to miniaturise, integrate, and automate various bench-top 
procedures into credit card-sized cassettes or chips. Microfluidics offers greater functionality 
and more sophisticated flow control than lateral flow devices, and potentially could expand the 
range of assay technologies that can be performed in formats similar to that of a test strip. The 
field is also often referred to as micro-total analysis or lab-on-a-chip. Although progress with 
developing a lab-on-a-chip concept has been slow, commercial devices using molecular assays 
to detect infectious agents are starting to appear on the clinical market (St John and Price, 
2014).  
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1.8.3.3. Microfluidic technology: Lab-on-a-chip 
Lab-on-a-chip has two sub-disciplines: (1) automating laboratory procedures with the aim of 
enhancing discoveries through high throughput parallel processing which may be needed for 
combinatorial biology and chemistry, drug screening, and other biological studies (Paegel and 
Joyce, 2010); and (2) creating autonomous, fully integrated POC devices, which are often 
disposable and aimed at assaying one or a few more analytes within a relatively short period 
of time (Hart et al., 2011). Microfluidic devices can be further classified as instrumented or un-
instrumented (Weigl et al., 2008). Instrumented devices typically consist of a disposable 
cassette accompanied by a portable analyser. The disposable cassette hosts a microfluidic 
circuit with reaction chambers and interconnecting channels as well as the required reagents 
for measurement of the target analytes. The analyser incorporates functionality for pumping, 
thermal control for incubation, enzymatic amplification and detection via optical signals, 
electrochemical signals or added mass. Un-instrumented devices are updated lateral flow strips. 
The actuators, such as finger-actuated pouches and exothermic reaction chambers, are 
integrated into the disposable cassette and no external processor is needed. At present these 
devices provide little flexibility in terms of reconfiguration and scalability. Handling of real 
physiological samples has also been a problem (Srinivasan et al., 2004).  
 
Another classification of these devices is to look at capture of target analytes using magnetic 
particles which can help with mixing, washing and buffer exchange, both in fluid flow and in 
stationary microfluidic device (van Reenen et al., 2014). Proteins are then detected via 
immunoassay and nucleic acids via molecular diagnostics which are generally more 
complicated than immunoassays (Hart et al., 2011). Recently an all-polymer microfluidic 
system which is highly sensitive and can provide acute virus detection within 15 minutes has 
been developed and tested on influenza virus identifying clinically relevant concentrations 
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(Kiilerich-Pedersen et al., 2013). A microfluidic device has also been produced which can 
detect cocaine in saliva (Wagli et al., 2013). 
 
1.8.3.3.1 Microspheres 
Lab-on-a-chip assay systems have been developed in which assays are performed on 
chemically-sensitised beads populated into etched silicon wafers with embedded fluid handling 
and optical detection capabilities. This electronic taste chip (ETC) approach allows complex 
assays to be performed with small sample volumes, short analysis times and markedly reduced 
reagent costs. Both ETC- and ELISA-based testing produce similar results (Christodoulides et 
al., 2007). The ETC system can provide an ultra-sensitive test for the measurement of salivary 
CRP, and has detected significant differences in concentrations between periodontally healthy 
individuals and those with chronic gingival inflammation and periodontitis (Christodoulides et 
al., 2005). Further work is being performed using microspheres to create a multiplexed protein 
biomarker assay to distinguish the severity of acute exacerbations of COPD (Walt et al., 2007). 
Blicharz et al., published an update to this work in 2009 demonstrating the fibre-optic 
microsphere-based antibody array that can simultaneously measure a panel cytokines 
implicated in pulmonary diseases (Blicharz et al., 2009). Currently the technology is used as a 
laboratory-based platform for inflammatory disease research and diagnostics; however due to 
its small footprint microsphere-based cassettes are being increasingly developed for use in POC 
(Blicharz et al., 2009). A microsphere-based cassette for the detection and quantification of IL-
8 provides good repeatability and reasonable sensitivity (Qiu et al., 2009). 
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1.8.3.4. Immunoassays 
An immunoassay tests for the presence or concentration of a macromolecule through the use 
of an antibody or immunoglobulin. In addition to the binding of an antibody to an antigen the 
other important feature is the production of a measurable signal in response to the binding by 
the linkage of a detectable label. 
 
1.8.3.4.1. Immunoassay labels 
1.8.3.4.1.1. Enzyme 
One of the most popular labels employed is enzymes for example, horseradish peroxisade, 
alkaline phosphatase or glucose oxidase. These enzymes allow for analyte detection because 
they produce an observable colour change in the presence of specific reagents. ELISAs have 
the ability to detect small concentrations of analytes with excellent sensitivity and specificity. 
However current ELISAs are laboratory-based and require numerous steps including sample 
preparation, microtitre plate wash and incubation these; in turn can result in a 4-hour test time 
for a normal laboratory-based ELISA through to result feedback. An ultrasensitive portable 
immuno-sensor has been developed using an enzyme immunoassay for the quantification of 
tauroursodeoxycholic acid in saliva to assess oro-ileal transit time. Results from this portable 
assay are accurate, with strong correlation to serum concentrations (Simoni et al., 2013). A 
POC ELISA test kit for serum canine viruses has also been shown to yield accurate results 
under field conditions (Litster et al., 2012). More recently a micro-a-fluidics ELISA for rapid 
and reliable CD4 cell count has been developed with the entire ELISA process complete in 
under 9 minutes; however a portable optical detection system is still needed to be used 
separately to the ELISA process (Wang et al., 2014).  
  
Chapter 1:  Introduction 
61 
1.8.3.4.1.2. Radioactive isotope 
A radioimmunoassay is analogous to an ELISA but utilises a radioisotope label. 
 
1.8.3.4.1.3. Fluorophore 
This method is analogous to an ELISA but utilises a fluorophore label which is a fluorescent 
compound that can re-emit light upon light excitation. 
 
1.8.3.4.1.4 Chemiluminescence 
This method is analogous to an ELISA but utilises a chemiluminescent substance as a label, 
which is a compound that emits light.  
 
1.8.3.4.1.5. Liposome 
This method involves a liposome encapsulated marker either coupled to an analyte or antibody.  
 
Despite significant technological advances, a number of challenges remain in developing an 
ideal POC test based on an immunoassays concept, with as described above refinements on 
sample preparation and time of incubation (which for some immunoassays can be several 
hours) as well as the need, to incorporate some form of optical or radioactive detection.  
 
Overall saliva-based testing offers numerous advantages to POC testing with a number of 
technologies demonstrating promise (Table 1.5). However, there is still considerable research 
that needs to be performed to establish saliva sampling in routine respiratory disease 
management, ranging from standardised sampling protocol and saliva-based biomarker 
quantification to, the ability of saliva to reflect disease status change. This thesis will attempt 
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to address these gaps in knowledge and provide the foundation upon which new technologies 
can be developed to enable POC testing of saliva to better manage COPD. 
 
Table 1.5: Technological approaches to salivary analysis. 
Technology Pros Cons 
Mass Spectrometry 
Extremely sensitive and 
accurate 
Sample preparation 
(fractionation) 
Lateral Flow Assays 
Simple;  
well established for other 
body fluids as a point of 
care test. 
Lack signal amplification 
and thus sensitivity falls 
short of immunoassays 
Microfluidics/ Lab-on-a-chip 
Small sample volumes; 
have been shown to 
produce similar results to 
enzyme immunoassays 
Stability of reagents on 
the chip;  
accuracy of chip 
manufacturing. 
Immunoassays 
Extremely sensitive and 
accurate 
Requires appropriate 
label detection 
machinery. 
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1.9. Salivary analysis in COPD 
Analysis of saliva in COPD patients has focused on therapeutic drug monitoring and 
biomarkers of pathogenesis. Strong correlations have been demonstrated between serum and 
saliva levels of theophylline (Salamzadeh et al., 2008) and saliva oxidative-stress related 
changes (Yigla et al., 2007). More recent work has identified a significant negative correlation 
between FEV1, salivary IL-8 and MMP-9 levels in COPD patients (Ji et al., 2014). Whilst the 
study of saliva to identify COPD-centric biomarkers is in its infancy, the above-mentioned 
studies all acknowledge the benefits that saliva sampling provides for ease of collection and 
testing. 
 
Within in the field of COPD a range of biomarkers have been extensively investigated in a 
variety of bio-fluids with the identification of relevant biomarkers continuing to expand. 
Although, access to samples remains a major issue, it is increasingly recognised that a panel of 
biomarkers may provide a more comprehensive model for COPD: (1) diagnosis, (2) disease 
status monitoring, (3) progression and (4) guide to therapy (Shaw et al., 2014). For this thesis 
work 3 COPD-relevant biomarkers have been selected that will be investigated in the saliva of 
COPD patients and healthy subjects. These biomarkers were selected based on a systematic 
review of the literature over the past 30 years (web of science: COPD, biomarkers). Biomarkers 
were selected that were well researched with respects to COPD pathogenesis, disease state 
monitoring and had been extensively investigated in numerous body-fluids. In conjunction to 
this the availability of saliva based or validated “body-fluid” immunoassays were also 
considered. The target biomarkers selected were CRP (Zhang et al., 2012), PCT (Tokman et 
al., 2011) and NE (Lucas et al., 2013). 
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1.9.1. C-Reactive Protein (CRP) 
CRP is a pentraxin protein (Figure 1.6) discovered in the 1930's by Oswald Avery during his 
research with streptococcus pneumoniae infection. He demonstrated that CRP levels were 
increased during the acute stage of an infection (Abernethy and Avery, 1941).  
 
Figure 1.6: Molecular structure of C-Reactive Protein (CRP). 
This figure (ribbon diagram) represents the 3-dimensional crystal structure of human CRP. 
CRP is a 206 amino acid polypeptide that has a variable molecular weight of approximately 
115 kilodaltons (kDa) (Black et al., 2004). 
 
CRP is synthesised in the liver and regulated by circulating levels of IL-6. Its physiological 
role is to bind to phosphocoline in order to activate the compliment system with levels of CRP 
rising rapidly in response to trauma, inflammation and infection (Du Clos, 2000). In healthy 
subjects, median levels of serum CRP range between 0.96 to 1.5mg/L (Ridker, 2003a, Jones et 
al., 2009, Yudkin et al., 1999). These levels have been shown to increase with age, body-mass 
index (BMI), smoking status and the co-existence of diabetes (Koenig et al., 1999). Although 
historically serum CRP levels less than 10mg/L have been considered clinically insignificant 
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(Black et al., 2004), it has now become established that levels above 1.5mg/L are associated 
with an increased risk of cardiovascular disease (1.5 to 3mg/L: moderate risk and greater than 
3mg/L: high risk) (Ridker, 2003b). Baseline CRP levels in healthy subjects have also been 
associated with metabolic syndrome and type 2 diabetes (Devaraj et al., 2009). 
 
1.9.1.1. CRP body fluid analysis in COPD 
A literature review conducted over the past 30 years (web of science: COPD, biomarkers, C-
reactive protein, serum, sputum, BAL, exhaled breath, electronic nose, urine, saliva) of studies 
using various body fluids to measure CRP levels in COPD patients these are described below 
under their particular medium. 
 
1.9.1.1.1. Serum 
The most extensively investigated body-fluid for CRP analysis in COPD patients is blood. 
Baseline median serum CRP levels in COPD subjects have been shown to range between 3.00 
to 8.75mg/L (Aksu et al., 2013, Pinto-Plata et al., 2006, de Torres et al., 2006, Chan et al., 
2010, Silva et al., 2015). COPD patients have been shown to have significantly higher serum 
CRP concentrations compared to healthy controls in the stable phase of their disease and serum 
CRP levels appear to increase from moderate to severe disease (Zhang et al., 2012). The 
evidence for increased baseline serum CRP levels resulting in an accelerated longitudinal 
decline in FEV1 is conflicting. Several studies have demonstrated that serum CRP levels are 
associated with an accelerated decline in FEV1 (Gan et al., 2004, Man et al., 2006, Higashimoto 
et al., 2009). However, a large cross-sectional analysis of approximately 1000 patients in 
another study showed no significant association between baseline serum CRP and the rate of 
decline in FEV1 (Fogarty et al., 2007). Increased serum CRP levels of greater than 3mg/L in 
all COPD patients is a strong long term predictor of COPD hospitalisation and mortality (Dahl 
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et al., 2007, Deng et al., 2014). Relationships have also been demonstrated between PROs and 
serum CRP levels in stable COPD patients; with increasing CRP levels significantly correlating 
to a worsening in MRC score (Garrod et al., 2007).  
 
Several studies have demonstrated an increase in serum CRP (greater than 10ng/ml) during an 
acute exacerbation of COPD (Kostikas et al., 2013, Hurst et al., 2006, Stolz et al., 2007b), with 
simultaneously elevated serum levels of CRP, fibrinogen and leucocytes associated with an 
increased risk of frequent exacerbations (Thomsen et al., 2013). Further elevated levels of 
serum CRP (greater than 15mg/L) also appear to distinguish community acquired pneumonia 
from an acute exacerbation of COPD (Huerta et al., 2013). Serum CRP levels greater than 
50mg/L during an acute exacerbation in conjunction with a positive smoking history, at least 2 
co-morbidities and confusion may assist in the identification of patients with a higher risk of 
mortality (Ruiz-Gonzalez et al., 2008). Significantly higher serum CRP concentration (8.8 
mg/L compared to 3.4mg/L) 14 days after an index exacerbation have also been demonstrated 
in a group of COPD patients who had a re-exacerbation, compared with those who remained 
exacerbation free over 50 days (Perera et al., 2007). A relationship however has not been 
established between annual exacerbation frequency and stable baseline serum CRP levels in 
COPD patients (Gompertz et al., 2001). 
 
1.9.1.1.2. Sputum 
Two studies have investigated the levels of CRP in sputum. Out of these studies one is written 
in Chinese although the English abstract concludes that CRP may be secreted from the local 
respiratory tract (Wu et al., 2005). The other study demonstrates no correlation between sputum 
and serum CRP levels in same-subjects (Broekhuizen et al., 2005). 
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1.9.1.1.3. Exhaled breath condensate (EBC) 
As described in Section 1.7.1.2, Page 42, it is not possible to make comparisons between 
different laboratories for the levels of biomarkers quantified in EBC. Only one study has 
investigated CRP in EBC of COPD patients and the text is in Russian. However the abstract 
highlights elevated levels of EBC CRP in COPD patients compared to healthy subjects 
(Dotsenko et al., 2008). 
 
1.9.1.1.4. Saliva 
No studies have yet been published investigating salivary CRP levels in COPD patients. 
However numerous works are now being published for salivary CRP in other disease states. 
There have been studies on unstimulated saliva that demonstrate elevated levels in patients 
with periodontal disease (Pederson et al., 1995, Christodoulides et al., 2005); however this 
conflicts with another small cohort study showing reduced CRP levels in patients with chronic 
periodontitis compared to healthy controls (Aurer et al., 2005). More recent work supports a 
significant association between salivary CRP concentrations and periodontitis (Shojaee et al., 
2013). Salivary CRP has also been investigated in haemodialysis patients (Pallos et al., 2015) 
and acute urticaria (Rao et al., 2011).  
 
Salivary levels of CRP have been found to be elevated in patients who have suffered an acute 
myocardial infarction (Floriano et al., 2009). Within this study a panel of salivary biomarkers 
including an electrocardiogram were found to have an excellent diagnostic accuracy 
comparable to the best serum multi-marker panels. This demonstrates saliva’s reflection of 
systemic status. Recent work has also demonstrated that salivary CRP accurately reflect serum 
levels (Byrne et al., 2013). The correlation between salivary CRP and serum is important as it 
supports the concept that testing of salivary CRP can be used as a direct surrogate to serum. 
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The current consensus is that whilst salivary CRP levels could mirror systemic events, design 
of meaningful clinical studies such as in patients with COPD should consider the co-existent 
presence of periodontitis as this could affect measured CRP levels and thus interpretation of 
salivary CRP should account for the co-variate effect of periodontitis (gum disease). 
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1.9.2. Procalcitonin (PCT) 
PCT is a peptide precursor of the hormone calcitonin (Figure 1.7) discovered in 1975 by Moya 
et al. It is composed of 116 amino acids and is produced by the neuroendocrine parafollicular cells 
of the thyroid gland during health.  
 
Figure 1.7: Molecular structure of Procalcitonin (PCT). 
This figure (ribbon diagram) represents the 3-dimensional structure of PCT. PCT is composed 
of 116 amino acids with a molecular weight of 13kDa (Maruna et al., 2000). 
 
Circulating levels of PCT in healthy subjects are undetectable (Maruna et al., 2000). Elevated 
levels in bacterial infection were first reported by Assicot et al. (Assicot et al., 1993) and since 
then it has become an important protein in the detection of bacterial inflammatory states 
(Maruna et al., 2000). Importantly, localised bacterial infections do not result in a significant 
increase in PCT alongside viral and non-infectious inflammation for example, autoimmune 
disorders (Oberhoffer et al., 1999). The production of PCT during inflammation is linked with 
bacterial endotoxin and inflammatory cytokines TNF-α, IL-1β and IL-6, with the site of 
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production believed to switch to the neuroendocrine cells of the lungs and/or intestine. (Müller 
et al., 2001).  
 
The most elevated levels of serum PCT levels are invariably found in acute severe bacterial 
infections, sepsis, and severe inflammation (Becker et al., 2010). PCT has been demonstrated 
to be more accurate than CRP in differentiating bacterial from non-infective causes of 
inflammation with a sensitivity of 88% compared to 75% and a specificity of 81% compared 
to 67% (Simon et al., 2004). In the same study Simon et al., also found PCT superior in 
distinguishing between bacterial and viral aetiology causes of inflammation with a sensitivity 
of 92% compared to 86% but a more comparable specificity of 73% compared to 70%. A 2012 
Cochrane review found no increase in mortality or treatment failure when serum PCT levels 
were used to guide initiation and duration of antibiotic treatment in patients with acute 
respiratory infections compared to healthy controls (Schuetz et al., 2012). Importantly serum 
PCT time-dependent decay is not affected by steroids (Perren et al., 2008). 
 
1.9.2.1. PCT body-fluid analysis in COPD 
A literature review conducted over a 30-year time frame (web of science: COPD, biomarkers, 
C-reactive protein, serum, sputum, BAL, exhaled breath, electronic nose, urine, saliva) for the 
quantification of PCT in various body-fluids in COPD patients; these are described below 
under the particular medium. 
 
1.9.2.1.1 Serum 
As discussed in Section 1.6.2, Page 36, the predominant cause of acute exacerbations in COPD 
is bacterial. There are several studies exploring the level of serum PCT during an acute 
exacerbation of COPD. Median serum PCT levels at exacerbation range from 0.09 to 0.10ng/ml 
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(Stolz et al., 2007b, Lacoma et al., 2011). Stolz et al., also demonstrated that that higher serum 
PCT levels were observed in patients who died in the 1 month following their acute 
exacerbation of COPD. In COPD patients with acute exacerbations requiring endotracheal 
intubation and mechanical ventilation median serum PCT levels (greater than 0.24ng/ml) are 
independently associated with an increased risk of mortality (Rammaert et al., 2009). Median 
levels of serum PCT (greater than 1.27ng/ml) can also been used to distinguish the presence of 
pneumonia from acute exacerbations of COPD (Bafadhel et al., 2011a). Current literature 
demonstrates that the use of PCT is associated with a reduction in antibiotic treatment initiation 
and duration without an increase in the rates of adverse patient outcomes including death, 
admission to an intensive care unit, re-exacerbation and hospital readmission (Blasi et al., 
2010). One study has demonstrated that antibiotic usage guided by serum PCT levels (greater 
than 0.25ng/ml) in COPD patients presenting to a hospital emergency department for an acute 
exacerbation resulted in an initial reduction in antibiotic exposure and interestingly a sustained 
reduction in total antibiotic exposure for up to 6 months after the hospitalisation event (Stolz 
et al., 2007a). However, other studies have shown that COPD patients with serum PCT levels 
less than 0.25ng/ml at presentation to hospital for an acute exacerbation of COPD may still 
benefit from treatment with antibiotics (Daniels et al., 2010, Falsey et al., 2012).  
 
Thus, serum PCT-guided antibiotic therapy has the potential to decrease unnecessary antibiotic 
use in non-bacterial acute exacerbations of COPD (Clark et al., 2014), thereby helping to 
reduce episodes of antibiotic resistance (Hayashi and Paterson, 2011), antibiotic-related 
adverse reactions (Soni et al., 2012), and potentially episode-associated healthcare costs 
(Heyland et al., 2011).  
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1.9.2.1.2. Saliva 
To date there are no reports in the literature on saliva-analysed PCT levels in COPD. A lone 
study demonstrated that salivary PCT levels in patients with periodontitis and poorly controlled 
diabetes (HbA1c greater than 7.0%) were not significantly higher than those for healthy control 
subjects, although a separate sub-analysis did demonstrate a significantly higher level in 
patients with severe periodontitis compared to healthy individuals (Bassim et al., 2008). In this 
study, salivary PCT levels did not significantly correlate with serum levels. A more recent 
study has also demonstrated no difference in salivary PCT levels between patients with 
generalised chronic periodontitis and healthy controls (Yousefimanesh et al., 2015). In contrast, 
another study has found significantly elevated median salivary PCT levels in individuals with 
chronic periodontitis (0.15ng/ml) compared to healthy controls (Hendek et al., 2015). Although 
the evidence is conflicting only Hendek et al., stored saliva samples at -80oC prior to analysis 
(the other studies stated storage of saliva samples at -20oC prior to analysis). Thus it is possible 
that chronic periodontitis has some effect on salivary PCT levels however presently the 
literature is inconclusive. It is thus prudent to document the presence of periodontitis when 
sampling saliva for PCT and include this co-variate in any statistical analysis for meaningful 
result interpretation. 
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1.9.3. Neutrophil Elastase (NE) 
NE is a 218 amino acid glycoprotein (Figure 1.8) which functions as a powerful serine 
proteinase, with the majority of NE found in the azurophil granules in the neutrophil cytoplasm. 
In humans, NE is encoded by the ELANE gene which resides on chromosome 19. NE 
hydrolyses proteins within the azurophil granules as well as proteins of the extracellular matrix 
following release from activated neutrophils (Takahashi et al., 1988). NE has a role in normal 
tissue turnover and host defence, but it also plays a role during acute and chronic inflammation 
(Lucas et al., 2013). 
 
Figure 1.8: Molecular structure of Neutrophil Elastase (NE). 
This figure (ribbon diagram) represents the 3-dimensional structure of NE. NE is composed of 
218 amino acids and has a molecular weight of NE 29.5kDa (Korkmaz et al., 2010). 
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1.9.3.1. NE body-fluid analysis in COPD 
A literature review conducted over a 30-year period (web of science: biomarkers, elastase, 
serum, sputum, BAL, exhaled breath, electronic nose, urine, saliva) of studies using various 
body fluids to measure NE levels in COPD patient; these are described below under the 
particular medium. 
 
1.9.3.1.1. Serum 
Serum NE/AAT ratio and FEV1 adjusted by pack years appears to be a reliable predictor of the 
development of COPD (Hoshino et al., 2000). Elevated serum levels of NE can identify acute 
exacerbations of COPD (Carter et al., 2013) and distinguish COPD patients from normal 
healthy adults (Yan and et al., 1988). It has also been shown that serum NE levels negatively 
correlate with FEV1 in stable COPD patients (Bizeto et al., 2008). Recent work however, has 
unexpectedly identified a reduction of serum NE at the onset of an acute exacerbation of COPD 
(Chillappagari et al., 2015).  
 
1.9.3.1.2. Sputum 
Sputum NE concentrations are elevated in COPD patients compared to healthy non-smokers 
(Baines et al., 2011), with concentrations of 3.3ug/ml compared to healthy smokers (1.45ug/ml) 
with higher levels of sputum NE observed in severe states (4.60ug/ml) compared with mild to 
moderate disease (2.4ug/ml) (Paone et al., 2011). Sputum NE levels significantly increase 
during an exacerbation and upon clinical resolution levels return back to their pre-exacerbation 
baseline levels (Ilumets et al., 2008). Sputum NE can distinguish bacterial from viral and 
pathogen-negative acute exacerbations of COPD, and also correlates with clinical severity of 
the exacerbation (Sethi et al., 2000). Even during stable phase COPD, the sputum of moderate 
to severe patients with potentially pathogenic micro-organisms contains a significantly higher 
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level of NE compared to those without potentially pathogenic micro-organisms in their sputum 
(Banerjee et al., 2004, Parameswaran et al., 2009). 
 
1.9.3.1.3. Bronchoalveolar lavage (BAL) 
Higher levels of NE in the BAL of COPD patients have been associated with an accelerated 
decline in FEV1 (Betsuyaku et al., 2000) and increasing COPD severity (Vlahos et al., 2012). 
Although BAL NE has been demonstrated to be elevated in COPD patients with frequent 
exacerbations the results were not statistically significant (Tumkaya et al., 2007).  
 
1.9.3.1.4. Saliva 
Salivary NE has not been investigated in COPD. Elevated NE levels have been demonstrated 
in the saliva of patients with periodontitis compared to healthy controls, although cigarette 
smoking appears to reduce salivary NE levels in patients with periodontitis (Pauletto et al., 
2000). A more recent study has also demonstrated a rise in salivary NE in subjects with chronic 
periodontitis (9.79ng/ml) compared to healthy subjects (1.35ng/ml) (Nizam et al., 2014). 
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1.10. Thesis Hypothesis and Objectives  
COPD is a common chronic progressive illness, the 2nd leading cause of chronic disability and 
currently ranks 3rd in global mortality rankings (Lozano et al., 2012). Exacerbations are a 
major feature of the disease process. These acute, as yet unpredictable episodes, severely and 
progressively impair the lung function and quality of life of COPD patients, leading to inability 
to work and unscheduled visits to secondary care. COPD exacerbations remain the second most 
common cause of emergency hospital admissions; with 1 in 3 of discharged patients being re-
admitted within 3 months. Thus exacerbations are important events in a COPD patient’s 
journey and are duly recognised in national and international COPD management guidelines 
(GOLD, 2016, NICE, 2010). Early diagnosis and treatment of COPD exacerbations can reduce 
their severity and limit the associated lung damage, yet often treatment is delayed because early 
“worsening of symptoms” goes unrecognised by COPD patients.  Specifically, as COPD 
symptoms can vary from day to day, patients have no means of judging the significance of such 
changes and so exacerbations remain unreported and untreated (Langsetmo et al., 2008). 
Therefore, there remains an unmet need to identify COPD exacerbations earlier ideally as part 
of proactive self-management initiatives so that prompt treatment can be initiated. This would 
improve COPD outcome as early intervention has been shown to halt COPD deterioration and 
prevent hospitalisation (Wilkinson et al., 2004).   
 
There is still no consistent test for practical COPD self-monitoring. With ever-increasing 
emphasis on the potential of inflammatory biomarkers (Thomsen et al., 2013) in enabling 
personalised disease monitoring and treatment (Agusti, 2014) and the merits of saliva as a 
plausible POC test medium, the overall ambition of my thesis is to establish a standardised and 
practical protocol for saliva self-sampling and quantitative reproducibility of a panel of three 
COPD-related biomarkers: CRP, PCT and NE in saliva. However, any clinical usefulness of 
Chapter 1:  Introduction 
77 
these biomarkers for portrayal of individual COPD status and early exacerbation alerts will 
require correlation with patient-defined events. Accordingly, this thesis will also develop and 
explore PRO, their reliability and relationship with the above-mentioned salivary target 
biomarkers.  
 
To address these concepts, the studies in this thesis will: 
 
 Determine the “best” type of saliva sample for near-patient testing. 
 Determine the factors required for near-patient sampling of saliva and the develop bespoke 
end-user sampling protocols. 
 Optimise and modify conventional assays to identify whether the target salivary biomarkers 
can be reproducibly quantified. 
 Determine the effects of blood contamination in saliva on target biomarker levels. 
 Create a simple COPD-PRO score and bespoke instruments to capture this score. 
 Correlate PRO data to salivary biomarker levels and spirometric volumes and develop a 
multidimensional health status score. 
 
The results of these experiments will provide the foundation for two community-based clinical 
studies, the objectives of which are:  
 
1. To evaluate whether target biomarker levels in saliva differentiate between health and 
COPD states.  
2. To establish whether the selected panel of salivary biomarkers can be used to longitudinally 
monitor COPD and identify onset of exacerbations.  
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These studies are crucial, as they will be the first to establish the role of salivary biomarkers 
and a novel PRO instrument in COPD, their ability to predict acute exacerbations and the 
relationship with PRO. Additionally, the longitudinal study will allow the identification of 
stable and exacerbation phenotypes. Furthermore, all work will be underpinned by qualitative 
studies utilising focus groups of patients with COPD as “experts by experience” to understand 
for self-management issues as well as determine end-user validity of saliva sampling and the 
PRO instrument. As management of long term chronic diseases is shifting towards community-
based personalised patient monitoring guided by subjective and objective measurements of 
health, outputs from my thesis could provide the necessary proof-of-concept required to drive 
development of novel POC bio-clinical tools for practical COPD surveillance.  
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2.1. Introduction 
Presently within COPD there are no studies, which demonstrate that random sampling of saliva 
provides accurate, reproducible data that can be used to monitor disease status (Chapter 1, Page 
63). This thesis will evaluate whether there is a role for saliva as a viable medium for the 
measurement of COPD-related target biomarkers, to determine clinical status and to enable 
prediction of acute exacerbations. However this will first require a standardisation of the 
methods for sampling, collection and processing of saliva to minimise confounding factors and 
possible contamination and to ensure optimal quality information (Chapter 1, Page 50). 
Presently, only CRP has a commercially available saliva based assay; albeit calibrated in 
healthy subjects, whilst PCT and NE will require modification of non-saliva based assays. 
Additionally, in recognition that biomarkers in isolation are not sensitive or specific enough to 
monitor COPD disease state without symptom assessment (Hurst et al., 2006). As discussed in 
Chapter 1, page 27 symptoms or PRO are now being recognised as important in the 
management of COPD with a variety of different instruments having been developed. However 
there remains an unmet need to develop a simple, effective PRO that can be possibly used as a 
daily diary within self-management protocols. In this thesis a novel PRO composed of 
clinically relevant COPD metrics was developed and incorporated into a purposeful diary for 
patient evaluation.  
 
2.1.1. Saliva 
As discussed in Chapter 1, Page 47, saliva is not just a passive “ultra-filtrate” of serum 
(Williamson et al., 2012), but a complex multi-factorial body fluid that is derived from 
numerous “salivary” glands located in and around the mouth. The argument for collection of 
whole unfractionated saliva for biomarker analysis in this thesis has been made (Chapter 1, 
Page 51), with specific consideration to what type of whole saliva to obtain (Chapter 1, Page 
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53). Unstimulated whole saliva via passive drool appears to be the more acceptable approach 
and thus will be the chosen method for saliva sampling throughout this thesis. Next 
consideration was given to a collection device for saliva sample deposition and subsequent 
storage of the said sample. 
 
2.1.2. Saliva collection devices 
A wide variety of commercially available saliva collection devices exist both for unstimulated 
and stimulated whole saliva. Saliva samples post production and deposition, are then shipped 
to the respective manufacturer’s laboratory for target analyte (protein, RNA or DNA) 
quantification. Unstimulated whole saliva via passive drool who the chosen method for saliva 
sampling. A review of commercially available containers that would aid this approach was 
undertaken.  
 
SalivaBio (Salimetrics, USA) has both a bespoke saliva collection aid and sample storage 
container (cryovial) for unstimulated whole saliva samples collected via passive drool. Saliva 
is channelled into the storage cryovial using the bespoke saliva collection aid which is placed 
into a user’s mouth and slots onto the top of the cryovial; thus forming a continuous pathway 
for saliva to flow from the user's mouth into the cryovial (Figure. 2.1). 
 
UltraSAL-2 (Oasis Diagnostics, USA) provides a product for the collection of unstimulated 
whole saliva via passive drool. This collector consists of two plastic pre-marked vestibules 
attached to a mouth piece (which acts as a saliva collection aid) and is designed to channel 
saliva into the vestibules (Figure. 2.2). 
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Figure 2.1: SalivaBio (Salimetrics, USA) passive drool collection device. 
A = collection aid; B = sample storage container (cryovial).  
 
 
Figure 2.2: UltraSal-2 passive drool saliva collection device. 
A = collection aid; B = sample storage container 
  
A 
A 
B 
B 
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A whole host of home saliva collector systems have been developed for genetic analysis of 
DNA and/or RNA, for example: Salivagene (Stratec Biomedical AG, Germany), Isohelix (Cell 
Projects, UK), Oragene (DNAgenotek, Canada), Saliva DNA Collection, Preservation, & 
Isolation (Norgen, Canada) and DNAgard (Biomatrica, USA). Saliva samples are retrieved by 
passive drool, spitting or stimulation. All samples are combined with a stabilisation buffer and 
shipped to the respective company’s laboratory. These devices merely provide a container for 
the deposition of saliva with no additional collection aid to help the passage of passive drool 
into a collector. 
 
Overall the wide array of collectors for unstimulated whole saliva via passive drool essentially 
function as a standard collection tube. Although both the SalivaBio kit (Salimetrics, USA) and 
UltraSAL-2 (Oasis Diagnostics, USA) provide a collection aid to channel saliva into a 
collector, the size of the cryovial (width: 10mm by length: 46mm) in the SalivaBio kit 
(Salimetrics, USA) was not felt to be ideal for COPD patients who would find difficultly in 
handling the vial either because of tremor (iatrogenic or caused from commonly prescribed 
treatments such as salbutamol (Committee, 2015)), and/or co-existing co-morbidities that 
affect grip, for example, osteoarthritis. In respects of both the SalivaBio (Salimetrics, USA) 
and UltraSAL-2 (Oasis Diagnostics, USA) it is unclear as to whether the insertion of a 
collection aid into the mouth and the pursing of lips around this aid would of itself actually 
stimulate saliva. Thus for collection of saliva samples in this thesis a standard 15ml centrifuge 
tube (Nunc, Denmark) was utilised. Target marked at 2mls (Figure 2.3) with a length of 120mm 
and an apex diameter of 15mm; hereon known as the saliva collector. 
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Figure 2.3: A marked 15ml centrifuge tube (Nunc, Denmark). 
 
This collector would reduce saliva sample handing prior to biomarker analysis as centrifugation 
of saliva (a pre-requisite in the methodology of salivary biomarker analysis) could be 
performed without the need to transfer the saliva into another container. In addition this 
collector provided an acceptable grip for COPD patients and was pre-marked to enable all 
subjects to be directed to the volume of saliva required; a collection aid device to facilitate 
saliva transfer was not provided. Finally, consideration was given to storage of the produced 
saliva sample. 
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2.1.3. Saliva storage 
In Chapter 1, page 50 it is discussed that saliva sample proteins degrade at room temperature 
on sampling. Thus for saliva that is not analysed immediately post sampling these samples will 
need to be maintained at 4oC (Esser et al., 2008) and long term stored as soon as possible 
(within 4 hours) post collection at -80oC (-20oC storage still results in protein degradation after 
6 months) prior to biomarker analysis (Schipper et al., 2007). Thus to incorporate these factors, 
all saliva samples were to be passively drooled by patients into an ice-cooled marked 15ml 
centrifuge tube (Nunc, Denmark) and transported on ice for storage until use in a -80oC freezer 
Guy Hilton Research Centre Freezer Room (Keele University, UK) within 2 hours of 
collection. 
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2.2. Statistical analysis 
Statistical analyses were performed using IBM SPSS Statistics Version 21 (IBM, USA) unless 
specifically stated. All data were processed using Microsoft Excel (Microsoft, USA). 
Parametric data are expressed as mean ± standard deviation (SD) while non-parametric as 
median, inter-quartile range (IQR). Non-parametric data where highlighted are logarithmically 
(base 10) transformed to allow for univariate analyses or other statistical techniques. Saliva 
samples for each biomarker that test below the lower limit of assay quantification (negative) 
will be assigned with the next number below and not zero for data analysis. Thus for salivary 
CRP concentrations below the lower limit of assay quantification (0.10ng/ml) were assigned 
as 0.09ng/ml for mathematical purposes; salivary PCT levels below the lower limit of assay 
quantification detection (0.10ng/ml) were assigned as 0.09ng/ml; salivary NE levels below the 
lower limit of assay quantification (2.2ng/ml) were assigned as (2.1ng/ml). This approach will 
enhance statistical accuracy and not result in a downward bias for the negative data (Muir K, 
2004).  A Wilcoxon signed-rank test was used to compare non-parametric paired data across 2 
groups. A paired t-test was used to compare parametric data across 2 groups. A repeated 
measures ANOVA is used to compare parametric data repeated in the same sample or 
individual more than twice. A Greenhouse-Geisser correction was applied to correct against 
violations of sphericity where it arose for the repeated measures analysis of variance 
(ANOVA). Friedman’s test was used to compare non parametric data repeated in the same 
sample or individual more than twice. Spearman’s rank correlation co-efficient was used to 
correlate parametric data and a Pearson’s test was used to correlate non-parametric data. A 
percentage CV was calculated for each sample by finding the standard deviation of results 1 
and 2 for that sample (if tested in duplicate). This result would be divided by the mean of result 
1 and 2 for that sample and multiplied by 100. Thus if 40 samples are analysed on 1 assay plate 
or kit a CV will be generated for each of the 40 samples. The intra-assay CV is then calculated 
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by the mean of all individual sample CVs (in this example 40 samples) tested on that plate or 
kit. An inter assay CV is calculated by first calculating a CV for the high and low controls 
tested on each assay or kit and then calculating the mean CV for each control sample CV across 
all individual assays or kits that are used. A p-value of less than 0.05 was considered 
statistically significant. A Bonferroni correction ($) was also applied to reduce the incidence 
of a Type 1 statistical error, which can occur when undertaking multiple comparison testing 
(Benjamini and Hochberg, 1995). 
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2.3. Patient recruitment 
All subjects who provided saliva samples in this thesis had to meet certain inclusion criteria 
for entry into one of 3 cohorts. Healthy never-smokers, healthy smokers and COPD. Healthy 
individuals were only accepted if they were never smokers and had no known co-morbidities, 
healthy smokers were only accepted if they had no known co-morbidities and a minimum 20 
pack year (a pack year is defined as smoking 20 cigarettes per day for 1 year) smoking history 
and COPD patients were only accepted if they had previously confirmed COPD on spirometry 
(Chapter 1, Page 21) according to the GOLD criteria and a minimum of 20 pack year smoking 
history. All COPD subjects were recruited independent of disease severity and co-morbidities, 
if any had to be stable prior to enrolment. Subjects in all 3 cohorts also had to be free of active 
infection at the point of recruitment. These individuals were recruited from known healthy 
volunteers, members of pulmonary rehabilitation groups in the Stoke-on-Trent area, UNHM 
outpatient department clinics and UHNM research groups. All demographic data was inputted 
into an appropriately secure database herein referred to as the Directorate of Respiratory 
Medicine's (University Hospital of North Midlands NHS Trust) research and outpatient clinic 
database. Demographic data, allocation of these individuals to the various experiments/studies 
in this thesis, and ethics approval numbers are described in Table 2.1, Page 89. All subjects 
were sent an information sheet and were subsequently invited to take part in the studies for this 
thesis and provided informed written consent. 
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Table 2.1. Thesis subjects’ demographics and allocation.  
Demographics 
Ethics 
Approval 
Healthy 
Non-Smokers 
(n = 28) 
Healthy 
Smokers 
(n = 32) 
COPD 
 
(n = 158) 
Age, a years  43.4 ± 18.2 40.0 ± 12.9 67.7 ± 7.9 
Gender, Male, 
(Female), n 
 9,19 20, 12 27, (28) 
BMI, a(kg/m2)  24.7 ± 6.1 25.2 ± 3.3 26.4 ± 6.3 
GOLD Stage  n/a n/a 
I: 23, II: 56, 
III: 58, IV: 16 
Chapter 2 09/H1203/77 
Randomly 
selected: 
multiple 
experiments 
Randomly 
selected: 
multiple 
experiments 
Randomly 
selected: 
multiple 
experiments 
Chapter 3 09/H1203/77 
Consecutively 
selected 
(n = 20) 
Consecutively 
selected 
(n = 25) 
Consecutively 
selected 
(n = 98) 
Chapter 4 12/NW/0623 n/a n/a 
Consecutively 
selected. 
No overlap with 
Chapter 3 
population 
(n = 60) 
Chapter 5 12/NW/0623 n/a n/a 
Randomly 
selected. 
Chapter 4 
population 
(n = 10) 
Chapter 6 
09/H1203/77 
& 
12/NW/0623 
Randomly 
selected: 
multiple 
experiments 
n/a 
Randomly 
selected: 
multiple 
experiments 
 
a = mean ± SD.  
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2.4. Optimisation of biomarker assays for saliva analysis 
Of the three target analytes being studied in this thesis only CRP has a commercially available 
kit for detection in saliva. Measurement of PCT and NE require the adaptation of conventional 
kits that have previously been validated on other biological fluids for example: blood (serum 
and or plasma), urine and sputum. 
 
2.4.1. Pre-analytical factors 
As discussed there are multiple factors to consider when undertaking saliva analysis. Collection 
and storage of saliva has been standardised with unstimulated whole saliva collected via 
passive drool (Chapter 1, Page 53) into ice-cooled centrifuge tubes (Section 2.1.2, Page 84). 
The transport of said sample for long-term storage at -80oC (Section 2.1.3, Page 85) unless 
immediate analysis is to occur with a transport time of no greater than 2 hours. Samples that 
required thawing were left to thaw at ambient room temperature. This protocol ensures that 
each saliva sample produced will be handled in the same way prior to biomarker analysis. All 
saliva samples would be tested in duplicate. 
 
2.4.2. Immunoassay factors 
Validation of the immunoassays will involve experiments to understand: 
1. Precision: The reproducibility of results within (intra) and between (inter) assays. This will 
be assessed by co-efficient of variation (CV). Published acceptable levels for 
immunoassays are an intra-assay CV of less than 10% and an inter-assay CV of less than 
15%. (Reed et al., 2002). These values served to act as a baseline minimum CV whilst 
conducting the initial experiments for the 3 immunoassays. They would be reconsidered as 
acceptable CVs if during the clinical studies described in Chapter 3, Page 213; Chapter 4, 
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Page 251, clinically significant differences in biomarker levels were noted at values less 
than 10%. 
2. Accuracy: This will be assessed via spike-and-recovery (spiking of unadulterated samples 
with fixed concentrations of all three biomarkers) and linearity-of-dilution experiments 
(effects of dilution on biomarker levels). 
3. Limit of detection: These will initially be based upon the limits documented in the kit insert 
for each immunoassay and further defined based on the optimal saliva dilution factor 
selected for each assay. 
 
2.4.2.1. Measurement of salivary C-Reactive Protein (CRP) levels 
To quantify salivary CRP levels in this thesis the Salivary CRP ELISA kit (Salimetrics, United 
States of America (USA)) was used; this immunoassay is specifically designed and validated 
for the quantification of salivary CRP. It is important to note however, that this ELISA is not 
intended for diagnostic use at the moment and is classified “for research use” in humans.  
 
Immunoassays can be classified either as “research use only” or “for diagnostic use”. The 
difference in the two classifications means that “research use only” assays are not able to 
represent an effective in-vitro diagnostic product, and manufacturers cannot make performance 
claims or give reference values; thus it is recommended when using “research use only” 
immunoassays that each researcher establishes their own reference range, standard curves, 
control levels and assay result reproducibility (Burd, 2010). 
 
Each kit consists of a 96 well microtitre plate coated with mouse anti-human CRP antibodies, 
lyophilised CRP standard: 3000pg/ml (reconstituted in 1ml of distilled (d)H2O), lyophilised 
CRP controls: low and high (reconstituted with 500ul of dH20), CRP antibody-enzyme 
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conjugate, CRP sample diluent, CRP assay diluent, ELISA wash buffer concentrate (diluted 
1:10 with dH20), Tetramethylbenzidine (TMB) substrate, 2-molar (M) sulfuric acid stop 
solution and an adhesive plate cover (Figure 2.4). Pre-analysis saliva samples need to be 
vortexed and centrifuged at 3000 revolutions-per-minute (rpm) for 15 minutes, then diluted 
(1:10) in the CRP sample diluent provided by the manufacturer. Sample dilution reduces the 
concentration of CRP into the working assay range: 0.01 to 3ng/ml. Thus at a 1:10 dilution the 
quantifiable salivary CRP range is 0.10 to 30ng/ml. For any sample above the upper limit of 
quantification for the ELISA, the manufacturer recommends dilution at a higher denominator; 
this theoretically means that the kit has no upper limit of quantification for CRP if the 
appropriate dilution is incorporated.  
 
 
Figure 2.4: Salivary CRP ELISA kit (Salimetrics, USA). 
This figure displays the entire kit: A = microtitre plate; in front of this and from left to right: 
Wash buffer concentrate, assay diluent, TMB substrate solution, 2M Stop solution, Sample 
diluent, CRP antibody conjugate, CRP standard 3000pg/ml, CRP High Control, CRP Low 
control. 
 
A 
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To perform an assay 50ul of diluted saliva, standards and controls are added to the wells in 
duplicate; thus 39 saliva samples can be tested in duplicate per microtitre plate (Table 2.2). 
Next 150ul of diluted CRP antibody-enzyme conjugate; (80ul of antibody-enzyme conjugate 
diluted 1:250 in 20mls of CRP assay diluent) is immediately added to each well using a 
multichannel pipette (VWR, USA). The microtitre plate is then covered and incubated at room 
temperature (20 to 23.3oC) for two hours on a shaker horizontal plate mixer (Medigenix 
Diagnostics, Germany) at 500rpm. The microtitre plate is subsequently washed and 200ul of 
TMB substrate is added to each well, after which there is a further incubation in the dark 
(achieved by enveloping the microtitre plate in aluminum foil (Wrap Film Systems, UK)) for 
30 minutes on the horizontal plate mixer at 500rpm. Finally, 50ul of 2M sulfuric acid stop 
solution is added turning the TMB yellow; the microtitre plate is placed on the horizontal mixer 
at 500rpm for a further three minutes or until all the wells have turned yellow. The microtitre 
plate is read (within 10 minutes) on a BioTek Synergy 2 ELISA plate reader (BioTek, USA) at 
450nm and 620nm; the latter is used as a secondary filter correction to eliminate absorption 
from the microtitre plate. Total analysis time including sample preparation is approximately 
four hours. 
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Table 2.2. Generic salivary CRP ELISA plate layout. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
3000 
pg/ml 
3000 
pg/ml 
Low 
Control 
Low 
Control 
S8 S8 S16 S16 S24 S24 S32 S32 
B 
1500 
pg/ml 
1500 
pg/ml 
S1 S1 S9 S9 S17 S17 S25 S25 S33 S33 
C 
750 
pg/ml 
750 
pg/ml 
S2 S2 S10 S10 S18 S18 S26 S26 S34 S34 
D 
375 
pg/ml 
375 
pg/ml 
S3 S3 S11 S11 S19 S19 S27 S27 S35 S35 
E 
187.5 
pg/ml 
187.5 
pg/ml 
S4 S4 S12 S12 S20 S20 S28 S28 S36 S36 
F 
93.75 
pg/ml 
93.75 
pg/ml 
S5 S5 S13 S13 S21 S21 S29 S29 S37 S37 
G 
0 
pg/ml 
0 
pg/ml 
S6 S6 S14 S14 S22 S22 S30 S30 S38 S38 
H 
High 
Control 
High 
Control 
S7 S7 S15 S15 S23 S23 S31 S31 S39 S39 
 
S = sample 
 
To calculate the levels of sample salivary CRP, a standard “curve” is created by plotting the 
standard concentrations against the corresponding average optical densities (Figure 2.5). This 
standard “curve” is generated via the equation: “𝑦 = 𝑚𝑥 + 𝑐” where “y” is the optical density, 
“𝑥” is the salivary CRP level; “𝑚” is the slope of the fitted line and “𝑐” is the intercept of the 
“𝑦” axis. Thus a sample of saliva processed on this ELISA generating an optical density of “𝑦” 
would have a salivary CRP concentration of: “𝑥 = 𝑎(
𝑦−𝑐
𝑚
)”, where “a” represents the dilution 
factor of the saliva sample. 
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Figure 2.5: Typical CRP “line-of-best-fit” for a salivary CRP ELISA. 
This scatter plot with line-of-best-fit represent each fixed concentration standard (3000, 1500, 
750, 375, 187.5, 93.75, 0pg/ml) plotted against its corresponding optical density generated by 
aliquoting 50ul of lyophilised standard onto an ELISA microtitre plate and then performing the 
ELISA. The completed microtitre plate is then read on a plate reader generating an optical 
density for the fixed concentration standards. A line-of-best-fit is then placed through these 
values to generate an equation. In this example an equation for the line-of-best-fit: y = 0.0002x 
+ 0.1042. This equation can be used to calculate CRP levels (x) in saliva samples with an 
unknown concentration but a known optical density (y). The r2 value (99% in this example) 
represents the accuracy of the line-of-best-fit equation.  
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2.4.2.2. Salivary CRP ELISA calibration experiments in COPD saliva samples. 
The manufacturer reports the Salivary CRP ELISA kit (Salimetrics, USA) performance 
characteristics in a manual (supplied as a kit insert) with a set of spiked CRP recovery and 
dilution experiments performed on the saliva of healthy subjects aged between 20 to 55 years. 
As the Salivary CRP ELISA (Salimetrics, USA) is classified as “research use only”, the 
recovery and dilution experiments reported by the manufacturer in the Salivary CRP ELISA 
kit (Salimetrics, USA) manual were replicated to establish standard curves, control levels and 
reproducibility in saliva of COPD patients, who invariably are outside the above targeted age 
range of the immunoassay. 
 
2.4.2.3. Aim 
1. To determine the intra-assay precision.  
2. To ascertain whether the recovery of CRP in COPD patients’ saliva spiked with a fixed 
concentration of CRP (provided as part of the ELISA kit control) is consistent and 
comparable to healthy human saliva. 
3. To ascertain the matrix effect of saliva on the recovery of endogenous CRP in five different 
(linear) dilutions of COPD patients’ saliva. 
4. To assign a limit of detection based on a selected saliva dilution. 
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2.4.2.4. Methods 
Six COPD patients (Table 2.3) recruited from the Directorate of Respiratory Medicine's 
research and outpatient clinic database (Section 2.3, Page 88) in the stable phase of their disease 
were randomly selected, gave informed written consent (Figure 2.21, Page 176) and provided 
six individual 2ml unstimulated whole saliva samples via passive drool into ice-cooled 
collectors (Nunc, Denmark).  
 
Table 2.3: COPD patient demographics. 
Demographics 
COPD Patients 
 (n = 6) 
Age, a years 71.7 ± 9.8 
Gender, Male, (Female), n 2 (4) 
*Smoking Status, Current (Ex), n 0 (6) 
Duration of COPD, a years 4.3 ± 1.2 
FEV1, a % predicted 39.7 ± 18.8 
FVC, a % predicted 65.1 ± 9.2 
BMI, a (kg/m2) 26.5 ± 4.3 
Exacerbations in the last 6 weeks, an 0 
Exacerbations in the last 1 year, an 4 ± 2 
Co–morbidities, n  
None 2 
Cardiovascular 0 
Type 2 Diabetes Mellitus 0 
Hypertension 4 
Gum Disease 0 
Other 2 
COPD Treatment, n  
Inhaled β2 agonists, Short Acting, (Long Acting) 6, (6) 
Nebulised β2 agonists (Short Acting) 0 
Inhaled Anti-cholinergic, Short Acting, (Long Acting) 2, (2) 
Nebulised Anti-cholinergic (Short Acting) 0 
Inhaled Steroid 6 
Oral Theophylline 2 
 
*All COPD patients had a greater than 20-year smoking pack year history. Data are presented 
as: a = mean ± SD; n = total number; SD = standard deviation. 
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Each sample was transported on ice to be stored at -80oC in the Guy Hilton Research Centre 
Freezer Room (Keele University, UK). Prior to analysis samples were thawed at ambient room 
temperature; vortexed and subsequently centrifuged at 3000rpm for 15 minutes prior to 
analysis. Saliva samples were stored for no longer than 1 week prior to biomarker analysis. 
The recovery experiment was performed by spiking 1:10 diluted saliva samples with three 
different concentrations of CRP: 50, 200 and 1000pg/ml respectively (Table 2.4). Saliva was 
spiked with the 3000pg/ml standard supplied in the Salivary CRP ELISA kit (Salimetrics, 
USA). These saliva dilution factors and spiking concentrations of CRP were selected as they 
were identical to the experimental protocol provided in the Salivary CRP ELISA kit 
(Salimetrics, USA) manual. The linear dilution experiment was performed in unadulterated 
saliva samples analysed at five different dilutions (1:2, 1:4, 1:8, 1:10 and 1:16) (Table 2.5). All 
samples were tested in duplicate and only one microtitre plate was required to perform both 
experiments; the ELISA microtitre plate layout is summarised in Table 2.6. 
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Table 2.4: Saliva spiking experiment protocol. 
 
* Standard A = Supplied lyophilised in the Salivary CRP ELISA kit (Salimetrics, USA). 
** Standard B = 50ul of Standard A combined with 100ul of CRP sample diluent. 
*** Standard C = 50ul of Standard B combined with 150ul of CRP sample diluent. 
 
Table 2.5: Saliva dilution experimental protocol. 
 Reagent/ Sample Volume (ul)  
Target 
Saliva 
dilution 
Neat 
Saliva 
CRP 
Sample 
Diluent 
1:2 
diluted 
neat 
saliva 
1:4 
diluted 
neat 
saliva 
1:8 
diluted 
neat 
saliva 
1:16 
diluted 
neat 
saliva 
Total Volume 
1:2 150ul 150ul     300ul 
1:4  150ul 150ul    300ul 
1:8  150ul  150ul   300ul 
1:10 15ul 135ul   150ul  300ul 
1:16  150ul    150ul 300ul 
 
  
 Reagent/Sample Volume (ul) 
Total 
Volume 
Target Spiked 
Concentration 
Neat 
Saliva 
CRP 
Sample 
Diluent 
*3000pg/ml 
Standard A 
**1000pg/ml 
Standard B 
***250pg/ml 
Standard C 
 
1000pg/ml 15ul 85ul 50ul   150ul 
200pg/ml 15ul 105ul  30ul  150ul 
50pg/ml 15ul 105ul   30ul 150ul 
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Table 2.6: The dilution and recovery experiment protocol for each COPD patients' 
sample of saliva. 
COPD Patients (1 - 6) 
Patient 1 
Saliva Sample 
1 
Patient 2 
Saliva Sample 
2 
Patient 3 
Saliva Sample 
3 
Patient 4 
Saliva Sample 
4 
Patient 5 
Saliva Sample 
5 
Patient 6 
Saliva Sample 
6 
Sample 1 
1:2 dilution 
Sample 2  
1:2 dilution 
Sample 3  
1:2 dilution 
Sample 4 
1:2 dilution 
Sample 5 
1:2 dilution 
Sample 6  
1:2 dilution 
Sample 1 
1:4 dilution 
Sample 2 
1:4 dilution 
Sample 3 
1:4 dilution 
Sample 4 
1:4 dilution 
Sample 5 
1:4 dilution 
Sample 6 
1:4 dilution 
Sample 1 
1:8 dilution 
Sample 2 
1:8 dilution 
Sample 3 
1:8 dilution 
Sample 4 
1:8 dilution 
Sample 5 
1:8 dilution 
Sample 6 
1:8 dilution 
Sample 1 
1:10 dilution 
Sample 2 
1:10 dilution 
Sample 3 
1:10 dilution 
Sample 4 
1:10 dilution 
Sample 5 
1:10 dilution 
Sample 6 
1:10 dilution 
Sample 1  
1:10 dilution 
1000pg/ml 
spike  
Sample 2 
1:10 dilution 
200pg/ml spike 
Sample 3 
1:10 dilution 
50pg/ml spike 
Sample 4  
1:10 dilution 
1000pg/ml 
spike  
Sample 5 
1:10 dilution 
200pg/ml spike 
Sample 6 
1:10 dilution 
50pg/ml spike 
Sample 1 
1:16 dilution 
Sample 2  
1:16 dilution  
Sample 3 
1:16 dilution  
Sample 4 
1:16 dilution 
Sample 5  
1:16 dilution  
Sample 6 
1:16 dilution  
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2.4.2.5. Statistical analysis 
The statistical tests employed are discussed in Section 2.2, Page 86. Specifically, for the 
recovery experiment a recovery percentage was calculated using the formula: 
“𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 =  100(𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝐶𝑅𝑃 𝑙𝑒𝑣𝑒𝑙 ÷ 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝐶𝑅𝑃 𝑙𝑒𝑣𝑒𝑙)”. For the 
dilution experiment a recovery percentage of CRP was calculated by assigning the 
unadulterated 1:10 diluted saliva sample's CRP level as 100% recovery: 
“𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 𝑝𝑒𝑟𝑐𝑒𝑡𝑎𝑔𝑒 = 100(𝑠𝑎𝑙𝑖𝑣𝑎 𝐶𝑅𝑃 𝑙𝑒𝑣𝑒𝑙 ÷ 𝑠𝑎𝑙𝑖𝑣𝑎 𝐶𝑅𝑃 𝑙𝑒𝑣𝑒𝑙 (1: 10) 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛)”  
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2.4.2.6. Results 
2.4.2.6.1. Precision 
The intra-assay CV for the microtitre plate was 5.6% an inter-assay CV could not be calculated 
as only one microtitre plate was used. 
 
2.4.2.6.2. Recovery: salivary CRP in spiked saliva sample experiment 
Accounting for the small sample size there was no significant difference in the levels of salivary 
CRP in the observed spiked COPD samples compared to the expected spiked COPD samples 
(p=0.248 by Wilcoxon Signed Rank Test). The recovery percentage of CRP for the spiked 
COPD saliva samples was greater than 90% (117 ± 26%) for all patients (Table 2.7). The 
recovery is greater than 100% at the lower spiked concentrations (samples 3, 5 & 6). The 
difference in recovery percentage of CRP (across all concentrations) between the COPD and 
healthy population saliva was not statistically significant (p=0.154 by paired t-test); thus sub-
analysis between the three individual concentrations cannot be performed (Figure 2.8).  
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Table 2.7: Salivary CRP levels and recovery across increasing spiked concentrations. 
Saliva 
Sample 
Endogenous 
CRP 
(pg/ml) 
Added  
Fixed 
Concentration 
CRP 
(pg/ml) 
Expected 
CRP 
(pg/ml) 
Observed 
CRP 
(pg/ml) 
Recovery 
(%) 
1 
268 
1554.63 
1000 
1000 
1268 
2544.63 
1228 
2685.88 
97% 
105.6% 
2 
516 
1463.34 
200 
200 
716 
1663.34 
661 
1523.24 
92% 
91.6% 
3 
93 
1463.34 
50 
50 
143 
1513.34 
166 
1389.34 
116% 
91.8% 
4 
205 
1266.43 
1000 
1000 
1205 
2266.43 
1303 
2423.10 
108% 
106.9% 
5 
348 
1199.78 
200 
200 
516 
1399.78 
678 
1352.03 
124% 
96.6% 
6 
163 
1299.76 
50 
50 
213 
1349.76 
348 
1326.27 
163% 
100.9% 
 
234, 155 
1381.55, 
188.80 
 
616, 794 
1588.34, 
687.49 
670, 664 
1456.29, 
836.78 
117 ± 
26% 
99 ± 7% 
 
CRP levels (pg/ml) are expressed as median, IQR; percentage recovery as mean ± SD. As 
saliva samples were tested in duplicate each value in black represents a mean of the duplicates. 
The data in red is the manufacturer’s quoted figures for their recovery experiments published 
in the Salivary CRP ELISA kit (Salimetrics, USA) manual on saliva of healthy individuals 
aged 20 to 55 (Appendix 2, Page 488). This manual doesn’t state whether samples were tested 
singularly, in duplicate or in triplicate. 
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Figure 2.6:  Salivary CRP recovery with increasing CRP concentrations. 
Bar chart representing mean salivary CRP percentage recovery at increasing spiked 
concentrations (50, 200, 1000pg/ml) with error bars ± SD (n = 2 per CRP concentration). The 
dark grey bars represent COPD saliva the white bars healthy subjects’ saliva data presented in 
the Salivary CRP ELISA kit (Salimetrics, USA) manual (Appendix 2, Page 488). There is no 
statistically significant difference in recovery between the two groups (ns: p=0.154) thus post-
hoc analysis between the individual concentrations cannot be performed. ns = no significance. 
 
Overall there is no significant difference in CRP percentage recovery and actual concentration 
of salivary CRP in spiked saliva samples between COPD patients and healthy subjects’ saliva 
at a 1:10 saliva dilution. 
  
ns 
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2.4.2.6.3. Linear dilution: endogenous salivary CRP across increasing saliva dilutions 
The recovery of endogenous CRP (recovery was compared to the 1:10 dilution as this is 
manufacturer recommended) was analysed to understand the effects of saliva sample dilution. 
Overall percentage recovery of endogenous CRP significantly improved in unadulterated saliva 
samples as the dilution factor increases (p<0.025 by repeated measures ANOVA with a 
Greenhouse-Geisser correction) (Table 2.8). Post-hoc analysis only demonstrated a significant 
improvement in recovery from 1:2 to 1:8 (p<0.003($) by paired t-test) and 1:2 to 1:16 
(p<0.002($)) dilutions. Interestingly unlike the manufacturers sample dilution recovery 
experiments (Table 2.9, Page 108) recovery of salivary CRP at dilutions lower than 1:10 was 
reduced. It is important to note the small sample size however as the manufacturer only tested 
saliva sample dilution CRP recovery on two saliva samples. All COPD patients’ saliva samples 
demonstrated an improvement in salivary CRP recovery as the dilution factor increased up to 
1:8. This recovery improved at 1:16 dilution for all saliva samples except for sample 5 where 
CRP recovery fell markedly when the dilution increased from 1:8 to 1:16. A potential 
explanation could be attributable to the low endogenous CRP levels in the saliva sample; 
however a similar finding was not observed for saliva sample 6. Half the saliva samples at 1:16 
dilution demonstrated a “super” recovery (Figure 2.7, Page 106). It is not possible to compare 
the manufacturers dilution recovery data to the COPD patients’ salivary CRP recovery data 
due to the manufacturer’s small sample size (n = 2) in their healthy dilution experiments (Table 
2.9, Page 108).  
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Figure 2.7: Salivary CRP recovery across increasing dilution. 
Bar chart representing salivary CRP percentage recovery at increasing salivary dilution (1:2, 
1:4, 1:8, 1:16) with error bars ± SD (n = 6). Overall there is a significant improvement in 
recovery with an increased dilution (p<0.025 by repeated measures ANOVA with a 
Greenhouse-Geisser correction). Post-hoc analysis identified a significant improvement in 
CRP recovery from 1:2 to 1:8, (**p<0.003($) by paired t-test) and 1:2 to 1:16 (*p<0.002($)) 
dilution. 
  
** 
* 
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Table 2.8: Endogenous salivary CRP levels and recovery percentage at increasing 
dilutions. 
  Salivary CRP (pg/ml)  
 Saliva Sample Dilution 
Saliva 
Sample 
Observed CRP 
(1:10 dilution) 
1:2 1:4 1:8 1:16 
1 268 (100%) 219 (82%) 278 (104%) 404 (151%) 348 (130%) 
2 516 (100%) 184 (36%) 347 (67%) 352 (68%) 684 (130%) 
3 93 (100%) 15 (16%) 18 (20%) 70 (76%) 132 (143%) 
4 205 (100%) 91 (45%) 58 (28%) 146 (71%) 284 (139%) 
5 348 (100%) 87 (25%) 134 (43%) 218 (69%) 252 (73%) 
6 163 (100%) 64 (40%) 88 (54%) 140 (86%) 136 (84%) 
Recovery (%) 
mean ± SD 
100% ± 0% 40% ± 23% 52% ± 31% 86% ± 33% 117% ± 30% 
 
Salivary CRP levels are multiplied by the dilution factor to allow standardisation of the results. 
The figures in brackets represent CRP recovery percentage when compared to the 1:10 dilution 
CRP level which is assigned as 100% recovery. 
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Table 2.9: Manufacturer endogenous salivary CRP levels and recovery percentage at 
increasing dilutions. 
 Salivary CRP (pg/ml)  
Saliva Sample Dilution 
Saliva 
Sample 
Expected 
CRP 
1:2 1:4 1:8 1:16 
1 *1259.61 
(100%) 
1219.36 
(96.8%) 
1152.32 
(91.5%) 
1269.44 
(100.8%) 
1226.56 
(97.4%) 
2 *1627.90 
(100%) 
1577.64 
(96.9%) 
1461.96 
(89.8%) 
1569.12 
(96.4%) 
1623.52 
(99.7%) 
Recovery 
(%) 
mean ± SD 
100% ± 0% 97% ± 0.1% 91% ± 1% 99% ± 3% 99% ± 2% 
 
* The manufacturer does not state at what saliva dilution factor this value was obtained. These 
values were obtained from the Salivary CRP ELISA kit (Salimetrics, USA) manual (Appendix 
2, Page 488). The levels of quantified CRP were multiplied by the dilution factor to allow 
standardisation of the results. 
 
Overall an increased saliva dilution beyond 1:8 improves recovery of salivary CRP in 
unadulterated saliva samples. Lower percentage recoveries were demonstrated at 1:2 and 1:4 
saliva dilutions for all COPD patients’ saliva compared to their respective 1:8 and 1:16 dilution 
although the sample size is small. 
 
2.4.2.7. Discussion. 
The above experiments replicated the recovery and linear dilution experimental protocols 
provided in the manual accompanying every Salivary CRP ELISA kit (Salimetrics, USA). 
COPD saliva samples spiked with CRP demonstrate a consistent recovery. An enhanced 
recovery (greater than 100%) was noted in samples 3 and 6 both of which were spiked with 
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50pg/ml. This may potentially be explained by considering the working range of the 
immunoassay (0.01 to 3ng/ml). It is possible that the accuracy of the immunoassay is reduced 
when approaching the lower limit of this working range. Thus a low CRP spike for samples 
with low levels of endogenous CRP when diluted 1:10 will require the quantification of CRP 
at the lower limit of the working range (0.01 to 3ng/ml), which may have a higher variability.  
 
This hypothesis may also provide an explanation for why the manufacturer only recommends 
further dilution of saliva beyond 1:10 only if the levels of salivary CRP are above the higher 
limit of the immunoassay working range (that is above the higher limit of quantification); as 
opposed to setting a higher minimum dilation level. If we considered a saliva sample diluted at 
1:10, and which has a CRP level above the higher limit of quantification for the immunoassay, 
a further dilation (1:20) for this saliva sample would result in the diluted sample (1:20) 
containing 50% less endogenous CRP than (1:10) sample. However as the 1:10 dilution was 
above the higher limit of quantification this increased dilution would result in the saliva sample 
being quantified in the mid-high working range (1.5 to 3ng/ml) of the immunoassay. This 
argument may support the hypothesis that the immunoassay is more prone to errors in salivary 
CRP quantification when the diluted saliva sample is approaching the lower limit of the assay’s 
working range. This is further supported by the enhanced recovery of salivary CRP that is 
apparent in unadulterated saliva samples diluted 1:16. The reduced recovery at the lower 
dilutions (1:2, 1:4, 1:8) possibly demonstrates the matrix effect of saliva and supports the 
manufacturer's recommendation of a minimum sample dilution of 1:10 for saliva samples 
tested with this particular immunoassay.  
 
Interrogation of the manufacturer's experimental data (Table 2.7, Page 103) demonstrated that 
the median endogenous levels of CRP in the healthy saliva samples are higher than in the 
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COPD saliva samples used for these experiments. This would result in a positive bias for the 
recovery of spiked samples. For example, the manufacturer's quoted figures for sample 6 are 
below:  
*Saliva 
Sample 
Endogenous 
CRP 
(pg/ml) 
Added 
CRP 
(pg/ml) 
Expected 
CRP 
(pg/ml) 
Observed 
CRP 
(pg/ml) 
Recovery 
(%) 
6 1299.76 50 1349.76 1326.27 100.9% 
 
*extract from Table 2.7, Page 103. 
 
 This sample was spiked with 50pg/ml of CRP. However as the endogenous level is 
1299.76pg/ml a recovery percentage using this value alone as an observed value would be 98%. 
It should also be noted that healthy saliva samples 2 and 3 have the same concentration of 
endogenous CRP and are thus likely to be the same individual. It would be more prudent to 
spike saliva samples with absent or “low” levels of endogenous CRP to better understand the 
recovery of a fixed concentration of CRP and reduce the positive bias introduced by higher 
endogenous levels. 
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2.4.2.8. Overall conclusion 
The intra-assay precision (CV) of 5.6% was below the maximum (10%) accepted error 
percentage that had been selected. This will continue to be calculated for all salivary CRP 
ELISAs performed throughout this thesis to ensure that both the intra- and inter-assay CV’s 
remain below the accepted and clinical thresholds. The recovery of salivary CRP is greater than 
90% for all spiked samples of saliva. Serial dilution of unadulterated saliva samples appears to 
improve the recovery of endogenous CRP with the most significant improvement observed 
across 1:2 to 1:8 dilutions. A minimum dilution of 1:10 appears to be appropriate; however 
further dilutions cannot be recommended in samples that are not above the higher limit of the 
assay working range (0.01 to 3ng/ml). When salivary CRP levels are above the higher limit of 
the assay working range it appears that there is a large variability in recovery when using a 
dilution of 1:16. Thus the results from higher dilutions would be discarded if the salivary level 
falls below what would have been quantified at a 1:10 dilution. The minimum limit of detection 
will be 10pg/ml as quoted in the Salivary CRP ELISA kit (Salimetrics, USA) manual. 
 
Whilst understanding the above caveats, the Salivary CRP ELISA kit (Salimetrics, USA) will 
be used throughout this thesis for COPD salivary CRP quantification, maintaining the same 
pre-analysis sample preparation; duplicate sample testing; minimum sample dilution (1:10) and 
test procedure as recommended by the manufacturer. 
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2.4.3. Optimisation of a serum-based Procalcitonin (PCT) assay for use with saliva 
A variety of ELISAs are commercially available for the quantification of human PCT for 
example: RayBiotech, (USA), Abcam (UK) and Sigma-Aldrich (USA); these are all labelled 
for “research use only”. The different classifications have previously been described (Section 
2.4.2.1, Page 91) and an immunoassay classified “for diagnostic use” was selected for 
modification. It is assumed that as no saliva-based PCT assay is commercially available, the 
choice of a serum-based PCT assay classified “for diagnostic use” would be more robust for 
modification to saliva. 
 
The VIDAS B.R.A.H.M.S PCT (bioMérieux, France) is an automated “for diagnostic use” 
quantitative assay processed on the bench-top VIDAS instruments (bioMérieux, France) for 
the determination of human PCT in serum or plasma using an enzyme-linked fluorescent assay 
(ELFA). The analyser used in this thesis is the mini VIDAS (bioMérieux, France) which 
comprises two analytical sections containing 6 testing slots per section. Thus 12 samples can 
be processed in unison. The mini VIDAS requires a monthly calibration where a quality control 
(QCV) test strip is analysed by the machine in each of the 12 test slots. If any value on each of 
the 12 test strips fall outside of the range quoted on the QCV kit insert (provided by the 
manufacturer) the QCV needs to be analysed again for that entire section. If the QCV fails for 
a second time the mini VIDAS needs to be serviced by a BioMérieux engineer. As this 
immunoassay has to date not been applied to saliva, experiments were designed to modify its 
application to suit PCT measurement in saliva. 
 
The steps involved in measuring serum PCT using the above automated quantification are 
discussed. Each PCT kit is supplied with a master-lot-entry (MLE) card, 60 ready-to-use multi-
well test-strips, 60 solid phase receptacles (SPR) pre-coated with mouse anti-human PCT and 
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two sets of lyophilised standards (S1 and S2) and controls (C1: low range; C2: high range); 
both standards and controls are reconstituted with 2mls dH2O (Figure 2.8). The purpose of the 
MLE, standards and controls is to calibrate the mini VIDAS analyser for PCT quantification in 
serum or plasma samples. 
 
 
 
Figure 2.8: VIDAS B.R.A.H.M.S PCT kit (bioMérieux, France). 
S = standard, C = control vial, SPR = solid-phase receptacle, T = test-strip 
 
Calibration starts first with entry of the MLE card then six test-strips containing 200ul of both 
standards (S1 and S2: tested in duplicate) and 200ul of high range (C1) plus low range (C2) 
control reagents (tested singularly) as well as 6 SPRs are inserted into the mini VIDAS 
(bioMérieux, France). The machine is then programmed to analyse the samples. Total analysis 
time is 25 minutes after which a set of results is printed (these values are used to calculate the 
inter-assay CV). This printout is compared to the reference data on the MLE card with 
T 
S C 
SPR 
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agreement between the two indicating that the mini VIDAS has been successfully calibrated. 
Any disagreement between the two requires the calibration process to be repeated. If the repeat 
calibration process fails, then the machine requires servicing by an BioMérieux engineer. The 
printout from the calibration can be used to calculate an inter-assay CV to determine the 
precision of the machine. Calibration is required monthly or on the opening of a new kit with 
a different batch number to the previously calibrated kit. In total each kit can analyse 27 
samples in duplicate and 30 samples in duplicate if calibration is not required. All assay steps 
are performed internally within the mini VIDAS (bioMérieux, France) machine; results are 
calculated automatically from two standard calibration curves with the working assay range 
being 0.05 to 200ng/ml. Once calibrated for sample processing, each test-strip requires 200ul 
of sample; the test-strip and one SPR are then loaded into the mini VIDAS (bioMérieux, 
France) and the machine is programmed to analyse the sample.  Each assay takes approximately 
25 minutes. There are no established references to date regarding the use of the mini VIDAS 
(bioMérieux, France) system for processing of saliva samples. 
 
2.4.3.1. Optimisation of a serum PCT immunoassay 
To investigate whether the mini VIDAS (bioMérieux, France) could quantify PCT in saliva, 
experiments on the recovery of PCT in spiked saliva samples were conducted. The VIDAS 
B.R.A.H.M.S PCT (bioMérieux, France) kit does not contain a sample diluent as neat serum is 
analysed by the instrument. As saliva contains mucin, making it a viscous body fluid (Rantonen 
and Meurman, 1998), experiments were also conducted to investigate the effects of dilution on 
PCT recovery in saliva. The saliva diluent selected was Phosphate Buffer Saline - Tween 20 
0.05% (Sigma, USA). Phosphate Buffer Saline - Tween (PBS-T) has a (pH), which is similar 
to human physiology and thus prevents protein denaturation; it also acts as an antibody-antigen 
staining stabiliser. 
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2.4.3.2. Aims 
1. To determine the intra- and inter-assay precision. 
2. To determine the effects of PBS-T on the levels of a fixed concentration of PCT provided 
as part of the PCT kit control. 
3. To establish the matrix effect of saliva on the recovery of a fixed concentration of PCT 
provided as part of the PCT kit control; specifically, whether there is a difference in PCT 
recovery in saliva at low and high PCT ranges. 
4. To explore this matrix effect in neat human saliva and at three different linear dilutions of 
saliva. 
5. To assign a limit of detection based on a selected saliva dilution. 
 
2.4.3.3. Methods 
Ten healthy non-smokers and six healthy smokers (Table 2.10) were randomly selected from 
the Directorate of Respiratory Medicine's research and outpatient clinic database (Section 2.3, 
Page 88); gave informed written consent and provided 4mls of unstimulated whole saliva via 
passive drool (Figure 2.21, Page 176) into ice-cooled collector tubes. Saliva samples were then 
transported on ice and stored in the Guy Hilton Research Centre Freezer Room (Keele 
University, UK) at -80oC. Prior to analysis all saliva samples were thawed at room temperature. 
All saliva samples were stored for no longer than 1 week prior to biomarker testing. The 
VIDAS B.R.A.H.M.S PCT (bioMérieux, France) assay is validated for serum and no protocol 
exists for pre-analysis saliva sample preparation. The same methodology as for salivary CRP 
quantification (Section 2.4.2.1, Page 92) was utilised, with all saliva samples vortexed and 
subsequently centrifuged at 3000rpm for 15 minutes.  
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Table 2.10: Healthy subject demographics. 
 Healthy Subjects 
Demographics 
Non-smokers 
 (n = 10) 
Smokers 
(n = 6) 
Age, a years 30.9 ± 9.6  36.2 ± 13.8 
Gender, Male, (Female), n 4 (6) 3 (3) 
BMI, a (kg/m2) 23.2 ± 3.5  25.9 ± 2.9 
Co–morbidities, n   
None 10 6 
Total Number of Oral Medications, an 0 0 
 
*co-morbidities include the presence of gum disease. Data are presented as: a = mean ± SD. 
 
Each VIDAS B.R.A.H.M.S PCT kit (bioMérieux, France) provides two control reagents (C), 
C1: High Range (16 to 20ng/ml) and C2: Low Range (1.5 to 2.0ng/ml). Each saliva sample 
was assigned to an individual vial of the low and high range controls; thus 32 individual vials 
(16 low range and 16 high range) were used. These controls were then used to spike both PBS-
T and saliva.  
 
The first step involved reconstituting all control vials with 2mls of dH2O. PBS-T was then 
prepared by dissolving (1.44g Na2HPO4, 0.211g NaH2PO4, and 8g NaCl) pre-prepared pouch 
(Sigma, UK) in 1000 ml of dH20. Subsequently 200ul of both the low and high range PCT 
controls were aliquoted into separate eppendorfs and diluted (1:2) with 200ul of PBS-T.  The 
next step involved 200ul of both the neat low and high range control plus 200ul of the diluted 
low and high range control (1:2) aliquoted into test-strips and analysed in duplicate on the mini 
VIDAS (bioMérieux, France). 
 
After this control experiment, 200ul of each unadulterated saliva sample were analysed neat 
and at three dilutions (1:2, 1:4 and 1:8) to determine endogenous PCT levels (Table 2.11). The 
saliva samples were then spiked with both the low and high range PCT control vials and 
Chapter 2:  Materials & Methods 
 
  
117 
analysed neat (low range PCT only) and at three different dilutions (Tables 2.12, 2.13).  These 
samples were analysed in duplicate using the mini-VIDAS (bioMérieux, France) to determine 
the recovery of PCT in saliva at the two concentrations and three saliva dilutions. The lower 
limit of quantification for PCT using a neat sample with the mini VIDAS (bioMérieux, France) 
is 0.05ng/ml. However as the target sample is diluted this would change (1:2 = 0.10ng/ml, 1:4 
= 0.20ng/ml, 1:8 = 0.40ng/ml). The volume of all samples aliquoted onto the test strips was 
kept constant at 200ul. 
 
Table 2.11: Unadulterated saliva dilution experimental protocol. 
 Reagent/Sample Volume (ul)  
Target 
Saliva 
dilution 
Neat Saliva PBS-T 
1:2 diluted 
neat saliva 
1:4 diluted 
neat saliva 
Total 
Volume 
1:2  400ul 400ul   800ul 
1:4  400ul 400ul  800ul 
1:8  400ul  400ul 800ul 
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Table 2.12: Low range PCT spiking experimental protocol. 
 
* Sample A = 200ul neat saliva combined with 200ul of PBS-T. 
** Sample B = 200ul Sample A combined with 200ul of PBS-T. 
 
Table 2.13: High range PCT spiking experimental protocol. 
 
* Sample A = 200ul neat saliva combined with 200ul of PBS-T. 
** Sample B = 200ul Sample A combined with 200ul of PBS-T. 
  
 Reagent/Sample Volume (ul)  
Target 
Dilution: 
Low Range 
Spiked 
Saliva 
Solution 
Neat 
Saliva 
Low 
Range 
PCT 
Control 
High 
Range 
PCT 
Control 
*Sample 
A 
**Sample 
B 
Total 
Volume 
95% neat 190ul  10ul   200ul 
1:2 100ul 100ul    200ul 
1:4  100ul  100ul  200ul 
1:8  100ul   100ul 200ul 
 Reagent/Sample Volume (ul)  
Target 
Dilution: 
High Range 
Spiked 
Saliva 
Solution 
Neat 
Saliva 
High 
Range 
PCT 
Control 
PBS-T 
*Sample 
A 
**Sample 
B 
Total 
Volume 
1:2 100ul 100ul    200ul 
1:4  100ul  100ul  200ul 
1:8  100ul   100ul 200ul 
Chapter 2:  Materials & Methods 
 
  
119 
2.4.3.4. Statistical analysis  
The statistical tests employed are discussed in Section 2.2, Page 86. Specifically, for these 
experiments the level of PCT in the controls was assigned as a 100% recovery.  
 
2.4.3.5. Results 
2.4.3.5.1. Precision 
The intra and inter-assay co-efficient of variance was 8.2 and 10.1% respectively utilising 4 
PCT kits for these experiments. 
 
2.4.3.5.2. Saliva diluent 
As discussed earlier Section 2.4.3.1, Page 114 PBS-T was chosen as a diluent for saliva. It was 
considered important to establish whether PBS-T would affect the level of PCT in both the low 
and high range controls. There was no statistically significant difference when comparing both 
the low range (n = 16) and high range (n = 16) PCT control levels to the low and high range 
PCT control levels when diluted 1:2 in PBS-T (low range p=0.08 by paired t-test and high 
range p=0.15 respectively), (Figure 2.14, Table 2.15, Page 123; Table 2.16, Page 126).  
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Figure 2.9: Comparison between PBS-T and Control levels. .
Bar chart with error bars ± SD for (A) high range (n = 16) and (B) low range control (n = 16) 
respectively. Both controls were diluted with PBS-T (1:2). Overall there was no statistically 
significant difference in the levels of PCT between both the low range and high range controls 
when compared to PBS-T diluted controls (ns: p=0.08, p=0.15 respectively by paired t-test). 
A 
B 
ns 
ns 
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In conclusion PBS-T as a diluent did not appear to interfere with the quantification of PCT in 
this immunoassay. 
 
2.4.3.5.3. Endogenous salivary PCT 
The next step was to investigate the endogenous levels of PCT in all saliva samples (n = 16) 
neat and at three dilutions (1:2, 1:4 and 1:8) (Table 2.14). This would allow for endogenous 
levels to be included in the recovery calculation of samples spiked with PCT so that a false 
enhanced recovery was not calculated.  
 
Table 2.14: Endogenous PCT levels in saliva from healthy individuals. 
 Saliva Sample Dilution (PBS-T) 
Healthy 
Subject 
Neat Saliva 1:2 1:4 1:8 
1 <0.05 <0.10 <0.20 <0.40 
2 <0.05 <0.10 <0.20 <0.40 
3 <0.05 <0.10 <0.20 <0.40 
4 <0.05 <0.10 <0.20 <0.40 
5 <0.05 <0.10 <0.20 <0.40 
6 <0.05 <0.10 <0.20 <0.40 
7 <0.05 <0.10 <0.20 <0.40 
8 <0.05 <0.10 <0.20 <0.40 
9 0.065 <0.10 <0.20 <0.40 
10 <0.05 <0.10 <0.20 <0.40 
*11 0.15 0.15 <0.20 <0.40 
*12 0.14 0.14 <0.20 <0.40 
*13 <0.05 <0.10 <0.20 <0.40 
*14 <0.05 <0.10 <0.20 <0.40 
*15 <0.05 <0.10 <0.20 <0.40 
*16 <0.05 <0.10 <0.20 <0.40 
 
*current smokers. 
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2.4.3.5.4. Healthy non-smoker saliva studies 
2.4.3.5.4.1. Low range recovery and linear dilution PCT experiments 
 
Saliva samples were spiked with low range PCT control to determine whether the levels of 
PCT were affected as the dilution ratio is increased (neat, 1:2, 1:4, 1:8). The recovery of PCT 
was calculated by assigning the levels of PCT in the low range control diluted 1:2 with PBS-T 
as 100%. Thus percentage recovery at each dilution ratio was derived from the following 
formula where 𝑥 is the diluent factor for saliva:   
 
“𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = 100 (
2(𝑃𝐶𝑇 𝑙𝑒𝑣𝑒𝑙 𝑖𝑛 𝐿𝑜𝑤 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑑𝑖𝑙𝑢𝑡𝑒𝑑 1:2 𝑤𝑖𝑡ℎ 𝑃𝐵𝑆−𝑇)
𝑥(𝑃𝐶𝑇 𝑙𝑒𝑣𝑒𝑙 𝑖𝑛 𝑠𝑎𝑙𝑖𝑣𝑎 𝑑𝑖𝑙𝑢𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑃𝐵𝑆𝑇−𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠 𝑃𝐶𝑇 𝑙𝑒𝑣𝑒𝑙) 
)”  
 
Mean PCT recovery increased as the dilution of saliva increased (neat saliva = 56 ± 26%; 1:2 
= 87 ± 15%; 1:4 = 91 ± 10%; 1:8 = 94 ± 6%) (Table 2.15; Figure 2.10). 
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Table 2.13: Low range PCT levels and recovery in healthy non-smokers. 
Subject 
*Control 
Level 
(ng/ml) 
*Control 
PBS-T 
1:2 
dilution 
(ng/ml) 
 
 
Neat 
Saliva 
Recovery 
(%) 
**Diluted 
Saliva 
1:2 
Recovery 
(%) 
**Diluted 
Saliva 
1:4 
Recovery 
(%) 
**Diluted 
Saliva 
1:8 
Recovery 
(%) 
1 1.64 1.56  17% 52% 69% 82% 
2 1.65 1.56  86% 86% 90% 91% 
3 1.63 1.60  51% 102% 101% 102% 
4 1.69 1.62  42% 72% 83% 89% 
5 1.69 1.54  45% 83% 86% 92% 
6 1.67 1.68  33% 96% 95% 95% 
7 1.64 1.68  76% 96% 95% 88% 
8 1.66 1.64  68% 88% 96% 100% 
9 1.66 1.66  100% 98% 103% 101% 
10 1.63 1.60  45% 92% 94% 98% 
Mean 
± SD 
1.66 ± 0.02 1.62 ± 0.05  56 ± 26% 87 ± 15% 91 ± 10% 94 ± 6% 
 
*Control refers to low range PCT control, **Diluted with PBS-T. The levels of quantified PCT 
were multiplied by the dilution factor to allow standardisation of the results. 
 
This increase in low range PCT recovery was statistically significant across the 3 dilutions 
(p<0.002 by a repeated measures ANOVA with a Greenhouse-Geisser correction). A separate 
post-hoc analysis showed a statistically significant improvement in PCT recovery between neat 
saliva and the 1:2 dilution (p<0.037($) by paired t-test), 1:4 dilution (p<0.014($)), and 1:8 
dilution (p<0.020($)). Comparing 1:2 dilution with 1:4 and 1:8 respectively, the improvement 
in mean recovery is not statistically significant (p=0.161 and p=0.374 respectively). Comparing 
the 1:4 and 1:8 dilution samples, the improvement in mean recovery was also not statistically 
significant (p=0.998).  
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Figure 2.10: Low range salivary PCT recovery in healthy non-smokers. 
Bar chart representing mean salivary PCT recovery at increasing dilution factor with error bars 
± SD (n = 10). Saliva was diluted with PBS-T. Across the three dilutions there is a significant 
increase in recovery p<0.002 by repeated measures ANOVA. A post-hoc analysis shows that 
there is a significant difference in PCT recovery between neat and all 3 dilutions of saliva 1:2 
(p<0.037($) by paired t-test), 1:4 (p<0.014($)) and 1:8 (p<0.02($)) saliva dilution (*p<0.002($) 
by paired t-test), and between 1:4 and 1:8 saliva dilution (**p<0.004($)) respectively. No 
significant difference in PCT recovery is demonstrated between 1:2 and 1:4 dilutions (p=0.087) 
respectively. The large SD error bar for the neat sample demonstrates that in some healthy 
subjects the matrix effect of saliva is large, these error bars narrow as the dilution ratio increases 
demonstrating that the matrix effect has been overcome. 
 
* 
** 
*** 
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In summary, diluting neat saliva improves PCT recovery; however there is no advantage in 
increasing the dilution from 1:2 to 1:4 or 1:8. Thus a 1:2 dilution appears to be optimal for 
recovery of low range PCT with further improvements in recovery not statistically significant.  
 
2.4.3.5.4.2. High range recovery and liner dilution PCT experiments 
Next it was determined whether PCT levels were affected by increasing the dilution of saliva 
with PBS-T (1:2, 1:4 and 1:8) in samples spiked with the high range PCT control. A neat 
sample of saliva was not spiked with the high range control as the concentration range is not 
high enough. The low range PCT spike for neat saliva (95% pure) required the saliva sample 
to be spiked with the high range control (Table 2.12). The results from the low range recovery 
experiment (Table 2.15) indicated a significant reduction in recovery in the neat sample. To 
generate a low range spike for neat saliva the high range PCT control was utilised. Thus it 
would not be possible using the controls in the VIDAS B.R.A.H.M.S PCT (bioMérieux, 
France) to generate a high range spike in neat saliva. Spiked high range PCT levels in neat 
saliva were investigated with recombinant PCT (Prospec, Israel) as a further experiment later 
in this chapter (Section 2.4.3.7, Page 134). 
 
The recovery of PCT was calculated by assigning the levels of PCT in the high range control 
diluted 1:2 with PBS-T as a 100%. Thus percentage recovery at each dilution was derived from 
the following formula where 𝑥 is the diluent factor for saliva.  
 
“𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = 100 (
2(𝑃𝐶𝑇 𝑙𝑒𝑣𝑒𝑙 𝑖𝑛 𝐻𝑖𝑔ℎ 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑑𝑖𝑙𝑢𝑡𝑒𝑑 1:2 𝑤𝑖𝑡ℎ 𝑃𝐵𝑆−𝑇)
𝑥(𝑃𝐶𝑇 𝑙𝑒𝑣𝑒𝑙 𝑖𝑛 𝑠𝑎𝑙𝑖𝑣𝑎 𝑑𝑖𝑙𝑢𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑃𝐵𝑆𝑇−𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠 𝑃𝐶𝑇) 
)”  
 
Overall mean PCT recovery percentage increased as the dilution of saliva with PBS-T 
increased (1:2 = 86 ± 8%; 1:4 = 90 ± 6%; 1:8 = 95 ± 4%) (Table 2.16, Figure 2.11).  
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Table 2.16: High range PCT levels and recovery in healthy non-smokers. 
Subject 
Control* 
Level 
(ng/ml) 
Control* 
PBS-T 
1:2 dilution 
(ng/ml) 
 
Neat Saliva 
PBS-T 
 
1:2 
Neat Saliva 
PBS-T 
 
1:4 
Neat 
Saliva 
PBS-T 
 
1:8 
1 18.26 18.08  78% 87% 94% 
2 19.49 18.46  86% 88% 95% 
3 20.27 18.64  68% 76% 87% 
4 19.32 19.14  91% 88% 94% 
5 19.41 19.28  92% 93% 96% 
6 19.13 18.84  91% 94% 94% 
7 19.77 19.84  88% 94% 96% 
8 20.25 20.02  85% 95% 100% 
9 18.51 18.86  95% 94% 99% 
10 19.98 20.04  89% 90% 91% 
Mean ± 
SD 
19.44 ± 0.67 19.12 ± 0.67  86 ± 8% 90 ± 6% 95 ± 4% 
 
*Control refers to high range PCT control. The levels of quantified PCT were multiplied by 
the dilution factor to allow standardisation of the results. 
 
There was a statistically significant increase in percentage scores for high range PCT recovery 
across the three dilutions (p<0.001 by repeated measures ANOVA). A post-hoc analysis shows 
that there was a significant difference in PCT recovery between 1:2 and 1:8 saliva dilution 
(p<0.002($) by paired t-test), and between 1:4 and 1:8 saliva dilution (p<0.004($)). No 
significant difference in PCT recovery was demonstrated between 1:2 and 1:4 (p=0.087) this 
result was also observed in the low range PCT recovery experiments between the same 
dilutions. 
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Figure 2.11: High range salivary PCT recovery in healthy non-smokers. 
Bar chart representing mean salivary PCT recovery at increasing dilution factor with error bars 
± SD (n = 10). Saliva was diluted with PBS-T. The figures in brackets represent the dilution 
factor. Across the three dilutions there was a significant increase in recovery (p<0.001 by 
repeated measures ANOVA). A post-hoc analysis shows that there was a significant difference 
in PCT recovery between 1:2 and 1:8 saliva dilution (*p<0.002($) by paired t-test), and 
between 1:4 and 1:8 saliva dilution (**p<0.004($)). No significant difference in PCT recovery 
was demonstrated between 1:2 and 1:4 (p=0.087).  
 
  
ns 
** 
* 
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It can be concluded that the possible matrix effect of saliva on high range PCT recovery can be 
overcome with increasing linear dilution of the saliva samples, from 1:2 to 1:8, 1:4 to 1:8 
respectively but not 1:2 to 1:4. 
 
Taken together the results for both the low and high range PCT experiments demonstrated a 
significant improvement in recovery of PCT in saliva with increasing linear dilution. However 
to add validity that the mini-VIDAS (bioMérieux, France) can be reliably used for the 
quantification of salivary PCT, a further sub-analysis was conducted to determine whether 
there was a difference in PCT recovery between the samples spiked with low range and high 
range PCT control.  
 
Overall there was no statistical difference between low range and high range PCT recovery 
across all dilutions (p=0.365 by two-way repeated measures ANOVA with Greenhouse-
Geisser correction). Thus accounting for the small sample size the matrix effect of saliva on 
the recovery of salivary PCT appears not to be increased when the concentration of PCT is 
lower. 
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2.4.3.5.5. Healthy smoker saliva studies 
It has been established that using the saliva of healthy non-smokers for validating serum based 
ELISA's for use with saliva is appropriate (Jaedicke et al., 2012). However as the mini VIDAS 
(bioMérieux, France) is a fluorescence-based immunoassay salivary PCT recovery was 
investigated in healthy smokers.  
 
2.4.3.5.5.1. Low range recovery and linear dilution PCT experiments 
Mean PCT recovery increased as the dilution of saliva increased (neat = 75 ± 43%, 1:2 = 81 ± 
23%; 1:4 = 87 ± 15%; 1:8 = 92 ± 9%) (Table 2.17, Figure 2.12). This increase in PCT recovery 
was not significant in different saliva dilutions for smokers (p=0.177 by repeated measures 
ANOVA with a Greenhouse-Geisser correction). Thus post-hoc analysis between the different 
saliva dilutions could not be performed. 
 
Table 2.17: Low range PCT levels and recovery in healthy smokers. 
Subject 
*Control 
Level 
(ng/ml) 
*Control 
PBS-T 
1:2 
dilution 
(ng/ml) 
 
 
Neat 
Saliva 
 
Neat 
Saliva 
PBS-T 
 
1:2 
Neat 
Saliva 
PBS-T 
 
1:4 
Neat 
Saliva 
PBS-T 
 
1:8 
11 1.59 1.50  45% 56% 71% 79% 
12 1.58 1.56  12% 63% 71% 82% 
13 1.71 1.66  114% 102% 101% 98% 
14 1.67 1.66  51% 62% 81% 93% 
15 1.66 1.62  85% 94% 95% 96% 
16 1.64 1.56  113% 110% 104% 100% 
Mean 
± SD 
1.64 ± 0.05 1.59 ± 0.06  75 ± 43% 81 ± 23% 87 ± 15% 92 ± 9% 
 
*Control refers to low range PCT control. The levels of quantified PCT were multiplied by the 
dilution factor to allow standardisation of the results. 
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Figure 2.12: Low range salivary PCT recovery in healthy smokers. 
Bar chart representing mean salivary PCT recovery at increasing dilution factor with error bars 
± SD (n = 6). Saliva was diluted with PBS-T. Overall there was an increase in the recovery of 
PCT as the dilution factor increased, but this was not statistically significant (ns: p=0.177 by 
repeated measures ANOVA). The large SD error bar in neat saliva can be explained by the 
variability in PCT recovery for neat saliva samples. Subjects 13 and 16 had a recovery 
percentage of greater than 100% for neat saliva whilst subject 12 had recovery percentage of 
only 12%. This demonstrates the matrix effect of saliva but also the variability of this effect in 
different healthy smokers. The SD error bars then narrow as the dilution increases indicating 
that the matrix effect of saliva and thus variability of PCT recovery is being reduced. 
 
  
ns 
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2.4.3.5.5.2. High range recovery and linear dilution PCT experiments  
Mean PCT percentage recovery increased as the dilution of saliva increased (1:2 = 86 ± 8%; 
1:4 = 90 ± 6%; 1:8 = 95 ± 4%) (Table 2.18, Figure 2.13). Using a repeated measures ANOVA 
with a Greenhouse-Geisser correction, there was no statistically significant improvement in 
high range PCT recovery in different saliva dilutions for smokers (p=0.138).  
 
Table 2.18: High range PCT levels and recovery in healthy smokers. 
Subject 
*Control 
Level 
(ng/ml) 
*Control 
PBS-T 
1:2 dilution 
(ng/ml) 
 
Neat Saliva 
PBS-T 
 
1:2 
Neat Saliva 
PBS-T 
 
1:4 
Neat Saliva 
PBS-T 
 
1:8 
11 18.86 19.04  67% 80% 92% 
12 18.99 18.99  64% 76% 85% 
13 16.78 17.12  102% 100% 98% 
14 17.05 16.03  79% 84% 89% 
15 16.84 16.84  92% 97% 99% 
16 16.61 16.43  106% 99% 100% 
Mean ± 
SD 
17.66 ± 1.17 17.28 ± 1.41  86 ± 8% 90 ± 6% 95 ± 4% 
 
*Control refers to high range PCT control. The levels of quantified PCT were multiplied by 
the dilution factor to allow standardisation of the results. 
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Figure 2.13: High range salivary PCT recovery in healthy smokers. 
Bar chart representing mean salivary PCT recovery at increasing dilution factor with error bars 
± SD (n = 6). Saliva was diluted with PBS-T. Overall there was an increase in the recovery of 
PCT as the dilution factor increased, but this was not statistically significant (ns: p=0.138 by 
repeated measures ANOVA). The larger SD error bars noted at the 1:2 dilution are due to 
subject 13 and 16 having a recovery percentage of greater than 100% for saliva this is consistent 
with what was observed for these healthy smokers in the low range experiment. Subject 12 also 
demonstrates the lowest PCT recovery at 1:2 dilution once again consistent with the results 
observed for this subject in the high range recovery experiment. The SD error bars narrow as 
the dilution factor increases and the matrix effect of saliva is reduced. 
 
ns 
Chapter 2:  Materials & Methods 
 
  
133 
A further sub-analysis was conducted between low and high range results to determine whether 
there is a statistical difference in PCT recovery percentage between the two concentrations. 
Overall there is no significant difference between low and high range PCT recovery in the 
saliva of healthy smokers across all dilutions (p=0.220, two-way repeated measures ANOVA 
with Greenhouse-Geisser correction). Thus accounting for the small sample size, there does 
not appear to be a matrix effect of smokers’ saliva on the recovery of salivary PCT across the 
range of tested PCT levels.  
 
A final exploratory analysis compared the data between healthy non-smokers and smokers’ 
saliva. There was no statistical difference in low and high range PCT recovery between the two 
populations (p=0.623 by two-way mixed model ANOVA). Interestingly the low range recovery 
of PCT in the saliva of smokers appears to be better than healthy non-smokers although this is 
not statistically significant. This may be explained by understanding the role of mucins in the 
matrix effect of saliva. Mucins can cause suppression of antibody binding in some 
immunoassays (Fulton et al., 1989); however the saliva of smokers has been shown to have a 
reduced and altered level of mucins (Taniguchi et al., 2013). Thus saliva matrix effect of 
smokers may be reduced compared to non-smokers resulting in a possible improvement in PCT 
recovery even at lower saliva dilutions. 
 
2.4.3.6. Conclusion 
Overall the recovery of PCT appears to be enhanced as the linear dilution of saliva is increased 
at both low and high ranges. The recovery of PCT in the saliva of healthy smokers is enhanced 
at lower dilutions albeit with a greater variability; but there is no statistically significant 
difference in recovery between healthy non-smokers and healthy smokers’ saliva at either low 
or high concentrations of PCT. 
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2.4.3.7. Recombinant human PCT recovery 
The previous experiments have established that PCT recovery in saliva spiked with both low 
and high range PCT controls is consistent with no significant difference between the two 
concentrations. However, the level of PCT in the low range control is between 1.58 to 
1.71ng/ml. Physiologically these represent “high” levels reflective of severe systemic 
inflammation (Castelli et al., 2004). Accordingly, the recovery of PCT was investigated at 
levels that approach the lower limit of quantification for the assay (0.05ng/ml) and if recovery 
was affected to determine whether these recovered levels were linear. 
 
2.4.3.7.1. Aims 
1. To ascertain the recovery of recombinant PCT levels in PBS-T at increasing spiked 
concentrations. 
2. To determine the recovery of recombinant PCT levels across a range of concentrations in 
spiked neat human saliva samples from healthy non-smokers. 
 
2.4.3.7.2. Methods  
Firstly, PBS-T was spiked with recombinant PCT (Prospec, Israel) to act as a control across a 
range of PCT concentrations: 0.625 to 100ng/ml (Table 2.19A-B). The recombinant PCT is 
supplied lyophilised as a 2000ng powder and was reconstituted in 1ml of dH2O. All samples 
were tested in duplicate using the mini-VIDAS (bioMérieux, France). Based on the results of 
this control experiment, three separate saliva samples were spiked with a known quantity of 
recombinant PCT (Prospec, Israel) across a range of concentrations: 0.625 to 20ng/ml (Figure 
2.19B). Saliva samples were chosen from three healthy non-smokers in whom I had previously 
demonstrated no detectable endogenous salivary PCT (Table 2.14, Page 121: Healthy Subjects 
1 to 3). All samples were tested in duplicate on the mini-VIDAS (bioMérieux, France). The 
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lower limit of quantification for PCT on the mini-VIDAS was 0.05ng/ml for neat saliva 
samples. 
 
Table 2.19A: Protocol for PBS-T spiked with recombinant PCT experiment. 
  Reagent/Sample Volume (ul) 
Target 
PBS-T 
Spike 
Recombinant 
 PCT 
(2000ng/ml) 
PBS-
T 
100ng/ml 
Spiked 
PBS-T 
Solution 
50ng/ml 
Spiked 
PBS-T 
Solution 
25ng/ml 
Spiked 
PBS-T 
Solution 
12.5ng/ml 
Spiked 
PBS-T 
Solution 
6.25ng/ml 
Spiked 
PBS-T 
Solution 
Total 
Volume 
100 ng/ml 20ul 380ul      400ul 
50 ng/ml  200ul 200ul     400ul 
25 ng/ml  200ul  200ul    400ul 
12.5 ng/ml  200ul   200ul   400ul 
6.25 ng/ml  200ul    200ul  400ul 
3.125 
ng/ml 
 200ul   
  200ul 400ul 
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Table 2.19B: Protocol for PBS-T spiked with recombinant PCT experiment. 
  Reagent/Sample Volume (ul) 
Target 
Saliva 
Spike 
Recombinant 
PCT 
(2000ng/ml) 
**Neat 
saliva 
20ng/ml 
Spiked 
Saliva 
 
10ng/ml 
Spiked 
Saliva 
 
5ng/ml 
Spiked 
Saliva 
 
2.5ng/ml 
Spiked 
Saliva 
 
1.25ng/ml 
Spiked 
Saliva 
Total 
Volume 
*20 ng/ml 8ul 392ul      400ul 
*10 ng/ml  200ul 200ul     400ul 
*5 ng/ml  200ul  200ul    400ul 
*2.5 ng/ml  200ul   200ul   400ul 
*1.25 
ng/ml 
 200ul   
 200ul  400ul 
*0.625 
ng/ml 
 200ul   
  200ul 400ul 
 
*Spiked saliva is a minimum 98% pure. **This same protocol was adopted with PBS-T instead 
of unadulterated saliva to achieve a concentration range of (0.625 to 20ng/ml) which would act 
as a control. 
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2.4.3.7.3. Statistical analysis 
The statistical tests employed are discussed in Section 2.2, Page 86. Specifically, a recovery 
percentage of PCT in PBS-T was calculated from the following formula: 
𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = 100 (
𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑃𝐶𝑇 𝑙𝑒𝑣𝑒𝑙
𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑃𝐶𝑇 𝑙𝑒𝑣𝑒𝑙
). Salivary PCT levels below the lower limit 
of quantification were not included in any analysis. 
 
2.4.3.7.4. Results 
2.4.3.7.4.1 Recombinant PCT levels in PBS-T  
The purpose of this experiment was to understand the actual recovery of recombinant PCT 
levels in spiked PBS-T samples so that a cross comparison with spiked saliva samples could 
be made (Table 2.20). 
 
Table 2.20. Recovery of PCT in spiked PBS-T samples. 
*Added  
Fixed 
Concentration 
Recombinant 
PCT 
 
(ng/ml) 
Observed 
PCT 
 
 
(ng/ml) 
Recovery  
 
 
 
(%) 
*Added 
Recombinant 
PCT 
 
 
(ng/ml) 
Observed 
PCT 
 
 
 
(ng/ml) 
Recovery  
 
 
 
(%) 
100 58.64 59% 20 4.23 21% 
50 27.27 55% 10 1.98 20% 
25 11.58 46% 5 0.82 16% 
12.5 5.29 42% 2.5 0.35 14% 
6.25 2.35 38% 1.25 0.13 10% 
3.125 0.96 31% 0.625 **<0.05 n/a 
Mean ± SD  45 ± 10%   16 ± 5% 
 
*Recombinant PCT concentration added to PBS-T, **below the lower limit of quantification 
for the immunoassay. 
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Overall there was a significant reduction in the observed recombinant PCT levels compared to 
the fixed (expected) concentration (p<0.008 by Wilcoxon signed rank test). The recovery at 
reducing concentrations was also reduced. However the reduction in the observed levels of 
salivary PCT compared to expected fixed concentration recombinant PCT levels was consistent 
across the range of PCT concentrations as determined by the r2 value of 99.8% for the line-of-
best-fit (Figure 2.14). This value indicates a 99.8% agreement for the line-of-best-fit between 
the observed compared to fixed concentrations of recombinant PCT.  
 
 
Figure 2.14: Recombinant PCT levels in PBS-T. 
This scatter plot with line-of-best-fit demonstrates observed PCT levels in PBS-T spiked with 
a fixed concentration of recombinant PCT (0.625, 1.25, 2.5, 3.125, 5, 6.25, 10, 12.5, 20, 25, 
50, 100ng/ml). 200ul of each spiked PBS-T sample was aliquoted onto a VIDAS B.R.A.H.M.S 
PCT test strip (bioMérieux, France) and analysed on the mini VIDAS instrument. Although 
the recovered levels of fixed concentrations of recombinant PCT in PBS-T were reduced, this 
reduction is linear across the spiked concentration range 0.625 to100ng/ml. The r2 value was 
0.998 for the line-of-best-fit: y = 0.5905 – 1.3629. 
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Overall the recovered levels of a fixed concentration of recombinant PCT in PBS-T is reduced 
on the mini VIDAS (bioMérieux, France) the reduction in these levels however is constant 
(linear). This experiment adds support that using the VIDAS B.R.A.H.M.S PCT kit 
(bioMérieux, France) can give a consistent quantification of salivary PCT levels. It also 
supports a minimum of dilution of saliva samples with PBS-T of 1:2, as further higher dilutions 
(1:4 and 1:8) will reduce the lower limit of quantification (1:4 = 0.20ng/ml and 1:8 = 
0.40ng/ml) for the immunoassay resulting in more saliva samples testing negative for PCT. 
 
2.4.3.7.4.2. Recombinant PCT levels and recovery in saliva 
The next step was to compare recovered levels between recombinant PCT spiked PBS-T and 
three spiked saliva samples chosen from the healthy non-smoker subjects who had provided 
saliva samples for these experiments (Table 2.14, Page 121) using the previously discussed 
(Section 2.4.3, Page 112) VIDAS B.R.A.H.M.S PCT (bioMérieux, France) immunoassay 
designed for analysis with the mini-VIDAS (bioMérieux, France), which has a lower limit of 
PCT quantification at 0.05ng/ml for neat serum samples. The saliva samples were spiked with 
0.625, 1.25, 2.5, 5, 10 and 20ng/ml of recombinant PCT. The method for this is described in 
Table 2.19B, Page 136. This experiment enabled a cross-comparison to be performed between 
each spiked healthy saliva sample and spiked PBS-T samples to ascertain the difference in 
actual PCT levels between the two spiked samples and a comparative recovery percentage at 
each PCT concentration (Table 2.21). The observed spiked saliva recombinant PCT levels have 
a linear relationship in all three healthy subject to the fixed concentration of recombinant PCT 
(20, 10, 5, 2.5, 1.25 and 0.625ng/ml) used to spike the saliva (Figure 2.15A-C). The r2 value 
indicates that the level of observed PCT concentrations can be calculated with at least 96% 
accuracy when the spiked concentration is known. 
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Table 2.22: Recombinant PCT levels and recovery in spiked saliva. 
  Subject 1 Subject 2 Subject 3 
*Fixed 
Concentration 
Added 
Recombinant 
PCT 
 
 
(ng/ml) 
Observed 
PBS-T 
PCT 
Level  
 
 
(ng/ml) 
Observed 
Salivary  
PCT 
Level  
 
 
(ng/ml) 
 
 
**Recovery 
(%) 
Observed 
Salivary  
PCT 
Level  
 
 
(ng/ml) 
 
**Recovery 
(%) 
Observed 
Salivary  
PCT 
Level  
 
 
(ng/ml) 
 
**Recovery 
(%) 
20 4.23 2.02 48% 3.29 78% 0.86 20% 
10 1.96 0.65 33% 1.11 57% 0.35 18% 
5 0.82 0.32 39% 0.48 59% 0.18 22% 
2.5 0.35 0.15 43% 0.19 55% 0.10 29% 
1.25 0.13 0.08 62% 0.11 87% 0.07 54% 
0.625 <0.05 <0.05 n/a <0.05 n/a <0.05 n/a 
mean ± SD   45 ± 11%  67 ± 14%  29 ± 15% 
 
*Added to both PBS-T and the three subjects’ saliva samples, **Compared to the observed 
PCT level in spiked PBS-T.  
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Figure 2.15A-B: Recombinant PCT levels in healthy non-smoker saliva. 
Scatter plot (n = 2) with line-of-best-fit for three separate samples of healthy non-smoker saliva 
spiked with recombinant PCT at six different concentrations: 20, 10, 5, 2.5, 1.25, 0.625ng/ml. 
200ul of neat spiked saliva samples were aliquoted onto a VIDAS B.R.A.H.M.S PCT test strip 
(bioMérieux, France) and analysed on the mini-VIDAS instrument. The r2 values are greater 
than 0.98 for both saliva samples (Subject 1: r2 = 0.9692, Subject 2: r2 = 0.9761). 
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Figure 2.15C: Recombinant PCT levels in healthy non-smoker saliva. 
Scatter plot (n = 1) with line-of-best-fit for three separate samples of healthy non-smoker saliva 
spiked with recombinant PCT at six different concentrations: 20, 10, 5, 2.5, 1.25, 0.625ng/ml. 
200ul of neat spiked saliva samples were aliquoted onto a VIDAS B.R.A.H.M.S PCT test strip 
(bioMérieux, France) and analysed on the mini-VIDAS instrument. The r2 values = 0.9868. 
 
2.4.3.7.4.3 Conclusion 
The recovery of recombinant PCT is lower than the low and high range manufacturer provided 
PCT controls which were used in the first set of spiking experiments above (Section 2.4.3.5.4, 
Page 122). It is important to note however that recovered PCT levels display a linear 
relationship to the expected spiked recombinant PCT concentrations for healthy non-smoker 
saliva. Although the levels may not be a genuine reflection of the actual concentrations of PCT 
in saliva this linearity adds reassurance that the salivary PCT levels will be consistently 
reported across the concentration ranges.  
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2.4.3.8. Spectral analysis experiment  
Based on the results of the PCT spiking and dilution experiments a further experiment was 
conducted to understand why there was a difference between expected and observed levels of 
recombinant PCT and the VIDAS BRAHMS PCT kit (bioMérieux, France) manufacturer 
supplied PCT controls (low and high range) which were both used to spike PBS-T and healthy 
saliva. Thus there may be compositional difference between the two and this was investigated 
utilising Fourier transform infrared (FTIR) spectroscopy. FTIR identifies and measures 
chemical bond vibrations within functional groups in complex biological mixtures and 
produces infrared absorption spectra “fingerprint” for the particular sample. 
 
2.4.3.8.1. Aim 
1. To ascertain the compositional difference if any between recombinant PCT and 
manufacturer-supplied PCT controls. 
 
2.4.3.8.2. Methods 
FTIR spectroscopy was performed on recombinant PCT (Prospec, Israel), two low and high 
range PCT controls from the VIDAS B.R.A.H.M.S PCT kit (bioMérieux, France) and two 
matched serum-saliva samples from our archived saliva bio-bank. Spectroscopy was conducted 
with the Alpha-T spectrometer (Bruker, UK) using a transmission mode in 400 to 900cm-1 
regions with a 4cm-1 resolution. The first step involved calibration of the spectrometer to 
accommodate for the spectral profile of air. Subsequently a sample was placed on a clear 
calcium fluoride disc and dried. This is necessary as water can produce background-
characteristic spectral interference (eliminated by drying), which can potentially disguise 
underlying spectra of interest. The calcium fluoride disc is then placed inside the spectrometer 
and analysed with the results provided after 30 seconds. 
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2.4.3.8.3. Results 
Spectral profiles for serum, saliva, recombinant PCT and both low and high range PCT controls 
are shown in Figure 2.16A-D. Serum has a variety of peaks reflecting the complexity of its 
composition. Saliva also has a variety of peaks although the profile as expected is different 
from serum. The recombinant PCT demonstrates two peaks (the second from left to right) 
would be consistent with a pure protein band; however both low and high range PCT controls 
provided in the VIDAS B.R.A.H.M.S PCT assay (bioMérieux, France) displayed a 
characteristic spectrum, which has similar features to human serum. This spectral profile is 
markedly different to that of the recombinant PCT indicating that there are likely additional 
proteins inherent in the VIDAS B.R.A.H.M.S PCT assay (bioMérieux, France) manufacturer-
supplied PCT controls (both low and high range) that enhances the recovery of PCT when 
analysed on the min-VIDAS (bioMérieux, France). 
  
Chapter 2:  Materials & Methods 
 
  
145 
 
 
 
 
Figure 2.16A-B: FTIR Spectra. 
Spectral profiles of A = serum; B = saliva.  
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Figure 2.16C-D: FTIR Spectra.  
Spectral profiles of C = low and high range PCT control provided in the VIDAS B.R.A.H.M.S 
PCT kit (bioMérieux, France). As the spectra for both these PCT controls were identical, only 
one representative spectrum is displayed. D = recombinant PCT.  
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2.4.3.9. Discussion 
PBS-T appears to be a suitable saliva diluent and does not affect the recovery of either low or 
high range PCT control provided in the VIDAS B.R.A.H.M.S PCT kit (bioMérieux, France). 
The recombinant PCT experiment demonstrated reduced PCT recovery compared to the low 
and high range controls at similar PCT concentrations. Spectral analysis of both recombinant 
PCT and the low and high range controls appears to offer an explanation with the spectra 
suggesting that both the low and high range controls may contain serum constituents which 
affect PCT recovery. 
 
The difference in spectra between recombinant PCT and both low and high range PCT controls 
could be explained by considering that the assay itself is designed to be tested on human serum. 
Thus the controls may be combined with a human serum substitute or a combination of proteins 
that form the major components of human serum to enable the analyser to detect them more 
easily. Fluorescence assays using serum have to overcome limitations associated with 
fluorescent labeling of the serum constituents, non-specific signals generated by the 
fluorescence and diffusion properties of the serum (Martin and Jett, 1986). These factors to a 
lesser or greater extent are accounted for by pre-sets on the machine upon calibration of a new 
PCT kit. The observed reduced recovery of recombinant PCT may be attributable to the VIDAS 
calibration. When the analyser is calibrated according to manufacturer’s instructions, the MLE 
card provides information on the expected fluorescence of serum and serum-PCT. Thus as 
saliva was our target test sample, this pre-set calibration and the consequent intrinsic serum-
fluoresce value would be incorrectly applied. This would result in an altered result and could 
also explain why the recovery was better at higher concentrations as a higher proportion of the 
fluorescence will be generated by PCT. In considering the results from Section 2.4.3.7.4, Page 
137 one could postulate that the combination of recombinant PCT with serum instead of PBS-
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T could have led to enhanced PCT recovery. The recovery of PCT improves as the linear 
dilution of saliva increases. However, it is important to note that as the dilution of the saliva 
sample increases the lower limit of PCT quantification for the mini VIDAS also increases: neat 
= 0.05, 1:2 = 0.10, 1:4 = 0.20 and 1:8 = 0.40. This has important implications for saliva PCT 
quantification, as meaningful “low” levels will not be quantifiable above dilutions of 1:4. A 
1:2 dilution of saliva with PBS-T is optimal for improving PCT recovery and low 
concentrations, without compromising the working assay range of the mini-VIDAS 
(bioMérieux, France). Optimal PCT recovery is obtained when diluting saliva 1:2; this is not 
affected by the concentration of PCT. Interestingly the saliva of smokers does not exhibit an 
enhanced matrix effect on PCT when compared to the saliva of healthy non-smokers. 
 
2.4.3.10. Overall conclusion 
Based on the above experimental results for future PCT analysis, the same pre-analysis saliva 
preparation as for CRP (Section 2.4.2.1, Page 92) will be adopted. The intra- and inter-assay 
precision (CV) of 8.2% and 10.1% respectively was below the maximum (10% and 15%) 
accepted error percentage that had been selected. This will continue to be calculated for all for 
the VIDAS B.R.A.H.M.S PCT immunoassays (bioMérieux, France) throughout this thesis to 
ensure that both the intra- and inter-assay precision (CV’s) remain below the accepted and 
clinical thresholds. All saliva samples will be tested in duplicate. Samples will be diluted 1:2 
in PBS-T (manufacturer recommendation is neat for serum) and each test strip will continue to 
receive 200ul of sample (this is in concordance with the manufacturers documented sample 
amount). The test procedure that occurs internally within the mini VIDAS (bioMérieux, 
France) does not need to be altered. Due to the 1:2 sample dilution the minimum limit of 
detection PCT for the mini VIDAS (bioMérieux, France) instrument will be 0.10ng/ml  
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2.4.4. Optimisation of a serum-based Neutrophil Elastase (NE) assay for use with saliva 
The PMN Elastase ELISA kit (Immundiagnostik, Germany) is a validated “for diagnostic use” 
immunoassay to quantify NE in stool, seminal plasma and serum. There is no published work 
with respects to whether this kit has been validated in saliva. Jaedicke et al 2012., have 
described how ELISAs can be modified to quantify target analytes in saliva; if the assay of 
choice quantifies target analytes in numerous body fluids then the serum-based methodology 
could be utilised. 
 
Each supplied PMN Elastase ELISA kit (Immundiagnostik, Germany) consists of a 96-well 
microtitre plate coated with sheep anti-elastase, ELISA wash buffer (diluted by 1:10 with 
dH2O), five lyophilised standards (10, 3.3, 1.1, 0.37 and 0ng/ml) and two lyophilised controls 
(0.65 and 1.60ng/ml respectively). Both standards and controls are reconstituted with 500ul of 
dH2O. A lyophilised detection antibody (reconstituted with 600ul of dH20 and diluted 1:20 in 
the ELISA wash buffer), Conjugate, TMB substrate and sulfuric acid stop solution (Figure 
2.17).  
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Figure 2.17: PMN Elastase ELISA kit (Immundiagnostik, Germany). 
This figure displays the contents of the ELISA kit. A = Microtitre plate; Row B from left to 
right: ELISA wash buffer, stop solution, conjugate, substrate, antibody; Row C from left to 
right: 5 sets of standards (0, 0.37, 1.1, 3.3. 10ng/ml); Row D from left to right: low and high 
control vials. 
 
The above ELISA requires the target sample to be diluted prior to analysis to reduce the 
concentration of NE into the working assay range: 0.011 to 10ng/ml. The method for serum 
NE for example involves a minimum sample dilution of 1:500 in the ELISA Wash Buffer. Thus 
at a 1:500 dilution the quantifiable range of serum NE is 5.5 to 5000ng/ml. For any sample 
above the working range of PMN Elastase ELISA kit (Immundiagnostik, Germany), the 
manufacturer recommends a further dilution; this theoretically means that the kit has no upper 
limit of quantification for NE if the appropriate dilution is incorporated. Subsequently to 
perform the immunoassay 100ul of target sample, standards and controls are added in duplicate 
to the wells; thus 40 serum samples can be tested in duplicate per microtitre plate (Table 2.22). 
A 
B 
C 
D 
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The microtitre plate is then incubated for one hour at room temperature (15 to 30oC) whilst on 
a horizontal plate mixer at 500rpm. After a wash step 100ul of detection antibody (mouse 
monoclonal antibody) is added to the wells. The microtitre plate is then left to incubate for a 
further hour at room temperature on a horizontal mixer. During this second incubation, a 
“sandwich” of anti-elastase-elastase-anti-elastase is formed. After a second wash-step, 100ul 
of conjugate (peroxide labeled goat-anti-mouse-POD) is added, and the microtitre plate is 
incubated for a further hour at room temperature on a horizontal plate mixer. After a third wash-
step, 100ul of TMB is added into each well; this is acted upon by the conjugated enzyme bound 
in the well and causes a blue discolouration. The microtitre plate is then incubated in the dark 
(achieved by enveloping the microtitre plate in aluminum foil (Wrap Film Systems, UK)) for 
20 minutes. Finally, 100ul of ELISA stop solution (sulfuric acid) is added turning the TMB 
yellow. The microtitre plate needs to be immediately read on the BioTek Synergy 2 ELISA 
plate reader (BioTek, USA) at 450nm and 620nm; the later being used as a reference. Total 
assay time including sample preparation is approximately five hours.  
 
Table 2.22: Generic NE microtitre plate layout. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 10 ng/ml 10ng/ml S1 S1 S9 S9 S17 S17 S25 S25 S33 S33 
B 3.3 ng/ml 1500 pg/ml S2 S2 S10 S10 S18 S18 S26 S26 S34 S34 
C 1.1 ng/ml 750 pg/ml S3 S3 S11 S11 S19 S19 S27 S27 S35 S35 
D 0.37 ng/ml 375 pg/ml S4 S4 S12 S12 S20 S20 S28 S28 S36 S36 
E 0 ng/ml 187.5 pg/ml S5 S5 S13 S13 S21 S21 S29 S29 S37 S37 
F 
High 
Control 
High 
Control 
S6 S6 S14 S14 S22 S22 S30 S30 S38 S38 
G 
Low 
Control 
Low 
Control 
S7 S7 S15 S15 S23 S23 S31 S31 S39 S39 
H Blank Blank S8 S8 S16 S16 S24 S24 S32 S32 S40 S40 
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To calculate the levels of sample NE, a four-parameter logistic regression model is used. This 
utilizes the known standards and generated optical densities at each standard concentration to 
generate a “curve-of-best-fit” (Figure 2.18). This “curve-of-best-fit” is generated via the 
equation “𝑦 = 𝑑 +
𝑎−𝑑
1+(
𝑥
𝑐
)
𝑏” where “y” is the optical density, “𝑥” is the log10 salivary NE level; 
“𝑎” is the optical density at 0ng/ml standard, “𝑑” is the optical density at 10ng/ml standard, 
“𝑐” is the point of inflection for the curve and “𝑏” is the steepness of the curve at point “𝑐”. 
Thus a sample of saliva processed on this assay generating an optical density of “𝑦” would 
have a log10 salivary NE concentration of “𝑥 = 𝑐(
−𝑎+𝑦
𝑑−𝑦
)
1
𝑏”. The value for “𝑥” would then need 
to be transformed to a number and multiplied by the dilution factor of the saliva sample.  
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Figure 2.18: Typical four-parameter logistic regression curve 
A “curve-of-best-fit” with the “+” in red representing the optical densities at each standard. As 
the “x” axis scale is logarithmic a zero point cannot be plotted. This “curve-of-best-fit” is 
generated via the equation “𝑦 = 𝑑 +
𝑎−𝑑
1+(
𝑥
𝑐
)
𝑏 “ where “y” is the optical density, “𝑥” is the log10 
salivary NE level; “𝑎” is the optical density at 0ng/ml standard, “𝑑” is the optical density at 
10ng/ml standard, “𝑐” is the point of inflection for the curve and “𝑏” is the steepness of the 
curve at point “𝑐”. The r2 value for this curve indicates that the “curve-of-best-fit” can calculate 
with 99.5% accuracy the level of NE. 
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2.4.4.1. Salivary NE ELISA calibration experiments  
In order to calibrate this ELISA for saliva I would need to assess precision, recovery and linear 
dilution and the minimum limit of detection based on the ideal sample dilution factor (Section 
2.4.2, Page 90). I conducted a series of experiments to understand recovery of salivary NE at 
both “low” and “high” concentrations to determine the effects of saliva sample linear dilution.  
 
2.4.4.1.1. Aims 
1. To determine the intra- and inter- assay precision. 
2. To ascertain the matrix effect of saliva on the recovery of a fixed concentration of NE 
provided as part of the PMN Elastase ELISA kit control, and determine whether there is a 
difference in NE recovery in saliva at low and high NE ranges. 
3. To evaluate this matrix effect in four different (linear) dilutions of human saliva. 
4. To assign a limit of detection based on a selected saliva dilution. 
 
2.4.4.1.2. Methods 
Five healthy non-smokers and five COPD patients (Table 2.23) were randomly selected from 
the Directorate of Respiratory Medicine's research and outpatient clinic database (Section 2.3, 
Page 88); gave informed written consent and provided 2mls of unstimulated whole saliva by 
passive drool (Figure 2.21, Page 176) into ice-cooled containers. Saliva samples were then 
transported on ice and stored in the Guy Hilton Research Centre Freezer Room (Keele 
University, UK) at -80oC. Prior to analysis all saliva samples were thawed at room temperature. 
Saliva samples were stored for no more than 1 week prior to biomarker analysis. 
 
The PMN Elastase ELISA kit (Immundiagnostik, Germany) is validated for the quantification 
of NE in stool, seminal plasma and serum; thus no protocol exists for pre-analysis saliva sample 
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preparation. The same pre-analysis saliva preparation as for salivary CRP quantification 
(Section 2.4.2.1, Page 92) was utilised. Prior to analysis each saliva sample was vortexed and 
then centrifuged at 3000rpm for 15 minutes to remove debris. Each sample was analysed 
unadulterated at four different dilutions (1:100, 1:200, 1:400 and 1:800) to determine 
endogenous levels of NE (Table 2.26). Based on the results from this experiment five samples 
were chosen and then respectively spiked with “low” NE (1.09ng/ml) and “high” NE 
(7.98ng/ml) concentrations using the standards provided in the kit. These spiked samples were 
then analysed at four varying linear dilutions of 1:100, 1:200, 1:400 and 1:800 (Table 2.27 and 
2.28). There was no adjustment made to the manufacturer's methodology of the kit and each 
sample was analysed in duplicate. Two microtitre plates were used to conduct these 
experiments (Table 2.24 and 2.25). 
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Table 2.23: Group demographics 
Demographics 
Healthy  
Non-Smokers 
(n = 5) 
COPD  
(n = 5) 
Age, a years 27.5 ± 1.0 65.7 ± 9.0 
Gender, Male, (Female), n 2 (3) 3 (2)  
Smoking Status, Current (Ex), n 0 (0) 0 (5) 
Duration of COPD, a years n/a 6.7 ± 2.9 
FEV1, a % predicted n/a 53.0 ± 13.6 
FVC, a % predicted n/a 73.6 ± 7.0 
BMI, a (kg/m2) 23.2 ± 2.6 25.2 ± 2.6 
Exacerbations in the last 6 weeks, an 0 0 
Exacerbations in the last 1 year, an 0 4 ± 1 
Co–morbidities, n   
None 5 0 
Cardiovascular Disease 0 2 
 Type 2 Diabetes Mellitus 0 0 
Hypertension 0 4 
Gum Disease 0 0 
Other 0 2 
COPD Treatment, n   
Inhaled β2 agonists,  
Short Acting, (Long Acting) 
0, (0) 5, (5) 
Nebulised β2 agonists (Short Acting) 0 0 
Inhaled Anti-cholinergic, Short Acting, (Long 
Acting) 
0, (0) 1, (4) 
Nebulised Anti-cholinergic (Short Acting) 0 0 
Inhaled Steroid 0 4 
Oral Theophylline, an 0 2 
 
Data are presented as: a = mean ± SD. 
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Table 2.24: Dilution saliva NE experiment microtitre plate layout. 
Healthy Subject 
(1 to 5) 
COPD Patients 
(6 to 10) 
Patient 
1 
Sample 
1 
Patient 
2 
Sample 
2 
Patient 
3 
Sample 
3 
Patient 
4 
Sample 
4 
Patient 
5 
Sample 
5 
Patient 
6 
Sample 
6 
Patient 
7 
Sample 
7 
Patient 
8 
Sample 
8 
Patient 
9 
Sample 
9 
Patient 
10 
Sample 
10 
Sample 
1 
1:100 
dilution 
Sample 
2  
1:100 
dilution 
Sample 
3 
1:100 
dilution 
Sample 
4  
1:100 
dilution 
Sample 
5 
1:100 
dilution 
Sample 
6  
1:100 
dilution 
Sample 
7 
1:100 
dilution 
Sample 
8  
1:100 
dilution 
Sample 
9 
1:100 
dilution 
Sample 
10  
1:100 
dilution 
Sample 
1 
1:200 
dilution 
Sample 
2 
1:200 
dilution 
Sample 
3 
1:200 
dilution 
Sample 
4 
1:200 
dilution 
Sample 
5 
1:200 
dilution 
Sample 
6 
1:200 
dilution 
Sample 
7 
1:200 
dilution 
Sample 
8 
1:200 
dilution 
Sample 
9 
1:200 
dilution 
Sample 
10 
1:200 
dilution 
Sample 
1 
1:400 
dilution 
Sample 
2 
1:400 
dilution 
Sample 
3 
1:400 
dilution 
Sample 
4 
1:400 
dilution 
Sample 
5 
1:400 
dilution 
Sample 
6 
1:400 
dilution 
Sample 
7 
1:400 
dilution 
Sample 
8 
1:400 
dilution 
Sample 
9 
1:400 
dilution 
Sample 
10 
1:400 
dilution 
Sample 
1 
1:800 
dilution 
Sample 
2 
1:800 
dilution 
Sample 
3 
1:800 
dilution 
Sample 
4 
1:800 
dilution 
Sample 
5 
1:800 
dilution 
Sample 
6 
1:800 
dilution 
Sample 
7 
1:800 
dilution 
Sample 
8 
1:800 
dilution 
Sample 
9 
1:800 
dilution 
Sample 
10 
1:800 
dilution 
 
Table 2.25: Spiked saliva NE experiment microtitre plate layout. 
Sample 1 Sample 7 Sample 8 Sample 9 Sample 10 
Low 
Spike 
High 
Spike 
Low 
Spike 
High 
Spike 
Low 
Spike 
High 
Spike 
Low 
Spike 
High 
Spike 
Low 
Spike 
High 
Spike 
Sample 
1  
1:100 
dilution 
Sample 
1 
1:100 
dilution 
Sample 
7 
1:100 
dilution 
Sample 
7 
1:100 
dilution 
Sample 
8 
1:100 
dilution 
Sample 
8 
1:100 
dilution 
Sample 
9 
1:100 
dilution 
Sample 
9 
1:100 
dilution 
Sample 
10 
1:100 
dilution 
Sample 
10 
1:100 
dilution 
Sample 
1 
1:200 
dilution 
Sample 
1 
1:200 
dilution 
Sample 
7 
1:200 
dilution 
Sample 
7 
1:200 
dilution 
Sample 
8 
1:200 
dilution 
Sample 
8 
1:200 
dilution 
Sample 
9 
1:200 
dilution 
Sample 
9 
1:200 
dilution 
Sample 
10 
1:200 
dilution 
Sample 
10 
1:200 
dilution 
Sample 
1 
1:400 
dilution 
Sample 
1 
1:400 
dilution 
Sample 
7 
1:400 
dilution 
Sample 
7 
1:400 
dilution 
Sample 
8 
1:400 
dilution 
Sample 
8 
1:400 
dilution 
Sample 
9 
1:400 
dilution 
Sample 
9 
1:400 
dilution 
Sample 
10 
1:400 
dilution 
Sample 
10 
1:400 
dilution 
Sample 
1 
1:800 
dilution 
Sample 
1 
1:800 
dilution 
Sample 
7 
1:800 
dilution 
Sample 
7 
1:800 
dilution 
Sample 
8 
1:800 
dilution 
Sample 
8 
1:800 
dilution 
Sample 
9 
1:800 
dilution 
Sample 
9 
1:800 
dilution 
Sample 
10 
1:800 
dilution 
Sample 
10 
1:800 
dilution 
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Table 2.26: Unadulterated saliva dilution experimental protocol. 
 Reagent/ Sample Volume (ul) 
Target 
Saliva 
dilution 
Neat 
Saliva 
ELISA 
Wash 
Buffer 
1:100  
diluted 
neat 
saliva 
1:200  
diluted 
neat 
saliva 
1:400  
diluted 
neat 
saliva 
Total Volume 
1:100 
diluted 
10ul 990ul   
 
1000ul 
1:200 
diluted 
 500ul 500ul  
 1000ul 
1:400 
diluted 
 500ul  500ul 
 1000ul 
1:800 
diluted 
 500ul   
500ul 1000ul 
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Table 2.27: Low range NE spiking experimental protocol. 
 Regent/ Sample Volume Total 
Volume 
Target 
Low Range 
(1.09ng/ml) 
Spiked 
Saliva 
Solution 
Neat 
Saliva 
1.1ng/ml 
Standard 
ELISA 
Wash 
Buffer 
1:100 
diluted  
low 
range  
spiked 
saliva 
1:200 
diluted  
low range  
spiked 
saliva  
1:400 
diluted  
low 
range  
spiked 
saliva 
 
1:100 
diluted 
10ul 990ul     1000ul 
1:200 
diluted 
  500ul 500ul   1000ul 
1:400 
diluted 
  500ul  500ul  1000ul 
1:800 
diluted 
  500ul   500ul 1000ul 
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Table 2.28: High range NE spiking experimental protocol. 
 
* Standard A = 10ng/ml manufacturer provided lyophilised standard 800ul combined with 
200ul of ELISA wash buffer. 
  
 Reagent/ Sample Volume Total 
Volume 
Target 
High 
Range 
(7.92ng/ml) 
Spiked 
Saliva 
Solution 
Neat 
Saliva 
8ng/ml 
Standard 
A 
ELISA 
Wash 
Buffer 
1:100 
diluted  
low 
range  
spiked 
saliva 
1:200 
diluted  
low range  
spiked 
saliva  
1:400 
diluted  
low 
range  
spiked 
saliva 
 
1:100 
diluted 
10ul 990ul     1000ul 
1:200 
diluted 
  500ul 500ul   1000ul 
1:400 
diluted 
  500ul  500ul  1000ul 
1:800 
diluted 
  500ul   500ul 1000ul 
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2.4.4.1.3. Statistical analysis 
The statistical tests employed are discussed in Section 2.2, Page 86. Specifically, for the 
recovery experiment a recovery percentage was calculated using the formula: 
“𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 =  100(𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑁𝐸 𝑙𝑒𝑣𝑒𝑙 ÷ 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑁𝐸 𝑙𝑒𝑣𝑒𝑙)” 
 
The expected level was calculated using the formula:  
“𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑁𝐸 𝑙𝑒𝑣𝑒𝑙 =  (𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠 𝑁𝐸 𝑙𝑒𝑣𝑒𝑙 + 𝑁𝐸 𝑠𝑝𝑖𝑘𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛)” 
 
Samples above the higher limit of quantification were not included in the analysis. Salivary NE 
units are given as ng/ml.  
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2.4.4.1.4. Results 
2.4.4.1.4.1. Precision 
The intra-assay CV for both microtitre plates was 4.8% and an inter-assay CV was 8.8%. 
 
2.4.4.1.4.2. Endogenous salivary NE levels 
Firstly, the ranges of endogenous NE in all saliva samples across 4 different dilutions (Table 
2.29) was investigated.  
 
Table 2.29: Endogenous salivary NE levels across varying dilutions in all subjects. 
Salivary NE 
(ng/ml) 
 
Saliva Sample Dilution 
Subject Sample  1:100 1:200 1:400 1:800 
Sample 1 Healthy 93 103 93 115 
Sample 2 Healthy 436 305 324 305 
Sample 3 Healthy *Outside Ref 1108 878 769 
Sample 4 Healthy *Outside Ref *Outside Ref 3918 3258 
Sample 5 Healthy 435 400 377 444 
Sample 6 COPD 620 469 421 389 
Sample 7 COPD 27 22 28 44 
Sample 8 COPD 48 51 40 77 
Sample 9 COPD 28 32 39 38 
Sample 10 COPD 38 57 57 68 
Salivary NE 
(ng/ml) 
Median, IQR 
 
71, 402 103, 354 209, 370 210, 362 
 
* Result above the higher limit of the assay working range (10ng/ml) for the ELISA. Salivary 
NE levels were multiplied by the dilution factor to standardise the results. Ref = reference 
range. 
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Across the four dilutions there was no significant difference in salivary NE levels (p=0.224 by 
Friedman’s test). Thus the levels of NE in saliva across the dilutions appear to be reproducible 
and not significantly affected by sample dilution. Saliva samples 1 and 7 to 10 were 
subsequently chosen to perform the spiking experiments below due to low levels of endogenous 
NE. 
 
2.4.4.1.4.2. Low spike NE saliva recovery and linear dilution experiments 
Salivary NE recovery was variable but improved from 1:100 and 1:200 dilutions compared to 
1:400 and 1:800 (Table 2.30, Figure 2.19). There was however no significant difference in 
salivary NE recovery across the 4 dilutions (p=0.120 by repeated measures ANOVA). 
 
Table 2.30: Low spike salivary NE levels across varying dilutions in both COPD and 
healthy subjects (n = 5). 
*Salivary NE 
(ng/ml) 
Saliva Sample Dilution 
Subject Sample 1:100 1:200 1:400 1:800 
Sample 1 160 (54%) 158 (52%) 256 (152%) 280 (150%) 
Sample 7 114 (76%) 102 (65%) 132 (89%) 130 (79%) 
Sample 8 108 (49%) 99 (41%) 116 (51%) 116 (45%) 
Sample 9 119 (77%) 107 (66%) 131 (83%) 114 (61%) 
Sample 10 146 (83%) 124 (63%) 166 (99%) 161 (83%) 
Recovery 
mean ± SD 
68% ± 15% 57% ± 11% 95% ± 37% 83% ± 40% 
 
*Salivary NE levels were multiplied by the dilution factor to allow for standardisation of the 
results. 
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Figure 2.19: Low range spiked saliva NE recovery.  
Bar chart with SD error bar of mean salivary NE recovery in samples spiked with low 
concentration NE at an increasing dilution factor (n = 5). There was no significant difference 
across dilutions (ns: p=0.120 by repeated measures ANOVA); thus intra-dilution analysis 
cannot be conducted. There is a large variation in the SD error bars as the dilution factor 
increased; this may be due to an increased error for the immunoassay as the lower limit of the 
assay working range (0 to 10ng/ml) is approached; similar to the salivary CRP ELISA as 
discussed above (Section 2.4.2.7, Page 108). 
 
  
ns 
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2.4.4.1.4.3. High spike NE saliva recovery and linear dilution experiments 
Overall there was an improvement in recovery percentage with an increased salivary dilution 
however this was not statistically significant (p=0.681) (Table 2.31, Figure 2.20). Subject 
samples 7, 8 and 9 demonstrated an improvement in salivary NE recovery as the dilution 
increased. Sample 9 was unique as recovery decreased; however, this was still above 80% in 
the 1:800 dilution. This occurred despite selecting samples with “low” endogenous NE 
concentrations and spiking with 7.92ng/ml which should have ensured that the spiked sample 
would be in the assay working range (0-10ng/ml). All five samples analysed at a dilution of 
1:100 were above the higher limit of quantification for the immunoassay.  
 
Table 2.31: High spike salivary NE levels across varying dilutions in both COPD and 
healthy subjects (n = 5). 
Salivary NE 
(ng/ml) 
Saliva Sample Dilution 
Subject Sample 1:100 1:200 1:400 1:800 
Sample 1 *Outside Ref *Outside Ref *Outside Ref *Outside Ref 
Sample 7 *Outside Ref 691 (83%) 767 (92%) 743 (89%) 
Sample 8 *Outside Ref 587 (67%) 718 (83%) 799 (93%) 
Sample 9 *Outside Ref 799 (96%) 771 (92%) 712 (85%) 
Sample 10 *Outside Ref 963 (113%) 901 (106%) 958 (113%) 
Recovery 
mean ± SD 
n/a 90% ± 20% 93% ± 10% 95% ± 12% 
 
* Result above the 10ng/ml higher limit of quantification for the ELISA. 
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Figure 2.20: High range spiked saliva NE recovery. 
Bar chart with SD error bar of salivary NE recovery percentage in samples spiked with high 
concentration NE at an increasing dilution factor (n = 5). There was no statistically significant 
difference across the 3 dilutions (ns: p=0.681 by repeated measures ANOVA) and thus intra-
dilution analysis could not be performed. 
 
Sub-analysis between the low and high range NE spiked saliva sample recovery results 
demonstrated no significant difference in recovery of salivary NE between the two 
concentration ranges (p=0.251 by two-way ANOVA). 
 
 
 
ns 
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2.4.4.1.5. Discussion 
The recovery of salivary NE improves with an increasing linear dilution and this effect is more 
apparent across low range NE spiking experiments. The high range NE recovery experiments 
demonstrated a consistent recovery of salivary NE (greater than 90%) across all 3 dilutions. Of 
interest despite selecting saliva samples with known low endogenous salivary NE levels for 
the spiking experiments, the high range spike of saliva plus dilution at 1:100 yielded salivary 
NE results above the working range for the immunoassay (0 to 10ng/ml). This suggests that 
the immunoassay loses effectiveness at concentrations that approach the higher limit of 
quantification. Interestingly within the low range spike experiments the recovery is 
approximately 30% lower in dilutions below 1:400; this effect is not seen in the high range 
spike experiment where recovery of NE is above 90% for 1:200, 1:400 and 1:800 salivary 
dilutions. Although a 1:400 dilution looks preferable to 1:200 as a minimum saliva sample 
dilution it is important to note the sample preparation time. For saliva samples that require 
1:200 dilution this would involve 7.5ul of saliva and 1.5mls of ELISA wash buffer. A further 
dilution to 1:400 would require a serial dilution or combining the wash buffer (which is used 
to dilute saliva) with a smaller volume of saliva. This is impractical due to the inherent viscosity 
of some saliva samples which does not allow for accurate pipetting of saliva volumes less than 
5ul. In view of this my preferred method would be to serially dilute a 1:200 saliva sample to 
achieve a 1:400 dilution. However, this will increase sample preparation time. A prolonged 
saliva sample preparation time would result in saliva being exposed at room temperature for 
longer where further degradation of NE may occur (Chapter 1, Page 50). Thus equilibrium 
needs to be reached between adequate sample dilution and maximum sample preparation time. 
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2.4.4.1.6. Overall conclusion 
Based on the above experimental results for future NE analysis, the same pre-analysis saliva 
preparation as for CRP (Section 2.4.2.1, Page 92) will be adopted. The intra- and inter-assay 
precision (CV) of 4.8% and 8.8% respectively was below the maximum (10% and 15%) 
accepted error percentage that had been selected. This will continue to be calculated for all 
PMN Elastase ELISA kit (Immundiagnostik, Germany) throughout this thesis to ensure that 
both the intra- and inter-assay precision (CV’s) remain below the accepted and clinical 
thresholds. All saliva samples will be tested in duplicate. The recovery of salivary NE appears 
to be consistent across increasing dilution for both low and high concentration NE samples, 
although a non-significant improvement is observed as the dilution factor increases. A saliva 
dilution of 1:200 was selected and the same test procedure as for serum was maintained. The 
quantifiable ELISA range for salivary NE with a sample dilution of 1:200 is 2.2 to 2000ng/ml. 
Overall, allowing for the above caveats and the small sample size, it can be concluded that 
modification of this serum-based assay can be used reliably on saliva. 
 
For saliva to be an effective diagnostic biological fluid, a standardised sampling protocol for 
saliva collection, processing and storage needs to be established (Chapter 1, Page 50); to deliver 
the most accurate and meaningful results (Mohamed et al., 2012). A review of the literature 
discussed later in this chapter (Section 2.5, Page 169) focusing on factors that can affect passive 
collection of unstimulated whole saliva and the saliva sampling methodology used in studies 
for the target biomarkers in this thesis. This review enabled the generation a pilot sampling 
protocol (Figure 2.21, Page 176).  
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2.5. Optimisation of protocols for saliva collection and processing 
The preferred method for saliva sampling in this thesis is unstimulated whole and 
unfractionated saliva collected via passive drool (Chapter, Page 53). A standardised pre-
sampling protocol needs to be provided for individuals prior to saliva sampling to ensure 
homogeneity of the collected samples. To accomplish this, it was important to understand the 
underlying physiology of unstimulated whole saliva production, the factors that could affect 
this complex production and in situ release of the target analytes under study, and potential 
influences on their variable levels from bloodstream diffusion and stimuli such as diurnal 
release cycles, stress, food intake and medication. 
 
2.5.1. Factors influencing unstimulated salivary flow and analyte levels 
2.5.1.1. Un-modifiable factors 
There are several un-modifiable factors that contribute to reduced unstimulated whole saliva 
flow rate. Flow is lower in women compared to men (Inoue et al., 2006) and in individuals of 
60 years of age and above (Affoo et al., 2015). The total protein composition of unstimulated 
whole saliva has not been found to be differ between genders (Agha-Hosseini et al., 2006).  
 
2.5.1.2. Circadian rhythm effects 
The flow rate of unstimulated whole saliva collected via passive drool has been demonstrated 
to show significant circadian rhythms with the highest flow observed in the afternoon, but 
interestingly total protein content in samples was not found to be variable (Dawes, 1975). 
Unstimulated whole saliva flow rate for samples collected in the morning appears to be 
significantly higher when collected at mid-morning (11:30) as opposed to early morning 
(07:30) (Flink et al., 2005). Circadian rhythms have been observed in salivary glucose (Atwood 
et al., 1991), IgA (Dimitriou et al., 2002) and cortisol (Powell et al., 2013). Salivary CRP levels 
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have been observed as being higher in the morning (07:00) on awakening than in the afternoon 
and evening (Izawa et al., 2013). There are no observations for diurnal effects on PCT and NE 
levels. 
 
2.5.1.3. Fasting and diet effects 
The flow rate of unstimulated whole saliva is decreased after fasting (Rahim and Yaacob, 1991, 
Johansson et al., 1984). Protein secretion however is not significantly altered; it has been 
demonstrated that prolonged fasting does not affect the level of total protein in unstimulated 
whole saliva of healthy individuals (Crosley et al., 2009). Acute dehydration has also been 
shown to decrease salivary flow and also increase total protein content (Walsh et al., 2004). 
Salivary flow can be affected by severe caloric restrictions (Humphrey and Williamson). Food 
or drink high in sugar content or caffeine can stimulate saliva flow rate and lower mouth pH 
levels; both leading to compromised antibody–antigen binding and enzyme activity in 
immunoassays (Granger et al., 2004). Thus avoiding food and fluid (except for water) or 
chewing gum for at least 30 minutes prior to saliva sampling is recommended (Chiappin et al., 
2007). Water consumption has been demonstrated to have no effect on the flow of unstimulated 
whole saliva (Davies et al., 2009) and rinsing the mouth with water prior to saliva sampling 
helps to eliminate residues that may hamper subsequent immunoassay analyses (Nunes et al., 
2011). Acute alcohol consumption has been demonstrated to reduce the total protein content of 
stimulated whole saliva (Enberg et al., 2001), the effects on composition of unstimulated whole 
saliva as yet have not been documented.  
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2.5.1.4. Medication effects 
The effects on saliva of commonly used medications have been extensively investigated; these 
are particularly important to recognise as many COPD patients also present with one or more 
active co-morbidities for which they are receiving specific treatments. 
 
Furosemide and bendroflumethiazide, which are both diuretics, are commonly used in the 
treatment of hypertension and cardiac failure. In healthy individuals they have not been shown 
to affect the salivary flow rate (Nederfors et al., 1989), or total protein content in unstimulated 
whole saliva (Nederfors et al., 2004). Captopril, an angiotensin converting enzyme inhibitor 
used in hypertension does not affect unstimulated saliva flow rates or composition in healthy 
individuals (Nederfors et al., 1995). Additionally, a β1-adrenergic antagonist (metoprolol) used 
in the treatment of ischaemic cardiac disease and hypertension, showed no effect on 
unstimulated salivary total protein concentration or composition (Johnson and Cortez, 1988). 
However, a study involving only males demonstrated that non-selective and β1-adrenergic 
antagonists significantly reduced total protein concentration but did not affect salivary flow in 
both stimulated and unstimulated whole saliva. A large observational study involving over 
1200 participants demonstrated that individuals on diuretics, anti-hypertensive and/or 
analgesics have a reduced unstimulated salivary flow (Narhi et al., 1992) athough the precise 
medication details were not published. Overall, the current working consensus is that these 
types of drugs have the potential to reduce salivary flow. 
 
2.5.1.5. Effects of commonly prescribed COPD medications  
COPD patients are invariably prescribed an array of medications to manage their disease. These 
include: β2-agonists, anti-muscarinic bronchodilators, inhaled and oral steroids, theophyllines 
and mucolytics. From this list, the medications that are particularly noted to be xerogenic are 
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anti-muscarinic bronchodilators (Committee, 2015). One study involving rats receiving 
chronic treatment with β2-adrenergic agonists demonstrated no effects on parotid saliva 
volume, protein concentration or composition (Johnson & Cortez, 1988). However, another 
study exploring chronic β2-adrenoreceptor agonist therapy in childhood asthmatics 
demonstrated decreased flow of stimulated whole and parotid saliva (Ryberg et al., 1991). 
Inhaled anti-muscarinic medications are associated with xerostomia and/or low salivary flow 
(Loesche et al., 1995). A cross-sectional study involving forty asthmatic subjects on inhaled 
corticosteroids and forty non-asthmatic adolescents (median age 13 years) demonstrated no 
difference in unstimulated salivary flow (Santos et al., 2012). Interestingly, it has been 
suggested that asthmatics have a significantly reduced rate of salivary flow which is 
independent of the disease process itself, and likely related to the prescribed inhaled β2-
adrenergic agonists and corticosteroids (Alavaikko et al., 2011). There are at present no 
documented observations on whether the flow of saliva is affected by theophyllines or 
mucolytics. Although it is difficult to draw direct conclusions from studies undertaken 
predominantly in children, it seems appropriate to hypothesise that the medications prescribed 
for COPD are likely to reduce salivary flow. 
 
2.5.1.6. Effects from blood contamination 
Blood and its components can leak into the oral mucosa as a direct result of micro-injury, for 
example: burns, abrasions from tooth brushing or cuts to the cheek tongue or gums. In addition 
to this, poor oral health and related intra-oral pathology such as periodontal disease; gingivitis, 
are likely to increase the chance of blood leakage (Granger et al., 2007a). Smoking can also 
contribute to poor oral health; although increased blood contamination in unstimulated whole 
saliva of smokers compared to non-smoker controls has not been demonstrated (Kim et al., 
2010). Tooth brushing and related micro-trauma leads to a significant effect on protein 
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composition of saliva due to contamination with serum constituents. Thus in saliva sampling 
protocols this should be considered by including a minimum brush to sampling time of 45 
minutes (Hoek et al., 2002). Accurate quantification of salivary blood contamination requires 
assessment of transferrin levels as urine dipstick testing can produce false positives due to 
endogenous salivary peroxidase (Schwartz and Granger, 2004a). Schwartz et al., measured and 
found that testosterone levels in saliva were increased when salivary transferrin was greater 
than or equal to 5000ng/ml. Dehydroepiandrosterone (DHEA) and cortisol were increased at 
transferrin levels greater than 10000ng/ml. In children blood contamination is rare and its 
effects on the measurement of salivary hormones (DHEA, cortisol and testosterone) is small 
(Granger et al., 2007a). For progesterone and estradiol the confounding effect of blood can be 
controlled by visual inspection of sample discolouration. This study also suggests that sampling 
of saliva should be avoided in the first 15 minutes post micro-injury and samples visibly 
contaminated with blood should be discarded (Kivlighan et al., 2005). Recent work has also 
revealed that blood contamination of saliva at 1%, affected the levels of four oxidative stress 
markers (advanced oxidation protein products, glycation end products, free reducing 
antioxidant power and total antioxidant capacity). However, 1% blood contaminated of saliva 
samples are visibly dis-coloured and thus it is possible to exclude these saliva samples from 
analysis by visual/macroscopic inspection (Kamodyova et al., 2015). Overall blood 
contamination appears to only exhibit an affect at visually discoloured or transferrin levels 
above 5000ng/ml. Presently, there are no target studies investigating the effects of blood 
contamination in saliva on salivary CRP, PCT and NE levels. Visual inspection appears to offer 
a crude method for blood contamination screening of saliva sample screen; as urine dipstick 
testing appears to generate false positives, the transferrin assay may be deemed to be more 
reliable.  
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2.5.2. Published saliva sampling protocols for target biomarkers under study 
Current review of the literature shows a varied methodology for sample collection when testing 
unstimulated whole saliva via drool for salivary CRP levels. Several studies do not mention 
whether the participants are fasted or not prior to saliva collection (Azar and Richard, 2011, 
Pederson et al., 1995, Punyadeera et al., 2011, Mohamed et al., 2012). Several studies quote 
(Navazesh, 1993) which states for unstimulated whole saliva collected via passive drool:  
 
Sit in an upright posture, head slightly tilted forward and subjects should refrain from smoking, 
eating or drinking for 1 to 2 hours prior to saliva sampling, rinse their mouths with water and 
then let saliva drip off the lower lip into a collection device (Miller et al., 2014).  
 
The commonest pre-sampling fasting protocol is for participants to provide a sample at 1 to 2 
hours after any food intake (Dillon et al., 2010, Topkas et al., 2012, Rao et al., 2010, Rao et al., 
2011). One study went a step further with pre-sampling fasting protocol by asking participants 
to refrain from drinking coffee, acidic/sweet liquids and smoking for 30 minutes prior to the 
visit (Ouellet-Morin et al., 2011). Another recent approach was to collect unstimulated whole 
saliva upon awakening in the morning (Pace et al., 2013). The only studies to have investigated 
salivary PCT levels do not mention whether there is any restriction on the participants' habits 
prior to saliva sampling (Yousefimanesh et al., 2015, Bassim et al., 2008). Similarly, studies 
exploring NE levels in unstimulated whole saliva do not distinguish restrictions prior to saliva 
sampling (Pederson et al., 1995, Cox et al., 2006). 
 
In the two studies that have utilised unstimulated whole saliva in COPD patients albeit not for 
CRP, PCT and NE quantification the protocols have stated fasting for 90 minutes (Yigla et al., 
2007, Ji et al., 2014). Ji et al., also documented that subjects were not allowed to brush their 
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teeth, eat, drink (except water) or smoke for at least 90 minutes before the visit. Subjects were 
also asked to watch a basket of lemons.  
 
Overall the review above provided the knowledge to generate a pilot saliva sampling protocol 
(Figure 2.21, Page 176). 
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Pre-Saliva Sample Collection 
 Please avoid alcohol for 12 hours before providing a sample. 
 During the hour prior to sampling do not eat, brush or floss teeth or use mouthwash.  
 Rinse your mouth with cold water and wait 5 minutes before saliva collection. 
 
Saliva Sample Collection 
 Sit in an upright position with your held tilted forward. 
 Yawning can also increase saliva. 
 When you are ready, hold the container in from of the mouth and simply drool or dribble 
saliva into the container. 
 The container has a marker level to help you know when a sufficient amount of saliva is 
collected. 
 Please close the container with the lid provided. 
 
Do NOT cough or clear your throat when producing a sample, there must not be any sputum 
or mucus in the sample. 
 
Figure 2.21: Pilot saliva sampling protocol. 
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2.5.3. Refinement of the pilot sampling protocol 
The pilot protocol (Figure 2.21, Page 176) was supplanted to make it more end-user specific. 
Within this pilot protocol several of the pre-sample saliva collection components cannot be 
altered.  These include minimum time from alcohol consumption, tooth brushing, flossing and 
mouth wash gargle to saliva sampling. However, one potentially modifiable factor is fast time.  
 
The method of choice for saliva collection in this thesis is passive unstimulated whole saliva 
via drool the benefits of which have been discussed (Chapter 1, Page 53). One limitation of 
this method is a reduced saliva flow compared to other sampling modalities for example: 
stimulated whole saliva. The factors that further limit salivary flow have been discussed earlier 
in this chapter (Section 2.5.1, Page 169). Briefly, COPD patients represent an older age range, 
are on a range of xerostermic medications and certain co-morbidities for example: diabetes 
mellitus all reduce saliva flow. These saliva-flow reduction factors are un-modifiable. 
Medication burden cannot be manipulated for fear of exacerbating the disease process. 
Importantly, COPD patients with concurrent type 2 diabetes mellitus may not be able to fast 
for prolonged periods of time due to problems with glycaemic control. Finally, COPD causes 
patients to suffer with breathlessness, although this does not affect salivary flow directly, it will 
affect patients’ perceptions of the saliva sampling process if the time to produce an adequate 
volume of saliva is prolonged due to an excessive fast induced saliva flow reduction.  
 
In view of this and the lack of studies investigating the flow of saliva in COPD patients a series 
of experiments was conducted to understand the effects of fasting on unstimulated whole saliva 
flow in COPD patients and its effects on the target analytes in this thesis. These experiments 
would have important implications on refinement of the pilot saliva sampling protocol (Figure 
2.21, Page 176).  
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2.5.4. Exploration of salivary flow in COPD patients and the optimal fast period prior to 
sampling 
Experiments were designed and conducted to address the following outstanding questions not 
addressed by the wider literature. 
 
2.5.4.1. Aims 
1. Is there a difference in the time taken to produce a set volume (2mls) of unstimulated whole 
saliva between healthy controls and COPD patients?  
2. What specific conditions provide for an optimal sample?  
a. Does the duration of fasting affect the rate at which a predetermined volume of 
saliva (2mls) is produced in COPD patients? 
b. Does this fasting period alter the level of biomarkers in saliva retrieved from COPD 
patients? 
 
2.5.4.2. Methods 
Six healthy non-smoker subjects and six COPD patients (Table 2.32) in the stable phase (acute 
exacerbation free for a minimum of six weeks) of their disease were recruited from the 
Directorate of Respiratory Medicine's research and outpatient clinic database (Section 2.3, 
Page 88). All participants gave informed written consent and had adhered to the pilot saliva 
sampling protocol (Figure 2.21, Page 176) prior to the start of the experiment. All saliva 
collections occurred between 09:00 to 12:00 and were conducted in the home environment of 
each participant. Prior to collection of saliva, the participants were asked to consume a snack 
of their choosing for example: toast, biscuits. Once they had finished eating they rinsed their 
mouths with water. Saliva was then drooled into provided ice-cool 15ml pre-marked centrifuge 
tubes (Nunc, Denmark), up to a marked set volume of 2mls; the time taken to produce this 
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volume was timed using the stop-watch function on an iPhone (Apple, USA). Samples were 
placed on ice and stored in the Guy Hilton Research Centre Freezer Room (Keele University, 
UK) at -80oC within 4 hours of collection. 
 
Healthy subjects only provided this initial saliva sample at baseline. COPD patients continued 
the experiment and were asked to provide repeat 2ml saliva samples every 30 minutes up to 
two hours, thus providing five samples in total. These samples were vortex and centrifuged at 
3000rpm for 15 minutes (Section 2.4.2.1, Page 92) prior to salivary CRP, PCT and NE analysis. 
The assay procedures were previously described for CRP (Section 2.4.2.1, Page 90), PCT 
(Section 2.4.3, Page 112) and NE (Section 2.4.4, Page 149). Biomarker analysis for CRP and 
NE was conducted on one microtitre ELISA plate whilst PCT required one VIDAS 
B.R.A.H.M.S PCT kit (bioMérieux, France). 
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Table 2.32: Demographic details for participating healthy and COPD patients. 
Demographics Healthy (n = 6) COPD (n = 6) 
Age, a years 57.3 ± 11.5 55.0 ± 8.2 
Gender, Male, (Female), n 3 (3) 1 (5) 
Smoking Status, Current (Ex), n 0 (2) 1 (5) 
Duration of COPD, a years n/a 7.7 ± 3.7 
FEV1, a % predicted 97.4 ± 8.8 45.5 ± 23.9 
FVC, a % predicted 97.4 ± 7.3 75.0 ± 14.4 
BMI, a(kg/m2) 26.2 ± 4.7 23.1 ± 1.4 
Exacerbations in the last 1 year, an 0 4.8 ± 3.5 
Co–morbidities, n 
None 4 1 
Heart Disease 0 1 
Type 2 Diabetes Mellitus 1 2 
Hypertension 0 4 
Gum Disease 0 2 
Other 1 1 
Treatment, n 
Inhaled β2 agonists, Short Acting, (Long 
Acting) 
0, (0) 6, (3) 
Nebulised β2 agonists (Short Acting) 0 3 
Inhaled Anticholinergic, Short, (Long Acting) 0, (0) 0, (4) 
Inhaled Steroid 0 6 
Oral Theophylline, n 0 1 
Total Number of Oral Medications, an 0.3 ± 0.5 4.5 ± 2.4 
 
Data are presented as: a = mean ± SD. 
 
2.5.4.3. Statistical analysis 
The statistical tests employed are discussed in Section 2.2, Page 86. Specifically, for these 
experiments to standardise the interpretation of these data, the overall time taken to produce a 
fixed volume of saliva was divided by this volume (2mls) to determine a rate of flow: ml/min. 
Salivary NE levels above the higher limit of quantification for the ELISA (2000ng/ml) were 
assigned as 2001ng/ml. No CRP samples were outside the limits of quantification (0.10 to 
30ng/ml) for the immunoassay. 
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2.5.4.4. Results 
Overall the healthy subjects were slightly older: 57.3 ± 11.5 years with a range of 47 to 78 
years compared to the COPD patients: 55.0 ± 8.2 years with a range of 45 - 65 years. Within 
the healthy cohort, subjects 2 and 4 were the only two to have chronic co-morbidities: type 2 
diabetes mellitus and osteoarthritis respectively and requiring regular medication. All COPD 
patients were receiving inhaled β2-short and long-acting agonists and inhaled steroids. In 
addition, COPD patients 7 and 9 received inhaled anticholinergic therapy. Patients 7, 8 and 11 
were also receiving nebulised β2 agonists. Within the COPD cohort, total oral medication was 
4.5 ± 2.4 tablets, only one COPD patient 8 was on an oral theophylline. COPD severity (FEV1 
% predicted) varied between mild to very severe (FEV1: 45.5 ± 23.9%, range: 16 to 83% 
predicted). COPD patient 8 had very severe disease with an FEV1 of 16% and accordingly was 
on continuous supplemental oxygen therapy. COPD patients 7 and 10 had stable chronic gum 
disease, which required no regular treatment. For the whole COPD cohort, the number of 
COPD exacerbations in the past 12 months was 4.8 ± 3.5 episodes (Table 2.32). The respective 
intra-assay CV for the CRP immunoassay was 7.8%; PCT immunoassay 4.8%; NE 
immunoassay 5.0%.  
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2.5.4.4.1. Time to produce 2mls of saliva 
2.5.4.4.1.1. Healthy subjects compared to COPD patients 
The results demonstrate that mean salivary flow rate was slightly faster in COPD patients 
(0.52ml/min) compared to healthy subjects (0.48mls/min); however this result was not 
statistically significant (p=0.25 by independent t-test). Interestingly the healthy subjects appear 
to have a higher degree of saliva flow rate variability compared to the COPD patients (Table 
2.33).  
 
Table 2.33: A comparison of the time taken by all healthy subjects and COPD patients to 
produce a set volume of saliva (2mls), with associated saliva flow rates.  
Healthy 
Subjects 
*Time to 2mls (mins) 
Saliva Flow Rate 
(ml/min) 
COPD 
Patients 
*Time to 2mls (mins) 
Saliva Flow Rate 
(ml/min) 
 1 
5.37 mins 
0.37 ml/min 
7 
4.50 mins 
0.44 ml/min 
2 
6.93 mins 
0.29 ml/min 
8 
40.13 mins 
0.05 ml/min 
3 
7.93 mins 
0.25 ml/min 
9 
2.47 mins 
0.81 ml/min 
4 
6.40 mins 
0.31 ml/min 
10 
3.40 mins 
0.59 ml/min 
5 
8.82 mins 
0.23 ml/min 
11 
3.93 mins 
0.51 ml/min 
6 
1.43 mins 
1.40 ml/min 
12 
2.85 mins 
0.70 ml/min 
Mean Flow ± 
SD  
0.47 ± 0.46 Mean Flow ± SD 0.52 ± 0.26 
 
*saliva sampling flow rates immediately post eating. 
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2.5.4.4.1.2. Saliva sampling flow rates in COPD patients over an increasing fast period 
Across the two hour fast time the mean salivary flow rate is variable within a narrow range 
(0.50 to 0.53ml/min) up to 90 minutes fast time (Table 2.34; Figure. 2.22). At two hour’s post 
eating, a further increase (0.59mls/min) is observed in the COPD patients’ cohort. Overall there 
was no statistically significant change in salivary flow rates across the sub-population (n = 5) 
with increasing fixed fast time (p=0.854 by repeated measures ANOVA).  This result does not 
allow for further sub-analysis to understand the intra-fast time differences of salivary flow 
between COPD patients. 
 
Table 2.34:  A comparison of the time taken to produce a set volume of saliva (2mls) at 
different fast times after eating and associated saliva flow rates in COPD subjects. 
COPD Patients 
 Fast Time  
(mins) 
0 30 60 90 120 
7 
Time to 2mls (mins) 
Saliva Flow (ml/min) 
4.50 
0.44 
6.15 
0.33 
6.50 
0.31 
6.27 
0.32 
3.03 
0.66 
*8 
Time to 2mls (mins) 
Saliva Flow (ml/min) 
40.13 
0.05 
n/a n/a n/a n/a 
9 
Time to 2mls (mins) 
Saliva Flow (ml/min) 
2.47 
0.81 
5.53 
0.36 
3.35 
0.60 
6.28 
0.32 
4.73 
0.42 
10 
Time to 2mls (mins) 
Saliva Flow (ml/min) 
3.40 
0.59 
1.73 
1.15 
2.50 
0.80 
2.40 
0.83 
1.83 
1.09 
11 
Time to 2mls (mins) 
Saliva Flow (ml/min) 
3.93 
0.51 
14.15 
0.14 
11.98 
0.17 
12.22 
0.16 
12.50 
0.16 
12 
Time to 2mls (mins) 
Saliva Flow (ml/min) 
2.85 
0.70 
2.92 
0.69 
2.95 
0.68 
2.28 
0.88 
3.17 
0.63 
 
Mean Flow ± SD 
0.52 
± 0.26 
0.53 
± 0.40 
0.51 
± 0.26 
0.50 
± 0.33 
0.59 
± 0.34 
 
*COPD patient 8 took over 30 minutes to produce the first sample hence there is no time 
recorded for 30, 60, 90 and 120 minutes. Each subsequent sample was approximately 500ul to 
ensure biomarker analysis could be performed for each time point. 
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There are interesting observations when examining the data for individual COPD patients, 
highlighting the inter- and intra- variability in salivary flow rates that can exist within a study 
cohort, especially when small (n = 6). COPD patient 7 demonstrated a decrease in salivary flow 
until the two hour fast time (0.44ml/min to 0.32ml/min), after which the flow rate increased to 
0.66ml/min. COPD patient 9's trajectory appears to be consistent with patients 7, 11 and 12 at 
the 30 minute interval. However at the subsequent fast times COPD patient 9 had another sharp 
rise in salivary flow rate at 60 minutes followed by a decline, then a rise again at 120 minutes. 
In contrast, COPD patient 10 had a rapid rise in saliva flow rate from 0 to 30 minute fast time, 
which subsequently falls from 60 to 90 minutes before rapidly rising by approximately 25% at 
the two hour fast time. COPD patient 11 demonstrates a rapid reduction in flow after 30 minutes 
of fasting from 0.51ml/min down to 0.14ml/min, which remained suppressed (0.14 to 
0.17ml/min) for the subsequent fast times. Interestingly, COPD patient 12 demonstrates a 
gradual reduction in flow rate as fast time increases up to one hour, followed by a substantial 
rise in salivary flow rate to 0.88ml/min, which decreases again by approximately 30% at the 
two hour mark to 0.63ml/min.  
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Figure 2.22:  Saliva flow time in COPD patients at fixed increasing fast times.  
Line chart of saliva flow time across increasing fixed fast times in COPD patients (n = 5). 
Overall there was no statistically significant change in salivary flow rates across this sub-
population with an increasing fixed fast time (p=0.854 by repeated measures ANOVA). 
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2.5.4.4.1.3. Discussion 
COPD patients compared to healthy subjects appear to take a slightly shorter time to produce 
a pre-set volume of 2mls of saliva immediately after eating. This is an unexpected finding, 
although it is not statistically significant as all six COPD patients were on both systemic and 
inhaled therapies that are also known to cause xerostomia (Table 2.32). One possible 
explanation is that the age ranges for the healthy cohort was higher than the COPD patients 
(Affoo et al., 2015). 
 
COPD patients 7, 8 and 11 exhibited the slowest salivary flow within their cohort; they were 
all receiving treatment with nebulised β2-agonists and aerosolised agonists via meter-dose 
inhalers.  COPD patient 8 had the most severe (FEV1 = 17%) disease of the entire cohort and 
correspondingly his salivary flow rate was the lowest. This patient’s total medication burden 
was the highest for the entire COPD cohort with eight oral medications and four inhaled 
medications in total. An overall explanation for an apparent “healthy-equivalent” saliva flow 
rate in this cohort of COPD patients remains elusive. It could be concluded that salivary flow 
in COPD patients is at least equivalent to healthy subjects although the number of subjects 
studied is small. The variability of salivary flow in healthy subjects is established (Neyraud et 
al., 2012); however this degree of variability is not as apparent in the COPD subjects and may 
be related to medication effect. Interestingly the flow rates for COPD patients’ saliva are 
equivalent to published values in healthy subjects (Skopouli et al., 1989, Fenoll-Palomares et 
al., 2004). 
 
Analysis of the overall COPD cohort data appears to show no significant change in the time 
taken to produce 2mls of saliva as the fast time increased. The data however indicate that for 
the majority of COPD patients the fastest time to produce a fixed volume of saliva was 
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immediately after eating; except for patient 10 whose time for producing set volume of   saliva 
increased with duration of fasting. An interesting observation was COPD patients 7, 9, 10 
apparent increase in salivary flow as they approached the two hour fast time. This might be 
explained as a “mouth-watering” phenomenon. These patients had their saliva sampling 
performed at 10:00am; so as the two hour time-point would be approaching 12:00, it is possible 
that the thought of lunch may enhance saliva production. The evidence for this phenomenon 
occurring in humans, and whether it can be triggered by either visual or olfactory cues is 
conflicting.  The current consensus is that there is no true olfactory-parotid salivary reflex in 
humans unlike canines; however atmospheric acidic stimuli, both oral and nasal, can cause 
irritation with an ensuing increase in salivary flow (Lee and Linden, 1991). A separate study 
demonstrated that an olfactory-submandibular reflex does exist (Lee and Linden, 1992). 
Interestingly it has also been shown that handling of food elicits an increase in the total volume 
of saliva in the mouth (Ilangakoon and Carpenter, 2011) perhaps in support of Lee et al. Visual 
cues on the other hand have not been established to increase the flow of parotid saliva 
(Drummond, 1995). Thus it could be concluded that an olfactory stimulus or handling of food 
may have led to an increase in the flow of whole saliva. This provides a potential explanation 
for COPD patient 7 who had begun to prepare a meal. The handling and olfactory stimulation 
of the food may have resulted in the 48% increase in salivary flow. 
 
2.5.4.4.1.4. Conclusion 
Overall 2mls is an acceptable volume for COPD patients to produce within a timeframe of 
approximately five minutes and the overall flow rate in this small group is no different to 
healthy subjects. The flow of saliva is accelerated after eating which subsequently slows and 
then accelerates towards the two hour fast time. The flow of saliva remains above 0.50mls/min 
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(range: 0.50 to 0.59mls/min), which would result in a minimum sampling time of 4 minutes to 
produce 2mls of saliva. 
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2.5.4.4.2. Salivary biomarker levels at different fast times 
2.5.4.4.2.1. Salivary CRP 
The median level of salivary CRP in all COPD patients increased significantly as fast time was 
extended (p<0.006 by Friedman’s test) (Table 2.35, Figure. 2.23). The post-hoc analysis 
however does not demonstrate a particular fast time as having a significant influence on 
salivary CRP levels perhaps due to the small sample size (Table 2.36). 
 
Table 2.35: Salivary CRP levels at increasing fast time in COPD patients. 
 
Salivary CRP 
(ng/ml) 
Fast Time (mins) 
COPD Patients 0 30 60 90 120 
7 2.13 2.44 2.81 3.70 2.98 
8 45.63 36.85 28.10 23.16 25.13 
9 0.71 1.10 1.13 1.38 1.54 
10 2.94 12.26 5.99 13.56 5.73 
11 0.71 0.90 0.83 1.01 1.28 
12 0.26 0.26 0.38 0.65 0.39 
Median, IQR 1.42, 2.03 1.77, 8.86 1.97, 4.29 2.54, 9.99 2.26, 3.69 
 
Table 2.36: Salivary CRP significance levels at increasing fast time in COPD patients. 
Salivary CRP 
(ng/ml) 
Fast Time (mins) 
Fast Time (mins) 0 30 60 90 120 
0 n/a p=0.271 p=0.343 p=0.344 p=0.344 
30 p=0.271 n/a p=0.892 p=0.171 p=0.499 
60 p=0.343 p=0.892 n/a p=0.248 p=0.752 
90 p=0.344 p=0.171 p=0.248 n/a p=0.752 
120 p=0.344 p=0.499 p=0.752 p=0.752 n/a 
 
Post-hoc analysis to determine significant differences in intra-fast time by Wilcoxon Signed 
Rank test. n/a = not applicable. 
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Figure 2.23: Salivary CRP levels at increasing fast time in COPD patients. 
Line chart representing salivary CRP levels in a COPD cohort at increasing fast time (n = 6). 
There was a significant increase in salivary CRP (p<0.006 by Friedman’s Test) as fast time 
increased (n = 6). Intra-fast-time analysis does not demonstrate any significant differences 
between the individual fast-time points. 
  
All COPD patients, except for patient 8, demonstrated higher levels of salivary CRP after two 
hours of fasting compared to baseline; although there are subtle individual variations. 
Interestingly COPD patient 8’s baseline salivary CRP level was well above the others and 
dramatically declined as fasting continued, with a small CRP rise between the 90 minutes and 
two hour fasted samples. In COPD patients 7 and 10 baseline levels of salivary CRP were also 
higher than their peers with the exception of patient 8. COPD patients 7 and 12 demonstrated 
a gradual increase in salivary CRP levels until the 90 minute fast time and fell thereafter. In 
patients 9 and 11, salivary CRP levels gradually rose as fast time increased, although patient 
11 does demonstrate a small rise and fall between 30 and 60 minutes fast times. Of note, 
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salivary CRP levels in COPD patient 10 were highly variable demonstrating a sine wave pattern 
as fast time increased. 
 
The median levels of CRP in the COPD cohort increased significantly as fast time increased 
with a reduction in levels between sampling at 90 and 120 minutes. Interrogation of the results 
revealed that only patient 8's salivary CRP level decreased as fast time increased with a small 
increase between 90 to 120 minutes. This patient's salivary CRP levels at all fast times were 
approximately 10 to 20 times higher than the other COPD patients. This could be explained by 
the patient having very severe COPD (FEV1 16%) and thus the elevated levels actually may 
reflect a systemic footprint of the advanced disease status. In the rest of the cohort, COPD 
patient 7 had higher levels of salivary CRP compared to patients 9, 11 and 12. Although patient 
7 had mild COPD (FEV1 83%), in the prior 12 months the patient has experienced 10 acute 
exacerbations requiring antibiotics and steroids. The higher CRP levels seen in patient 10 likely 
reflect a severe disease state (FEV1 28%) as well as a background history of gum disease; with 
both also likely contributing to sine wave fluctuations in levels. 
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2.5.4.4.2.2. Salivary PCT  
The median levels of salivary PCT in the six COPD patients demonstrated no change over the 
2-hour fast time. As expected this result was not statistically significant (p=0.828 by 
Friedman’s test) (Table 2.37; Figure. 2.24). 
 
Table 2.37: Saliva PCT levels at increasing fast time in all COPD patients. 
 
Salivary PCT 
 (ng/ml) 
Fast Time (mins) 
COPD Patients 0  30  60 90 120  
7 0.10 <0.10 <0.10 <0.10 0.27 
8 0.20 0.21 0.22 0.29 0.21 
9 <0.10 <0.10 <0.10 <0.10 <0.10 
10 <0.10 <0.10 <0.10 <0.10 <0.10 
11 <0.10 <0.10 <0.10 <0.10 <0.10 
12 <0.10 <0.10 <0.10 <0.10 <0.10 
Median, IQR 0.09, 0.01 0.09, 0.004 0.09, 0.004 0.09, 0.004 0.09, 0.09 
 
*salivary PCT below the lower limit of assay quantification 0.10ng/ml assigned as 0.09ng/ml.  
 
The median levels of salivary PCT across patient cohort remained the same for the entire 120 
minutes post eating. COPD patients 9 10, 11 and 12 had salivary PCT levels below the lower 
limit of assay quantification (0.10 ng/ml) throughout the fast period. The reason for COPD 
patient 7’s sudden rise in PCT at the 2 hour fast time is unclear; it is possible it could be due to 
existent gum disease or the onset of an inflammatory response. This PCT rise at 2 hours is 
however not reflected in concomitant salivary CRP levels for this patient: CRP did rise 
markedly from baseline (Table 2.35) at the 90 minute fast point. COPD patient 8's baseline 
salivary PCT level was higher than the others and was mirrored concomitant in his salivary 
CRP levels; again this likely reflects the underlying severe disease state and frequent 
exacerbation status.   
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Fig. 2.24: Salivary PCT levels at increasing fast time in COPD patients. 
 
Line chart representing COPD patients salivary PCT levels at increasing fast time (n = 6). There 
was a no significant change in salivary PCT levels (p=0.828 by Friedman’s Test) as fast time 
increased.   
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2.5.4.4.2.3. Salivary NE 
The median levels of salivary NE in COPD saliva appeared to rise as the fast time increased 
but not statistically significant (p<0.119 by Friedman’s Test) (Table 2.38; Figure. 2.25), 
although as 2 patients had levels above the higher limit of quantification for the entire 
experiment it is difficult to fully interpret these results. 
 
Table 2.38: Salivary NE levels at increasing fast time in all COPD patients. 
Salivary NE (ng/ml) Fast Time (minutes) 
COPD Patients 0 30 60 90 120 
7 >2000 >2000 >2000 >2000 >2000 
8 >2000 >2000 >2000 >2000 >2000 
9 185 >2000 >2000 >2000 >2000 
10 42 433 112 1273 >2000 
11 278 282 394 316 518 
12 4 4 3 34 4 
Median, IQR 232, 1493 1199, 1172 1180, 1810 1619, 1437 1983, 1121 
 
*salivary NE above the higher limit of assay quantification 2000ng/ml assigned as 2001ng/ml. 
 
COPD patients 7 and 8 demonstrated stable salivary NE levels above the higher limit of 
quantification (2000ng/ml) for the immunoassay throughout the two hour test period. COPD 
patient 7 had higher levels of CRP and PCT throughout the fast time although there was more 
variability when compared to peers. The high NE levels in patient 8 reflect concomitant high 
salivary CRP and PCT levels. In contrast COPD patient 9's salivary NE levels increased from 
185ng/ml at baseline to 2001ng/ml at 30 minutes and then remained high thereafter; in this 
patient concomitant salivary CRP levels showed gradual increase over the fast time (although 
levels are low in comparison to peers) whilst PCT did not change.  
 
COPD patient 10’s trajectory for salivary NE levels mirrored changes in CRP levels; there was 
an immediate large progressive rise in NE levels as fast time increased from 42ng/ml at start 
time to greater than 2000ng/ml at two hours. COPD patient 11 demonstrated a much steadier 
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increase in salivary NE with fast time; also reflected in salivary CRP levels. Interestingly 
COPD patient 12 demonstrated very low levels of salivary NE throughout the two hour fasting 
period; consistent with this patient’s salivary CRP levels (the lowest of all COPD patients in 
this experiment) and negative salivary PCT levels. 
  
Chapter 2:  Materials & Methods 
 
  
196 
 
 
Figure 2.25: Salivary NE levels at increasing fast time in COPD patients. 
Line chart representing COPD patients salivary NE levels at increasing fast time (n = 6). The 
line for COPD Patients 7 and 8 shares the line for COPD patient 9 as the salivary NE levels are 
the same from the 30 minute fast time towards 2 hours. There was a no significant change in 
salivary NE levels (p=0.118 by Friedman’s Test) as fast time increased. 
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2.5.4.4.2.4. Discussion 
Overall salivary CRP in COPD patients’ significantly increases up to 90 minutes post fasting 
with levels then reducing at the 2-hour time-point. Interestingly for patient 8 who had the most 
severe disease, CRP levels were the highest post food consumption and steadily declined over 
the two fast period. This observation for COPD patients over two hours may be consistent with 
an initial micro trauma caused by eating which results in higher levels of salivary CRP due to 
blood contamination. Subsequently as the effects of this trauma subside levels fall and perhaps 
if the experimental observations had continued beyond the 2 hour period, levels might have 
reduced further. This would then be consistent with a diurnal effect that has previously been 
observed demonstrating lower salivary CRP levels in the afternoon compared to the morning 
(Izawa et al., 2013). Salivary PCT is stable across 2 hours, with negligible levels for 4 out of 
the 6 COPD patients. This is consistent with the literature, in that PCT levels are normally 
undetectable during “stable health”.  Salivary NE levels are difficult to interpret due to 3 
subjects providing samples that were above the higher limit of quantification for the assay for 
the entire experiment. A significant change over the 2 hours is not demonstrate although 
median levels increase, which like CRP may possibly be related to oral microtrauma. There are 
no published studies for the diurnal variation of NE in saliva; however it is possible that 
contrary to CRP salivary NE levels could be elevated in the afternoon compared to the morning. 
 
2.5.4.5. Overall conclusion 
These preliminary experiments appear to show that most COPD patients can effortlessly 
produce 2mls of saliva within an acceptable timeframe. The effect of xerostermic medications 
in this small COPD group do not appear to significantly influence the flow of saliva when 
compared to healthy subjects and that this saliva volume in clinical studies would not cause a 
problem with patient compliance. Overall salivary biomarker levels do fluctuate post fasting: 
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for PCT. The diurnal changes in salivary CRP warrant attention to time-of-day of testing in 
sample collection protocols whilst the NE results are difficult to interpret but perhaps in a few 
subjects demonstrate the effects of oral microtrauma. 
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2.5.5. Blood contamination in saliva experiments 
Blood contamination appears to have a small effect on salivary hormone levels (Chapter 
2.5.1.6, Page 173); however the potential effects on salivary CRP, PCT and NE have not 
previously been explored. To quantify and compare the levels of blood contamination in saliva 
a commercially available transferrin assay (Biocare Diagnostics, China) and an 8-parameter 
urine reagent stick (Siemens, Germany) were utilised. A transferrin assay was selected as a 
review of the literature highlighted several studies that had quantified salivary transferrin as a 
surrogate for salivary blood contamination (Granger et al., 2007a & Kivlighan et al., 2005). If 
blood contamination is shown to significantly affect the salivary levels of CRP, PCT and NE 
this will have important implications for saliva sampling protocols and pre-analysis saliva 
sample preparation (Section 2.4.2.1, Page 92).  
 
2.5.5.1. Aims 
Accordingly, experiments were carried out to: 
1. Determine effects of blood contamination on levels of CRP, PCT and NE in human saliva. 
2. Explore whether urine reagent sticks can provide meaningful information on blood 
contamination in human saliva samples. 
 
2.5.5.2. Methods 
Firstly, both the transferrin assay and urine reagent test stick assay were modified for saliva-
based testing. 
 
2.5.5.2.1. Transferrin assay 
The transferrin assay used in this experiment is a lateral flow test-strip (Figure 2.26) designed 
for use with stool samples. The test procedure involves adding 100ul of substrate to 1.5mls of 
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assay buffer, which is provided in a purpose-built container: Three drops of the mixture are 
then aliquoted onto the test-strip (S). This is performed by removing a detachable head (which 
reveals a stoma) on the assay solution container, inverting the bottle and pressing. To 
understand the volume per drop and thus standardise the amount of substrate-assay buffer 
mixture being dispensed onto the test-strip, a volume per drop was caluculated. This was 
achieved by aliquoting a series of drops into a 1.5ml eppendorf up to a volume of 500ul. In 
total 17 drops were required to reach the target volume which equates to a volume per drop of 
29.41ul. A volume of 30ul was used for ease of titration and thus 90ul substrate-assay buffer 
solution needs to be dispensed onto the test strip. The assay can then be read after 15 minutes. 
A line is required to form at point (C) for the test to be valid. If transferrin is present above the 
detection threshold, a line appears at point (T). The assay has a lower limit of quantification of 
10ng/ml. 
 
 
Figure 2.26: Transferrin assay test strip.  
Samples are deposited at the point (S). A control line must appear at the point (C); if transferrin 
is present in the sample above the lower limit of quantification (10ng/ml) a line will also appear 
at point (T). The colour intensity of the line at either point (C) or (T) is not important. 
S T C 
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A review of the literature does not identify transferrin levels that can contaminate and affect 
the biomarkers to be investigated in this thesis; yet there is suggestion that certain proteins can 
be affected at levels greater than or equal to 5mg/l, with possible effects observed at levels 
greater than 10mg/l (Section 2.5.1.6, page 172). This assay's lower limit of quantification is 
10ng/ml. Baseline transferrin levels in unstimulated whole saliva via drool in healthy subjects 
have been shown to be less than 4mg/L (Schwartz and Granger, 2004); thus using this assay in 
its unmodified form would have likely resulted in all saliva samples testing positive for blood. 
The assay was modified to reduce the lower limit of quantification from 10ng/ml to 4mg/l. This 
was achieved by reducing the volume of saliva combined with assay buffer from 90ul to 0.25ul.  
 
2.5.5.2.2. Urine reagent stick 
The 8-parameter urine reagent stick (Siemens, Germany) (Figure 2.27) used to assess urinary 
blood contamination contains a series of eight reagent squares which change colour when 
immersed in urine. The colour change for the blood reagent square (A) is compared to a 
reference chart after approximately 60 seconds to quantify the level of blood. The chemistry 
for the blood reagent square is based on haemoglobin's pseudo-peroxidase activity to catalyse 
a reaction between hydrogen peroxide and TMB. This produces a colour change (Figure 2.27) 
from green to dark blue depending on the quantity of haemoglobin. A review of the literature 
(Section 2.5.1.6, Page 173) demonstrates that this method can be unreliable as saliva 
peroxidases can interfere with this reaction, thereby resulting in an increased rate of false 
positives. It may be hypothesised that a high false positive rate generated by the urine blood 
reagent square due to saliva peroxidases may be overcome by reading the reagent square after 
a shorter time frame than recommended for urine. 
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Figure 2.27: Urine reagent stick and colour chart. 
A = blood reagent square, Blood = colour reference chart 
 
The test procedure for the blood reagent square on the 8-parameter urine stick was modified. 
To avoid having to immerse the entire urine reagent stick in saliva 10ul of saliva was aliquot 
onto the reagent square (this volume covered the whole square in saliva) and the colour change 
was subsequently read after 5 seconds; timed with the stopwatch function on an iPhone (Apple, 
USA) 
 
Forty-eight randomly selected saliva samples from 8 different COPD patients’ (6 samples per 
patient) (Table 2.39) who were previously recruited from the Directorate of Respiratory 
Medicine's research and outpatient clinic database (Section 2.3, Page 88) tested for blood 
contamination. Each COPD patient had previously given informed written consent and had 
A 
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provided multiple unstimulated whole saliva samples via passive drool across a varying but 
short time-frame (2 month) All COPD patients had adhered to the pilot sampling protocol 
(Figure 2.21, Page 176) and all samples were collected in ice-cooled collectors and stored in 
the Guy Hilton Research Freezer Room (Keele University, UK) at -80oC as part of an 
established saliva bank until analysis. Analysis of said saliva samples occurred no later than 6 
months after collection. Each sample had previously tested for salivary CRP, PCT and NE 
using the methods described earlier in this chapter for CRP (Section 2.4.2.1, Page 90), PCT 
(Section 2.4.3, Page 112) and NE (Section 2.4.4, Page 149). The purpose of testing multiple 
samples in the same individual was to understand whether there was any inter-sample blood 
contamination variability. Blood contamination was tested for using the modified transferrin 
assay (Biocare Diagnostics, China) and modified 8-parameter urine reagent stick (Siemens, 
Germany) as described above. Pre-analysis sample preparation involved sample thawing at 
room temperature; vortexed and centrifuged at 3000rpm for 15 minutes (Section 2.4.2.1, Page 
92) as per salivary biomarker analysis. Each sample was tested in duplicate with the modified 
transferrin assay and 8-parameter urine reagent stick. 
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Table 2.39: Demographic details of COPD patients. 
Demographics COPD Patients (n = 8) 
Age, a years 67.3 ± 8.7 
Gender, Male, (Female), n 5 (3) 
Smoking Status, Current (Ex), n 0 (8) 
Duration of COPD, a years 6.8 ± 4.7 
FEV1, a % predicted 52.4 ± 17.6 
FVC, a % predicted 78.4 ± 10.9 
BMI, a(kg/m2) 24.7 ± 2.8 
Exacerbations in the last 1 year, an 5.8 ± 2.8 
Co–morbidities, n 
None 1 
Heart Disease 2 
Type 2 Diabetes Mellitus  0 
Hypertension 5 
Gum Disease 2 
Other 2 
Treatment, n 
Inhaled β2 agonists, Short Acting, (Long Acting) 8, (7) 
Nebulised β2 agonists (Short Acting) 0 
Inhaled Anticholinergic, Short, (Long Acting) 1, (7) 
Inhaled Steroid 6 
Oral Theophylline, n 2 
 
Data are presented as: a = mean ± SD. 
 
2.5.5.3. Statistical analysis 
The statistical tests employed are discussed in Section 2.2, Page 86. Specifically, salivary 
biomarker data were logarithmically transformed to allow univariate analysis and 
determination of covariate effect: age, gender, BMI, time of day of sampling, percentage 
positive blood contamination and total co-morbidities on salivary biomarker levels. For the 
transferrin assay saliva samples were assigned a score: 0 = no contamination and 1 = positive 
contamination to allow statistical testing. For the 8-parameter urine stick saliva samples were 
assigned a score: 0 = no contamination and 1 = positive contamination. This allowed correlation 
with transferrin values. The 8-parameter urine stick results were also divided according to the 
respective colour changes using the heamolysed colour scale (Figure 2.27): 0 = negative, 1 = 
trace, 2 = small, 3 = moderate, 4 = large. Spearman’s Rank test was used to assess correlations 
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between the 2 modified assays. Only salivary PCT levels were below the lower limit of assay 
quantification (0.10ng/ml) in this experiment; these samples were assigned as 0.09ng/ml for 
calculation purposes. 
 
2.5.5.4. Results 
In total 13 out of 48 saliva samples tested positive for transferrin and 20 out of 48 samples tested 
positive for blood using the modified testing procedure described above (Table 2.40). The level 
of blood contamination in this group of COPD patients (n = 8) was: transferrin assay (27 ± 
23%) and 8-parameter urine stick (42 ± 39%). All saliva samples that were positive for blood 
using the transferrin assays were also tested positive for blood when using the 8-parameter 
urine stick.  
 
Salivary CRP levels were not significantly different between samples that were classified as 
contaminated with blood either by urine dipstick (p=0.205 by Univariate analysis; p=0.118 
unadjusted for covariates) or transferrin assay (p=0.672; p=0.228 unadjusted for covariates) 
when adjusted for the covariates of age, BMI, gender, COPD disease severity and total co-
morbidities. Sub-analysis of the salivary biomarker levels across the 5 different colour scales 
for the 8-parameter urine sticks revealed no significant difference for: CRP (p=0.170 by 
Kruskall Wallis test), PCT (p=0.562) and NE (p=0.08). There was no significant correlation 
(p=0.677 by Spearman’s Rank test) between the transferrin assay and 8-parameter urine testing. 
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Table 2.40: Demographic breakdown of all saliva samples tested for blood contamination. 
Demographics 
Blood Contamination 
Negative Positive 
Transferrin Assay, n 35 13 
Urine Reagent Stick, n 28 20 
Salivary Biomarkers (Transferrin assay),  
CRP, ng/ml 3.16, 3.68 5.13, 3.50 
PCT, ng/ml 0.09, 0.03 0.11, 0.06 
NE, ng/ml 204, 586 1076, 1133 
Salivary Biomarkers (8-parameter urine test stick),  
CRP, ng/ml 3.59, 3.22 4.25, 5.24 
PCT, ng/ml 0.09, 0.04 0.09, 0.05 
NE, ng/ml 278, 535 721, 1301 
 
Salivary biomarker data is presented as median, IQR.  
 
2.5.5.5. Discussion 
Approximately 27% of the samples tested positive for transferrin, however there was no effect 
on salivary biomarker levels when adjusted for covariates. This result implies that the routine 
testing for blood in saliva samples is unnecessary as significant levels of contamination which 
I defined as greater than 4000ng/ml do not appear to affect salivary CRP, PCT and NE levels. 
Whilst urine reagent sticks appeared to generate comparatively higher false positive results, 
there was 100% agreement with a positive transferrin test. Thus modifications in colour change 
timing for reading the reagent stick may provide useful information. Urine reagent sticks 
therefore may have a role in identifying saliva samples that are not contaminated with blood. 
 
2.5.5.6. Conclusion 
Blood contamination in saliva does not appear to significantly affect levels of CRP, PCT and 
NE. Urine reagent sticks can provide an accurate and easy assessment on blood contamination 
in collected saliva samples with the developed modified protocol. Thus saliva samples will be 
tested for blood contamination by aliquoting 10ul of saliva onto the blood reagent square of 
the urine reagent stick and reading the colour change after five seconds. Although salivary 
levels of CRP, PCT and NE are not affected, blood contamination testing will provide a 
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possible insight into pre-sampling protocol adherence, for example: tooth brushing may lead 
to oral microtrauma and leeching of serum proteins into saliva if the time between sampling 
and brushing is not adhered to. Testing for blood contamination will be conducted for randomly 
chosen saliva samples throughout this thesis. It will occur at the pre-biomarker analysis saliva 
sample preparation stage (Section 2.4.2.1, Page 92) post vortex and centrifugation.  
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2.5.6. Refined saliva sampling and collection protocol 
Taking all above experimental data together, duration of fasting does not have an impact on 
the production of a pre-set volume of saliva. Regarding biomarker levels in the collected saliva, 
PCT and NE levels are not significantly altered as the fast time increases; this is not the case 
for CRP. This has important implications as the pilot protocol (Figure 2.21, Page 176) is to 
have participants abstain from food for at least 2 hours prior to their saliva collection. The 
experiments on salivary analyte levels across increased fast time (Section 2.5.4.4.2, Page 188) 
demonstrates that it is not necessary to have such a prolonged fast time, as there is probably a 
minimal effect on the eventual levels of the biomarkers, at least for PCT and NE.  With respects 
to CRP, as the fast time does appear to affect the level of CRP, sampling should be carried out 
at a consistent time of day for each subject. A reduction in fast time from two hours can be 
justified. Accordingly, the new protocol will stipulate a fast time of 30 minutes prior to saliva 
collection. The result for CRP further enforces that a consistent time of day for sampling as far 
as is practically possible needs to be adhered to with the diurnal effect of saliva sampling on 
CRP, PCT and NE levels being incorporated in analyses throughout this thesis. 
 
The pilot protocol (Figure 2.21, Page 176) was accordingly updated and would be provided to 
patients for all further saliva sampling in this thesis. With respects to blood contamination 
samples visually discoloured with blood will be discarded and participants providing a visually 
discoloured saliva sample will be asked to produce a further sample after approximately 30 
minutes. Saliva samples will be randomly tested to quantify the level of blood contamination 
in the COPD population using an 8-parameter urine test stick (Siemens, Germany) with the 
modified protocol developed earlier in this chapter (Section 2.5.5.2.2, Page 200). 
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Pre-Saliva Collection Instructions 
 Please avoid alcohol for 12 hours before providing a sample. 
 You only need to fast for 30 minutes prior to providing a sample  
 Avoid tooth brushing, flossing or mouthwash for at least 1 hour prior to providing a sample. 
 Please let us know if you have recently used inhalers. 
 
Saliva Sample Collection 
 Rinse your mouth with cold water before saliva collection. 
 Sit in an upright position with your held tilted forward. 
 Thinking of lemons may help. 
 When you are ready, hold the container in front of the mouth and simply drool or dribble 
saliva into the container. 
 The container has a marker level to help you know when a sufficient amount of saliva is 
collected. 
 Please close the container with the lid provided. 
 
Do NOT cough or clear your throat when producing a sample, there must not be any sputum 
or mucus in the sample. 
 
Figure 2.28: Refined saliva sampling protocol. 
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2.6. Development of a COPD PRO Score 
COPD is a complex disease, the assessment and monitoring of which cannot be accurately 
encompassed by spirometry, biomarkers or symptom assessment in isolation. As discussed in 
Chapter 1, Page 34 there remains the need to combine these metrics to produce an accurate 
model of disease status and to capture the “biological march” of COPD in patients. 
 
Having a standardised procedure for saliva collection and processing and established methods 
for biomarker analysis, a PRO score was developed to encompass measureable aspects of 
COPD-related features and incorporation into a patient self-assessment diary. A variety of 
questionnaires have been previously developed and their pros/cons discussed (Chapter 1, Page 
27; Table 1.4, Page 30). Such questionnaires are invariably completed by COPD patients at 
intermittent intervals with a varied recall period. At present there remains the need to develop 
a PRO that can used daily which is accurate in monitoring COPD disease state and simple for 
patients to use. It is now increasingly recognised that a more suitable alternative to periodic 
symptom assessment would be a COPD health status questionnaire that is capable of capturing 
patient-driven disease relevant metrics on a frequent regular basis (Leidy et al., 2014). Such a 
questionnaire within the context of a daily diary would need to be simple and non-intrusive 
specifically avoiding the degree of complexity often associated with, for example the SGRQ 
(Jones, 2001) which is in-practical for daily monitoring. Additionally, PRO scores in COPD 
need to assess some or all of the key symptoms that are important to COPD patients: dyspnoea 
(breathlessness), cough and sputum production, effects on wellbeing and the ability to perform 
activities of daily living (ADL) (Walters et al., 2012). Sputum metrics could include colour, 
volume and texture, the relevance of which have been discussed (Chapter 1, Page 32). Although 
the PRO questionnaires discussed in Chapter 1, Page 27 provide meaningful measures on 
symptom burden, there remains a need to shift from a periodic assessment to a daily patient-
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driven completed diary. This approach is required to examine the temporal and dynamic nature 
of symptoms and health status in COPD patients.  
 
The EXACT-RS (respiratory symptoms) has been shown to be a reliable and valid instrument 
for evaluating respiratory symptoms daily in stable COPD (Leidy et al., 2014). The Shortness 
of Breath and Daily Activates questionnaire has also been shown to be a reliable, valid and 
response measure of dyspnoea when assessed daily in randomised control trials for medical 
product development in COPD patients (Tabberer et al., 2015). The CAT score incorporated 
into a daily diary has been demonstrated to increase during an acute exacerbation of COPD 
when measured daily (Alahmari et al., 2014).  
 
2.6.1. Wellbeing and Self-Assessment diary 
Working from this knowledge base, a PRO was designed and called: “COPD Wellbeing Score” 
questionnaire which enquired about (1) breathlessness, (2) ADL, (3) cough and (4) sputum 
metrics (Figure 2.29). The responses for breathing score, ADL and cough were specifically 
configured so that patients could assign a value based on the baseline or “normal” burden 
(Burge and Wedzicha, 2003). This questionnaire was incorporated in the first instance into a 
paper-based diary “Wellbeing Self-Assessment Dairy” (Figure 2.29) for use alongside salivary 
biomarker testing in a community based study on COPD patients (Chapter 3, Page 213).   
Chapter 2:  Materials & Methods 
 
  
212 
1. Breathing Score 
How was your breathing today? 
Excellent = 1; Good = 2; Fair = 3; Bad = 4; Very Bad = 5 
2. Activity of Daily Living Score 
Has your breathing affected your ability to perform daily activities such as self-
wash/dress, cooking, housework? 
Not at all = 1; A little = 2; A fair amount = 3; Much = 4; Very much = 5. 
3. Do you have a cough? 
Yes = 1; No = 0 
If Yes, 
Much better than usual = 1, Usual =2, Same = 3, Worse = 4, Much worse = 5 
4. Sputum Amount 
How much sputum have you produced? 
None = 1; Up to 5mls (1 teaspoon) = 2; Up to 15mls (1 tablespoon) = 3; Up to 30mls (1 
egg cup) = 4; Up to or greater than 50mls (1 cup) = 5. 
5. Sputum Texture 
How would you describe the produced sputum? 
Watery = 1; Sticky Liquid = 2; Semi-solid = 3; Solid = 4. 
6. Sputum Colour (Participants were provided with a colour chart) 
What is the colour of your sputum?  
Watery, clear, transparent = 1; Watery, cloudy, colourless = 2; Creamy = 3; Light green = 
4; Dark green = 5. 
 
Figure 2.29: COPD Wellbeing Score - manual self-assessment diary. 
The numerical figure after each response indicate the score attached to that particular item. 
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Chapter 3: 
 
Exploration of Levels of C-Reactive Protein, 
Procalcitonin and Neutrophil Elastase in Saliva: 
Comparison Between Health and COPD. 
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3.1. Introduction 
As discussed in Chapter 1, Page 46 saliva is increasingly used as a non-invasive easily 
accessible bio-sample for POC diagnostics instead of blood (Denny et al., 2008, Wong, 2008) 
to inform on infection (Blackbourn et al., 1998, Gallo et al., 1997, Ikuta et al., 2000, Li et al., 
1996, Thieme et al., 1992), drugs (Berlin et al., 2011, Mandel, 1993) and disease states 
(Hanemaaijer et al., 1998, Ji and Choi, 2015, Kaufman and Lamster, 2002, Miller et al., 2010, 
Raff, 2009, Sugimoto et al., 2010, Tishler et al., 1996, Zhang et al., 2015).  
 
Within the field of respiratory medicine, studies using saliva as a bio-sample have explored 
isolation of respiratory tract infections (Robinson et al., 2008) and monitoring of smoking 
status (Berlin et al., 2011, Fagan et al., 2015) and therapeutic drugs (Henkin, 2012).  
 
Salivary eosinophil cationic protein can differentiate between asthmatic and healthy subjects 
(Schmekel et al., 2001). Increased salivary CRP and haptoglobin levels are demonstrated in 
childhood allergic asthma (Rao et al., 2011); raised salivary leukotriene levels differentiate 
aspirin-intolerant asthmatics from tolerant counterparts (Gaber et al., 2008). Recent work has 
demonstrated that inhaled corticosteroid in patients with asthma results in reduced 
concentrations of salivary mucin (Navarrete et al., 2015). 
 
Biomarkers in various body fluids have been associated with COPD pathogenesis and clinical 
outcome (Barnes et al., 2006, Koutsokera et al., 2013). The importance of CRP, PCT and NE 
in COPD has been clearly demonstrated (Chapter 1, Page 64, 69 and 73). Yet despite the merits 
that saliva could offer to practical monitoring of COPD and its exacerbations, only two studies 
have explored its potential clinical role (Ji et al., 2014, Yigla et al., 2007). Ji., et al investigated 
IL-8 and MMP-9, both markers of inflammatory response, demonstrating an inverse correlation 
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with lung function measured by FEV1. They concluded that salivary analysis may be suitable 
for assessment of disease severity in COPD. Yigla., et al explored markers of COPD 
pathogenesis (total antioxidant status, uric acid, peroxidase and super oxide dismutase) in both 
saliva and BAL. They demonstrated that salivary analysis was comparable to BAL. 
 
Presently a gap in knowledge exists for saliva levels of PCT and NE in healthy subjects both 
non-smokers and smokers and for the role of salivary CRP, PCT and NE in patients with 
COPD. The relationship between saliva and serum concentrations of PCT and NE has also yet 
to be clarified. In this community-based cohort study, to address these gaps in the literature 
CRP, PCT and NE levels were explored in unstimulated whole saliva via passive drool 
(Chapter 1, Page 53) using commercially-validated and in-house modified immunoassays, 
(Chapter 2, Page 90). This determined differences between healthy subjects with normal lung 
function and patients with COPD. The target biomarkers were measured at 3 time points within 
a 14-day period. As smoking can influence steady-state biomarker levels (Cazzola et al., 2008), 
the control cohort included life-long never-smokers and current smokers.  
 
Additionally, recognising that biomarkers in isolation may lack sensitivity or specificity for 
disease monitoring in COPD without symptom assessment (Hurst et al., 2006) a novel PRO 
instrument: COPD Wellbeing score was designed (Chapter 2, Page 211) and utilised as part of 
a purposeful paper-based diary “Wellbeing and Self-assessment diary” (Chapter 2, Figure 2.29, 
Page 212). Diary responses were used to determine whether components of the COPD 
Wellbeing score correlated with salivary biomarker levels. 
 
In order to relate salivary biomarker levels to COPD status, data in COPD patients were 
analysed relative to the GOLD stage (percentage predicted FEV1) (Vestbo et al., 2013);
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alongside MRC scores. This provided sufficient information for correlations between target 
salivary biomarkers and validated COPD-relevant objective and subjective clinical metrics. For 
further validation of saliva biomarkers, randomly chosen study participants across all cohorts 
also provided simultaneous blood samples. 
 
The objectives for this chapter: 
1. To further determine the precision of the saliva based and modified immunoassays.  
2. To understand whether saliva sampling is feasible in a study setting with COPD patients. 
3. To understand whether the COPD Wellbeing assessment score can be used as a PRO 
instrument and the relationship of said scores with salivary biomarkers. 
4. To evaluate whether target biomarker levels in saliva can be used to differentiate between 
health and COPD status (Chapter 1, Page 77). 
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3.2. Materials and methods 
3.2.1. Study design 
From January 2010 to March 2012, 143 individuals were recruited consecutively from the 
Directorate of Respiratory Medicine's research and outpatient clinic databases (Chapter 2, Page 
88) to one of 3 cohorts: life-long never-smokers (n = 20); current smokers (greater than 20 pack 
years) (n = 25); or COPD, confirmed by spirometry (Koko Legend II, nSpire, USA) according 
to GOLD criteria (n = 98) (Vestbo et al., 2013). Patients with other respiratory disorders were 
excluded. All never-smokers and smoker subjects had normal lung function. Participants were 
monitored over 14 days (3 visits, one week apart). At visit 1, demographic details were recorded 
(Table 3.1); participants with any infection or unstable illness in the preceding 6 weeks were 
excluded. On each visit, the MRC dyspnoea score was recorded (Fletcher, 1960), spirometry 
(Koko Legend II, nSpire, USA) performed and unstimulated whole saliva via passive drool 
collected (2ml). All participants were provided with, and asked to complete, a daily paper 
(Wellbeing and Self-assessment diary) (Chapter 2, Figure 2.29, Page 212), which incorporated 
scores on breathing, ADL, cough presence and sputum features (volume, colour and texture. 
In-between scheduled visits, study participants were asked to contact me on developing any 
change in symptoms. An exacerbation in COPD patients was defined as an increase in 
respiratory symptoms for two consecutive days, with at least two major symptoms (dyspnoea, 
sputum purulence, sputum volume) or a major plus a minor symptom (wheeze, cold, sore 
throat, cough) (Mackay et al., 2014). Randomly-selected subjects provided simultaneous saliva 
and blood samples. The study had received prior approval from the South Staffordshire 
Research Ethics Committee, 09/H1203/77; Informed written consent was obtained from all 
participants before enrolment into the study. 
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3.2.1.1. Unstimulated whole saliva collection and processing 
Each study participant was provided with verbal instructions and a printed protocol for pre-
saliva collection (Chapter 2, Figure 2.28, Page 209). Briefly, participants were asked to abstain 
from alcohol for at least 12 hours; fast for 30 minutes; refrain from brushing their teeth and 
smoking for 30 minutes, prior to providing saliva samples. Oral hygiene was checked and 
mucosal examination performed at each visit. All visit samples were collected at same time of 
day for each subject where practical. Immediately before collection participants rinsed their 
mouths with 10mls water; they then sat in an upright position, tilted their heads forward, and 
allowed saliva to pool in the mouth before passively drooling into an ice-cooled marked 
centrifuge tubes (Nunc, Denmark) up to a marked set volume of 2mls.  
 
Collected saliva samples were transported on ice and stored in the Guy Hilton Research Centre 
Freezer Room (Keele University, UK) at -80oC until analysis. Pre-saliva analysis sample 
preparation involved thawing of stored saliva samples and centrifugation at 3000rpm for 15 
minutes (Chapter 2, Page 92). All saliva sample measurements were undertaken within three 
months of storage; all biomarker assays were performed in duplicate. Thirty randomly selected 
saliva samples were tested for blood contamination using an 8-parameter urine regent strip 
(Siemens, Germany) with a modified testing procedure (Chapter 2, Page 200). 
 
3.2.1.2. Analysis of biomarkers in saliva 
Saliva biomarker analysis for CRP, PCT and NE was optimised in Chapter 2, Page 90. Briefly, 
CRP was measured in 15ul of saliva using a Salivary ELISA kit (Salimetrics Europe, UK) 
(Chapter 2, Page 90), which has a range of quantification of 0.10 to 30ng/ml. Salivary PCT and 
NE were measured using in-house modified commercial serum based ELISAs. PCT was 
determined in 100ul of saliva diluted 1:2 in PBS-T using VIDAS® BRAHMS PCT kit 
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(bioMérieux, France) (Chapter 2, Page 112) which has a range of quantification of 0.10 to 
400ng/ml. NE was measured in 7.0ul of saliva diluted 1:200 in ELISA wash buffer using PMN-
Elastase ELISA kit (Immundiagnostik, Germany), (Chapter 2, Page 149) which has a range of 
quantification of 2.2 to 2000ng/ml. 
 
3.2.1.3. Analysis of biomarkers in blood 
Peripheral blood was collected in supplement-free tubes and ethylene diaminetetra-acid 
vacutainer tubes (BD Bioscience, New Jersey, USA). Samples were then centrifuged at 
2000rpm for 15 minutes; retrieved serum was stored at -80oC until analysis. Serum CRP was 
measured using ADVIA 2400 Chemistry System (Siemens, Germany) with a lower limit of 
detection as 0.3mg/L; concentrations below this limit were assigned as 0.29mg/L. Serum PCT 
and NE were quantified using same assay kits as for saliva, but following manufacturers’ 
protocols. Serum levels were expressed as ng/ml except for CRP (mg/L). All assays were 
performed in duplicate. 
 
  
Chapter 3:  Healthy & COPD Cohort Study 
 220  
3.3. Statistical analysis 
The statistical tests employed are discussed in Chapter 2, Page 86. Specifically, biomarker data 
were logarithmically transformed to allow Univariate Analysis and determination of covariate 
effect. The reproducibility of salivary biomarker levels was explored using Bland-Altman plots 
expressing the change within a subject. Reproducibility of both the immunoassays and salivary 
biomarker levels was also assessed using CV. 
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3.4. Results 
In total 143 individuals were recruited all control subjects had normal lung function; and 98 
COPD patients (GOLD Stage I, 16; Stage II, 32; Stage III, 39; Stage IV, 11) were all ex-
smokers (over 20 pack year history). Thirty-six COPD patients experienced an exacerbation 
during the course of the community-based cohort study; all controls remained clinically stable. 
Salivary levels of CRP, PCT and NE were measured in all participants (Table. 3.1), with an 
intra- and inter-assay co-efficient of variances of less than 7% and less than 12% respectively 
for all 3 assays. Microscopic blood contamination was tested in 30 randomly selected saliva 
samples using an 8-parameter urine test strip (Siemens, Germany) according to the 
methodology described in Chapter 2, Page 200. Overall there was no significant positive 
contamination detected and no saliva samples were discarded or repeated due to visual 
discolouration. 
 
During the study all participants provided feedback on the method of saliva collection used. 
The general consensus revealed that saliva sampling was preferable to blood. However, study 
participants felt that the aperture of the collector resulted in saliva spillage although 
interestingly the research nurse and study participants both commented that this improved, as 
they got familiar with the sampling process. Further refinements to saliva collection methods 
incorporating patient feedback is considered in Chapter 6, Page 384. 
 
Additionally, patients provided informal feedback on the provided Wellbeing and Self-
Assessment diary; in addition to the structured questions they wished to see a “free-text” area 
to enter their own thoughts related to their health status this is addressed in Chapter 4, Page 
251.  
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Table 3.1: Subject demographics and salivary biomarker profiles for the healthy non-smokers, 
smokers and stable COPD subjects (n = 107).  
Data presented as a = mean ± SD and b = median, IQR. P-values represent the difference between 
control and stable COPD subjects. *Combined with hypertension, **Components of the COPD 
Wellbeing Score. NES = never-smokers, Sm = smokers. ***GOLD classification has been previously 
described Chapter 1, Table 1.2, Page 24. 
 
Control Subjects  
(n = 45) 
Stable COPD Subjects P-
value (n = 62) 
Demographics NES Sm  ***I ***II ***III ***IV 
 (n = 
20) 
(n = 
25) 
(n = 62) 
(n = 
12) 
(n = 19) (n = 25) (n = 6) 
Age, a years 53 ± 17 42 ± 12 67 ± 7 65 ± 10 64 ± 8 68 ± 5 72 ± 4 <0.001 
Gender,  
Male, (Female) 
7, (13) 17, (8) 34, (28) 4, (8) 12, (7) 13, (12) 5, (1) =0.525 
FEV1,  
a(% predicted) 
98.1 ± 
3.7 
99.7 ± 
4.7 
55.7 ± 
22.0 
90.4 ± 
9.2 
64.4 ± 
7.6 
44.1 ± 
3.7 
25.1 ± 
4.2 
<0.001 
BMI, a (kg/m2) 
29.8 ± 
3.6 
25.4 ± 
3.3 
27.3 ± 
7.8 
28.0 ± 
7.0 
28.6 ± 
2.6 
27.3 ± 
1.9 
19.8 ± 
3.6 
=0.378 
Co-Morbidities 
None 15 20 27 9 10 5 3  
*Cardiovascular 3 3 31 2 7 19 3  
Type 2 Diabetes 1 2 10 1 2 7 0  
Gum Disease 2 0 1 0 0 1 0  
Treatment 
Inhaled β2 Agonist  
Short, (Long) Acting 
0, (0) 0, (0) 0, (0) 9, (8) 19, (16) 25, (25) 6, (6)  
Inhaled 
Anticholinergic  
Short, (Long) Acting 
0, (0) 0, (0) 0, (0) 1, (3) 2, (8) 3, (18) 0, (5)  
Inhaled Steroid 0 0 0 8 17 25 6  
Oral Theophylline 0 0 0 0 1 7 2  
Symptom and sputum metrics, b 
MRC Score 
1.00, 
0.25 
1.00, 
0.25 
4.00, 
1.67 
3.00, 
2.25 
4.00, 
1.50 
5.00, 
1.00 
5.00, 
0.00 
<0.001 
**Breathing Score 
2.00, 
1.00 
2.00, 
0.25 
3.00, 
0.00 
3.00, 
1.00 
3.00, 
0.00 
3.00, 
0.00 
3.00, 
0.75 
<0.001 
**ADL Score 
1.00, 
0.00 
1.00, 
0.00 
3.00, 
2.00 
1.00, 
2.00 
3.00, 
2.00 
4.00, 
2.33 
3.00, 
1.50 
<0.001 
**Cough         
**Sputum Amount 
1.00, 
0.00 
1.00, 
1.00 
2.00, 
2.00 
1.50, 
1.00 
2.00, 
1.84 
3.00, 
1.00 
2.50, 
2.50 
<0.001 
**Sputum Colour 
3.00, 
0.00 
3.00, 
0.00 
3.00, 
1.00 
3.00, 
0.75 
3.00, 
0.83 
3.00, 
1.00 
3.50, 
1.00 
<0.001 
**Sputum Texture 
1.00, 
1.00 
2.00, 
0.00 
2.00, 
0.00 
2.00, 
0.50 
2.00, 
0.00 
2.00, 
0.00 
2.00, 
0.00 
<0.001 
Salivary Biomarkers, b 
CRP, ng/ml 
0.89, 
0.35 
1.70, 
1.07 
1.66, 
2.30 
1.62, 
1.36 
2.44, 
2.63 
1.45, 
2.34 
2.34, 
5.94 
<0.002 
PCT, ng/ml 
0.09, 
0.03 
0.13, 
0.09 
0.09, 
0.04 
0.10, 
0.06 
0.09, 
0.04 
0.09, 
0.04 
0.11, 
0.03 
<0.012 
NE, ng/ml 
152,  
96 
408, 
748 
189, 508 
227, 
104 
161, 
491 
189, 
687 
163, 
181 
<0.001 
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3.4.1. Biomarkers across health status 
To reduce the potential bias of stable baseline metrics for the exacerbation cohort within the 
COPD group only stable COPD participants (n = 62) were included in the between-group 
analyses. 
 
3.4.1.1. Salivary CRP 
Salivary CRP levels differed between the 3 groups (p<0.002 by ANOVA), with significant 
increase in COPD patients (median: 1.66ng/ml, IQR: 2.55ng/ml) compared to never-smokers 
(0.89, 0.35ng/ml, p<0.001($) by Mann Whitney U), but not to smokers (1.70, 1.07ng/ml, 
p=0.604). Smokers had higher salivary CRP levels than never-smokers (p<0.001($)) (Figure 
3.1). These differences remained statistically significant (p<0.05 by Univariate Analysis) 
following adjustment for age, gender, sampling time and total co-morbidities; but not for BMI 
(p=0.401). 
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Figure 3.1: Salivary CRP levels from healthy non-smoker, healthy smokers and stable 
COPD subjects.  
A box and whisker plot representing salivary CRP levels in healthy non-smokers and smokers 
alongside stable COPD patients (n = 107). The horizontal bar represents the median; the box 
length represents the interquartile range. Outliers are identified by o (1.5 x the interquartile 
range) Salivary CRP levels differed between the 3 groups (p<0.002 by ANOVA), with 
significant increase in stable COPD patients compared to non-Smokers (*p<0.001($) by Mann 
Whitney U), but not to healthy smokers (p=0.604). Smokers had significantly higher salivary 
CRP levels than never-smokers (*p<0.001($)). These differences remained statistically 
significant (p<0.05 by Univariate Analysis) following adjustment for age, gender, sampling 
time and total co-morbidities; but not for BMI (p=0.401). 
* 
* 
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The CV for salivary CRP variability within subjects was 13%, 27% and 15% for never-
smokers, smokers and stable COPD respectively. The Bland‐Altman plot with upper and lower 
limits (1.96 SD) combing all 3 groups (n = 107) showed good data consistency (difference 
between stable baseline values), with only 2 outliers (Figure 3.2). 
 
 
Figure 3.2: Baseline variability of salivary CRP levels across healthy non-smokers, health 
smokers and stable COPD.  
A Bland-Altman plot of baseline salivary CRP variability in healthy non-smokers and smokers 
alongside stable COPD patients (n = 107). The upper and lower bars represent 1.96 standard 
deviations from the mean. Almost all replicates bar 2 outliers fell within the 95% limits of 
agreement (difference between stable baseline values). 
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3.4.1.2. Salivary PCT 
Salivary PCT levels differed between groups (p<0.012). Salivary PCT was significantly 
elevated in healthy smokers (0.13, 0.09ng/ml) compared to never-smokers (0.09, 0.03ng/ml, 
p<0.011($)) and COPD patients (0.09, 0.04ng/ml, p<0.01($)); but not between COPD patients 
and never-smokers (p=0.362) (Figure 3.3). Following covariate adjustment (age, BMI, gender, 
sampling time and total co-morbidities), there was no significant difference (p=0.563) between 
cohorts. Gender adjustment showed salivary PCT levels were generally lower in females, (0.11 
compared to 0.14 ng/ml [males]: p<0.05).  
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Figure 3.3: Salivary PCT levels from healthy non-smokers, healthy smokers, stable 
COPD subjects.  
A box and whisker plot of salivary PCT levels in healthy non-smokers and smokers alongside 
stable COPD patients (n = 107). The horizontal bar represents the median; the box length 
represents the interquartile range. Outliers are identified by o (1.5 x the interquartile range) and 
* (3 x the interquartile range). Salivary PCT levels differed between groups (p<0.01). Salivary 
PCT was significantly elevated in healthy smokers compared to non-smokers (*p<0.01($)) and 
COPD patients (*p<0.01($)); but not between COPD patients and never-smokers (p=0.362). 
Following co-variate adjustment, there was no significant difference (p=0.563) between 
cohorts. Gender adjustment showed salivary PCT levels were generally lower in females, (0.11 
compared to 0.14ng/ml [males]: p<0.05). 
 
 
* 
* 
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The CV for PCT variability within subjects was 19%, 15% and 14% for never-smokers, 
smokers and stable COPD respectively. The Bland‐Altman plot with upper and lower limits 
(1.96 SD) combing all 3 groups (n = 107) showed good data consistency, with only 4 outliers 
(Figure 3.4). 
 
Figure 3.4: Baseline variability of salivary PCT levels across healthy non-smokers, health 
smokers and stable COPD.  
A Bland-Altman plot of baseline salivary PCT variability in healthy non-smokers and smokers 
alongside stable COPD patients (n = 107). The upper and lower bars represent 1.96 standard 
deviations from the mean. All replicates bar 4 outliers fell within the 95% limits of agreement 
(difference between stable baseline values). 
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3.4.1.3. Salivary NE 
Differences in salivary NE levels were observed between cohorts (p<0.001), irrespective of 
covariate adjustment (p<0.01). Healthy smokers had significantly raised NE levels (408, 
748ng/ml) compared to never-smokers (152ng/ml, 96ng/ml, *p<0.001($)), and stable COPD 
patients (189, 508ng/ml, *p<0.001($)); with no significant difference between never-smokers 
and stable COPD patients (p=0.234) (Figure 3.5). Age appeared to affect salivary NE levels 
(p<0.04), with around 60ng/ml decline for every increasing decade in COPD patients, 
regardless of treatment.   
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Figure 3.5: Salivary NE from healthy non-smokers, healthy smokers and stable COPD subjects.  
A box and whisker plot of salivary NE levels in healthy non-smokers and smokers alongside 
stable COPD patients (n = 107). The horizontal bar represents the median; the box length 
represents the interquartile range. The horizontal bar represents the median; the box length 
represents the interquartile range. Outliers are identified by o (1.5 x the interquartile range). 
Differences in salivary NE levels were observed between cohorts (*p<0.001), irrespective of 
covariate adjustment (p<0.011). Healthy smokers had significantly raised NE compared to 
never-smokers (p<0.001($)), and stable COPD patients (189ng/ml, 508ng/ml, *p<0.001($)); 
with no significant difference between healthy non-smokers and stable COPD patients 
(p=0.234).  
 
* 
* 
Chapter 3:  Healthy & COPD Cohort Study 
 231  
The CV for NE variability within subjects was 32%, 41% and 37% for never-smokers, smokers 
and stable COPD respectively. The Bland‐Altman plot with upper and lower limits (1.96 SD) 
combing all 3 groups (n = 107) showed good consistency of data (difference between stable 
baseline values) with only 7 outliers (Figure 3.6).  
 
 
Figure 3.6: Baseline variability of salivary NE levels across healthy non-smokers, health smokers 
and stable COPD.  
A Bland-Altman plot of baseline salivary NE variability in healthy non-smokers and smokers 
alongside stable COPD patients (n = 107). The upper and lower bars represent 1.96 standard 
deviations from the mean. All replicates bar 7 outliers fell within the 95% limits of agreement 
(difference between stable baseline values). 
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3.4.2. Stratification by disease severity in stable COPD patients 
No significant difference was found across COPD severity defined by FEV1 for: Age, BMI, 
CRP, PCT, NE, breathing score, sputum colour and sputum texture: (p=0.378; p=0.402; 
p=0.558; p=0.945; p=0.619; p=0.126; p=0.823; p=0.227) FEV1 significantly decreased as 
COPD patients’ severity increased (p<0.001), whilst MRC, ADL and Sputum Amount 
significantly increased: (p<0.001; p<0.002; p<0.011 respectively)  
 
3.4.3. Subject-completed PRO scores 
All study participants completed a paper-based Wellbeing and Self-Assessment diary (Chapter 
2, Figure 2.29, Page 212) and MRC score. MRC scores significantly correlated with two 
components of the COPD Wellbeing score (Figure 2.29, Page 212) Breathing score (r = 0.55; 
95% Confidence Interval (CI): 0.34 to 0.70) and ADL score (r = 0.47; 95% CI: 0.25 to 0.64; 
p<0.001 by Spearman's Rank Correlation Co-efficient).  
 
3.4.3.1. PRO scores across health status 
Inter-group analysis demonstrated differences in all components of the COPD Wellbeing score 
between stable COPD, never-smokers and smoker subjects (p<0.001) (Table 3.1). There was 
no significant difference however between never-smokers and smokers for any COPD 
Wellbeing score components. 
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3.4.3.2. Correlation of salivary biomarker levels to subject-completed PRO score. 
To understand and identify whether a relationship exists between the components of the COPD 
Wellbeing Score, MRC and salivary biomarkers further sub-analysis was undertaken. 
 
3.4.3.2.1. Whole study population analysis 
Analysis between salivary biomarkers, COPD Wellbeing score components and MRC score 
across all participants (n = 143), (Table 3.2) revealed correlation of salivary CRP with ADL (r 
= 0.23, p<0.02); sputum amount (r = 0.23, p<0.02) and colour (r = 0.24, p<0.02). Salivary PCT 
did not significantly correlate with any of the PRO instrument metrics. Salivary NE only 
correlated with MRC score (r = 0.29, p<0.01). 
 
Table 3.2: Correlations of whole study population (n = 143) symptom scores and sputum metrics 
to salivary biomarker levels. 
 
 COPD Wellbeing Score 
Salivary 
Biomarkers 
MRC 
Score 
Breathing 
Score 
ADL 
Score 
Sputum 
Amount 
Sputum 
Colour 
Sputum 
Texture 
CRP 
r = 0.08, 
p=0.216 
r = 0.05, 
p=0.448 
r = 0.23, 
p<0.02 
r = 0.23, 
p<0.02 
r = 0.24, 
p<0.02 
r = 0.08, 
p=0.219 
PCT 
r = 0.16, 
p=0.425 
r = 0.05, 
p = 0.903 
r = 0.02, 
p=0.778 
r = 0.08, 
p=0.219 
r = 0.16, 
p = 0.425 
r = 0.07, 
p=0.278 
NE 
r = 0.29, 
p<0.01 
r = 0.09, 
p=0.135 
r = 0.004, 
p=0.952 
r = 0.05, 
p=0.386  
r = 0.02, 
p=0.692 
r=0.12, 
p=0.06 
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3.4.3.2.2. COPD population sub-analysis 
Separate sub-analysis on all COPD subjects (n = 98) for the COPD Wellbeing and MRC score 
(Table 3.3) (note the COPD Wellbeing score had been designed for use in COPD patients), 
(Chapter 2, Page 211) demonstrated salivary CRP correlated with MRC score (r = 0.16, 
p<0.01), breathing score (r = 0.14, p<0.02) (Figure 3.7A-B) sputum amount (r = 0.15, p<0.01), 
colour (r = 0.32, p<0.001) and texture (r = 0.13, p<0.03). Salivary PCT correlated with 
breathing score (r = 0.13, p<0.04) (Figure 3.7C), sputum amount (r = 0.13, p<0.03) and colour 
(r = 0.23, p<0.001). Salivary NE did not correlate with any clinical features. Sputum amount 
and colour correlated with breathing (r = 0.34, p<0.001) and ADL scores (r = 0.34, p<0.001); 
texture correlated only with ADL (r = 0.24, p<0.001).  
 
Table 3.3: Correlations of all COPD patients (n = 98) symptom scores and sputum metrics to 
salivary biomarker levels. 
 
 COPD Wellbeing Score 
Salivary 
Biomarkers 
MRC 
Score 
Breathing 
Score 
ADL 
Score 
Sputum 
Amount 
Sputum 
Colour 
Sputum 
Texture 
CRP 
r = 0.16, 
p<0.006 
r = 0.14, 
p<0.02 
r = 0.11, 
p=0.07 
r = 0.15, 
p<0.013 
r = 0.32, 
p<0.001 
r = 0.13, 
p<0.032 
PCT 
r = 0.04, 
p=0.443 
r = 0.13, 
p<0.04 
r = 0.12, 
 p=0.05 
r = 0.13, 
p<0.033 
r = 0.23, 
p<0.001 
r = 0.11, 
p=0.077 
NE 
r = -0.07, 
p=0.221 
r = 0.11, 
p=0.081 
r = 0.03, 
p=0.646 
r = 0.08, 
p=0.218 
r = 0.07, 
p=0.265 
r = -0.12, 
p=0.15 
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Figure 3.7A-B: Correlations of COPD patients’ PRO and salivary biomarkers levels.  
Scatter plot with line-of-best-fit between all COPD PRO and salivary biomarkers (n = 98). (A) 
Salivary CRP correlated to MRC score (r = 0.16, p<0.01); (B) Salivary CRP correlated to 
Breathing score (r = 0.14, p<0.02) and (C) Salivary PCT correlated to Breathing score (r = 
0.13, p<0.04). 
B 
A r = 0.16 
p<0.01 
r = 0.14 
p<0.02 
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Figure 3.7C: Correlations of COPD patients’ PRO and salivary biomarkers levels.  
Scatter plot with line-of-best-fit between all COPD PRO and salivary biomarkers (n = 98). (C) 
Salivary PCT correlated to Breathing score (r = 0.13, p<0.04). 
  
C r = 0.13 
p<0.04 
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Overall the MRC score and all components of the COPD Wellbeing Score demonstrated 
relevant correlations with salivary biomarkers and intra-correlations as well as comparisons 
with FEV1. Sputum texture however did not offer any additional information beyond other 
sputum metrics after assessment of the total number of individual significances for each sputum 
parameter (Table 3.2, Page 233; Table 3.3, Page 234; Table 3.4 Page 238) and thus further 
refinement of the COPD Wellbeing score would remove this component, (Chapter 4, Page 
251).  
 
3.4.4. COPD Patient exacerbation sub-population 
Thirty-six COPD patients experienced an exacerbation at day 11 ± 3 during the study period 
(Table 3.4). This assessment was performed on either visit 2 or 3 during the study where the 
COPD patients would provide information on the onset of an exacerbation following the 
previous visit. There was no difference in the median baseline exacerbation frequency (1 to 3 
episodes per year) between these patients and those COPD patients that remained stable 
throughout the study.  During an exacerbation episode as would be expected there was a 
reduction in FEV1 (p<0.001), breathing and ADL scores (p<0.006 and p<0.0014); alongside 
changes in sputum (amount: p<0.001, texture: p<0.05 and colour: p<0.001 respectively). 
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Table 3.4: Same COPD patients in stable and exacerbation phase (n = 36) demographics, salivary 
biomarker levels and symptom profiles.  
Demographics Stable Exacerbation p-value 
Age, a years 68 ± 9 ***  
Gender, Male (Female) 17 (19) ***  
FEV1, a(% predicted) 53 ± 23 48 ± 19 <0.001 
BMI, a (kg/m2) 24.0 ± 6.3 ***  
Co-Morbidities 
Nil 5 ***  
Cardiovascular  30 ***  
Type 2 Diabetes Mellitus 4 ***  
Gum Disease 2 ***  
Treatment 
Inhaled β2 agonists  
Short, (Long) Acting 
35, (32) ***  
Inhaled Anticholinergic 
Short, (Long) Acting 
5, (25) ***  
Inhaled Steroid 31 ***  
Oral Theophylline 6 ***  
Symptom & Sputum Metrics, b 
MRC Score 5.00, 1.25 5.00, 1.25 =0.15 
**Breathing Score 3.00, 0.00 4.00, 1.00 <0.006 
**ADL Score 3.00, 1.00 4.00, 2.00 <0.014 
**Increased Cough 0 10 <0.001 
**Sputum Amount 2.00, 2.00 3.00, 2.25 <0.001 
**Sputum Colour 3.00, 1.00 4.00, 0.41 <0.001 
**Sputum Texture 1.94, 0.33 2.06, 0.41 <0.05 
Salivary Biomarkers, b 
CRP, ng/ml 1.61, 1.10 7.35, 10.04 <0.001 
PCT, ng/ml 0.09, 0.06 0.50, 0.71 <0.001 
NE, ng/ml 128, 190 769, 1680 <0.001 
 
Data are presented as: a = mean ± SD or b = median, IQR. P-values represent the difference between 
the two cohorts. *Hypertension included with cardiovascular disease, **COPD Wellbeing Score 
components. ***Variables remained unchanged during an exacerbation from stable values. 
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3.4.4.1. Salivary biomarker levels during a COPD exacerbation 
Comparison of paired stable and pre-treatment exacerbation saliva samples from those COPD 
patients who experienced an exacerbation during the community-based cohort study, 
demonstrated significant elevation in all target salivary biomarkers with exacerbation onset 
(p<0.001), (Figure 3.8). Median salivary CRP concentration increased by 5.74ng/ml (95% CI: 
3.72 to 11.47); median salivary PCT concentration increased by 0.38ng/ml, (95% CI: 0.31 to 
0.54) and median salivary NE concentration increased by 539ng/ml (95% CI: 169 to 982) from 
baseline stable levels during an exacerbation of COPD. 
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Figure 3.8A-B: Salivary biomarkers in COPD exacerbations. 
Box and whisker plots of all 3 salivary biomarker levels in COPD patients in the stable phase 
and during an acute exacerbation of COPD (n = 36). The horizontal bar represents the median; 
the box length represents the interquartile range. Outliers are identified by o (1.5 x the 
interquartile range) and * (3 x the interquartile range). A = salivary CRP; B = salivary PCT. A 
significant elevation in all target salivary biomarkers with exacerbation onset is observed 
(*p<0.001). 
A 
B 
* 
* 
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Figure 3.8C: Salivary biomarkers in COPD exacerbations. 
Box and whisker plots of all 3 salivary biomarker levels in COPD patients in the stable phase 
and during an acute exacerbation of COPD (n = 36). The horizontal bar represents the median; 
the box length represents the interquartile range. Outliers are identified by o (1.5 x the 
interquartile range) and * (3 x the interquartile range). C = salivary NE levels in COPD patients 
during their stable and exacerbation states.  A significant elevation in all target salivary 
biomarkers with exacerbation onset is observed (*p<0.001). 
- 
  
C * 
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3.4.5. Comparison of subject-matched saliva and serum biomarker levels 
Relationships between saliva and serum biomarkers were studied in 22 randomly-selected 
subjects, providing a total of 66 paired saliva–serum samples. Salivary CRP levels were 
approximately 200 times lower than serum; salivary PCT and NE levels were about two-fold 
higher. Salivary CRP and PCT correlated with serum equivalents, r = 0.82, (95% CI: 0.72 to 
0.87), p<0.001 by Spearman's; and r = 0.53, (95% CI: 0.33 to 0.69), p<0.006 respectively 
(Figure 3.9A-B). Salivary and serum NE did not correlate (r = -0.24, p=0.24).  
 
3.4.5.1. Intra-biomarker correlations 
Biomarker cross-analysis demonstrated salivary PCT correlated with serum and salivary CRP, 
r = 0.53, (95% CI: 0.33 to 0.69), p<0.006; and r = 0.73, (95% CI: 0.59 to 0.83), p<0.001 
respectively (Figure 3.9C-D). Salivary NE correlated with both salivary CRP, r = 0.45, (95% 
CI: 0.23 to 0.63), p<0.001, and salivary PCT, r = 0.58, (95% CI: 0.39 to 0.72), p<0.001 (Figure 
3.9E-F). 
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Figure 3.9A-B: Correlations between same subject serum and salivary biomarkers.  
Scatter plots with a line-of-best-fit between salivary and serum biomarker levels in the same 
subject (n = 22). These study participants provided both serum and saliva samples on the same 
visit. A = Salivary CRP levels correlated to serum CRP (r = 0.82, p<0.001); B = Salivary PCT 
levels correlated to serum PCT (r = 0.60, p<0.006). 
A 
B 
r = 0.82 
p<0.001 
r = 0.60 
p<0.006 
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Figure 3.9C-D: Correlations between same subject serum and salivary biomarkers.  
Scatter plots with a line-of-best-fit between salivary and serum biomarker levels in the same 
subject (n = 22). These study participants provided both serum and saliva samples on the same 
visit. C = Salivary PCT levels correlated to serum CRP (r = 0.53, p<0.006); D = Salivary PCT 
levels correlated to salivary CRP (r = 0.73, p<0.001);  
  
r = 0.53 
p<0.006 
r = 0.73 
p<0.001 
C 
D 
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Figure 3.9E-F: Correlations between same subject serum and salivary biomarkers.  
Scatter plots with a line-of-best-fit between salivary and serum biomarker levels in the same 
subject (n = 22). These study participants provided both serum and saliva samples on the same 
visit. E = Salivary NE levels correlated to salivary CRP (r = 0.45, p<0.001) and, F = Salivary 
NE levels correlated to salivary PCT (r = 0.58, p<0.001).  
E 
F 
r = 0.45 
p<0.001 
r = 0.58 
p<0.001 
Chapter 3:  Healthy & COPD Cohort Study 
 246  
3.4. Discussion 
As disease management shifts increasingly towards POC, there is urgency to develop easier, 
less stressful sampling methods especially for monitoring chronic conditions. Having 
established that levels of CRP, PCT and NE can be measured in saliva, this is the first study to 
explore their potential role of salivary CRP, PCT and NE in COPD.  
 
Salivary biomarker targets in COPD patients of varying severity were compared to controls 
(never-smokers and smokers) under real world/working conditions; hence study participants 
with co-morbid conditions were included provided these were clinically stable at time of 
enrolment. To minimise across-cohort demographic variations and circadian influences, 
analysed measurements were then adjusted for potential covariate bias (Janes and Pepe, 2008), 
including sampling times (Izawa et al., 2013).  Non-smoker salivary CRP levels at 0.89ng/ml 
(IQR: 0.35ng/ml) compared favourably to previous observations showing a healthy CRP range 
of 0.02 to 2.5ng/ml in saliva (Izawa et al., 2013, Topkas et al., 2012). Serum CRP has been 
shown to distinguish between COPD and controls (Gan et al., 2004), but not healthy smokers 
from non-smokers (Pinto-Plata et al., 2006). However, no difference in salivary CRP levels 
was demonstrated between my study cohorts following all-covariate adjustment, possibly 
because my controls had relatively high BMIs; indeed, significant differences emerged when 
adjustment excluded BMI. In support, strong correlations between serum CRP and BMI have 
been previously demonstrated (Choi et al., 2013). Whilst correlations between serum CRP 
levels and FEV1 have been reported (Broekhuizen et al., 2006, de Torres et al., 2006), in this 
study there was no association between salivary CRP and FEV1 in stable COPD; this possibly 
reflects the inhaled corticosteroid usage in the COPD patients (Pinto-Plata et al., 2006).  
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This study is the first to explore the presence of PCT in saliva. There was no difference in 
salivary PCT levels between stable COPD patients and healthy controls following covariate 
adjustment. This is not surprising as PCT is normally hardly detectable in blood (below 
0.05ng/ml) unless there is presence of bacterial infections and sepsis or following trauma 
(Uzzan et al., 2006). In agreement with previous observations (Ozcaka et al., 2011, Weitz et 
al., 1987) salivary NE was found to be higher in smokers, but not in stable COPD patients 
(Higashimoto et al., 2008); possibly because all study COPD patients were ex-smokers. 
 
The observed increases in salivary CRP, PCT and NE during COPD exacerbations reflect the 
well-documented elevated CRP and PCT levels in blood (Broekhuizen et al., 2006, Stolz et al., 
2007a, Uzzan et al., 2006) and NE levels in sputum (Ilumets et al., 2008, Ozcaka et al., 2011), 
and have clinical implications. Whilst salivary CRP (or any of the other analytes) may not be 
sufficiently sensitive for evaluating COPD risk and outcome, it could serve as a potential 
surrogate for determining exacerbation onset. However, evidence for CRP or any biomarker in 
isolation to confirm an exacerbation is minimal. On the other hand, these results give support 
to future development of single-platform immunodiagnostics for near-patient measurement of 
salivary CRP alongside other readily available biomarkers, for example, PCT, to enable 
sufficient confidence for exacerbation prediction and stratified intervention. 
  
Alongside such developments, there is still a need to improve understanding of the association 
between biomarker/physiological measurements and PRO in COPD (Paladini et al., 2010). This 
is particularly crucial as no one parameter appears to be sufficiently sensitive or specific in 
monitoring disease status or predicting exacerbation onset. This study reveals significant 
differences in self-assessed symptom scores and sputum metrics (COPD Wellbeing Score) in 
COPD patients, similar to studies using SGRQ and CAT (Nishimura et al., 2013). Furthermore, 
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significant correlations were observed between salivary levels of CRP and PCT and the 
breathing component of the COPD Wellbeing Score, with simultaneous changes occurring in 
both target analyte levels and breathing plus the ADL component of the COPD Wellbeing 
Score during exacerbations of COPD. As other PRO instruments have shown similar 
correlations (Tu et al., 2014), it is likely that particular COPD symptoms will be shown to be 
driven by underlying inflammatory events, with those very severe COPD exacerbations 
requiring hospitalisation possibly exhibiting different clinical and inflammatory profiles 
(Huerta et al., 2013). 
 
Thus, biomarkers or symptoms in isolation will not be sensitive or specific enough to monitor 
longitudinal wellbeing in COPD, and combined bio-clinical profiling is essential, particularly 
if the long-term goal is to enable patient-led prediction of exacerbations and prompt 
intervention. Indeed, combining serum CRP with one increased major exacerbation symptom 
(dyspnoea, sputum volume or purulence) was found to be more sensitive than CRP alone in 
diagnosing exacerbations (Hurst et al., 2006). Of 36 biomarkers analysed, none were sensitive 
or specific enough to diagnose exacerbations without symptom assessment (Hurst et al., 2006). 
 
Most serum components are present in saliva, although compositional differences show that 
saliva is not a passive ultra-filtrate of serum (Rehak et al., 2000).  Biomarkers can enter saliva 
by cellular diffusion or active transport, ultra-filtration within salivary glands and/or via the 
gingival sulcus (Spielmann and Wong, 2011).  The precise mechanisms explaining CRP, PCT 
and NE presence in saliva are unclear. Whilst blood contamination via micro-leakages, 
crevicular fluid overflow from micro-injuries or poor oral health is plausible, biomarker 
measurements in my study were not affected by adjustment for gum disease; samples also 
tested negative for blood. 
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 Both salivary CRP and PCT levels correlated with serum counterparts.  Saliva-serum CRP 
correlations have been previously established (Ouellet-Morin et al., 2011, Punyadeera et al., 
2011). Although Ouellet-Morin et al observed a moderate to strong association between saliva 
and serum CRP, lower correlations were found at serum CRP below 2000 ng/ml compared to 
higher CRP (greater than or equal to 2000 ng/ml).  However, Punyadeera et al., demonstrated 
saliva to serum CRP correlation at concentrations up to 5mg/L. Whilst these studies suggest 
that prediction of serum CRP from saliva CRP is more accurate at higher serum concentrations, 
strong correlations at both low and high CRP levels have been demonstrated. The only study 
on saliva to serum PCT relationship (Bassim et al., 2008) showed no significant correlation 
between the two fluids; however, saliva samples were stored at -27oC rather than the 
recommended -80oC (Slavkin, 1998). 
 
No correlation was found between saliva and serum NE levels. Whilst one possible explanation 
could be localised NE production not manifesting systemically, this contradicts the observed 
moderate to strong correlation of salivary NE to both salivary CRP and PCT levels. An 
alternative explanation could be the rapid inactivation of NE in-vivo (Carter et al., 2013), 
leading to comparatively slower inactivation in saliva than serum.  
 
In acknowledgement that there may be some study limitations which require consideration. 
Although subjects had three assessments over 14 days, longitudinal studies are required and 
essential in order to establish steady–state baselines for the target salivary analytes. These 
would offer precise correlations of biomarker changes to PRO, specifically in the important 
prodromal period leading to an exacerbation. Furthermore, as BMI-matched cohorts appear to 
influence salivary CRP between-group differences, BMI status may need consideration in 
future larger studies.   Another possible shortfall is that this study did not specifically exclude 
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for potential microbial airway colonisation in the COPD group, although participants were 
excluded in the event of any infection or unstable illness in the preceding six weeks to 
enrolment. Acknowledging that the presence of lower airway bronchial colonisation can be 
associated with elevated serum CRP levels in stable COPD patients (Marin et al., 2012), and 
with increased exacerbation frequency (Patel et al., 2002). In mitigation, separate analysis for 
the COPD subjects that underwent an exacerbation and for those who remained stable 
throughout the study; thus minimising bias on target biomarker level results.  Furthermore, 
there was no difference in median exacerbation frequency between the exacerbation group and 
the stable group, which may indirectly indicate that airway microbial colonisation was not 
significantly different between the two groups. 
 
In conclusion this first study established that levels of CRP, PCT and NE can be reliably and 
reproducibly measured in saliva, providing useful clinical information as blood. All three target 
salivary biomarkers increased during COPD exacerbations, with CRP and PCT correlating with 
patient-derived metrics. These findings provide the conceptual basis for the further 
development of salivary biomarkers, alongside PROs, for practical POC monitoring of COPD 
and prediction of exacerbations. This concept will be further explored in a longitudinal cohort 
study (Chapter 4, Page 251). 
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4.1. Introduction  
The study described in Chapter 3, Page 213 has demonstrated that CRP, PCT and NE can be 
reliably detected in the saliva of healthy non-smokers, smokers and COPD patients with 
measurable differences between the three groups (Chapter 3, Page 223). In, addition all three 
biomarkers demonstrate a significant rise during an acute exacerbation of COPD. A novel PRO 
(COPD Wellbeing Score) (Chapter 2, Page 210) could also be used in a purposeful paper-based 
diary (Wellbeing and Self-Assessment diary) (Chapter 2, Figure 2.29, Page 212) with 
correlations between components of this score, the levels of three salivary biomarkers and 
conventional MRC score. Additionally, clinically-relevant changes in the COPD Wellbeing 
score were also observed during exacerbations (Chapter 3, Table 3.4, Page 238).  
 
COPD is a complex disease the severity and progression of which is primarily graded by FEV1 
(% predicted). On the other hand, COPD patients do not uniformly exhibit a monotonous 
decline in FEV1 over time (Casanova et al., 2014). Furthermore, FEV1 only weakly correlates 
with PROs (Casanova et al., 2011). This heterogeneity and lack of a complete comprehensive 
COPD assessment for health status monitoring and progression alongside difficulties in early 
diagnosis support the need for well-designed longitudinal studies that assess the “biological 
march” from unaffected but at risk individuals to those with very severe end-stage COPD 
(Bourbeau et al., 2014).  
 
4.1.1. COPD health status monitoring 
4.1.1.1. Spirometry 
As described above FEV1 decline in COPD patients is variable. Sub-populations within the 
general COPD population have been identified, for example frequent exacerbators (defined as 
more than 2 acute exacerbations per annum) are known to have an accelerated decline in FEV1 
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compared to non-frequent exacerbators (Wedzicha et al., 2013). Increased rates of decline in 
FEV1 have also been observed in COPD patients with the following characteristics: current 
smokers, bronchodilator reversibility and emphysema over a 3-year monitoring period (Vestbo 
et al., 2011).  
 
4.1.1.2. Patient reported outcomes (PRO) 
Current longitudinal studies of PROs in COPD patients have focused on PRO assessments over 
time points several months or years apart. A reduction in FEV1, 6-minute walk distance and 
SGRQ between two time points 4 years apart has been reported; interestingly the study also 
demonstrated a significant reduction in serum CRP (Fu et al., 2014). A decline in exercise 
capacity at 6 monthly intervals over 5 years has also been observed (Oga et al., 2005). A 
separate study with the same protocol (6 monthly assessments over 5 years) investigating 
changes in PROs such as health status, dyspnoea and psychological status also identified a 
significant deterioration in these outcomes. (Oga et al., 2007). Oga et al., found that the 
deterioration in PROs correlated weakly to changes in physiological metrics. A recent study 
assessed changes in CAT Score at baseline and after 1 year in a stable COPD cohort and 
demonstrated a corollary relationship with MRC score (de Torres et al., 2014). 
 
Daily longitudinal symptom monitoring has been used to identify COPD exacerbations, but 
there is lack of information on whether such data can provide sufficient advance warning for 
exacerbation prediction (Johnston et al., 2013). One study utilising a paper-based daily 
symptom diary demonstrated 2 distinct groups: (1) “gradual” with a change in symptoms 4 
days prior to an exacerbation and (2) “sudden” with a change in symptoms on the day of an 
exacerbation (Aaron et al., 2012).  
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Issues relating to compliance and faked-entries for paper-based diaries persist. A recent study 
that utilised paper-based daily diary scores of clinically relevant COPD symptom metrics 
demonstrated a “sharp” increase in scores 2 days prior to an exacerbation of COPD (Walters 
et al., 2012). However, Walters et al 2012., reported a total daily diary compliance of only 53%. 
It can be argued that the validity of this study’s observations; specifically, the challenges of 
validity of unobserved paper diary records as well as, the results and conclusions from paper-
based diary studies are well documented (Stone et al., 2002, Kudielka et al., 2003).  
 
Digitalised (electronic-based) daily diaries could help overcome the aforementioned 
limitations. An electronic-based diary appears to offer obvious advantages over a paper-based 
platform for example: remote data access and supervision; however, a number of key issues 
need to be considered: 
 
1. Does electronic information accurately represent information collected by paper? 
2. Do participants prefer electronic data capture? 
3. Is individual compliance improved? 
4. Can the habit of retrospective data entries be reduced? 
 
Data collected electronically has been shown to be valid and of comparable quality to data 
obtained via paper survey, for the same eventual clinical outcomes.  Importantly, patients also 
appear to prefer electronic data entry over paper (Tiplady et al., 2010, Ring et al., 2008, Bliven 
et al., 2001, Ryan et al., 2002, Boyer et al., 2002, Jamison et al., 2002). 
 
Several studies have demonstrated reduced compliance with paper diaries compared to 
electronic entries; with one study showing only 11% compliance (Stone et al., 2003). 
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Interestingly, paper diaries showed a high rate of “faked” compliance, suggesting retrospective 
data entry (Meltzer et al., 2008). This implies that electronic diaries with compliance-
enhancing features are a more effective and reliable method for the collection of daily diary 
data than a paper-based diary (Lauritsen et al., 2004). Electronic diaries thus appear to 
encourage patients to comply with pre-set protocols and prevent retrospective data entry. 
Electronic diaries that have the ability for participants to provide a “usability evaluation” allow 
the researchers to pick up on areas that are sub optimal. Additionally, participants are willing 
to generate ideas on how to improve the diary interface (Stinson et al., 2006). Electronic diaries 
can also be more easily verified, analysed and summarised than a paper form as data does not 
need to be manually inputted into a database (Walker et al., 2004). 
 
In conclusion from the literature review an electronic diary would provide a clear advantage 
over a paper-based diary for data validity in a longitudinal study. For such an electronic diary 
to be engaging to patients, its design would need to provide a clear, simple and intuitive 
interface. 
 
4.1.1.3. Biomarkers 
It is recognised that serum biomarkers cannot be reliably ascertained on a single measurement 
and multiple measurements over time are required to give a more reliable and precise estimate 
of their levels in stable COPD (Aaron et al., 2010). The ECLIPSE study monitored a panel of 
6 serum biomarkers: white blood cell count, CRP, IL-6, IL-8, fibrinogen and TNF-α and 
identified distinct sub-populations observed at baseline and at one year follow up. A cohort of 
COPD patients (30%) did not show evidence of systemic inflammation whilst 16% had 
evidence of persistent systemic inflammation with the latter group having a higher co-
morbidity and annual exacerbation frequency (Agustí et al., 2012). Presently there are no 
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studies that have monitored biomarkers or panels of biomarkers in COPD patients at a greater 
frequency than annually. 
 
4.1.2. Multidimensional monitoring of health status 
As discussed in Chapter 1, Page 27, multidimensional scores appear to provide a more 
comprehensive assessment of long term mortality. A study monitoring BODE scores over 2 
years concluded that BODE was superior to FEV1 in monitoring progression of COPD; 
however, this study did not attempt to combine the two parameters (Casanova et al., 2014). 
 
Presently there is an incomplete understanding of multidimensional sub-populations in COPD 
and their relationship to monitoring health status in COPD. The combination of some systemic 
biomarkers perform better than single biomarkers in identifying the causal aetiology of an acute 
exacerbation of COPD (Shaw et al., 2014). 
 
The combination of both biomarkers and PROs appears to be a valid strategy as biomarkers in 
isolation are not sensitive enough for diagnostic precision, without symptoms to determine an 
exacerbation of COPD (Hurst et al., 2006). Recent work has used baseline study-enrolment 
characteristics to create sub-population clusters, which were then followed-up longitudinally 
for 3 years. These clusters had variable baseline demographics and differed regarding outcomes 
(Rennard et al., 2015). This is one of the first instances where a combination of baseline 
variables has been used to define sub-population clusters, with the particular cluster being 
monitored longitudinally over a protracted time period. There is however the potential of 
missing a possible temporal component of any of these variables, by just taking a snap-shot of 
data at study enrolment. Overall a well-designed longitudinal study incorporating a holistic 
dynamic of, for example, spirometric indices, PROs and biomarker levels would allow better 
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characterisation of the variable sub-population phenotypes known to exist within the whole 
COPD population. Such an approach enables corollary analysis to determine how all 3 chosen 
metrics would work best together towards design of a sensitive tool for monitoring an 
individual’s COPD journey. 
 
This chapter describes a community-based longitudinal study for COPD patients designed to 
understand whether frequent saliva based testing of the three target biomarkers (CRP, PCT and 
NE) alongside spirometry and the COPD Wellbeing Score could be used to monitor health 
status in COPD. The objectives for this study were:  
 
1. To further determine the precision of the saliva based and modified immunoassays 
2. To understand whether the COPD Wellbeing and Self-Assessment score can be used daily 
in COPD patients. 
3. To explore whether dynamic pattern changes between these 3 chosen metrics could provide 
an early warning (prediction) of deterioration in health status, for example, during the 
“prodromal phase” of an exacerbation.  
4. To determine the baseline variability in these 3 metrics during stable phases of COPD, and 
whether a corollary relationship between them could be established. 
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4.2. Materials & Methods 
4.2.1. Development of an electronic Wellbeing & Self-Assessment diary 
Acknowledging the potential benefits of electronic diary data capture discussed above (Section 
4.1.1.2, Page 253) and the work undertaken in Chapter 3, Page 213 (demonstrating that the 
COPD Wellbeing Score provided potentially meaningful results), an electronic-based 
Wellbeing and Self-Assessment diary was developed. 
 
The results from Chapter 3, Page 221 generated ideas for refinement of the paper-based 
Wellbeing and Self-Assessment diary. The individual components of the COPD Wellbeing 
Score (Breathing, ADL, cough, sputum colour and volume) remained; sputum texture was 
removed (Chapter 3, Page 237). In response to informal patient feedback in the community-
based cohort study (Chapter 3, Page 221), a free-text section was incorporated for COPD 
patients to document their thoughts on how they were feeling and to send messages to the 
research team. The electronic platform was extended to include a separate section for the 
clinical research team to manage their patients and to record: (1) medical and medication 
details; (2) physiological and biological metric results; and (3) a free-text section for clinical 
observations, serving as healthcare reported outcomes (HRO). This latter section would permit 
future cross-reference between the PROs and HROs. 
 
4.2.1.1. Design process 
The initial phase in the construction of the electronic Wellbeing and Self-Assessment diary was 
the design of a story board with key features for the diary and a working logic algorithm for 
how each diary “page” self-interacts. This story-board acted as a framework for the software 
developers (Serious Games International Ltd, Coventry, UK) in the design process. The 
electronic Wellbeing and Self-Assessment Diary App also required a secure support-website 
Chapter 4:  COPD Longitudinal Monitoring  
 259  
to “host” the diary, thus acting as a data repository. The website allowed two-way data transfer 
and crucially remote data observation for entries submitted by patients via the electronic 
Wellbeing and Self-Assessment diary. Both the App and website were programmed by Serious 
Games International.  
 
4.2.1.2. Story-board 
4.2.1.2.1. Electronic platform 
The first step was to choose the software platform for the electronic diary and the hardware 
platform to host the software. The iOS (Apple, USA) operating system was chosen for the 
electronic Wellbeing and Self-Assessment diary development and an iPad (Apple, USA) as the 
platform to install the electronic diary. The advantages of using a tablet over a smart phone 
included: a larger display with better material presentation and easier handling for the target 
patient group. Once installed, the iPad (Apple, USA) required mobile internet capability for 
data transmission to the host website. In the event of poor connectivity, the App functionality 
allowed storage of daily diary data entry until sufficient connectivity was available to transmit 
the data. 
 
4.2.1.2.2. Electronic Wellbeing and Self-Assessment diary components 
4.2.1.2.2.1. Home screen 
The home screen allowed log-in with a unique user name and password (Figure 4.1A). 
 
4.2.1.2.2.2. Logged-in screen 
This screen acted as a welcome page for both COPD patients and the clinical research team. 
This page had two “buttons” for separate access into (1) the Wellbeing and Self-Assessment 
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Diary for patients; and (2) the HRO section for the clinical research team which had its own 
password-protection (Figure 4.1B). 
 
4.2.1.2.2.3. COPD Wellbeing and Self-Assessment screen 
The paper-based COPD Wellbeing and Self-Assessment diary (Chapter 2, Figure 2.29, Page 
212) developed in Chapter 2, Page 210 served as the template for this section. COPD patients 
could select an appropriate response by touching a particular bullet point next to the set of 
questions and assigned an appropriate score (Figure 4.2A-B). Once all entries were completed, 
the assessment was sent by pressing a “submit” button at the bottom of the page. This page 
also contained the “free-text” section where COPD patients could record any other information 
or queries. Once submitted, this section was locked out until the next day to prevent changes 
in entries and/or multiple entries. In the event of missing entries, a message (excluding a blank 
“free-text” section) would appear when the submission button was pressed informing the 
patient that some questions still required a response. If the electronic diary was not submitted 
by 12:00, an alert would be generated to remind individuals. This alert also set off a tone and 
appeared in the notification centre of the iOS (Apple, USA). 
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Figure 4.1A: Electronic Wellbeing and Self-Assessment diary log-in screen shots. 
These screen shots were captured from the electronic Wellbeing and Self-Assessment diary. 
A: Home screen where COPD patients or the research team press the green button to log-in the 
diary which leads to a welcome screen (B).  
 
 
A 
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Figure 4.1B: Electronic Wellbeing and Self-Assessment diary log-in screen shots. 
B: with a welcome message and two buttons. For the COPD patients to complete the diary they 
would select the green button “COPD Wellbeing Score”. The clinical research team press the 
red “Research Team Access” button and enter a password-protected “page” where they 
compete the HRO.  
B 
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Figure 4.2A: COPD Wellbeing Scores in the COPD Wellbeing and Self-Assessment 
Diary. 
These “screen-shots” show the COPD Wellbeing Score section which COPD patients are asked 
to complete daily. Each question is answered by pressing the grey “Select” button. This will 
then turn green and an appropriate score is assigned to the response. There is a free text section 
(white rectangular box) and the green button at the bottom (“Save and Submit Today’s Entry”) 
allows for the completed diary entry to be submitted.  
  
A 
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Figure 4.2B: COPD Wellbeing Scores in the COPD Wellbeing and Self-Assessment Diary.  
This figure (B) shows the “Thank You” message after a diary entry has been successfully 
completed and submitted. This information is then transmitted to the host website once the 
green “Save and Submit Today’s Entry” button is pressed. 
 
 
  
B 
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4.2.1.2.2.4. Research team section screen. 
The HRO (research team section) was only accessible by members of the research team and 
allowed demographic, clinical and physiological data entry (Figure 4.3). This will be password 
protected and only accessible by the research team. If during monitoring, patients were 
undergoing an exacerbation, the research team could press on an exacerbation button at the top 
of the page. This then allowed all recorded COPD Wellbeing Scores during the event to be 
flagged as red on the host website (thereby differentiating them from scores recorded during 
the stable phase) (Figure 4.4). On patient recovery, the research team would then deselect the 
option. 
 
Pressing submit will complete the entry; however the research team can go back and add 
additional entries as this component of the electronic diary will not “lock-out” post entry 
submission. This section will also contain the log-out button so that COPD patients cannot 
“accidently” exit the electronic Wellbeing and Self-Assessment diary. The previous submitted 
entry also appears to ensure continuity with COPD patient details submitted at the previous 
visit. This is particularly important for the free-text section which will have a clinical log of 
the patient’s condition. 
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1. COPD History: Duration (Years) 
2. Smoking Habit: Never Smoker, Current Smoker, Ex-Smoker 
3. Shortness of breath at rest: Y/N; on exertion: Y/N 
4. MRC Score: 1 to 5 
5. BMI: variable 
6. Other Respiratory Illness Y/N 
a. TB, Bronchiectasis. 
7. Other known medical conditions 
a. Heart failure, MI, Angina, Diabetes, Hypertension 
8. Respiratory medications. 
9. Number of hospital admissions for COPD in the past 12 months. 
10. How many acute exacerbations in the last 12 months? 
11. Free text section for further clinical information and the assessment of gum disease. 
 
Figure 4.3: Research team structured clinical log. 
The research team’s section incorporates a structured log with the following questions (1 to 10) 
all of which will need to be populated before an entry can be submitted plus a free text section 
(11). This section will automatically populate with the previous entry that was submitted. Y = 
yes; N = no; TB = tuberculosis; MI = myocardial infarction. Essentially the log serves as a 
portable electronic medical history of the patient. 
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Figure 4.4A: The Research team section screenshots. 
Screenshots of the clinical research team section which allows for a comprehensive clinical 
history to be documented. Once a response has been selected the dark grey button turns light 
grey. The exacerbation menu can be accessed by pressing setting (S) on the top bar. 
 
S 
A 
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Figure 4.4B: The Research team section screenshots.  
This figure highlights the exacerbation menu where pressing the red exacerbation button (B) 
will flag all entries of the COPD Wellbeing Score as an exacerbation on the host-website. This 
figure also highlights the log-out button (C) and the patient reminder button (D). 
 
B 
C 
D 
B 
Chapter 4:  COPD Longitudinal Monitoring  
 269  
4.2.1.2.3. Host website components 
In parallel to the development of the Wellbeing and Self-Assessment Diary App, a dedicated 
password-protected website was constructed to host, monitor and store submitted data. The 
website had its own domain entry; functionality also allowed registration of unique COPD 
patient profiles and graphical display of patients’ metrics over time to help identify clinical 
deterioration.  
 
4.2.1.3. Development and publication 
Over a period of 4 months the electronic Wellbeing and Self-Assessment diary and its website 
were constructed by the software developers, tested by myself and the developers and refined, 
ready for use in the community-based longitudinal study described later in this chapter. 
Prototype electronic diaries were “published” to allow for critique and refinement; with 
Version 1.0 of the electronic Wellbeing and Self-Assessment Diary appearing on the Apple 
App Store (Apple, USA) 07th January 2013 for downloading onto an iPad at no financial cost. 
The name given to the electronic Wellbeing and Self-Assessment diary “App” was (COPD-
SPOC); this term was used following the recommendation of 23 characters for App names by 
the Apple store (Apple, USA). The host-website was also published on the worldwide web on 
the 07th January 2013. URL: http://nstaffs.pipeten.co.uk/index.php/nscontrol677/mlogin 
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4.2.2. Longitudinal study design 
From November 2012 to July 2014 individuals with COPD, confirmed by spirometry according 
to GOLD criteria (GOLD, 2016), were recruited consecutively from the Directorate of 
Respiratory Medicine’s research and outpatient clinic database (Chapter 2, Page 88). These 
COPD patients satisfied criteria of frequent exacerbators (Wedzicha et al., 2013) (defined as 
greater than or equal to two exacerbations per annum) who self-managed their condition and 
had a course of “rescue” medications (antibiotics and steroids) at home which they normally 
used to initiate treatment if they felt they were about to have an acute exacerbation. Patients 
had to be clinically stable and acute exacerbation free for at least six weeks prior to study 
enrolment. This was a community-based study where COPD patients were monitored 
longitudinally in their own home from enrolment at stable baseline through the exacerbation 
period and two weeks’ post-exacerbation recovery. Exacerbation length was defined as the 
period between the date on which an exacerbation was confirmed and the date on which the 
COPD patient reported a return to their normal breathing (Johnston et al., 2013) and completed 
treatment (antibiotics and steroids). Any patient who felt they needed to recommence treatment 
for a further deterioration of their COPD (re-exacerbation) within the two-week post-
exacerbation-recovery phase continued to be monitored until they reported a return to their 
usual self. In this way exacerbations and recovery were patient-defined. COPD patients were 
provided with an iPad (Apple, USA) pre-installed with the electronic Wellbeing and Self-
Assessment diary (COPD-SPOC App) and a unique user-login identification number, which 
would allow diary entry and completion of the self-assessment. The iPad (Apple, USA) had 
3G mobile data transmission and reception capacity (Vodafone, UK) in order to allow 
transmission of all submitted data to the host-website. Patients were also encouraged to enter a 
free-text comment as often as possible. A paper-based version of the electronic Wellbeing and 
Self-Assessment diary was available (Appendix 1, Page 485); however none of the enrolled 
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COPD patients requested a paper-based diary either at enrolment or by converting from the 
electronic diary to a paper-based diary during the study. Patients provided written feedback on 
the diary which will be further explored and discussed in Chapter 5, Page 361. 
 
At visit one, conducted by myself and a specialist respiratory nurse (research team) in the 
patients’ home, a comprehensive HRO was entered into the research section of the electronic 
Wellbeing and Self-Assessment diary (Section 4.2.1.2.2.4, Page 265). This included COPD 
patient demographics, a full clinical history, duration of COPD diagnosis, smoking history, 
MRC dyspnoea score, childhood and other respiratory diseases, co-morbidities and 
medications. Oral hygiene was checked and recorded. Prior to enrolment patients were 
instructed on the saliva collection protocol (Chapter 2, Figure 2.28, Page 209) and a hard copy  
of this protocol was also provided at visit one. Patients were asked to provide 2mls of 
unstimulated whole saliva via passive drool into an ice-cooled 15ml marked centrifuge tubes 
(Nunc, Denmark). Spirometry was performed using a portable Koko Legend spirometer 
(nSpire, USA).  
 
During the first visit, each patient received a “walk-through” on how to use the iPad and 
installed electronic Wellbeing and Self-Assessment diary; specifically how to complete and 
submit the COPD Wellbeing Score section (Figure 4.2A, Page 258) once a day, preferably 
aiming to complete their entry at the same time each day. They were informed that their diary 
scores would be remotely monitored daily by the research team and that a change in symptoms, 
or diary non-completion, would trigger contact by myself or the nurses. The patients could also 
initiate direct mobile contact with then team between the hours of 08:00 to 20:00 Monday to 
Sunday if they so wished or via the free-text section in the electronic diary.  
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Following the first visit, patients were followed up weekly in their own home by the research 
team to obtain a 2ml sample of saliva, perform spirometry and update the HRO. The only 
deviation to this protocol was patients who reported they felt unwell or feeling they were about 
to have an acute exacerbation of COPD. In these circumstances they were advised to contact 
the research team so that an immediate visit could be organised outside of the study hours 
(08:00 to 20:00) within 12 hours. Patients had been taught to produce and deposit a 2ml sample 
of saliva prior to the commencement of any treatment. Spare saliva collectors and plastic 
envelopes were provided to each COPD patient at enrolment; collected samples were kept in 
their home freezer and collected by the team during the “emergency visit”, when spirometric 
and full clinical assessment would also be repeated. The study received prior approval from 
NRES Committee North West - Greater Manchester South, 12/NW/0623; all participants gave 
informed written consent. 
 
4.2.2.1. Unstimulated whole saliva collection and processing 
Each participant received verbal instructions and a printed protocol for saliva collection 
(Chapter 2, Figure 2.28, Page 209). Briefly, patients were asked to abstain from alcohol for at 
least 12 hours; fast for 30 minutes; refrain from brushing their teeth and smoking for 30 
minutes, prior to providing saliva samples. Oral hygiene was checked and a mucosal 
examination was performed at each visit. All visit saliva samples were collected at the same 
time of day for each COPD patient as far as practically possible. Immediately before collection 
COPD patients rinsed their mouths with 10mls tap water; they then sat in an upright position, 
tilted their heads forward, and allowed saliva to pool in the mouth before passively drooling 
into ice-cooled collectors up to a pre-marked volume of 2mls.  
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Collected saliva samples were transported on ice and stored within 4 hours of collection in the 
Guy Hilton Research Centre Freezer Room (Keele University, UK) at -80oC until analysis. Pre-
saliva analysis sample preparation involved sample thawing and centrifugation at 3000rpm for 
15 minutes (Chapter 2, Page 91). All saliva sample measurements were undertaken within three 
months of storage; all biomarker assays were performed in duplicate. Random saliva samples 
were tested for blood contamination with an 8-parameter urine regent strip (Siemens, Germany) 
using a modified testing procedure (Chapter 2, Page 200). 
 
4.2.2.2. Analysis of biomarkers in saliva 
Protocols for analysis of CRP, PCT and NE levels in saliva were established in Chapter 2, Page 
83. Briefly, CRP was measured in 15ul of saliva using a Salivary ELISA Kit (Salimetrics 
Europe, UK), (Chapter 2, Page 90) which has a range of quantification of 0.10 to 30ng/ml. 
Salivary PCT and NE were measured using in-house modified commercial serum based 
ELISAs. The PCT was determined in 100ul of saliva diluted 1:2 in PBS-T using a VIDAS 
BRAHMS PCT kit on the mini-VIDAS instrument (bioMérieux, France) (Chapter 2, Page 112) 
which has a range of quantification of 0.10 to 400ng/ml. The NE was measured in 7.0ul of 
saliva diluted 1:200 in ELISA wash buffer using PMN-Elastase ELISA Kit (Immundiagnostik, 
Germany), (Chapter 2, Page 149), which has a range of quantification of 2.2 to 2000ng/ml. 
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4.3. Statistical Analysis 
The statistical tests employed are discussed in Chapter 2, Page 86. Specific extra tests for this 
study are documented in this section. A power calculation was conducted during the 
preliminary study design process which demonstrated that a minimum sample size of 40 COPD 
patients was required to detect a significant change in baseline salivary biomarker levels for 
prediction of the onset of an acute exacerbation of COPD. Thus minimum target patient 
recruitment for this study was set at 40 COPD patients.  
 
To conduct preliminary analysis of the longitudinal data set (PRO, saliva biomarkers and 
spirometry) the data was split into four distinct classifications (Table 4.1). These divisions 
made data processing and interpretation easier and also facilitated identification of any early 
signals/subtle changes in the period leading to the onset of an acute COPD exacerbation 
(prodromal phase).  
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Table 4.1: Data classification definitions. 
 COPD Disease Phase 
 
*Stable Prodromal **Exacerbation 
Post-
Exacerbation-
Recovery 
Definition 
The period from 
enrolment to 8 
days prior to the 
onset of an 
exacerbation 
The period 
between 7 to 1 
days prior to 
the onset of an 
exacerbation 
The period from 
exacerbation onset 
and start of 
treatment (Day 0) 
to treatment 
completion and 
when patients felt 
their breathing 
had normalised  
(Day 7) 
The immediate 
period (14 
days) following 
treatment 
completion 
 
*COPD patients had to be stable for at least 6 weeks prior to enrolment into the community-
based longitudinal study.  
**exacerbation phase onset was COPD patient-defined; the first day (Day 0) of this phase was 
when patients felt they needed to commence treatment for an acute exacerbation of COPD. The 
length of the exacerbation phase for all COPD patients was set at 7 days, equivalent to the 
number of days of their usual prescribed course of treatment with antibiotics (amoxicillin 
500mg three times a day or doxycycline 100mg once a day) and prednisolone 30mg a day. 
 
COPD patients’ stable phase data collected across multiple time-points (PROs, spirometry and 
salivary biomarkers) were used for initial data analyses across the 4 phases. Latent class growth 
analysis (LCGA) was performed on the three salivary biomarkers (log transformed) and 
spirometric values (FEV1 and FVC). Change point analysis (CPA) with Cumulative sum charts 
(CUSUM) (where needed) was used to analyse the COPD Wellbeing Scores. Index 
exacerbation data were grouped into principal components using factor analysis (Bafadhel et 
al., 2011b) and exacerbation salivary biomarkers, using area under the curve (AUC) and 
receiver operating characteristics (ROC), were split into clinically meaningful thresholds.  A 
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Bonferroni correction was applied in cases of multiple comparison testing. A p-value of less 
than 0.05 was considered statistically significant. 
  
4.3.1. Latent class growth analysis 
Latent class growth analysis is a statistical technique that groups a variable repeatedly 
measured longitudinally into hypothetical trajectory classes. Latent class growth analysis 
(LCGA) has been increasingly recognised for its usefulness in identifying homogenous sub-
populations within a larger heterogeneous population, and particularly for the identification of 
meaningful individual sub-population clusters based on their trajectories over time (Jung and 
Wickrama, 2008). Hence this analysis could be applied to COPD patient populations to 
determine sub-population clusters based on common longitudinal variability of a target 
variable. This approach could provide meaningful information on COPD patients as certain 
parameters for example: FEV1 do not manifest a monotonous decline over time (Casanova et 
al., 2014). Thus grouping COPD patients based on a variable change over time may provide a 
more comprehensive assessment of the particular variable in question for example: FEV1. 
 
LCGA was applied to better understand whether clusters existed for FEV1, FVC and all three 
salivary biomarkers within the stable prodromal phase data. The baseline co-variates (Age, 
Gender, BMI, FEV1, Total Co-morbidities) for these identified COPD patient clusters were 
then tested using multinomial analysis to explore whether significant differences in these 
characteristics existed between the clusters. 
 
LCGA is an iterative process where calculation occurs in a step-wise approach with increasing 
cluster numbers; meaning that the target population would be analysed assuming that just 1 
sub-population cluster exists then 2 sub-population clusters and so on. To determine whether 
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the optimal number of sub-population clusters have been chosen a goodness-of-fit and posterior 
probabilities tests were employed. This is important as a model can become increasingly 
complex and thus prone to error when too many parameters (in this chapter: clusters) are 
applied. I utilised two goodness of fit tests: Bayesian information criterion (BIC) and Bootstrap 
log-likelihood (BLRT). The BIC value determines the goodness of fit for the model in which 
the lower the value, the more optimal the number of clusters (Nylund et al., 2007). The BLRT 
attaches a statistical significance on whether an increased number of clusters (n compared to 
n-1) in the model results in a significant improvement in the allocation of subjects to their 
respective clusters (McLachlan and Peel, 2004). The results from these tests generate a 
statistical significance of whether increasing the number of clusters would improve sub-
population cluster membership. The BIC value and p-value can be used as a guide in 
conjunction with posterior probabilities to decide the overall number of sub-population clusters 
(Posada and Buckley, 2004).  
 
In using the above approach, it is first important to understand the way LCGA assigns 
individuals to a particular sub-population cluster. When a LCGA model is calculated each 
individual (for example, COPD patients in this study) are assigned to a cluster based on the 
trajectory of a target value (for example, salivary biomarker or spirometric indices in this study) 
over time. Cluster membership is however assigned based on the highest posterior probability 
across the number of clusters being tested.  
 
For example: If COPD patient “x” is being tested in a 3 cluster LCGA their posterior 
probability membership for each cluster may be as follows: Cluster 1: 75%, Cluster 2: 15%, 
Cluster 3: 20%. The LCGA analysis would assign this COPD patient as belonging to cluster 1 
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based on the highest posterior probability (expressed as a percentage). However, this COPD 
patient “x” may also share features with the other 2 sub-population clusters.  
 
Thus looking at the posterior probabilities for cluster membership can help to decide the 
optimal number of clusters to create as homogenous a sub-population as possible (Rzewuska 
et al., 2015). 
 
4.3.2. Change point analysis (CPA) 
Change point analysis (CPA) is a statistical technique that aims to identify a time-point when 
a longitudinally repeated measured variable changes its probability distribution. This allows 
for the location of multiple change points in trajectory of real time life data sets and is sensitive 
to subtle changes. The analysis is a combination of CUSUM (a sequential analysis technique) 
and bootstrapping which assigns a confidence interval for each change. The technique is 
superior to CUSUM in isolation and other methods for example moving averages and can be 
applied to non-parametric data (Gavit et al., 2009). This mathematical technique will be applied 
to the daily COPD Wellbeing Score across the 4 defined COPD phases (Table 4.1), but not to 
salivary biomarkers or spirometric indices due to the reduced number of data points as these 
parameters were quantified weekly.  
 
4.3.3. Factor analysis 
Factor analysis was conducted on the index exacerbation values for spirometry, PROs and 
salivary biomarkers to understand whether the principal components of an exacerbation can be 
grouped together. 
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4.4. Results 
In total 60 COPD patients passed the inclusion/exclusion criteria and were recruited into the 
study; subsequently 3 patients were withdrawn due to illness and 2 due to non-compliance with 
the study protocol. The remaining 55 COPD patients were all ex-smokers (greater than 20 pack 
year history; and stopped smoking for over 1 year) and represented various stages of disease 
severity (GOLD Stage I, 7; Stage II, 24; Stage III, 19; Stage IV, 5). The cohort characteristics 
are shown in Table 4.2. Total duration of all COPD patients in the community-based 
longitudinal study was 14.3 ± 9.9 weeks. All patients (apart from 6) experienced at least one 
exacerbation during the study period. 
 
These 55 COPD patients (Table 4.3) were sub-divided into two cohorts: 49 exacerbators and 6 
non-exacerbators who remained stable throughout their participation in the community-based 
longitudinal study. As noted above, despite all recruited COPD patients having reported a 
minimum of two exacerbations in the preceding 12 months prior to enrolment, there were 6 
COPD patients who failed to exacerbate. Furthermore, some of the patients who had an acute 
event, exacerbated early on in the study period and therefore had a reduced recorded data-
length for their stable phase (Table 4.4, Page 282). 
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Table. 4.2: Total study population baseline and stable phase characteristics.  
 
 
COPD Patients  
(n = 55) 
Demographics 
 I II III IV *p-
value 
(n = 55) (n = 7) (n = 24) (n = 19) (n = 5) 
Age, ayears 68.4 ± 7.8 70.1 ± 5.5 66.3 ± 8.2 70.5 ± 7.9 67.8 ± 7.4 =0.227 
Gender, Male (Female) 27 (28) 2 (5) 13 (11) 10 (9) 2 (3) =0.214 
Duration of COPD, ayears 8.1 ± 6.5 10.9 ± 10.1 6.6 ± 4.4 9.4 ± 7.7 6.8 ± 3.1 =0.732 
FEV1, a % predicted 
53.6 ± 
18.2 
86.4 ± 6.6 59.9 ± 9.0 40.6 ± 4.2 25.5 ± 7.5 <0.001 
FVC, a % predicted 
77.8 ± 
14.6 
102.6 ± 10.3 80.0 ± 9.1 72.0 ± 7.3 54.8 ± 8.7 <0.001 
BMI, a(kg/m2) 27.0 ± 5.4 29.1 ± 5.2 28.3 ± 5.5 24.9 ± 4.9 25.5 ± 5.3 =0.086 
MRC Score, b n 3.00, 1.00 3.00, 0.50 3.00, 1.50 3.00, 1.00 3.00, 2.75 =0.997 
Exacerbations in the last 1 
year, an 
4.3 ± 2.4 4.9 ± 3.3 4.3 ± 1.1 4.2 ± 3.6 4.2 ± 1.3 =0.940 
Co-morbidities  
None 13 3 5 3 2  
Cardiovascular 12 1 7 2 2  
Type 2 Diabetes Mellitus 7 2 2 2 1  
Hypertension 21 3 9 7 2  
Gum Disease 1 0 1 0 0  
Other 23 3 9 9 2  
COPD Treatment  
β2-Agonists, 
Short Acting, (Long Acting) 
54, (47) 7, (5) 24, (19) 19, (19) 4, (4)  
Anticholinergic, 
Short Acting, Long Acing) 
4, (40) 0, (4) 1, (18) 1, (15) 2, (3)  
Inhaled Steroid 48 5 20 18 5  
Oral Theophyllines 14 1 6 4 3  
 
Data presented as a = mean ± SD unless and b = median, IQR. *P-value represents significance 
across COPD severity as defined by GOLD (I = 7, II = 24, III = 19 and IV = 5) by one-way 
ANOVA.  
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Table. 4.3: Exacerbation and non-exacerbator cohort characteristics.  
Demographics 
 
COPD Patients 
 
(n = 55)  
Exacerbators Non-Exacerbators p-value 
(n = 49) (n = 6)  
Age, ayears 68.2 ± 8.0 70.3 ± 6.4  =0.524 
Gender, Male (Female) 25 (24) 2 (4) =0.544 
Duration of COPD, ayears 7.8 ± 6.4 10.5 ± 7.5 =0.350 
*FEV1, a(% predicted) 50.4 ± 16.8 63.4 ± 27.9  =0.131 
*FVC, a(% predicted) 76.9 ± 14.3 84.9 ± 16.7  =0.209 
BMI, a (kg/m2) 27.3 ± 5.5 24.4 ± 4.2 =0.213 
MRC Score, b n 3.0, 1.0 3.0, 0.0 =0.148 
Exacerbations in the last 1 year, an  4.6 ± 2.4 2.3 ± 0.5 <0.021 
Exacerbations in the study, an 1.3 ± 0.5 0  
Co-morbidities 
 
None 11 2  
Cardiovascular 12 0  
Type 2 Diabetes Mellitus 7 0  
Hypertension 19 2  
Gum Disease 1 0  
Other 20 3  
COPD Medications 
 
β2 Agonists, Short Acting, (Long Acting) 48, (43) 6, (4)  
Anticholinergic, Short Acting, (Long Acting) 3, (36) 1, (4)  
Inhaled Steroid 45 3  
Oral Theophylline 13 1  
 
Data presented as a = mean ± SD and b = median, IQR. P-value represents significance between 
COPD patients who exacerbated and those who remained stable throughout their participation 
in the study. *FEV1 values represent the stable phase data.  
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Table 4.4: Total length of pre-exacerbation phase in the exacerbation cohort. 
*Total recruited 
COPD patients 
Length of time: 
Stable phase 
Length of time: 
prodromal phase 
Total length of 
time: 
**Pre-exacerbation 
phase 
49 13 days 7 days 20 days 
39 28 days 7 days 35 days 
29 42 days 7 days 49 days 
19 74 days 7 days 81 days 
9 251 days 7 days 258 days 
 
*COPD patients who had suffered at least one exacerbation during the community-based 
longitudinal study (n = 49) **Pre-exacerbation phase is defined as the stable plus prodromal 
phase. 
 
Although the exacerbation phase can be variable in practice, all COPD patients reported a 
return to normal after completing treatment (antibiotics and steroids) on Day 7 of the 
exacerbation phase. Following this, each COPD patient had a minimum 2-week post-
exacerbation-recovery phase as this was pre-set in the study protocol. Therefore any COPD 
patients who re-exacerbated within this two-week time-frame remained in the study until they 
had completed further treatment and then achieved a 2 week post-exacerbation-recovery phase.  
 
In this study, a sub-population of COPD patients underwent further acute exacerbations (n = 
15), termed a re-exacerbation within the index post-exacerbation-recovery phase at 10.9 ± 7.7 
days, requiring further treatment with antibiotics and steroids (Table 4.5). There was a 
significantly lower FEV1 at stable baseline (p<0.02 by independent t-test) in this COPD patient 
sub-population (exacerbation cohort). None of the other parameters was significantly different 
between the 2 sub-populations (age: p=0.135, BMI: p=0.236, FVC: p=0.369 and total co-
morbidities: p=0.273). 
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The length of study participation for the COPD patients in the exacerbation cohort (n = 49) was 
13.0 ± 8.5 weeks whilst for the non-exacerbation cohort (n = 6) was 25.3 ± 14.8 weeks. The 
non-exacerbator patients were kept in the study for longer to allow sufficient time for them to 
have an acute event as well as to collect background data on biomarker levels and other metrics 
over time. As such, this cohort, albeit small, provided a much needed control group for the 
exacerbation cohort and allowed cross-comparison. 
 
Cardiovascular disease and hypertension were the commonest co-morbidities present in 27 out 
of 55 COPD patients; all co-morbidities remained stable throughout the study. All salivary 
biomarker level, spirometric index and PRO (COPD Wellbeing score) data were cross-
referenced to the HRO data recorded by the research team in the electronic COPD Wellbeing 
and Self-Assessment diary to ensure there were no factors present that could bias the results. 
No changes in medications or co-morbidity status occurred for all COPD patients during their 
participation in the study; the only treatment change occurred when COPD patients were 
undergoing an acute exacerbation of COPD. None of the participating patients were admitted 
to hospital as a result of their exacerbations. There was no significant blood contamination in 
any of the tested saliva samples. 
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Table. 4.5: Single and re-exacerbator cohort characteristics.  
Demographics 
 
COPD Exacerbators Cohort 
 
(n = 49)  
Single 
Exacerbators 
Re-exacerbators 
p-value 
(n = 34) (n = 15)  
Age, ayears 69.3 ± 7.5 65.6 ± 8.7  <0.136 
Gender, Male (Female) 19 (15) 5 (10) <0.452 
Duration of COPD, ayears 8.4 ± 6.3 6.5 ± 6.8 <0.352 
*FEV1, a(% predicted) 55.38 ± 17.24 45.7 ± 13.79 <0.017 
*FVC, a(% predicted) 78.2 ± 15.3 74.2 ± 11.6  <0.287 
BMI, a (kg/m2) 27.9 ± 5.9 25.9 ± 4.2 <0.237 
MRC Score, b n 3.0, 1.0 3.0, 1.5 <0.154 
Exacerbations in the last 1 year, an  4.6 ± 2.4 5.2 ± 3.0 <0.215 
Exacerbations in the study, n 1 2   
Co-morbidities 
 
None 8 2  
Cardiovascular 11 0  
Type 2 Diabetes Mellitus 4 0  
Hypertension 13 2  
Gum Disease 1 0  
Other 16 3  
Total Co-morbidities, an 1.4 ± 1.1 1.1 ± 0.7 <0.274 
COPD Medications 
 
β2 Agonists, Short Acting, (Long Acting) 33, (30) 6, (4)  
Anticholinergic, Short Acting, (Long Acting) 3, (22) 1, (4)  
Inhaled Steroid 31 3  
Oral Theophylline 9 1  
 
Data presented as a = mean ± SD and b = median, IQR. P-value represents significance between 
the two groups. *FEV1 values represent the stable phase data.  
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4.4.1. Patient reported outcomes (PRO)s 
4.4.1.1. The capture of electronic PROs 
PRO (COPD Wellbeing Scores) were captured using the electronic Wellbeing and Self-
Assessment diary (Figure 4.2, Page 263). Once submitted these can then be viewed on the host-
website by the research team both as the individual component scores and graphically as line 
charts (Figure 4.5) to allow COPD surveillance and identify deteriorations in health status. 
  
Chapter 4:  COPD Longitudinal Monitoring  
 286  
 
Figure 4.5A: Host-website screenshot. 
This screenshot of the host-website represents the research teams’ view of the electronic 
Wellbeing and Self-Assessment diary; specifically the COPD Wellbeing Scores submitted by 
patients during the community-based study. A = This display highlights the recorded 
components of the COPD Wellbeing scores, the traffic light alerts on the left of the 
submissions: red = exacerbation and green = stable; the free-text entry is to the right of the 
submitted scores. In this particular patient, the stable (S), exacerbation (E) and post-
exacerbation recovery (R) phases are demonstrated. The data can also be displayed 
longitudinally as a chart (Figure 4.5B) highlighting the fluctuations in the COPD patients’ 
symptoms.   
R 
S 
E 
A 
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Figure 4.5B: Host-website screenshot. 
This screenshot of the host-website represents the research teams’ view for the electronic 
Wellbeing and Self-Assessment diary specifically the graphical display for the COPD 
Wellbeing Scores that have been submitted by the COPD patients in the community based 
study. This displays longitudinally the fluctuations in this COPD patients’ symptoms which 
are represented in scores in Figure 4.5A. 
  
B 
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4.4.1.2. Results 
Out of a total of 5461 possible unique daily electronic Wellbeing and Self-Assessment diary 
entries, 5371 were completed and transmitted successfully to the host-website (98.4%). The 90 
data diary entries that were not completed were due to COPD patient non-compliance despite 
prompting by the research team. 
 
4.4.1.3. PRO analysis 
All symptom data were split into the previously discussed 4 COPD disease phases (Table 4.1, 
Page 275) and analysed accordingly. The stable-prodromal-phase total COPD Wellbeing 
Scores in the patient exacerbator cohort (n = 49) were also compared with the control cohort 
(n = 6). 
 
Unlike saliva and spirometry which were performed weekly, the wellbeing diary scores were 
collected daily. For each wellbeing component, the score range was set from 1 to 5, with 5 
reflecting worst status. To analyse these COPD Wellbeing Scores, CPA was used, with 
CUSUM charting where indicated, to understand the day to day score fluctuations and changes 
in trajectories. Firstly, each of the individual components which were assigned an individual 
score (Figure 2.29, Page 212) to establish a median stable phase score for each component of 
the COPD Wellbeing score (breathing, ADL, cough, sputum production and colour) for each 
COPD patient. This score was considered the baseline burden for that component of the COPD 
Wellbeing score and was then deducted from the daily scores across all four phases to 
standardise the results for each COPD patient. Thus a COPD patient who symptomatically is 
in the stable phase of their COPD would score less than or equal to 0 (normal or reduced 
symptom burden), and a COPD patient with worsening symptoms would have a total score of 
greater than or equal to 1 (worsening in symptom burden). The component scores were then 
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summed to create a total component scores (termed total COPD Wellbeing Score); this allowed 
statistical analysis across the entire COPD patient population. If significant differences existed 
in the stable phase COPD Wellbeing score these would then be divided into sub-populations; 
the assignment of COPD patients into these sub-populations would form the first component 
of a multidimensional score (Section 4.4.4, Page 350) based on PROs, spirometry (Section 
4.4.2, Page 299) and salivary biomarkers (Section 4.4.3, Page 313).  
 
4.4.1.4. Stable and prodromal phases 
The COPD Wellbeing score in the preceding five-week period (stable plus prodromal phase) 
towards an exacerbation phase demonstrated a single stable trajectory of symptoms up to 4 
days prior to the onset of an acute exacerbation.  At this time point there was a significant 
positive change (increased symptom burden) in the trajectory of the COPD Wellbeing scores 
in all COPD subjects who exacerbated (p<0.01 by CPA). The mean change in the COPD 
Wellbeing score at that time point is from 0.17 to 1.32 (Figure 4.6). Cross-analysis of the 
median stable phase total COPD Wellbeing Score between the exacerbator (17, 6) cohort (n = 
49) and non-exacerbator (14, 5) cohort (n = 6) revealed no significant difference (p=0.097 by 
Mann-Whitney U test). Using the CPA data, the exacerbation cohort (n = 49) was split into 2 
separate groups according to the lead time interval in symptom change: (a) Patients who had 
experienced a rise in COPD Wellbeing scores at 4 days and more from the onset of an acute 
exacerbation of COPD (Group 1: n = 42) and (b) Patients who experienced a change in scores 
3 days or closer to the exacerbation onset (Group 2: n = 7) (Table 4.6). The purpose of this split 
was to create a multidimensional score based on COPD patients’ phenotypes (Section 4.4.4, 
Page 350). 
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Figure 4.6: Stable and prodromal phase COPD Wellbeing scores.  
A line chart (black) showing the mean COPD Wellbeing scores of those patients who 
exacerbated (n = 49) in the 5 immediate weeks preceding the onset of an exacerbation. The two 
red lines represent control limits for the maximum range within which the COPD Wellbeing 
Score is expected to vary over assuming no change has occurred. These control limits are 
calculated as mean Scores ± 2 SD. Points outside the control limits indicate a clinically relevant 
change has occurred; for display, the shift in the blue band indicates the statistically significant 
change in the trajectory. A clear change was seen at time point -4 days prior to the onset of the 
exacerbation (p<0.01 by CPA).  
  
Stable Phase Prodromal 
Phase 
Time-points leading to an exacerbation onset (Days) 
Exacerbation onset 
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Table 4.6: COPD Wellbeing Score sub-populations based on stable-prodromal data. 
COPD Patient Symptom Group Membership 
1 1 
2 1 
3 1 
4 1 
5 1 
6 1 
7 1 
8 1 
9 1 
10 2 
11 1 
12 1 
13 2 
14 2 
15 1 
16 1 
17 1 
18 1 
19 1 
20 1 
21 1 
22 1 
23 1 
24 1 
25 1 
26 1 
27 1 
28 1 
29 1 
30 1 
31 1 
32 1 
33 2 
34 2 
35 1 
36 1 
37 1 
38 1 
39 2 
40 1 
41 1 
42 1 
43 1 
44 1 
45 2 
46 1 
47 1 
48 1 
49 1 
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4.4.1.5. Exacerbation phase 
Next the change in COPD Wellbeing scores was determined within the defined exacerbation 
phase, during which all exacerbator patients (n=49) took their standby 7-day course of 
antibiotics (amoxicillin 500mg three times a day or doxycycline 100mg a day) and prednisolone 
30mg a day. Overall during the exacerbation phase there was a steady consistent fall in 
symptom burden with no statistically significant shift in trajectory identified (Figure 4.7). Sub-
analysis of the CUSUM chart showed that the COPD Wellbeing scores begin to fall below the 
mean exacerbation phase score (and hence patient start returning to their/normal self) at day 3 
post-exacerbation onset (Figure 4.8). 
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Figure 4.7: Exacerbation phase COPD Wellbeing Score. 
The line chart demonstrates the change in mean COPD Wellbeing scores during the 
exacerbation phase (n = 49). During this phase, patients are receiving treatment with steroids 
and antibiotics. The two red lines represent control limits for the maximum range in which the 
COPD Wellbeing Scores are expected to vary over assuming no change has occurred.  These 
control limits are calculated as mean Scores ± 2 SD. Points outside the control limits indicate 
a clinically relevant change has occurred; for display a shift in the blue band reflects a 
statistically significant change in the trajectory. The chart demonstrates a decrease in symptom 
burden with mean scores returning towards baseline in a stable trajectory.  
  
Post-Exacerbation-Recovery Onset 
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Figure 4.8: Cumulative Sum chart of COPD Wellbeing score. 
This line chart represents the cumulative sum (CUSUM) chart used in the change point analysis 
(CPA) for the exacerbation phase. A positive gradient indicates COPD Wellbeing scores above 
the average, whereas a negative gradient indicates reducing symptom scores towards baseline. 
Although the CPA did not demonstrate a statistically significant change in the trajectory of the 
COPD Wellbeing Score, the CUSUM for the exacerbation phase demonstrates that the score 
starts to return to baseline at around day 3 of the exacerbation phase (also reflected as day 3 
post-start of treatment). 
  
Post-Exacerbation-Recovery Onset 
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4.4.1.6. Post-exacerbation-recovery phase 
Within the post-exacerbation-recovery phase there appears to be a statistically significant 
worsening in mean COPD Wellbeing Scores (0.76 to 0.98) at day 10 (p<0.05) (Figure 4.9). 
This positive shift however may reflect the sub-population of COPD patients who re-
exacerbated and correlates with the observed mean re-exacerbation time-point (10.9 ± 7.7 days) 
post completion of treatment in the re-exacerbator cohort.  
 
The advantages of using the CPA approach to analyse the complex dynamics of the symptom 
data is highlighted in Figure 4.9. Although the mean COPD Wellbeing Scores have not 
exceeded the expected mean variability defined by the confidence intervals (red lines), it does 
demonstrate that there is a statistically significant change in the trajectory of the scores which 
would not have been identified through conventional analytical techniques (Section 4.3.2, Page 
278). 
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Figure 4.9: Post-Exacerbation-Recovery COPD Wellbeing Score. 
The line chart demonstrates the change in mean COPD Wellbeing scores in the post-
exacerbation-recovery phase following an index exacerbation of COPD. During this phase, 
patients had returned to using their usual medications. The two red lines represent control limits 
which are the maximum range that the values COPD Wellbeing Score are expected to vary 
within assuming no change has occurred. These control limits are calculated as mean Scores ± 
2 SD. Points outside the control limits indicate a clinically relevant change has occurred; for 
display, the shift in the blue band reflects a statistically significant change in the trajectory at 
around day 10 (p<0.05) 
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4.4.1.7. COPD sub-population of re-exacerbators 
Stable baseline COPD Wellbeing scores, index exacerbation score at day 1 and the index post-
exacerbation recovery score at day 1 were compared between the single exacerbator group (n 
= 35) and the re-exacerbator group (n = 14). COPD Wellbeing Scores were not significantly 
different between the single and re-exacerbation groups in the stable phase (p=0.922); at day 1 
of the index exacerbation phase (p=0.278); or at day 1 of the post-exacerbation-recovery phase 
(p=0.564) (Table 4.7).  
 
Table 4.7: Comparison of COPD Wellbeing Scores between single exacerbator and re-
exacerbator patients. 
COPD Wellbeing 
Score 
Single 
Exacerbators 
(n = 35) 
Re-Exacerbators 
(n =14) 
p-value 
Stable Phase 17, 6 16, 4 p=0.922 
Exacerbation Phase 19, 4 23, 4 p=0.278 
Post-Exacerbation-
Recovery Phase 
17, 6 17, 5 p=0.564 
 
Data are presented as median, IQR. 
 
Change point analysis (CPA) of the post-exacerbation-recovery phase for the entire group (n = 
49) identified a significant change in trajectory of the COPD Wellbeing Score at day 10 post-
exacerbation-recovery phase (Figure 4.9). However, analysis of the COPD Wellbeing Score at 
day 10 post-exacerbation-recovery between the 2 groups is not statistically significant (p<0.467 
by Mann-Whitney U test). This result is unusual but perhaps highlights the importance of daily 
symptom monitoring to isolate the change in symptom burden trajectorially for each patient.  
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In conclusion, PRO analysis on symptoms revealed an increase in the COPD Wellbeing score 
at around 4 days prior to an exacerbation onset.  Recovery whilst on treatment appears to be 
uniform, with a clear improvement in the COPD Wellbeing Score after 3 days (although this 
was not statistically significant). Additionally, in the post-exacerbation recovery phase 
following treatment completion, there appears to be a significant but subtle shift in symptoms 
at day 10.  
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4.4.2. Spirometry 
Spirometry was conducted on all COPD patients at study enrolment and then weekly during 
the study course.  As described 49 out of 55 COPD patients reported at least one acute 
exacerbation of COPD during the study. As with PRO analysis, spirometry data was split into 
4 phases according to the criteria in Table 4.1, Page 275. This allowed comparative analysis of 
spirometric metrics across the various phases, particularly the stable-prodromal period, to 
determine any signals predictive of the onset of an acute exacerbation. With respects to the 
COPD patients who did not exacerbate (n = 6), their stable phase spirometric data acted as a 
control. 
 
4.4.2.1. Forced expiratory volume in one second (FEV1) 
Analysis across the 4 phases in COPD patients who experienced at least one exacerbation (n = 
49) showed a statistically significant difference in FEV1 values (p<0.001 by repeated measures 
ANOVA. Using post-hoc analysis, a significant reduction in FEV1 values was observed as 
expected between the stable and exacerbation phases respectively (p<0.006($) by paired t-test); 
but no statistically significant difference between stable and prodromal or post-exacerbation-
recovery phases (p=0.154 and p=0.999 respectively).  A statistically significant difference was 
noted between prodromal and post-exacerbation recovery FEV1 values (p<0.038($)), but not 
between the prodromal and exacerbation phases (p=0.287). A significant improvement in FEV1 
was also observed, as would be expected, between exacerbation and post-exacerbation-
recovery phases (p<0.001($)) (Figure 4.10, Table 4.8). Cross analysis between the exacerbator 
(n = 49) and non-exacerbator (n = 6) control cohorts demonstrated no statistically significant 
difference in stable phase FEV1 (p=0.133, by independent t-test). Although the non-exacerbator 
cohort appears to have a much higher stable phase FEV1, it is important to note the large SD 
and difference in sample sizes between the 2 cohorts. 
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Figure 4.10: Forced expiratory volume in one second across the 4 defined COPD phases. 
Box and whisker plots for Forced expiratory volume in one second (FEV1) across the 4 disease 
phases: (1) Stable; (2) Prodromal; (3) Exacerbation; (4) Post-exacerbation-recovery for COPD 
patients who had at least one exacerbation (n = 49). The stable phase is defined as between 35 to 8 
days prior to a patient-defined onset of an exacerbation. The prodromal phase is defined as between 
7 to 1 days leading to an exacerbation onset. The exacerbation phase is defined as the onset of the 
acute episode and start of treatment (Day 0) to treatment completion and return to baseline (Day 7 
post exacerbation). The post-exacerbation-recovery phase is defined as the immediate 14 days post 
treatment completion. There was a significant statistical difference across the 4 phases (p<0.001 
by Repeated Measures ANOVA). Post-hoc analysis showed a significant difference between the 
stable and exacerbation phases (**p<0.006($) by paired t-test); between the prodromal and post-
exacerbation-recovery phases (*p<0.038); and the exacerbation and post-exacerbation-recovery 
phases (***p<0.001($)) but not between prodromal and exacerbation phases (p<0.288). There was 
no statistically significant difference between the stable phase and both prodromal and post-
exacerbation-recovery phases (p=0.154 and p=0.999 respectively).   
** 
* 
*** 
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Table 4.8: FEV1 values across the whole COPD study cohort. 
 FEV1 (% predicted) 
COPD patients 
(n = 55) 
Stable 
Phase 
Prodromal 
Phase 
Exacerbation 
Phase 
Post Exacerbation 
Recovery Phase 
Exacerbators 
(n = 49) 
50.4 ± 18.7 48.9 ± 19.5 46.0 ± 18.8 51.4 ± 19.3 
Non-
Exacerbators 
(n = 6) 
63.4 ± 27.9 n/a n/a n/a 
 
Data presented as mean ± SD. 
 
4.4.2.1.1. Latent class growth analysis (LCGA) 
Using the exacerbator cohort (n = 49) data, LCGA was performed on FEV1 values across the 
stable-prodromal period at 5 different time points, each 1 week apart from each other, 
progressing towards an acute exacerbation of COPD (n = 49). This time-frame was consistent 
with the analysis performed on the equivalent time period for the COPD Wellbeing Scores 
(Section 4.4.1.4, Page 289). Exacerbator data was chosen as there was a fixed time-point to 
anchor the end of their stable-prodromal phase values and the commencement of an acute 
event. For the COPD patients who did not exacerbate in the study (n = 6), as would be expected 
there was no option to determine the location of their equivalent phase comparable to the 
exacerbator cohort. 
 
An iterative LCGA using the BIC and BLRT p-value was conducted to determine the pilot 
number of sub-population clusters (Table 4.9) for COPD patients’ stable and prodromal phase 
FEV1 values. Although the BIC reduced from 2 to 3 sub-population clusters, there was not a 
statistically significant improvement in goodness-of-fit (p=0.314 by BLRT). The posterior 
probability matrix at 2 sub-population clusters (Table 4.10) demonstrated a high level of 
homogeneity between the 2 clusters; thus 2 sub-population clusters were chosen for stable 
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phase FEV1 values. The LCGA populated the separate sub-population clusters with the 
following number of COPD patients: Cluster 1 = 14, Cluster 2 = 35. The membership of each 
COPD patient to their respective cluster is shown in Table 4.11. Overall, each cluster formed 
2 discrete sub-populations of COPD patients with an inter-cluster overlap of 1% for cluster 1 
and 5% for clusters 2. Each sub-population cluster was defined as “moderate” or “severe” range 
based on the established GOLD criteria (GOLD 2016). These sub-population clusters exhibited 
2 unique stable phase FEV1 value trajectories (Figure 4.11). 
 
Table 4.9: LCGA Goodness of fit tests for stable-prodromal FEV1 data. 
LCGA BIC BLRT (p-values) 
1 cluster 1824 n/a 
2 cluster 1672 p<0.049 
3 cluster 1558 p=0.314 
 
The BIC value represents the goodness-of-fit test for the LCGA analysis; basically the lower a 
value, the better the model. The p-value determines whether there is a significant improvement 
in the model with “n” clusters compared to “n-1”. Of interest is the finding of a minimal 
improvement in the BIC from 2 to 3 clusters and the lack of statistical significance (p=0.314) 
when increasing the clusters from 2 to 3. LCGA = latent class growth analysis, BIC = Bayesian 
information criterion, BLRT = Bootstrap log-likelihood. 
 
Table 4.10: Homogeneity of COPD patients cluster membership for stable-prodromal 
FEV1 data. 
Cluster 1 (n = 14) 2 (n = 35) 
1 1% 99% 
2 95% 5% 
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Table 4.11: Exacerbator COPD patient cluster membership for stable-prodromal FEV1 
data. 
COPD Patient Cluster Membership 
1 2 
2 2 
3 2 
4 1 
5 2 
6 2 
7 1 
8 2 
9 2 
10 2 
11 1 
12 2 
13 1 
14 2 
15 1 
16 2 
17 2 
18 1 
19 2 
20 1 
21 2 
22 1 
23 2 
24 2 
25 2 
26 2 
27 2 
28 1 
29 2 
30 2 
31 2 
32 1 
33 2 
34 2 
35 1 
36 2 
37 2 
38 2 
39 2 
40 2 
41 2 
42 2 
43 1 
44 1 
45 2 
46 2 
47 2 
48 2 
49 1 
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Figure 4.11: Forced expiratory volume in one second clusters in the stable-prodromal 
period.  
This line chart represents the latent class growth analysis for the mean percentage predicted 
forced expiratory volume in one second (FEV1) values for COPD patients who experienced at 
least one acute exacerbation of COPD (n = 49) in the stable and prodromal phases. This period 
is defined as 5 weeks prior to the onset of an exacerbation and each interval represents 1 week. 
Cluster 1 = 14 and Cluster 2 = 35 COPD patients. The values represent the mean FEV1 at each 
time-point for the respective clusters. 
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4.4.2.1.2. Baseline characteristics associated with cluster membership. 
A further separate sub-analysis was conducted to explore whether there was any significant 
difference between the 2 sub-population clusters for a panel of known COPD co-variates. 
Overall there was no significant difference between the “moderate” and “severe” clusters for: 
age, gender, BMI and total co-morbidities (p=0.718, p=0.631, p=0.335 and p=0.326 
respectively by Binomial Analysis); although as perhaps to be expected FVC (% predicted) 
was significantly lower in the “severe” cluster (p<0.02) (Table 4.12). Analysis between these 
2 clusters and the control cohort demonstrated a significant difference for FVC (p<0.032 by 
one-way ANOVA), but no difference in age (p=0.718), gender (p=0.631), BMI (p=0.335) and 
total co-morbidities (p=0.326) respectively.  Sub-population cluster 1 “moderate” had the 
lowest number of COPD patients (n = 15). Sub-population cluster 2 “severe” consisted of the 
highest number of COPD patients (n = 35), which was to be expected as the majority of COPD 
patients in the study had severe disease status.  
 
The above results suggest two unique trajectories of FEV1 during the stable-prodromal phase 
for the studied COPD patients. Interestingly GOLD classification for COPD disease severity 
(Vestbo et al., 2013) sets four FEV1 thresholds; within this patient cohort there is no indication 
to increase the classification of COPD patients based on sub-population clusters by more than 
2. 
 
These 2 identified clusters will be used later in a corollary analysis (Section 4.4.4, Page 350) 
to form a multidimensional score of COPD patients encompassing symptoms, spirometry and 
salivary biomarkers. 
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Table 4.12: Covariates comparison between the 2 patient exacerbator clusters for FEV1 
and control non-exacerbator cohort. 
Baseline 
Covariates 
COPD 
Sub-Population Clusters for FEV1 
Exacerbation Cohort (n = 49) 
COPD 
Control Group 
Non-Exacerbation Cohort 
1 
(n = 14) 
2 
(n = 35) 
*p-value (n = 6) **p-value 
Age, ayears 69.1 ± 6.3 67.8 ± 8.6 p=0.828 70.3 ± 6.4 p=0.718 
Gender  
Male, 
(Female) 
8,7 17, 18 p=0.430 2, 4 p=0.631 
BMI, a(kg/m2) 28.3 ± 6.1 26.9 ± 5.3 p=0.915 24.4 ± 4.2 p=0.335 
Total 
Co-
Morbidities, an 
1.5 ± 1.2 1.2 ± 0.9 p=0.511 0.8 ± 0.8 p=0.326 
FVC 
a(% predicted) 
84.4 ± 14.7 74.0 ± 13.1 p<0.02 85.0 ± 16.9 p<0.032 
 
Data presented as a = mean ± SD. *P-value indicated the statistical significance between the 2 
patient exacerbator sub-population clusters (n = 49) and the control non-exacerbator cohort (n 
= 6) by Binomial logistic regression: **p-value indicates the statistical significance between 
the same groups by one-way ANOVA. 
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4.4.2.2. Forced vital capacity (FVC) 
Analysis across the 4 study-defined phases in COPD patients who experienced at least one 
acute exacerbation (n = 49) revealed a statistically significant difference in FVC (p<0.001 by 
repeated measures ANOVA). Post-hoc analysis showed a significant reduction between the 
stable and prodromal phase FVC values (p<0.018($) by independent t-test) and between the 
stable phase and exacerbation phase values (p<0.001($)). There was no statistically significant 
difference between the stable and post-exacerbation-recovery phase FVC values (p=0.999). A 
significant reduction was also demonstrated between the prodromal and exacerbation phase 
FVC values (p<0.034($)), but not between the prodromal and post-exacerbation-recovery 
phase FVC values (p=0.076). A significant improvement was observed in FVC between the 
exacerbation and post-exacerbation-recovery phases (p<0.001($)) (Figure 4.12), (Table 4.13). 
Cross-analysis between the exacerbator (n = 49) and non-exacerbator (n = 6) cohorts 
demonstrated no statistically significant difference in stable phase FVC (p=0.141, by 
independent t-test). Although there appeared to be a large difference in mean stable FVC 
between these 2 cohorts, it is important to note the wide standard deviation ranges and the large 
difference in sample sizes between them. 
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Figure 4.12: Forced vital capacity across the 4 defined COPD phases. 
Box and whisker plots for forced vital capacity (FVC) across the 4 disease phases: (1) Stable; (2) 
Prodromal; (3) Exacerbation; (4) Post-exacerbation-recovery for the COPD patients who exacerbated 
(n = 49). The stable phase is defined as between 35 to 8 days prior to a patient-defined onset of an 
exacerbation. The prodromal phase is defined as between 7 to 1 days leading to an exacerbation onset. 
The exacerbation phase is defined as the onset of the acute episode and start of treatment (Day 0) to 
treatment completion and return to baseline (Day 7 post exacerbation). The post-exacerbation-recovery 
phase is defined as the immediate 14 days post treatment completion. Outliers are identified by o (1.5 x 
the interquartile range). There was a significant statistical difference in FVC across the 4 phases 
(p<0.001 by repeated measures ANOVA). Post-hoc analysis showed a significant reduction between 
the stable and prodromal phase FVC values (*p<0.018($) by independent t-test) and between the stable 
phase and exacerbation phase values (**p<0.001($)). There was no statistically significant difference 
between the stable and post-exacerbation-recovery phase FVC values (p=0.999). A significant 
reduction was also demonstrated between the prodromal and exacerbation phase FVC values 
(*p<0.034($)) but not between the prodromal and post-exacerbation-recovery phase FVC values 
(p=0.076). Significant improvement was observed in FVC between the exacerbation and post-
exacerbation-recovery phases (p<0.001($)). 
** 
* 
* 
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Table 4.13: FVC values across the whole study cohort. 
 FVC (% predicted) 
COPD 
patients 
(n = 55) 
Stable Phase 
Prodromal 
Phase 
Exacerbation 
Phase 
Post Exacerbation 
Recovery Phase 
Exacerbators 
(n = 49) 
75.3 ± 14.6 71.8 ± 15.3 67.2 ± 16.2 75.4 ± 15.3 
Non-
Exacerbators 
(n = 6) 
84.9 ± 16.7 n/a n/a n/a 
 
Data presented as mean ± SD 
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4.4.2.2.1. Latent class growth analysis 
Utilising data from the exacerbator cohort (n = 49), latent class growth analysis (LCGA) was 
performed on FVC values across the stable-prodromal period at 5 different time points, each 1 
week apart from each other progressing towards an acute exacerbation of COPD. 
 
As before, an iterative LCGA was conducted using the BIC and BLRT p-value to determine 
the pilot number of sub-population clusters (Table 4.14) for COPD patients’ stable-prodromal 
phase FVC values. Although the BIC value reduced from 1 to 2 sub-population clusters this 
was not statistically significant (p=0.286 by BLRT). Thus for FVC in the COPD exacerbator 
group (n = 49) there are no discrete sub-population clusters (Figure 4.13).  
 
This result is interesting and can be explained by understanding how the LCGA clusters COPD 
patients. LCGA assigns COPD patients to a particular sub-population cluster not only on the 
target variable, in this case FVC, but also the change in that target variable over time. Thus 
although the percentage predicted FVC levels across the COPD patients falls within a wide 
range (Table 4.2, Page 280), the rate of change of FVC at different points lacks enough 
variability to classify the COPD patients into further sub-population clusters unlike FEV1. 
Accordingly, FVC will not be included in the final correlative analysis as it appears not to 
provide any further information on the sub-populations within the exacerbation cohort (n = 49). 
 
Table 4.14: LCGA Goodness of fit tests for stable-prodromal FVC data.  
LCGA BIC BLRT (p-values) 
1 cluster 1728 n/a 
2 cluster 1679 p=0.286 
 
 
Chapter 4:  COPD Longitudinal Monitoring  
 311  
 
 
 
 
Figure 4.13: Forced vital capacity cluster across stable-prodromal phases.  
This line chart represents the latent class growth analysis for the mean percentage predicted 
forced vital capacity (FVC) values for COPD patients who experienced at least one acute 
exacerbation of COPD (n = 49) in the stable and prodromal phases. This period is defined as 5 
weeks prior to the onset of an exacerbation and each interval represents 1 week. The values 
represent the mean FVC at that time-point for the respective clusters. There were no identifiable 
distinct sub-population clusters for FVC in this COPD exacerbator cohort. 
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4.4.2.3. COPD sub-population: re-exacerbators 
The next analysis looked to determine whether stable phase FEV1, FVC and the index 
exacerbation and post-exacerbation-recovery spirometry values were significantly different 
between the single-exacerbator and re-exacerbator groups (Table 4.15). Overall stable phase 
FEV, values were significantly lower in the sub-population who re-exacerbated compared to 
those who remained stable (p<0.017 by independent t test). Utilising the LCGA sub-population 
clusters for FEV1 (Table 4.11, Page 303) there was a significant difference between the total 
number of COPD patients who re-exacerbated between the two clusters (p<0.001 by Mann 
Whitney U Test).  
 
Table 4.15: Spirometry values between single and re-exacerbators 
 COPD Patients (n = 49)  
Spirometry 
(% predicted) 
Single 
Exacerbators 
(n = 34) 
Re-Exacerbators 
(n = 15) 
p-value 
Stable Phase:  
FEV1 
55.4 ± 17.2 45.7 ± 13.8 p<0.017 
Exacerbation Phase: 
FEV1 
50.2 ± 17.8 41.9 ± 14.7 p=0.110 
Post-exacerbation-
recovery Phase 
FEV1  
54.6 ± 19.6 44.0 ± 16.6 p=0.069 
Stable Phase: 
FVC 
78.2 ± 15.3 74.2 ± 11.6 p=0.286 
Exacerbation Phase 
FVC 
70.5 ± 15.0 67.9 ± 15.1 p=0.904 
Post-exacerbation-
recovery Phase 
FVC 
77.1 ± 15.9 70.9 ± 12.8 p=0.999 
 
Data presented as mean ± SD.  
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4.4.3. Salivary biomarker levels. 
Salivary CRP, PCT and NE levels were measured in all the studied 55 COPD patients. Analyte 
measurements were carried out using a total of; (1) 20 Salimetrics CRP ELISA kits 
(Salimetrics, USA) with an intra- and inter-assay CV of 9.6% and 14.5% respectively; (2) 
Thirty VIDAS B.R.A.H.M.S PCT (bioMérieux, France) with an intra- and inter-assay CV of 
9.4% and 12.1% respectively; and (3) Twenty PMN Elastase ELISA kit (Immundiagnostik, 
Germany) with an intra-assay CV of 4.0% and inter-assay CV of 9.3% respectively. 
 
49 out of 55 COPD patients reported at least one acute exacerbation. Out of these 49 COPD 
patients, 47 patients experienced a rise in at least 1 salivary biomarker; 40 COPD patients 
experienced a rise in at least 2 salivary biomarkers; and 20 COPD patients experienced a rise 
in all 3 salivary biomarkers during the prodromal and exacerbation phases. 
 
The study protocol involved weekly saliva sampling; when a patient felt that they were about 
to have an exacerbation, a saliva sample was taken on the same day in the provided collector 
tubes and kept in their freezer until collected by the research team as soon as possible within 
12 hours. Saliva prodromal phase samples from the exacerbator cohort were therefore from 
varying time points (5.24 ± 1.93 days) up to 7 days prior to the onset of an exacerbation.  
 
As before, salivary biomarker levels were split into the 4 previously described phases (Table 
4.1, Page 275) to aid analysis and to determine whether saliva prodromal phase biomarker data 
differed from stable baseline so as to be predictive of an exacerbation onset. The non-
exacerbator COPD cohort (n = 6) acted as the control group and their stable phase salivary 
biomarker levels were cross-compared to the exacerbator cohort (n = 49). 
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4.4.3.1 Salivary C-reactive Protein (CRP) 
Analysis across the 4 defined phases in the exacerbator cohort (n = 49) showed a statistically 
significant change in salivary CRP levels (p<0.001 by Freidman's Two-way ANOVA). Post-
hoc analysis further demonstrated that salivary CRP levels were significantly increased during 
an exacerbation (4.20, 6.33 ng/ml) compared to stable phase (2.38, 1.54 ng/ml, p<0.003($) by 
Wilcoxon Signed Rank Test). Prodromal phase salivary CRP (2.91, 4.27 ng/ml), was also 
significantly higher than stable phase (p<0.001($)), with no significant difference found 
between post-exacerbation-recovery phase and the stable phase data salivary CRP (p=0.208). 
(Table 4.16, Figure 4.14). Salivary CRP levels in this exacerbator cohort were increased in the 
prodromal (mean sample collection: 5.3 ± 1.9 days) prior to the onset of an exacerbation), and 
exacerbation phases compared to stable phase in 42 out of 49 COPD patients (Figure 4.15). 
Cross-analysis between the exacerbators (n = 49) and non-exacerbators (n = 6) demonstrated 
no statistically significant difference in stable phase salivary CRP levels between the two 
cohorts (p=0.282, by Mann-Whitney U Test). 
 
Table 4.16: Salivary CRP levels across the whole COPD study cohort. 
 Salivary CRP (ng/ml) 
COPD 
patients 
(n = 55) 
Stable 
Phase 
Prodromal 
Phase 
Exacerbation 
Phase 
Post Exacerbation 
Recovery Phase 
Exacerbators 
(n = 49) 
2.4, 1.5 2.9, 4.3 4.2, 6.3 2.5, 2.9 
Non-
Exacerbators 
(n = 6) 
1.7, 0.2 n/a n/a n/a 
 
Data presented as median, IQR.  
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Figure 4.14: Salivary C-reactive protein (CRP) levels across the 4 defined COPD phases 
in the whole patient exacerbator group. 
Box and whisker plots for salivary C-reactive protein (CRP) levels across the 4 disease phases: (1) 
Stable; (2) Prodromal; (3) Exacerbation; (4) Post-exacerbation-recovery for the whole exacerbator 
group (n = 49). Outliers are identified by o (1.5 x the interquartile range) and * (3 x interquartile 
range). The stable phase is defined as between 35 to 8 days prior to a patient-defined onset of an 
exacerbation. The prodromal phase is defined as between 7 to 1 days leading to an exacerbation 
onset. The exacerbation phase is defined as the onset of the acute episode and start of treatment 
(Day 0) to treatment completion and return to baseline (Day 7 post exacerbation). The post-
exacerbation-recovery phase is defined as the immediate 14 days’ post treatment completion. There 
was a significant statistical difference across the 4 phases (p<0.001 by Freidman’s Two-way 
ANOVA). Post-hoc analysis showed that salivary CRP levels were significantly increased during 
an exacerbation compared to stable phase (**p<0.003($) by Wilcoxon Signed Rank Test). 
Prodromal phase salivary CRP was also significantly higher than stable phase (*p<0.001($)), with 
no significant difference demonstrated between post-exacerbation-recovery phase and stable phase 
salivary CRP (ns: p=0.208). 
* 
** 
ns 
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Figure 4.15: Salivary C-reactive protein (CRP) levels across the 4 defined COPD phases 
in patients who experienced raised analyte levels. 
Box and whisker plots for salivary CRP levels across the 4 disease phases: (1) Stable; (2) Prodromal; (3) 
Exacerbation; (4) Post-exacerbation-recovery are shown only in those COPD patients who experienced a 
rise in CRP in either the prodromal and exacerbation phases (n = 42). Outliers are identified by o (1.5 x the 
interquartile range) and * (3 x interquartile range). The stable phase is defined as between 35 to 8 days 
prior to a patient-defined onset of an exacerbation. The prodromal phase is defined as between 7 to 1 days 
leading to an exacerbation onset. The exacerbation phase is defined as the onset of the acute episode and 
start of treatment (Day 0) to treatment completion and return to baseline (Day 7 post exacerbation). The 
post-exacerbation-recovery phase is defined as the immediate 14 days’ post treatment completion. The 
statistical analysis for this data set is identical to the whole patient exacerbator group (Figure 4.14). There 
was a significant statistical difference across the 4 phases (p<0.001 by Freidman’s Two-way ANOVA). Post-
hoc analysis showed that salivary CRP levels were significantly increased during an exacerbation compared 
to stable phase (**p<0.003($) by Wilcoxon Signed Rank Test). Prodromal phase salivary CRP was also 
significantly higher than stable phase (*p<0.001($)), with no significant difference demonstrated between 
post-exacerbation-recovery phase and stable phase salivary CRP (ns: p=0.208). 
  
* 
** 
ns 
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To understand whether a cut-off could be attributed to exacerbation phase salivary CRP levels, 
a further sub-analysis was conducted utilising an area under the curve (AUC) analysis with 
receiver operating characteristics (ROC) curves for the whole patient exacerbator group. 
Overall there was significant AUC = 0.70, p<0.001, 95% CI (0.58 to 0.80) (Figure 4.16). 
Sensitivity and specificity at 3 levels of salivary CRP for detecting the onset of acute 
exacerbation is shown in Table 4.17. These points were selected as they represented optimal 
salivary CRP values for sensitivity, specificity and both parameters combined.  
 
Table 4.17: Sensitivity and specificity of exacerbation phase salivary CRP levels. 
Salivary CRP (ng/ml) Sensitivity Specificity 
0.39 98% 2% 
2.91 70% 63% 
6.21 37% 90% 
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Figure 4.16: ROC curve of salivary CRP levels. 
This ROC curve highlights the sensitivity and specificity of salivary CRP in distinguishing the 
onset of a COPD exacerbation. Overall there is a significant AUC = 0.70, p<0.001, 95% CI 
(0.58 to 0.80). This highlights that salivary CRP levels at the onset of an exacerbation can be 
used with moderate diagnostic accuracy. 
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4.4.3.1.1. Latent class growth analysis 
Latent class growth analysis (LCGA) was performed on salivary CRP levels from the 
exacerbator patient cohort (n = 49) across the stable-prodromal phases at 5 different time 
points, each 1 week apart, progressing towards the onset of an exacerbation, 
 
An iterative LCGA using the BIC and BLRT p-value was conducted to determine the pilot 
number of sub-population clusters (Table 4.18) for COPD patients’ salivary CRP levels. 
Although the BLRT favoured increasing the number of clusters from 3 to 4, there was only a 
minimal improvement in the BIC beyond 3 clusters; the posterior probability matrix (Table 
4.19) also demonstrated a high level of homogeneity between the clusters. Each cluster formed 
three discrete COPD sub-populations with an inter-cluster overlap of less than 1% for clusters 
1 and 2 and no overlap for cluster 3. 3 sub-population clusters within the exacerbator group 
were chosen to interrogate salivary CRP levels across the stable-prodromal phase: Cluster 1 = 
41; Cluster 2 = 4; and Cluster 3 = 4 patients. The membership of each COPD patient in their 
respective cluster is shown in Table 4.20. Each sub-population cluster was defined as “low”, 
“mid” and “high” range based on the relative levels of salivary CRP to each other. Thus sub-
population cluster 1 was defined as “low-range”; cluster 2 as “mid-range” and cluster 3 as 
“high-range”. Overall these sub-population clusters exhibited three unique salivary CRP level 
trajectories across the stable-prodromal phases (Figure 4.17).  
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Table 4.18: LCGA Goodness of fit tests for stable-prodromal salivary CRP levels. 
LCGA BIC BLRT (p-values) 
1 cluster 1401 n/a 
2 cluster 1240 p<0.001 
3 cluster 1217 p<0.001 
4 cluster 1217 p<0.001 
 
The BIC value represents the goodness-of-fit; basically the lower value; the better the model. 
The p-value represents whether there is a significant improvement in the model with “n” 
clusters compared to “n-1”. Of importance is the finding of minimal improvement in the BIC 
from 3 to 4 clusters. 
 
Table 4.19: Homogeneity of COPD patients cluster membership for stable-prodromal 
salivary CRP levels. 
Cluster 1 (n = 41) 2 (n = 4) 3 (n = 4) 
1 97% 3% 0% 
2 0% 100% 0% 
3 0% 0% 100% 
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Table 4.20: Exacerbator COPD patient cluster membership for stable-prodromal 
salivary CRP levels.  
COPD Patient Cluster Membership 
1 3 
2 1 
3 1 
4 1 
5 1 
6 1 
7 1 
8 1 
9 1 
10 1 
11 1 
12 1 
13 1 
14 1 
15 1 
16 1 
17 3 
18 1 
19 1 
20 1 
21 1 
22 1 
23 1 
24 3 
25 1 
26 1 
27 1 
28 1 
29 1 
30 1 
31 2 
32 3 
33 1 
34 2 
35 1 
36 1 
37 2 
38 1 
39 1 
40 2 
41 1 
42 1 
43 1 
44 1 
45 1 
46 1 
47 1 
48 1 
49 1 
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Figure 4.17: Salivary CRP clusters across the stable-prodromal phases. 
This line chart represents the LCGA for the mean salivary CRP levels for COPD patients who 
experienced at least one acute exacerbation of COPD (n = 49) in the stable and prodromal 
phases. This period is defined as 5 weeks prior to the onset of an exacerbation phase and each 
interval represents 1 week. Cluster 1 = 41, Cluster 2 = 4, Cluster 3 = 4 COPD patients. The 
values represent mean salivary CRP levels at each time-point for the respective clusters. 
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4.4.3.1.2. Baseline characteristics associated with cluster membership 
A separate sub-analysis was conducted to explore whether there were significant differences 
between the 3 clusters for a panel of known COPD co-variates (age, gender, BMI, total co-
morbidities, FEV1 and FVC). Multinomial analysis between the 3 clusters cross compared with 
each other demonstrated no significant difference in the 6 tested co-variates between each sub-
population cluster (Table 4.21, Page 325). Following on, a further sub-analysis was performed 
between the patient exacerbator individual clusters and the non-exacerbator control cohort (n 
= 6) to determine if there was a significant difference between each sub-population cluster and 
the control cohort (Table 4.22, Page 326). Overall there was no significant difference between 
the 3 exacerbator sub-population clusters and the control non-exacerbator cohort for all co-
variates: age (p=0.653), gender (p=0.188), BMI (p=0.308), total co-morbidities (p=0.540), 
FEV1 (p=0.298) and FVC (p=0.345 by one-way ANOVA). 
 
Sub-population cluster 1 “low-range” salivary CRP consists of COPD patients (n = 41) with a 
lower age and total co-morbidities and much better lung function compared to sub-population 
clusters 2 and 3. This cluster demonstrated a subtle increased trajectory in salivary CRP levels 
towards the onset of an exacerbation (Figure 4.17). Sub-population cluster 2 “medium-range” 
salivary CRP (n = 4) had the lowest FEV1 and FVC, reflecting a more severe disease status 
cohort despite the levels of salivary CRP in a “mid-range”. The trajectory for this cluster 
appeared to be more variable than cluster 1 (Figure 4.17). Sub-population cluster 3 “high-
range” salivary CRP (n = 4) had the highest total number of recorded co-morbidities and 
comparatively mid-range FEV1 and FVC values. This sub-population cluster demographic is 
interesting as patients within this cluster had the- highest stable-prodromal phase salivary CRP 
and co-morbid burden despite having an FEV1 similar to cluster 1. These observations could 
reflect the presence of a cohort of COPD patients with an accelerated disease progression 
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driven by an enhanced systemic inflammatory status consequent on a higher co-morbidity 
burden. Cluster 3 also demonstrated a variable trajectory similar to cluster 2. The control non-
exacerbator cohort was not significantly different than the 3 sub-population clusters for any of 
the tested covariates 
 
In summary, salivary CRP levels appear to rise somewhere up to 7 days prior to exacerbation 
onset. LCGA reveals 3 distinct sub-population clusters of COPD exacerbator patients based on 
the trajectory of stable-prodromal phase salivary CRP levels over the preceding 5 weeks to an 
exacerbation onset, with subtle differences existing between the different clusters. However 
these differences were not statistically significant to each other or the control cohort (Table 
4.21; Table 4.22). These clusters will be used in the corollary analysis (Section 4.4.4, Page 
350) to form a multidimensional classification score of COPD patients encompassing 
symptoms, spirometry and salivary biomarkers. 
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Table 4.21: Multinomial regression of covariates between the 3 exacerbator sub-
population clusters for salivary CRP. 
Baseline Covariates 
COPD Exacerbator 
Sub-Population Clusters for Salivary CRP 
(n = 49) 
*Cluster 2 
(n = 4) 
*Cluster 3 
(n = 4) 
**Cluster 3 
Age, years p=0.468 p=0.811 p=0.614 
Gender  
Male, (Female) 
p=0.342 p=0.466 p=0.583 
BMI, kg/m2 p=0.117 p=0.586 p=0.208 
Total 
Co-Morbidities, n 
p=0.145 p=0.700 p=0.187 
FEV1 (% predicted) p=0.996 p=0.818 p=0.913 
FVC (% predicted) p=0.423 p=0.630 p=0.615 
 
*p-values compared to cluster 1 (n = 41), **p-values compared to cluster 2. 
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Table 4.22: Covariates comparisons between the 3 patient exacerbator clusters and non-
exacerbator control cohort for salivary CRP.  
Baseline 
Covariates 
COPD Exacerbator Clusters 
for sCRP 
 (n = 49) 
COPD  
Control 
Non-
Exacerbator 
Cohort 
*p-value 
1 
(n = 41) 
2 
(n = 4) 
3 
(n = 4) 
(n = 6) 
Age, years 67.7 ± 8.1 
68.7 ± 
7.8 
72.3 ± 
6.7 
70.33 ± 6.4 p=0.653 
Gender  
Male, (Female) 
20, 21 2, 2 3, 1 2, 4 p=0.188 
BMI, (kg/m2) 27.8 ± 5.7 
24.3 ± 
5.7 
25.4 ± 
2.7 
24.40 ± 4.2 p=0.308 
Total 
Co-Morbidities, 
n 
1.22 ± 
0.99 
1.25 ± 
0.96 
1.75 ± 
0.95 
0.83 ± 0.8 p=0.540 
FEV1  
(% predicted) 
51.7 ± 
18.6 
39.3 ± 
12.7 
48.8 ± 
24.3 
63.44 ± 27.9 p=0.298 
FVC 
(% predicted) 
77.9 ± 
15.0 
67.8 ± 
10.6 
76.5 ± 
5.0 
84.95 ± 16.9 p=0.345 
 
Data are presented as mean ± SD. *p–value indicate the difference between the 3 patient 
exacerbator sub-population clusters (n =49) and the control non-exacerbator patient cohort (n 
= 6). sCRP = salivary CRP levels. 
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4.4.3.2. Salivary Procalcitonin (PCT) 
Analysis across the 4 defined phases in the COPD exacerbator patient cohort (n = 49) 
demonstrated a statistically significant change in salivary PCT levels (p<0.001). Post-hoc 
analysis further showed that salivary PCT levels were only significantly increased at 
exacerbation onset (0.12, 0.11 ng/ml) compared to the stable phase (0.09, 0.09 ng/ml, 
p<0.001($)) (Table 4.23). Prodromal phase salivary PCT levels were not statistically 
significantly higher than stable phase salivary PCT (p=0.07), nor was there significant 
difference to post-exacerbation-recovery phase salivary PCT (p=0.453) (Figure 4.18). 
However, within the exacerbator cohort salivary PCT was increased during the prodromal 
(mean sample collection time: 5.4 ± 1.6 days) prior to the onset of an exacerbation) and 
exacerbation phases compared to stable phase in 30 of 49 COPD patients (Figure 4.19). Cross-
analysis between the exacerbators (n = 49) and control non-exacerbators (n = 6) cohorts 
demonstrates no statistically significant difference in stable phase salivary PCT levels 
(p=0.484, by Mann-Whitney U Test). 
 
Table 4.23: Salivary PCT levels across the whole COPD study cohort. 
 Salivary PCT (ng/ml) 
COPD 
patients 
Stable Phase 
Prodromal 
Phase 
Exacerbation 
Phase 
Post-Exacerbation-
Recovery Phase 
Exacerbators 
(n = 49) 
*0.09, 0.01 *0.09, 0.09 0.12, 0.11 *0.09, 0.50 
Non-
Exacerbators 
(n = 6) 
*0.09, 0.00 n/a n/a n/a 
 
Data presented as median, IQR. *Values below the lower limit of assay quantification assigned 
as 0.09ng/ml for statistical analysis 
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Figure 4.18: Salivary Procalcitonin (PCT) levels across the 4 defined COPD disease 
phases in the whole exacerbator group. 
Box and whisker plots for salivary CRP levels across the 4 disease phases: (1) Stable; (2) Prodromal; 
(3) Exacerbation; (4) Post-exacerbation-recovery for the whole exacerbator group (n = 49). Outliers are 
identified by o (1.5 x the interquartile range) and * (3 x interquartile range). The stable phase is defined 
as between 35 to 8 days prior to a patient-defined onset of an exacerbation. The prodromal phase is 
defined as between 7 to 1 days leading to an exacerbation onset. The exacerbation phase is defined as 
the onset of the acute episode and start of treatment (Day 0) to treatment completion and return to 
baseline (Day 7 post exacerbation). The post-exacerbation-recovery phase is defined as the immediate 
14 days post treatment completion.  There was a significant statistical difference across the 4 phases 
(p<0.001 by Freidman’s Two-way ANOVA). Post-hoc analysis showed salivary PCT was only 
significantly increased in the exacerbation phase compared to stable phase (*p<0.001($) by Wilcoxon 
signed rank test). Prodromal phase salivary PCT was not significantly higher than stable phase salivary 
PCT (ns: p=0.07); no significant difference was demonstrated between post-exacerbation-recovery 
phase and stable salivary PCT (p=0.453) 
 
* 
ns 
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Figure 4.19: Salivary Procalcitonin (PCT) levels across the 4 defined COPD phases in 
patients who experienced raised analyte levels. 
Box and whisker plots for salivary CRP levels across the 4 disease phases: (1) Stable; (2) Prodromal; (3) 
Exacerbation; (4) Post-exacerbation-recovery are shown only in those COPD patients who experienced a 
rise in PCT in either the prodromal and/or exacerbation phase (n = 30). Outliers are identified by o (1.5 x the 
interquartile range) and * (3 x interquartile range). The stable phase is defined as between 35 to 8 days prior 
to a patient-defined onset of an exacerbation. The prodromal phase is defined as between 7 to 1 days leading 
to an exacerbation onset. The exacerbation phase is defined as the onset of the acute episode and start of 
treatment (Day 0) to treatment completion and return to baseline (Day 7 post exacerbation). The post-
exacerbation-recovery phase is defined as the immediate 14 days post treatment completion. The statistical 
analysis for this data set is identical to whole patient exacerbator group (Figure 4.18). There was a significant 
statistical difference across the 4 phases (p<0.001 by Freidman’s Two-way ANOVA). Post-hoc analysis 
showed salivary PCT was only significantly increased in the exacerbation phase compared to stable phase 
(*p<0.001($) by Wilcoxon signed rank test). Prodromal phase salivary PCT was not significantly higher 
than stable phase salivary PCT (ns: p=0.07); no significant difference was demonstrated between post-
exacerbation-recovery phase and stable salivary PCT (p=0.453) 
* 
ns 
Chapter 4:  COPD Longitudinal Monitoring  
 330  
To understand whether a cut-off could be attributed to exacerbation phase levels of salivary 
PCT, a further sub-analysis was conducted utilising AUC analysis with ROC curves. Overall 
there was significant AUC = 0.63, p<0.03, 95% CI (0.52 to 0.74) (Figure 4.20). Sensitivity and 
specificity at 2 levels of salivary PCT for detecting the onset of acute exacerbation is shown in 
Table 4.24. These points were chosen as they represented optimal salivary PCT values for 
sensitivity, specificity and both parameters combined. 
 
Table 4.24: Sensitivity and specificity of exacerbation phase salivary PCT levels. 
Salivary PCT (ng/ml) Sensitivity Specificity 
0.11 57% 67% 
0.23 16% 86% 
 
  
Chapter 4:  COPD Longitudinal Monitoring  
 331  
 
 
Figure 4.20: ROC curve of salivary PCT levels. 
This ROC curve highlights the sensitivity and specificity of salivary PCT in distinguishing an 
acute exacerbation of COPD. Overall there is a significant AUC = 0.63, p<0.03, 95% CI (0.52 
to 0.74) This highlights that salivary PCT levels at the onset of an exacerbation can be used 
with moderate diagnostic accuracy.   
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4.4.3.2.1. Latent class growth analysis 
Latent class growth analysis (LCGA) was performed on salivary PCT levels from the 
exacerbator cohort (n = 49) across the stable-prodromal period at 5 different time points, each 
1 week apart progressing towards an acute exacerbation of COPD. 
 
As previously, an iterative LCGA was conducted using the BIC and BLRT p-value to 
determine the pilot number of sub-population clusters (Table 4.25) for COPD patients’ salivary 
PCT levels. From this result, the posterior probabilities for cluster membership (Table 4.26) 
were assessed and it was determined whether increasing the cluster number improved or 
worsened the homogeneity of the created sub-populations. Overall sub-population cluster 
membership was shown to be the most discrete at 2 clusters: Cluster 1 = 41 and Cluster 2 = 8 
COPD patients. The membership of each COPD patient to their respective cluster is shown in 
Table 4.27. Overall each cluster formed two completely discrete sub-populations of COPD 
exacerbator patients with no inter-cluster overlap. Each sub-population cluster was defined as 
“low” or “high” range based on the relative levels of salivary PCT to each other, with cluster 
1 assigned as “low” and cluster 2 as “high” range. These sub-population clusters exhibited 2 
unique salivary PCT trajectories over the stable-prodromal (Figure 4.21). 
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Table 4.25: LCGA Goodness of fit tests for stable-prodromal salivary PCT levels.  
LCGA BIC BLRT (p-values) 
1 cluster -146.563 n/a 
2 cluster -290.948 p<0.001 
3 cluster -267.597 p=1.000 
 
The p-value represents whether there is a significant improvement in the model with “n” 
clusters compared to “n-1”. 
 
Table 4.26: Homogeneity of COPD patients cluster membership for stable-prodromal 
salivary PCT levels. 
Cluster 1 (n = 41) 2 (n = 8) 
1 100% 0% 
2 0% 100% 
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Table 4.27: COPD patients cluster membership for stable-prodromal salivary PCT levels.  
COPD Patient Cluster Membership 
1 1 
2 1 
3 1 
4 1 
5 1 
6 1 
7 1 
8 1 
9 1 
10 2 
11 1 
12 1 
13 1 
14 1 
15 1 
16 2 
17 2 
18 1 
19 1 
20 1 
21 1 
22 2 
23 1 
24 2 
25 1 
26 1 
27 1 
28 1 
29 1 
30 1 
31 1 
32 1 
33 1 
34 2 
35 1 
36 1 
37 1 
38 1 
39 1 
40 2 
41 1 
42 2 
43 1 
44 1 
45 1 
46 1 
47 1 
48 1 
49 1 
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Figure 4.21: Salivary PCT clusters across the stable-prodromal phases. 
This line chart represents the LCGA for the mean salivary PCT levels for COPD patients). who 
experienced at least one acute exacerbation of COPD (n = 49) in the stable and prodromal 
phases. This period is defined as 5 weeks prior to the onset of an exacerbation phase and each 
interval represents 1 week. Cluster 1 = 41 and Cluster 2 = 8 COPD patients. The values 
represent mean salivary PCT levels at each time-point for the respective clusters. 
 
  
0.115 0.109 0.117 0.109 0.116
0.848
0.398
0.523
0.466
0.345
0.
0.225
0.45
0.675
0.9
-5 -4 -3 -2 -1
S
a
li
v
a
ry
 P
C
T
 (
n
g
/m
l)
Cluster 1
Cluster 2
Exacerbation 
Onset 
Stable Phase Prodromal 
Phase 
Time points leading to an exacerbation onset (Weeks) 
Chapter 4:  COPD Longitudinal Monitoring  
 336  
4.4.3.2.2. Baseline characteristics associated with cluster membership 
A further separate sub-analysis was conducted to investigate if there were significant 
differences in co-variates (age, gender, BMI, total co-morbidities, FEV1 and FVC) between the 
2 sub-population clusters and also between these exacerbator clusters and the control non-
exacerbator cohort. There was no significant difference in covariates between the 2 exacerbator 
clusters: age (p=0.702), gender (p=0.352), BMI (p=0.419), total co-morbidities (p=0.301), 
FEV1 (p=0.801) and FVC (p<0.690 by Binomial analysis respectively) (Table 4.28). Also no 
significant differences were found between the individual clusters and the control non-
exacerbator cohort (n = 6) for all covariates: age (p=0.414), gender (p=0.570), BMI (p=0.343), 
total co-morbidities (p=0.442), FEV1 (p=0.071) and FVC (p=0.145 respectively) (Table 4.28). 
 
Sub-population cluster 1 “low-range” salivary PCT had comparatively the lowest age, total 
number of co-morbidities and better lung function compared to cluster 2 “high-range” salivary 
PCT (Table 4.28). In contrast to cluster 1, the trajectory of cluster 2 declined towards the onset 
of an acute exacerbation; however salivary PCT levels still remained significantly elevated 
compared to cluster 1 (Figure 4.21). Although this analysis was conducted on an exacerbator 
cohort it may perhaps not be expected that elevated PCT levels would occur several weeks 
prior to an exacerbation. This cluster could possibly reflect a sub-population of patients with a 
high systemic inflammatory response or chronic bacterial airway colonisation. These two 
identified clusters for salivary PCT will also be used in the corollary analysis (Section 4.4.4, 
Page 350) to form a multidimensional score of COPD patients encompassing symptoms, 
spirometry and salivary biomarkers. 
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Table 4.28: Covariates comparison between the 2 patient exacerbator clusters and non-
exacerbator control cohorts for salivary PCT. 
Baseline 
Covariates 
COPD 
Sub-Population 
Clusters for sPCT 
Exacerbation Cohort 
 (n = 49) 
*p-value 
COPD Control 
Non-Exacerbation 
Cohort 
**p-value 
1 
(n = 41) 
2 
(n = 8) 
 (n = 6)  
Age, years 67.6 ± 8.3 71.1 ± 5.1 p=0.702 70.3 ± 6.4 p=0.414 
Gender 
male, (female) 
20, 21 5,3 p=0.352 2, 4 p=0.570 
BMI, kg/m2 27.6 ± 5.6 26.0 ± 5.1 p=0.419 24.4 ± 4.2 p=0.343 
Total 
Co-Morbidities 
1.2 ± 1.0 1.5 ± 1.1 p=0.301 0.8 ± 0.8 p=0.442 
FEV1 
(% predicted) 
52.6 ± 
18.7 
39.4 ± 
14.7 
p=0.801 63.4 ± 27.9 p=0.071 
FVC 
(% predicted) 
78.4 ± 
14.6 
69.8 ± 
10.5 
p=0.690 85.0 ± 16.9 p=0.145 
 
Data presented as mean ± SD unless stated. * P-value represents the difference between the 2 
patient exacerbator sub-population clusters; **p-value represents the difference between the 
exacerbator sub-population clusters and the non-control control cohort. sPCT = salivary PCT 
levels. 
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4.4.3.3. Salivary Neutrophil Elastase (NE) 
Analysis across the 4 defined phases in the COPD exacerbator patient cohort who experienced 
at least one acute exacerbation (n = 49) showed revealed a statistically significant change in 
salivary NE levels (p<0.011). Post-hoc analysis demonstrated that salivary NE levels were 
increased during an exacerbation (745, 1260 ng/ml) compared to the stable phase (381, 1336 
ng/ml, p<0.012($)). Prodromal phase salivary NE levels (900, 1904 ng/ml) were also 
significantly higher than stable phase (p<0.007($)) but no significant difference between post-
exacerbation-recovery phase and stable phase salivary NE levels (p=0.322) (Table 4.29, Figure 
4.22). Salivary NE in the exacerbator cohort was increased in the prodromal phase (mean saliva 
sample time: 5.5 ± 1.7 days) prior to the onset of an exacerbation) and exacerbation phases 
from baseline in 35 out of 49 COPD patients (Figure 4.23). Cross-analysis between the 
exacerbator (n = 49) and non-exacerbator (n = 6) cohorts demonstrated no statistically 
significant difference in stable phase salivary NE levels (p=0.265, by Mann-Whitney U Test). 
 
Table 4.29: Salivary NE levels across the whole COPD study cohort. 
 Salivary NE (ng/ml) 
COPD 
patients 
Stable Phase 
Prodromal 
Phase 
Exacerbation 
Phase 
Post-Exacerbation-
Recovery Phase 
Exacerbators 
(n = 49) 
381, 1336 900, 1904 745, 1260 270, 1412 
Non-
Exacerbators 
(n = 6) 
71, 164 n/a n/a n/a 
 
Data presented as median, IQR. 
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Figure 4.22: Salivary Neutrophil Elastase (NE) levels across the 4 defined COPD phases 
in the whole COPD exacerbator cohort. 
Box and whisker plots for salivary CRP levels across the 4 disease phases: (1) Stable, (2) Prodromal, 
(3) Exacerbation, (4) Post-exacerbation-recovery (n = 49). Box and whisker plots for salivary CRP 
levels across the 4 disease phases: (1) Stable, (2) Prodromal, (3) Exacerbation, (4) Post-exacerbation-
recovery (n = 49). The stable phase is defined as between 35 to 8 days prior to a patient-defined onset 
of an exacerbation. The prodromal phase is defined as between 7 to 1 days leading to an exacerbation 
onset. The exacerbation phase is defined as the onset of the acute episode and start of treatment (Day 
0) to treatment completion and return to baseline (Day 7 post exacerbation). The post-exacerbation-
recovery phase is defined as the immediate 14 days post treatment completion. There was a significant 
statistical difference across the 4 phases (p<0.011 by Freidman’s Two-way ANOVA). Post-hoc analysis 
showed that salivary NE levels were significantly increased during an exacerbation compared to the 
stable phase (*p<0.012($)) by Wilcoxon signed rank test). Prodromal phase salivary NE levels were 
also significantly higher than stable phase (**p<0.007($)) with no significant difference demonstrated 
between post-exacerbation-recovery and stable NE phase levels (p=0.322).  
** 
* 
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Figure 4.23: Salivary Neutrophil Elastase (NE) levels across the 4 defined COPD phases 
in patients who experienced raised analyte levels. 
Box and whisker plots for salivary NE levels across the 4 disease phases: (1) Stable; (2) Prodromal; (3) 
Exacerbation; (4) Post-exacerbation-recovery in COPD patients who experienced a rise in either prodromal 
or exacerbation phase (n = 35). Outliers are identified by o (1.5 x the interquartile range). The stable phase 
is defined as between 35 to 8 days prior to a patient-defined onset of an exacerbation. The prodromal phase 
is defined as between 7 to 1 days leading to an exacerbation onset. The exacerbation phase is defined as the 
onset of the acute episode and start of treatment (Day 0) to treatment completion and return to baseline (Day 
7 post exacerbation). The post-exacerbation-recovery phase is defined as the immediate 14 days post 
treatment completion. The statistical analysis for this data set is identical to whole patient exacerbator group 
(Figure 4.22). There was a significant statistical difference across the 4 phases (p<0.011 by Freidman’s Two-
way ANOVA). Post-hoc analysis showed that salivary NE levels were significantly increased during an 
exacerbation compared to the stable phase (*p<0.012($)) by Wilcoxon signed rank test). Prodromal phase 
salivary NE levels were also significantly higher than stable phase (**p<0.007($)) with no significant 
difference demonstrated between post-exacerbation-recovery and stable NE phase levels (p=0.322). 
 
 
** 
* 
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To understand whether a cut-off could be attributed to exacerbation phase salivary NE levels, 
a further sub-analysis was conducted utilising AUC analysis with ROC curves. Overall there 
was no statistical significance in AUC (0.57, p=0.210, 95% CI (0.52 to 0.74)). This was an 
interestingly result and suggests that in isolation, salivary NE is not able to give absolute cut-
offs for an acute exacerbation and thus stable-prodromal phase levels need to be established 
for each individual COPD patient. 
 
4.4.3.3.1. Latent class growth analysis 
Latent class growth analysis (LCGA) was performed on salivary NE levels from the 
exacerbator cohort (n=49) across the stable-prodromal period at 5 different time points, each 1 
week apart, progressing towards an acute exacerbation.  
 
As previously, an iterative LCGA was conducted using the BIC and BLRT p-value to 
determine the pilot number of sub-population clusters (Table 4.30) for COPD patients’ salivary 
NE. From this result the posterior probabilities for cluster membership (Table 4.31) were 
assessed and it was determined whether increasing the cluster number improved or worsened 
the homogeneity of the created sub-populations. Each cluster formed 3 discrete COPD patient 
sub-populations; however, unlike similar analyses on salivary CRP and PCT levels, the NE 
inter-cluster overlap was higher. Cluster 1 demonstrated a 98% membership rate and cluster 2 
approximately 93%; and cluster 3 was reduced at 94% with a small overlap into cluster 2 only. 
These overlaps are small and so the clusters are considered to be essentially discrete. Thus the 
3 sub-population clusters were used to interrogate salivary NE across the stable-prodromal 
period of the exacerbator cohort. Cluster 1 = 24, Cluster 2 = 4 and Cluster 3 = 21 patients. I 
defined each sub-population cluster as “low”, “medium” or “high” range based on the relative 
levels of salivary NE to each other (Figure 4.24). Accordingly, sub-population cluster 1 was 
defined as “low-range”, sub-population cluster 2 as “medium-range” and cluster 3 as “high-
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range”. The membership of each COPD patient in their respective cluster is shown in Table 
4.32. 
 
Table 4.30: LCGA Goodness of fit tests for stable-prodromal salivary NE levels.  
LCGA BIC BLRT (p-values) 
1 cluster 3375.884 n/a 
2 cluster 3235.409 p<0.001 
3 cluster 3147.219 p<0.001 
4 clusters 3128.913 p=0.249 
 
The p-value represents whether there is a significant improvement in the LCGA model with 
“n” clusters compared to “n-1”. 
 
Table 4.31: Homogeneity of COPD patients cluster membership for stable-prodromal 
salivary NE levels. 
Cluster 1 (n = 24) 2 (n = 4) 3 (n = 21) 
1 98% 0% 2% 
2 1% 5% 94% 
3 0% 93% 7% 
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Table 4.32: COPD patients cluster membership for stable-prodromal salivary NE levels.  
COPD patient Cluster Membership 
1 3 
2 3 
3 1 
4 1 
5 1 
6 3 
7 3 
8 2 
9 3 
10 3 
11 1 
12 1 
13 1 
14 2 
15 1 
16 3 
17 3 
18 3 
19 1 
20 1 
21 1 
22 3 
23 3 
24 3 
25 1 
26 2 
27 3 
28 1 
29 1 
30 3 
31 1 
32 1 
33 3 
34 3 
35 3 
36 3 
37 3 
38 1 
39 1 
40 1 
41 2 
42 3 
43 1 
44 1 
45 1 
46 1 
47 3 
48 1 
49 1 
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Figure 4.24: Salivary NE clusters across the stable-prodromal phases. 
This line chart represents the LCGA for the mean salivary NE levels for COPD patients who 
experienced at least one acute exacerbation of COPD (n = 49) in the stable and prodromal 
phases. This period is defined as 5 weeks prior to the onset of an exacerbation phase and each 
interval represents 1 week. Cluster 1 = 24, Cluster 2 = 4, Cluster 3 = 21 COPD patients. The 
values represent mean salivary NE levels at each time-point. 
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4.4.3.3.2: Baseline characteristics associated with cluster membership 
Further separate sub-analysis was conducted to investigate if there were significant difference 
in covariates (age, gender, BMI, total co-morbidities, FEV1 and FVC) across the 3 exacerbator 
sub-population clusters and between theses clusters and the non-exacerbator control cohort. 
There was a significant statistical difference in total co-morbidities between sub-population 
clusters 1 and 3 (p<0.001 by multinomial analysis) and cluster 2 compared to 3 (p<0.001) 
(Table 4.33). Comparison between the individual exacerbator clusters and the non-exacerbator 
control cohort (n = 6) also demonstrated a significant difference in co-morbidities between the 
2 groups (p<0.001) (Table 4.34). 
 
Sub-population cluster 1 “low-range” salivary NE had the highest FEV1, age and total co-
morbidities compared to clusters 2 and 3 (Table 4.34). This was different to both salivary CRP 
and PCT data where the low-range clusters were associated with a low co-morbidity burden.  
 
Cluster 3 “high-range” has the lowest FEV1 consistent with the increased severity of COPD 
(Table 4.34). This demographic is consistent with that observed in both the high-range 
inflammation profiles for both salivary CRP and PCT sub-population clusters. Cluster 2 “mid-
range” is of interest, with a significant degree of oscillation in salivary NE levels this variability 
is also displayed in the sub-population cluster 2 albeit that the patients therein did not have any 
co-morbidities (Figure 4.24); such variability in analyte levels was also observed in the sub-
population cluster 2 for salivary CRP (Figure 4.17, Page 322) although not to the same 
magnitude. There was also a significant difference in co-morbid burden between the 3 
exacerbator sub-population clusters and the non-exacerbator control cohort (p<0.008). The 3 
salivary NE clusters for the exacerbator cohort will also be used in the corollary analysis 
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(Section 4.4.4, Page 350) to form a multidimensional score of COPD patients encompassing 
symptoms, spirometry and salivary biomarkers. 
 
Table 4.33: Multinomial regression of covariates between the 3 exacerbator sub-
population clusters for salivary NE. 
Baseline 
Covariates 
*Cluster 3 
(n = 21) 
*Cluster 2 
(n = 4) 
**Cluster 3 
(n = 21) 
Age, years p=0.357 p=0.152 p=0.299 
Gender 
male, (female) 
p=0.991 p=0.438 p=0.426 
BMI, kg/m2 p=0.586 p=0.321 p=0.255 
Total 
Co-Morbidities 
p=0.134 p<0.001 p<0.001 
FEV1 
(% predicted) 
p=0.176 p=0.739 p=0.456 
FVC 
(% predicted) 
p=0.361 p=0.705 p=0.498 
 
*P-values compared to cluster 1 (n = 24); **P-values compared to cluster 2. 
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Table 4.34: Covariate comparison between the 3 patient exacerbator clusters for salivary 
NE and the non-exacerbator control cohort. 
Baseline 
Covariates 
COPD 
Sub-Population Clusters 
 
Exacerbation Cohort (n = 49) 
COPD 
Control 
Non-Exacerbator 
Cohort 
 
1  
(n = 24) 
2  
(n = 4) 
3  
(n = 21) 
(n = 6) *p-value 
Age, years 
69.3 ± 
8.1 
62.8 ± 
11.4 
67.9 ± 
8.5 
70.3 ± 6.4 p=0.421 
Gender 
male, (female) 
12, 12 2, 2 2, 4 2, 4 p=0.882 
BMI, kg/m2 
28.5 ± 
5.2 
22.6 ± 3.7 
26.9 ± 
5.8 
24.4 ± 4.2 p=0.117 
Total 
Co-Morbidities 
1.6 ± 1.0 0.0 ± 0.0 1.1 ± 0.9 0.8 ± 0.8 p<0.008 
FEV1 
(% predicted) 
54.5 ± 
19.4 
47.6 ± 9.9 
46.2 ± 
18.6 
63.4 ± 27.9 p=0.233 
FVC 
(% predicted) 
77.1 ± 
15.2 
73.5 ± 9.9 
77.5 ± 
14.3 
85.0 ± 16.9 p=0.616 
 
Data are presented as mean ± SD. *P–value represents the difference between the exacerbator 
sub-population clusters and the non-exacerbator control cohort. sNE = salivary neutrophil 
elastase.   
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4.4.3.4. COPD sub-population re-exacerbators 
Within the exacerbation cohort (n = 49) there were 15 COPD patients who re-exacerbated 
within 14 days. Stable phase salivary levels were compared for the target biomarkers with the 
index exacerbation and post-exacerbation-recovery equivalent levels between the single 
exacerbator (n = 34) and re-exacerbator (n = 15) groups (Table 4.35). Overall only index 
exacerbation phase salivary CRP levels were found to be significantly higher in the sub-
population who re-exacerbated compared to those who remained stable following recovery 
from their first index episode (p<0.04 by Mann Whitney U Test). Additionally, the presence of 
2 or more raised salivary biomarkers at an index exacerbation was also higher in the re-
exacerbation group (p<0.016) There was no significant difference in exacerbation and post-
exacerbation-recovery phase salivary CRP levels between the 2 sub-populations (p=0.572 and 
p=0.680 respectively). 
 
For the sub-population clusters identified using LCGA, CRP was not significantly different 
between the single and re-exacerbation groups (p=0.674 by Kruskal-Wallis test); nor was PCT 
(p=0.719 by Mann Whitney U test) or NE (p=0.596 by Kruskal-Wallis test). 
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Table 4.35: Comparison of salivary biomarker levels between single and re-exacerbator 
patient cohorts. 
 COPD Patients (n = 49)  
Salivary biomarkers 
(ng/ml) 
Single 
Exacerbators 
(n = 34) 
Re-Exacerbators 
(n = 15) 
p-value 
Stable phase:  
CRP 
2.43, 2.19 2.70, 1.20 p=0.572 
Exacerbation phase: 
CRP 
3.38, 6.48 7.46, 6.69 p<0.043 
Post-Exacerbation-
Recovery phase  
CRP 
2.51, 3.29 2.50, 1.39 p=0.680 
Stable phase  
PCT 
0.09, 0.09 0.09, 0.01 p=0.411 
Exacerbation phase 
PCT 
0.10, 0.10 0.12, 0.11 p=0.556 
Post-Exacerbation-
Recovery phase  
PCT 
0.09, 0.07 0.09, 0.01 p=0.300 
Stable phase  
NE 
513, 1955 449, 651 p=0.930 
Exacerbation phase 
NE 
755, 1817 739, 749 p=0.843 
Post-Exacerbation-
Recovery phase  
NE 
258, 1952 311, 700 p=0.797 
Total Number of 
Raised Biomarker 
1.5 ± 1.0 2.3 ± 0.8 p<0.016 
 
Salivary biomarkers are expressed as median, IQR and total number of raised biomarkers as 
mean ± SD. 
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4.4.4. Stable COPD individual-specific multi-dimensional composite score 
Utilising the whole patient exacerbator real-life dataset and the generated sub-population 
clusters within for each COPD patient for each parameter studies (stable-prodromal phase 
wellbeing, FEV1 and salivary biomarkers), an overall composite score was produced for each 
individual. This score was split into 4 distinct groups each one integer greater than each other 
to ensure the allocations were even:  
 
 Group 1 = composite score greater than or equal to 3 but less than 4; 
 Group 2 = score greater than or equal to 4 but less than 5; 
 Group 3 = score greater than or equal to 5 but less than 6; 
 Group 4 = score greater than or equal to 6. 
 
Group membership of: Group 1: 11; Group 2: 20; Group 3: 15 and Group 4: 3 patients (Table 
4.36). Correlations of each group’s composite scores were then performed to COPD disease 
severity and MRC score as well a sub-analysis for across-group differences in age, BMI, total 
co-morbidities, re-exacerbation and annual exacerbation frequency.  
 
Overall there was a statistically significant correlation between the composite score and COPD 
disease severity (r = -0.400, p<0.005 by Spearman’s Rank correlation co-efficient) but not with 
MRC score (r = 0.251, p=0.081), although a clear trend was noted. Sub-analysis did not reveal 
a statistically significant difference in re-exacerbation (p=0.439), BMI (p=0.215), annual 
exacerbation frequency (p=0.832), total co-morbidities (p=0.583) and age (p=0.836 by 
Kruskal-Wallis test respectively) across the 4 groups. 
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Table 4.36: Multidimensional composite score for each COPD exacerbator patient. 
COPD 
Patient 
Salivary 
CRP 
Salivary 
PCT 
Salivary 
NE 
Mean 
Biomarker 
cluster 
Symptom 
Cluster 
FEV1 
Cluster 
Composite 
Score 
Multifactor 
Group 
Allocation 
1 3 1 3 2.33 1 2 6.33 4 
2 1 1 3 1.67 1 2 4.67 3 
3 1 1 1 1.00 1 2 4.00 3 
4 1 1 1 1.00 1 1 3.00 1 
5 1 1 1 1.00 1 2 4.00 3 
6 1 1 3 1.67 1 2 4.67 3 
7 1 1 3 1.67 1 1 3.67 1 
8 1 1 2 1.33 1 2 4.33 3 
9 1 1 3 1.67 1 2 4.67 3 
10 1 2 3 2.00 2 2 6.00 4 
11 1 1 1 1.00 1 1 3.00 1 
12 1 1 1 1.00 1 2 4.00 3 
13 1 1 1 1.00 2 1 4.00 3 
14 1 1 2 1.33 2 2 5.33 2 
15 1 1 1 1.00 1 1 3.00 1 
16 1 2 3 2.00 1 2 5.00 3 
17 3 2 3 2.67 1 2 5.67 3 
18 1 1 3 1.67 1 1 3.67 1 
19 1 1 1 1.00 1 2 4.00 2 
20 1 1 1 1.00 1 1 3.00 1 
21 1 1 1 1.00 1 2 4.00 2 
22 1 2 3 2.00 1 1 4.00 2 
23 1 1 3 1.67 1 2 4.67 2 
24 2 2 3 2.33 1 2 5.33 3 
25 1 1 1 1.00 1 2 4.00 2 
26 1 1 2 1.33 1 2 4.33 2 
27 1 1 3 1.67 1 2 4.67 2 
28 1 1 1 1.00 1 1 3.00 1 
29 1 1 1 1.00 1 2 4.00 2 
30 1 1 3 1.67 1 2 4.67 2 
31 1 1 1 1.00 1 2 4.00 2 
32 1 1 1 1.00 1 1 3.00 1 
33 1 1 3 1.67 2 2 5.67 3 
34 2 2 3 2.33 2 2 6.33 4 
35 3 1 3 2.33 1 1 4.33 2 
36 1 1 3 1.67 1 2 4.67 2 
37 1 1 3 1.67 1 2 4.67 2 
38 1 1 1 1.00 1 2 4.00 2 
39 1 1 1 1.00 2 2 5.00 3 
40 2 2 1 1.67 1 2 4.67 2 
41 1 1 2 1.33 1 2 4.33 2 
42 1 2 3 2.00 1 2 5.00 3 
43 1 1 1 1.00 1 1 3.00 1 
44 1 1 1 1.00 1 1 3.00 1 
45 1 1 1 1.00 2 2 5.00 3 
46 1 1 1 1.00 1 2 4.00 2 
47 1 1 3 1.67 1 2 4.67 2 
48 1 1 1 1.00 1 2 4.00 2 
49 1 1 1 1.00 1 1 3.00 1 
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4.4.5. Exacerbation phase phenotypes 
To determine the presence of any distinct phenotypes in the exacerbation phase of the tested 
COPD metrics an exploratory factor analysis was conducted. All exacerbators (n = 49) data 
was utilised on day 1 of an exacerbation alongside other demographics. Overall factor analysis 
demonstrated 3 distinct phenotypes in COPD patients at the onset of an exacerbation: 
Phenotype 1 components (FEV1, FVC), Phenotype 2 (total co-morbidities, BMI, MRC score) 
and Phenotype 3 components (salivary CRP, salivary PCT and salivary NE) (Figure 4.25). 
Interestingly age, total number of exacerbations and co-morbidities did not improve the 
homogeneity of the respective phenotypes. This result could reflect that the variables in each 
of these phenotypes groups may be combined into a single multidimensional outcome factor, 
so that COPD exacerbations can be classified or characterised into groups based on the 
particular profile mix of PROs, spirometric status and salivary biomarker levels. 
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Figure 4.25: Factor plot of the 3 exacerbation phenotypes. 
This 3D factor plot displays the relationship between the exacerbator group (n = 49) data for 
each identified phenotype. Blue box = Phenotype 1; Yellow box = Phenotype 2, Red box = 
Phenotype 3 
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Salivary PCT 
Salivary NE 
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4.5 Discussion 
This study is the first in COPD patients to investigate daily PROs and weekly salivary 
biomarker levels alongside spirometry, with correlation to HROs. The electronic Wellbeing 
and Self-Assessment diary allowed for accurate daily symptom monitoring with a compliance 
rate of approximately 98%. This is greater than reported in most studies (62% to 92%) in COPD 
patients who have used electronic diaries for daily symptom capture (Cummings et al., 2010, 
Kulich et al., 2015, Sund et al., 2009, Walters et al., 2012). Diary compliance in my study was 
also far in excess of the 80% considered “high” compliance for electronic diary assessments 
(Morren et al., 2009). 
 
Analysis of the COPD Wellbeing score data utilised several novel approaches. Firstly, a 
baseline symptom burden was calculated and used to standardise the COPD Wellbeing Score 
across all COPD patients. This approach dispenses with the need to establish a cut-off value 
for clinically significant scores which was required in other symptom score studies (de Torres 
et al., 2014). Data exploration then utilised CPA which is capable of detecting multiple and 
subtle changes in longitudinal sets of data. This test provides a confidence level indicating the 
likelihood that a change has occurred and a confidence interval indicating when the change 
occurred (Taylor, 2014). These analytical approaches are more sensitive than moving-averages 
(Gavit et al., 2009) which have been employed in other COPD studies involving daily diary 
data (Alahmari et al., 2014). Using sensitive CPA, wellbeing scores in the stable-prodromal 
period showed no significant variation until around 4 days prior to the onset an exacerbation. 
This demonstrates COPD Wellbeing score reproducibility over the observation period, a key 
component of valid symptom assessment (Leidy et al., 2014).  
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The enhanced symptom burden from 4 days before exacerbation onset is also consistent with 
previous observations (Aaron et al., 2012). The gradient of symptom improvement was linear 
across the 7-day exacerbation phase when COPD patients were receiving treatment with 
antibiotics and steroids. This, coupled with the observation that all salivary biomarker levels 
had returned towards baseline levels post-treatment highlights that recovery on the treatment 
initiation was consistent for the whole COPD exacerbator cohort. This may provide a possible 
explanation for why short treatment courses for acute exacerbations of COPD appear to be as 
effective as longer treatments (El Moussaoui et al., 2008). Interestingly, analysis of the post-
exacerbation-recovery phase demonstrated a worsening in COPD Wellbeing score trajectory 
at day 10. However, analysis of the scores on that day did not reveal a significant change. This 
further supports the argument that snap-shot data is not enough to predict and monitor 
wellbeing in COPD. Additionally, it confirms that capture of symptoms via daily self-
assessment diaries requires a far higher compliance than has currently been acceptable in the 
literature.  It has been previously demonstrated that median time to a re-exacerbation event is 
between 29 to 43.5 days (Leuppi et al., 2013); this is much later than my observations but could 
be related to my COPD patient cohort having a frequent exacerbator phenotype. 
 
The results for spirometry revealed a significant reduction in both FEV1 and FVC during an 
acute exacerbation of COPD. However, neither assessment declined significantly in the 
prodromal phase. The LCGA data was interesting and demonstrated that there was no 
variability in the change of FVC across the stable-prodromal. FEV1 demonstrated 2 clusters 
with different trajectories. This is consistent with the known variability of FEV1 decline over 
time in the COPD population (Casanova et al., 2014). Importantly the LCGA of spirometry to 
generate the sub-population clusters does so without using an arbitrary cut-off; thus there is no 
a priori assumption about the rate of FEV1 change prior to analysis (Herpel et al., 2006). The 
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result for FVC is interesting as it appears to demonstrate that the rate of change over time is 
consistent irrespective of underlying disease severity.  
 
The COPD patients who re-exacerbated within this study (n = 15) had more severe disease (as 
judged by their FEV1); this has previously been observed in other published studies which have 
demonstrated an increased risk of re-exacerbation in COPD patients with worse lung function 
re-exacerbating within 90 days of an index exacerbation (Liu et al., 2015, Liu et al., 2007). 
 
All 3 target salivary biomarkers demonstrated a significant increase during an acute 
exacerbation of COPD. These results are consistent with the study findings in Chapter 3, Page 
239. Both salivary CRP and NE levels increased in the prodromal phase. Although PCT was 
significantly higher in the whole COPD exacerbator group (n = 49) at exacerbation, this was 
not reflected in the prodromal phase. As discussed in Chapter 1, Page 69. PCT is highly 
selective for the presence of bacterial infections (Jaresova et al., 1999). It is plausible that a rise 
may occur in the prodromal phase of a bacterial-driven acute exacerbation, with the magnitude 
of the rise being dependent on bacterial load and severity of the infective episode. However, as 
bacteria account for 50 to 69% of COPD exacerbations (Chapter 1, Page 37) this may provide 
a partial explanation for why a rise in prodromal phase PCT levels was only observed in 
approximately 40% of the exacerbator cohort. Unfortunately, sputum microbiological profiles 
were nor examined in the study. 
 
A review of the literature (web of science: search term: Exacerbation prediction COPD), 
revealed no studies to date that have investigated the predictive value over time of an early rise 
in physiological metrics or biomarkers of inflammation in COPD. All 3 salivary biomarkers 
returned to stable phase levels once the exacerbation has been treated. Interestingly the post-
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exacerbation-recovery phase levels of all 3 biomarkers do not appear to predict a re-
exacerbation event. However, the index exacerbation phase salivary CRP levels and total 
number of raised biomarkers were observed to be higher in patients who re-exacerbated. In 
general, my results are in agreement with studies that have shown elevated levels of multiple 
biomarkers in stable COPD to be associated with an increased risk of exacerbation (Thomsen 
et al., 2013). This result might suggest that the index exacerbation was perhaps more severe; 
however, normalisation of all 3 salivary biomarkers occurred at the end of the 
exacerbation/treatment phase, thereby implying that the medication given had been effective. 
It is possible that within the complexity of an exacerbation, all components may not have been 
considered, for example eosinophilic inflammation shows a high responsiveness to steroids 
and has been demonstrated to be a distinct phenotype in acute exacerbations of COPD 
(Bafadhel et al., 2011b). Therefore, the re-exacerbation group in my study would have had a 
return to baseline for the salivary biomarkers tested following the 7-day course of high dose 
steroids but relapsed at around day 10 in the post-exacerbation-recovery phase due to a 
sustained eosinophilic-driven process possibly requiring a longer steroid course; peripheral 
eosinophil counts were not examined in my study 
 
The LCGA approach highlighted several clusters for all 3 target salivary biomarkers based on 
their levels and trajectory over the stable-prodromal phases. These clusters highlight that even 
in a small cohort of patients there is variability in salivary biomarker trajectories although these 
clusters were not associated with re-exacerbation risk. Multinomial analysis however revealed 
that the total number of co-morbidities is a significant discriminatory component of the salivary 
NE cluster. The prevalence of co-morbidities has been shown in a recent systematic review to 
be a consistent factor in the phenotyping of COPD subjects (Pinto et al., 2015). The 3 baseline 
salivary clusters identified in this study will require an iterative validation process before their 
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relevance to clinical outcome is determined. The further validation of these clusters within 
much larger patient cohorts could lead to targeted and personalised drug therapy for these 
patient sub-populations. Unfortunately, the literature demonstrates that current studies 
invariably attempt to cluster individuals with COPD based on “a snapshot in time” view of 
objective and subjective metrics; therefore, confusion exists as to whether subjects remain in 
the same cluster over time (Han et al., 2010a). Thus for COPD patient cluster studies to be 
meaningful and accurate there is a need for them to incorporate a temporal design and analysis 
of longitudinal real-life data to reflect the variability of COPD-relevant metrics over time. 
 
This study has also attempted to establish a novel composite individual score based on a profile 
of PROs, spirometry and salivary biomarkers. This multidimensional composite score showed 
significant correlation with COPD disease severity and a trend with MRC score. Further work 
needs to be undertaken to understand the role of this multidimensional scoring system and its 
relevance to COPD outcomes and management.  
 
The control cohort (n = 6) who did not experience an acute exacerbation served as a control 
cohort. They were classified as frequent exacerbators prior to enrolment into the community-
based longitudinal study; however their baseline annual exacerbation frequency was overall 
lower at 2 episodes per year compared to that of the exacerbator cohort at 4 episodes per year. 
This is interesting and perhaps highlights the need to split the frequent exacerbator phenotype 
into a further “frequent-frequent” sub-population based on an annual exacerbation frequency 
of greater than 4 acute episodes. 
 
In acknowledgement that there exist limitations to the study and these need to be considered. 
Cluster membership appears to be discrete; however the study was exploratory with 
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comparatively small patient numbers. The next step would be to utilise the defined clusters in 
a much larger cohort of patients and monitor said patients over a longer time frame. Although 
3 exacerbation phenotypes were identified, the specific aetiology of the exacerbations was not 
characterised. Although this would add further classification information to my results, it could 
also be considered d as an advantage as clustering was completely blinded from aetiology. The 
principle components of these phenotypes could again be followed up longitudinally to 
understand any variations between them and their relationship to the stable phase clusters.  
 
An arbitrary, albeit structured process has been utilised, for assigning individual scores in the 
multidimensional composite score; for example, COPD patients with higher levels of stable-
prodromal phase inflammation were assigned into a higher score and indeed this may be an 
incorrect presumption.  There is therefore a need to monitor these sub-population clusters to 
clarify whether higher inflammatory levels are related to a worse long-term outcome. Finally, 
the COPD population in this study are a distinct cluster in their own right (frequent exacerbators 
was a study inclusion criterion). Longitudinal monitoring needs to be applied to non-frequent 
exacerbators to understand whether the same trajectories in PRO, spirometry and salivary 
biomarkers exist and their relationship to health status monitoring. 
 
Results from this study provide the foundation for a COPD health status monitoring algorithm 
for earlier exacerbation recognition and re-exacerbation risk. Additionally, multidimensional 
stable phase clusters have been identified for both the stable-prodromal and exacerbation phase 
data which lend themselves to further testing. Importantly, as none of the exacerbators required 
hospital admission for their acute episodes it could be argued that the study methods represent 
a successful self-management protocol. Within the framework of this thesis, the patient 
experience in respect of such monitoring [electronic wellbeing self-assessment and self-testing 
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of saliva] would be a valuable step towards further development of a viable bio-clinical 
intervention for point-of-care prediction of COPD exacerbations. This will be further 
investigated in dedicated workshops in the next two chapters (Chapter 5, Page 361 and Chapter 
6, Page 384). 
 
4.6. Conclusion 
All 3 target salivary biomarkers can identify an exacerbation of COPD from the stable phase 
and both CRP and NE appear to identify a prodromal phase. The CRP level at exacerbation 
and the disease severity as measured by FEV1 appear to be the best predictors of the likelihood 
of a re-exacerbation within 2 weeks of an index exacerbation. COPD patients at their baseline 
stable phase appear to have 3 unique cluster trajectories: low-range, medium-range and high-
range inflammation. These clusters are apparent for both salivary CRP and NE, whilst salivary 
PCT appears to exhibit just low-range and high-range inflammatory clusters. Salivary NE, 
appears to have a significant association with co-morbidity burden. 
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5.1 Introduction 
PROs are increasingly advocated within the wider healthcare and clinical research. They are 
seen to provide invaluable subjective information particularly when assessing the effects of a 
proactive intervention on patients and also in screening specific health disorders (Li et al., 
2007). They have been shown to be important in COPD management and numerous PROs exist 
in the wider literature (Chapter 1, Page 27). In this thesis a novel PRO score was developed 
encompassing clinically-relevant COPD metrics (COPD Wellbeing score) (Chapter 2, Page 
210). This was incorporated into a purposeful paper-based diary (Wellbeing and Self-
Assessment diary, (Chapter 2, Figure 2.29, Page 212) and tested in a community-based cohort 
study (Chapter 3, Page 213). The results of the community-based cohort study demonstrated 
that components of the COPD Wellbeing Score correlated with MRC score and salivary 
biomarkers (Chapter 3, Page 233). Based on the results for the paper-based Wellbeing and Self-
Assessment diary and a literature review on the limitations of paper-based symptom diary 
(Chapter 4, Page 254) an electronic Wellbeing and Self-Assessment diary (Chapter 4, Page 
258) was designed. This electronic Wellbeing and Self-Assessment diary installed on an iPad 
(Apple, USA) was provided to COPD patients in a pilot community-based longitudinal study 
to understand COPD patients’ symptom self-management and the correlation of these 
symptoms to health status and salivary biomarkers (Chapter 4, Page 270). 
 
5.1.1. The concept of COPD self-management 
In recent times work on patient self-management has demonstrated the efficacy of involving 
and empowering patients in their own care (Trappenburg et al., 2013). Specifically, for COPD 
patients, the most recent update of the Cochrane Database of Systematic Reviews demonstrated 
that self-management programmes reduce the probability of COPD-related hospital admissions 
and also increase patient wellbeing (Zwerink et al., 2014). To date, the diversity in content and 
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duration of the self-management programmes reviewed, have elicited no clear 
recommendations regarding the most effective form and content of self-management in COPD 
(Zwerink et al., 2014). However, a major feature common to all the self-management 
programmes reviewed is some form of patient self-assessment of their condition.  
 
Arguably, self-monitoring demands a significant shift in patients’ behaviour; a change which 
has been proposed could be attained only if patients’ self-efficacy is such that they have enough 
confidence in their ability to successfully respond to certain events (Bischoff et al., 2012). Self-
efficacy is defined as ‘‘the belief in one’s capabilities to organise and execute the courses of 
action required to produce given attainments” (Bandura, 1995). This cognitive construct is 
different from simply believing in a positive outcome; rather, it refers to a person’s judgement 
about their ability and skills required to carry out a specific behaviour. Self-efficacy beliefs 
held by individuals are considered to be a central and persuasive factor in determining the 
course of action required, the degree of effort given and a person’s perseverance to continue in 
the face of challenges and difficulties (Bandura, 1989).   
 
Most patient self-management programmes, based in the theory of self-management, (Ryan 
and Sawin, 2009) are founded on Bandura’s work on self-efficacy (Bandura, 1989, Bandura, 
1995, Bandura, 1997). Within the context of COPD patients, effective patient self-management 
including self-monitoring of symptoms might involve seeking treatment for a potential acute 
exacerbation of COPD before it becomes a full-blown event with associated consequences on 
respiratory reserve; thus avoiding the necessity for A&E attendance and hospital admission. 
Currently, this level of well-designed and guided patient self-management seems to be limited 
and acute COPD exacerbations remain a leading cause of unscheduled GP visits and the most 
common cause of emergency hospital admissions (Wedzicha and Vestbo, 2012). Yet it has 
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been shown that patients use online applications regularly when healthcare interaction is 
available (In 't Veen et al., 2012).  
 
The implementation of two or more of the following factors result in a fall in COPD 
exacerbations and reduced healthcare utilisation: (1) an extensive self-management programme 
with an individualised action plan (Sedeno et al., 2009). This educates patients in the 
management of their condition which empowers them to recognise the signs of a clinical 
deterioration and initiate prompt treatment; (2) “advanced” access to care, which includes a 
knowledgeable healthcare provider (Fromer, 2011). This ensures that patients are monitored 
and assessed by healthcare providers with expertise in COPD; (3) guideline-based therapy to 
ensure up-to-date evidence-based treatment for COPD is being provided (NICE, 2010); (4) a 
clinical registry system containing population information. This provides a database for 
healthcare professionals to ensure that all patients are receiving standardised care (Adams et 
al., 2007).  
 
5.1.1.1. Telehealthcare 
Advances in telehealthcare technologies including medical Apps, computer programmes, 
diagnostic algorithms; all of which utilise different interfaces (e.g. tablet computer, laptop, 
mobile phone, video conference technology) to interact with patients, seem to offer a 
mechanism to help meet these criteria cost-effectively (McLean et al., 2013). However, the 
current systems do not offer an analytical or decision-making structure; nor have they been 
widely embraced by all. Research across a range of conditions demonstrates mixed responses 
to different mobile health technologies in terms of both patient satisfaction and also their use 
as part of effective interventions, in terms of both real economic efficiency and clinical efficacy 
(Abrams and Geier, 2006, Barlow et al., 2007, Car et al., 2012, Parker and Hawley, 2013). 
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To date, telehealthcare in COPD can be divided into two systems; the first is one in which 
patients monitor their symptoms at home and log them electronically and the second is where 
patients are asked to report their symptoms via, for example, a telephone and/or computer 
(Polisena et al., 2010). Both systems have been demonstrated to reduce hospital attendance and 
exacerbation frequency (Alrajab et al., 2012, Polisena et al., 2010, McLean et al., 2012). PROs 
however, do not seem to improve with telehealthcare although the evidence for this is 
conflicting. The variety of measurement instruments for these PROs within studies hinders 
direct comparison (Polisena et al., 2010). Relevant effects have been observed in a successful 
self-manager sub-group, representing about 40% of COPD patients (Bucknall et al., 2012). 
Overall it remains unclear whether improvements in these PROs are driven primarily by 
objective improvements in physical health or by subjective improvements in perceptions of 
agency or control. Additionally, in most interventions, transfer was shown to be reliant on 
automated algorithms for interpretation. Care providers can recognise important changes in 
essential measurements, but delays occur as the systems are only active during office hours.  
 
The purpose of the electronic Wellbeing and Self-Assessment diary was to utilise mobile health 
technology to provide both a platform to improve COPD patients’ self-management and also, 
a direct link to a COPD specialist care team; thus implementing two of the factors outlined 
above, as critical for a fall in acute exacerbations and reduced health care utilisation. All COPD 
patients recruited into the community-based longitudinal study (Chapter 4, Page 270) had been 
previously self-managed their disease. This self-management consisted of initiating treatment 
for acute exacerbations of COPD with “rescue” medications (antibiotics and steroids) 
prescribed by their general practitioner (GP) and kept in reserve at the patients’ own home in 
line with NICE COPD guidance (NICE, 2010). The COPD patients were not formally 
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monitored and they relied on their own judgement as to whether they needed to commence 
treatment.  
 
A qualitative study was conducted with the objective (Chapter 1, Page 78) of understanding 
whether the self-management ecosystem provided in the community-based longitudinal study 
(Chapter 4, Page 270), centered upon the electronic Wellbeing and Self-Assessment diary 
(Chapter 4, Page 258) supported by myself and the research team of COPD specialist nurses, 
could improve patients’ self-management by increasing their self-efficacy: Specifically, their 
judgement and confidence in their ability and skills required to determine appropriate self-care 
(Ryan and Sawin, 2009). 
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5.2. Methods 
All participating COPD patients were asked to provide their written feedback during the 
community-based longitudinal study (Chapter 4, Page 271) on the use of the electronic 
Wellbeing and Self-Assessment diary in the free-text section of the diary, and on completion 
of the study their thoughts were recorded on the electronic diary in the HRO section. The 
community-based longitudinal study design is described in Chapter 4, Page 270.  
 
Briefly, the electronic Wellbeing and Self-Assessment Diary installed on an iPad (Apple, USA) 
was provided to COPD patients to be completed daily in conjunction with weekly visits by 
myself and a respiratory specialist research nurse to assess health status. All COPD patients 
were taught and shown how to use the iPad (Apple, USA) and electronic Wellbeing and Self-
Assessment diary on their first visit by myself. They were encouraged to contact the research 
team (me or the named clinical research nurse (Ms Pauline Jones/ Ms Vicki Adamson)) if any 
problems arose and informed that help would be provided if required. COPD patients were 
aware that their diary entries would be monitored remotely by myself and the clinical research 
nurses with any deterioration in symptoms triggering contact by either myself or the research 
nurses. In addition, COPD patients were also aware that on commencement of treatment for an 
acute exacerbation of COPD either myself or the research nurses would visit as soon as possible 
and no later than 12 hours after contact been initiated. This level of support was available 7 
days a week (7.30am to 7.30pm). A paper-based version of the electronic Wellbeing and Self-
Assessment diary (Appendix 1, Page 485) was also available if required or preferred; though 
none of the COPD patients chose to use this method. The average duration of each COPD 
patient in the study was 9.5 weeks with 98% diary entry compliance. Overall all COPD patients 
documented that the electronic Wellbeing and Self-Assessment diary was end-user friendly, 
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encompassed symptoms relevant to their condition of COPD and helped with the management 
of their disease. 
 
To elucidate these concepts further, COPD patients' attitudes and experiences were explored 
by setting up semi-structured workshops at eight months after the start of the community-based 
longitudinal study (Chapter 4, Page 270). COPD patients who had completed or were still 
active within the community-based longitudinal study were invited to take part (Figure 5.1). 
As such, they formed a purposive sample (Ritchie, 2014). 
 
Figure 5.1: Population and workshop recruitment.  
This figure demonstrates COPD patient recruitment into the focus groups from the community 
based longitudinal study (Chapter 4, Page 270). Active represents patients who were still active 
in the longitudinal study whilst completed represents patients who have finished the study. 
 
 
COPD Patients 
 (n=31) 
Active 
(n=11) 
Completed 
(n=20) 
Agreed to 
participate 
(n=10: active n=3, 
completed n =7) 
Workshop 1 
(n = 3, active n = 1, 
completed n = 2) 
Workshop 2 
(n = 4, active n = 0, 
completed n = 4) 
Workshop 3 
(n = 3), active n=2, 
completed n =1) 
Community-based Longitudinal Study Qualitative Study 
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5.2.1. Workshop demographics 
Fifteen COPD patients responded that they wished to be involved in the workshops; 
unfortunately, 5 COPD patients had an acute exacerbation and could not attend on the set dates.  
The COPD patient demographics are described in Table 5.1. 
 
Table 5.1: Workshop demographics. 
 
Male 
(n = 7) 
Female 
(n = 3) 
Age, years 72.15 ± 10.52 63.55 ± 9.81 
BMI, (kg/m2) 22.78 ± 2.45 24.68 ± 6.85 
Co-morbidities, n 1.65 ± 0.65 1.78 ± 0.68 
FEV1, (% predicted) 49.25 ± 5.62 48.78 ± 6.82 
FVC, (% predicted) 72.25 ± 8.29 74.25 ± 9.25 
 
Data presented as mean ± standard deviation unless stated. 
 
Due to the debilitating nature of COPD, specifically severe breathlessness which often limits 
fluent speech, the number of participants in each workshop was deliberately kept small. This 
then facilitated much time and opportunity for each COPD patient to fully engage in the 
discussion.  
 
The main purpose of this workshop approach was to facilitate the generation of data by 
interaction between the COPD patients, who were able to present their own views and 
experiences but also to hear others’ contributions. In this way they were then enabled to reflect 
further upon their own viewpoint and contributions and make additional comments. COPD 
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patients were able to ask questions of each other, which prompted further additional 
spontaneous comments from others: “A workshop is therefore, not a collection of individual 
interviews with comments directed solely through the researcher” (Finch, 2014). Rather, it is 
synergistic (Stewart, 2007) with the interaction of the group members used to generate data 
and insights (Berg, 2012).  
 
5.2.2. Data collection 
In preparation for the workshops, due consideration was given to a venue, information that I 
wanted to elicit, and the structure of the groups. The venue chosen was the location known and 
frequented by all COPD patients for their exercise-based treatment (pulmonary rehabilitation). 
A series of questions was constructed with the help of a clinical psychologist (Dr. Kathryn 
Kinmond, Manchester Metropolitan University) and refined (Table 5.2) to seek a better 
understanding of the following factors: how far the COPD patients engaged with and embraced 
the use of the electronic Wellbeing and Self-Assessment Diary and iPad (Apple, USA) ; the 
impact of daily monitoring of their symptoms and weekly visits from the clinical research team 
(myself and the COPD research nurses) in terms of monitoring their condition; how they felt 
about this approach to self-management of their COPD; and how far the relationship between 
the patients and the clinical research team impacted on their self-monitoring of their condition.  
  
Chapter 5:  End-User Experience on the Electronic Diary 
 371  
Table 5.2: Workshop questions. 
1. How did you learn about the study? 
2. What did you think when you first saw the *iPad diary? 
a. How helpful/useful was it, to have the *iPad Diary demonstrated to you? 
b. How could it have been better? 
c. Are there any extra bit that we have missed or you would like to see added? 
3. How long did it take you to feel ok using the *iPad Diary? 
a. What do you think about the design? 
i. For example, the colours, layout, brightness, buttons? 
b. Were you able to tell us about all your symptoms easily? 
c. The free space that you could enter a message was it a good thing? 
d. Did you find it a pain to use? 
4. What was it like to have a weekly visit from Polly/Vicki? 
a. Did you find it helpful? 
b. Did it make you feel more in control of your COPD? 
c. Did you like the fact that someone was looking at your diary every day and your 
progress? 
i. What was good? 
ii. What was bad? 
5. In what way do you think your life was different by being in the study using the *iPad 
Diary? 
6. Have we missed anything? 
 
*Throughout the longitudinal community study COPD patients referred to the electronic 
Wellbeing and Self-Assessment diary as the iPad Diary for simplicity. 
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All three workshops were purposefully facilitated by the clinical research nurse (moderator). 
The rationale for this was that the nurse was from the same geographical area as the COPD 
patients and thus, shared a common use of regional dialect; additionally, patients were familiar 
with her and the aim of the workshops was to facilitate the COPD patients to engage in open 
discussion. Arguably, the different roles of COPD patients and researcher became more blurred 
as the discussion and interactions evolved such that at times during the workshops the COPD 
patients took over some of the ‘interviewing’ of each other and the researcher became an active 
listener (Egan, 2013).  No audio-recording took place so the conversations were transcribed in 
“real-time” by myself and the clinical psychologist for each focus group. Every session 
commenced with a general introduction, a demonstration of the electronic Wellbeing and Self-
Assessment dairy to act as an aide de mémoire and then the main discussion. During the 
workshops all COPD patients were encouraged to talk freely about their experiences and at the 
end of the session asked to raise anything that had not already been covered. Each workshop 
lasted two hours.  All COPD patients received a copy of the questions (Table 5.2) to be 
discussed one week prior to the workshop. In this way it was aimed to offer the COPD patients 
an opportunity to give informed consent to take part, as they were as fully briefed as possible, 
including being made aware of the questions that were going to be asked of them. All COPD 
patients gave consent to their conversation being transcribed and quotes being used. 
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5.3. Data analysis 
Data transcription and analysis proceeded simultaneously. The “substantive” approach 
(Spencer, 2014) to data analysis; specifically, the Framework Method (Gale et al., 2013) was 
used to analyse the workshop transcripts. The Framework Method sits within a broad family 
of thematic analysis methods (Braun and Clarke, 2006) which identify commonalities and 
differences in qualitative data, before focusing on relationships between different parts of the 
data, “thereby seeking to draw descriptive and/or explanatory conclusions clustered around 
themes” (Gale et al., 2013a). It is being used increasingly in health research, particularly when 
there is a multidisciplinary research team engaged in analysis. The Framework Method is a 
highly systematic method of catergorising and organising what may seem like unmanageable 
qualitative data. It is not aligned to a particular epistemological, philosophical, or theoretical 
approach. Rather, like thematic analysis (Braun and Clarke, 2006) it is a flexible tool that can 
be used with many qualitative approaches that aim to generate themes. In the analysis phase 
the gathered data is sifted, charted and sorted in accordance with key issues and themes. This 
involves a 5 step process (Gale et al., 2013): 
 
1. Familiarisation where the researcher(s) become familiarised with the transcripts of the data 
collected. 
2. Identifying a thematic framework where emerging themes are recognised and documented. 
3. Indexing where one identifies portions or sections of data that correspond to a particular 
theme. 
4. Charting where specific pieces of data that were indexed in the previous stage are now 
arranged into charts of the themes 
5. Mapping and interpretation which is the final stage involves the analysis of key 
characteristics from the charts and interpretation of these characteristics. 
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The Framework Method further embraces involvement in analysis by all members of the 
research team, regardless of their level of research experience (Gale et al., 2013). This approach 
then seemed wholly appropriate to our workshop team (myself as the clinician, Dr Kinmond 
as clinical psychologist and Ms Jones as the clinical research nurse).  As someone with limited 
experience in qualitative research, by using this method approach I was able to engage in both 
a multi-disciplinary and multi-experience-level approach to the analysis of the workshop data. 
After each workshop there was a team de-brief to discuss the key themes. Following which, 
myself and the clinical psychologist prepared individual reports containing a transcript of the 
conversation and key themes to have emerged from the session; reports were then exchanged 
and mapped. Finally, after all three workshops were completed, a face-to-face team meeting 
was held to discuss the overall results and final refinement of the concluding report. The 
Framework Method has no allegiance either to inductive, deductive or combined thematic 
analysis (Gale et al., 2013). For this study, a combined approach was deemed appropriate as 
the study had some specific issues to explore (evidenced in the workshop questions), but also 
aimed to consider other unexpected aspects of the participants’ experience and the way they 
assigned meaning to phenomena. 
 
As any form of qualitative or quantitative analysis is not a purely technical process, but 
influenced by the researchers’ characteristics, experiences and disciplinary paradigms (Ritchie, 
2014), critical reflection across the research team member occurred throughout the process. 
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5.4. Results 
The data was grouped into four major themes. “Technology” covered the aspects in relation to 
the electronic Wellbeing and Self-Assessment diary; this included the impact of its use on 
patients’ self-efficacy (Bandura, 1995) and self- management (Ryan and Sawin, 2009) of their 
condition. “Humanity” covered COPD patients’ experiences in relation to the clinical research 
team. A third theme of “Interactions with the GP” was clear in the stories of all COPD patients. 
The final theme “All alone” illustrates the very real isolation and fear of the COPD patients as 
they face life and managing their condition without the electronic Wellbeing and Self-
Assessment diary and the clinical research team. 
 
5.4.1. Technology 
It was initially felt that the demographics of the study population might mean that in the 
community-based longitudinal study (Chapter 4, Table 4.2, Page 280) there would be a small 
but significant use of the paper-based version (Appendix 1, Page 485) of the electronic 
Wellbeing and Self-Assessment diary, which had been offered as an alternative to the 
electronic diaries. Clearly there was initial apprehension from some COPD patients about using 
the electronic Wellbeing and Self-Assessment diary. As one stated “It was scary; I was 
frightened about making mistakes; I didn't want to break it; If you do x and y you might put in 
a wrong answer”. Although this was not universal as another COPD patient exclaimed “At last! 
I've got an iPad; Bees knees!”  Such mixed responses resonate with published research which 
report mixed responses by patients across a range of conditions, to different technologies in 
healthcare (Abrams and Geier, 2006, Barlow et al., 2007, Car et al., 2012, Parker and Hawley, 
2013). Unexpectedly one COPD patient felt “differently” empowered because of the 
technology and the impact of this on his physical disabilities: “I have an essential tremor so I 
wouldn’t do a written diary. I had no problems using it”. This perhaps reminds of the need to 
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consider the ‘whole person’ when offering intervention (Crossley, 2000) as one approach may 
not be relevant to all. 
 
Despite the feelings of apprehension, no paper-based versions of the electronic Wellbeing and 
Self-Assessment diaries were used either at enrolment or during the community-based 
longitudinal study (Chapter 4, Page 270) by switching from the electronic Wellbeing and Self-
Assessment to paper-based diary. This level of uptake may have been attributable to the fact 
that the participants were aware that the paper-based version of the electronic Wellbeing and 
Self-Assessment diary entries would be collected only weekly. Thus, remote symptom 
monitoring would not be possible.  
 
All COPD patients felt that the electronic Wellbeing and Self-Assessment diary and iPad 
(Apple, USA) provided were simple to use and there were no problems with the colours or 
fonts. The majority of COPD patients also provided suggestions on how the electronic 
Wellbeing and Self-Assessment Diary could be refined further. The bulk of these suggestions 
focused on how the COPD patients felt that their symptoms could be portrayed more accurately 
or that there were other symptoms of relevance. As one COPD patient stated, “There’s not 
enough space for writing comments”. Some COPD patients even wanted the ability to enter 
the electronic Wellbeing and Self-Assessment Diary more than once a day. COPD patients 
were clearly feeling empowered and there was evidence of their self-efficacy (Bandura, 1995) 
as they felt able to contribute to further refinement of the electronic Wellbeing and Self-
Assessment Diary.  
 
The electronic Wellbeing and Self-Assessment dairy helped to provide a strong sense of 
support. Comments included “Can keep an eye on you”; “Feel better using the App”; “Feel it 
Chapter 5:  End-User Experience on the Electronic Diary 
 377  
is a must”; “Be snookered without the App”; “Cut off without this”; “Provides security like 
pulmonary rehab”; “Feels secure”; “Someone knows what is happening”. This last comment 
was echoed both verbally (with a resounding; “mm”; or “yes!”) and non-verbally by participant 
nods. It was perhaps best summed up by one participant who exclaimed “It's like a lifeline”.  
 
Other telehealth systems do not seem to have offered patients quite the same level of support 
and wellbeing (Car et al., 2012). So perhaps it was the combination of the electronic Wellbeing 
and Self-Assessment Diary together with the other features of the care provided that made the 
COPD patients feel supported. This would link into the work reviewed above (Section 5.1.1.1, 
Page 364), which showed that a fall in exacerbations and reduced healthcare utilisation 
demanded application of two or more variables which the community-based longitudinal study 
in Chapter 4, Page 251 implemented; such reduced illness and healthcare utilisation surely 
indicating a psychosocial impact of effective telehealthcare which links directly to our COPD 
patients’ comments. 
 
The electronic Wellbeing and Symptom Diary also fulfilled an educational role which 
empowered the COPD patients. One COPD patient stated “Before I didn’t even look at the 
colour of my sputum or think about how I feel but I do now”. Another one commented “You 
get that used to filling it in that it makes you more aware and think about how you are today. 
I’m more confident about my self-management than before starting the trial”. This led to an 
improved confidence and possibly better self-management as the COPD patients were made 
aware of clinically relevant parameters in their disease. These comments suggest an increase 
in patients’ self-efficacy (Bandura, 1995) and find resonance in the effective self-management 
(Ryan & Sawin, 2009) championed by self-management programmes (Zwerink et al., 2014). 
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5.4.2. Humanity 
The research team conducted routine weekly visits to assess health status. They were also 
available either in person or via the phone if COPD patients noticed a clinical deterioration 
indicated on the electronic Wellbeing and Self-Assessment Dairy. If the patients decided to 
commence treatment for an exacerbation this would also trigger a visit from either myself or 
the nurse. Thus, the research nurse team helped to provide a safety net not only during 
exacerbations but also when COPD patients were well. One COPD patient commented, “Off 
day; unwell the nurses will ring up which is good”. Another COPD patient commented proudly, 
“The nurse came out when I started treatment which is fantastic”. Some COPD patients felt 
that the clinical research team provided a bridge between existing healthcare provision and 
home self-management, particularly as there seemed to be a reluctance to contact the GP. 
Again, this resonates with the points discussed previously (Section 5.1.1.1, Page 364) which 
highlights the need for a holistic approach and that there are different components to 
implementing an intervention so that it can be received as efficaciously.  
 
This was further illustrated by COPD patients’ comments and regret that their condition meant 
that they would be frequent users of the healthcare system. Many were not comfortable with 
this. As one COPD patient commented “You don’t want to go to your GP every day”. This 
individual clearly wanted to engage with self-management (Ryan & Sawin, 2009) and the 
electronic Wellbeing and Self-Assessment diary together with our visits, supported this.  
 
All COPD patients found the electronic Wellbeing and Self-Assessment diary useful with many 
stressing the communication/human contact features of the system (Egan, 2013). One COPD 
patient stated, “It’s good because you have contact with someone. If you’re having a good day, 
then it doesn’t matter.”. However, “If someone is there and replies when you need it then that’s 
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fine”. This contact was “virtual” contact with a clinician. However, importantly, our visits 
seemed also to be a vital part of the system; this perhaps raises questions about the true efficacy 
of the electronic monitoring alone as effective patient self-management (Ryan & Sawin, 2009).  
 
As one COPD patient commented “Nice that nurse comes in and says you are unwell go to the 
hospital”; and another commented unsurely, “better you make that judgement than me”.  
Perhaps with increased experience of the accuracy and effectiveness of their own decision 
making, this apparent uncertainty might be alleviated. Or, maybe, given the isolating nature of 
many chronic conditions, including COPD the “humanity” and human contact offered by a 
clinical team is an essential feature of effective technological intervention. As one commented 
appreciatively, “I loved you coming”. The human contact was clearly very important and 
COPD patients felt valued and cared for, “This wasn’t just an extra level of care, but a personal 
level of care for me”. The security offered by the clinical research team's visits was clearly key 
to the success of the remote monitoring diary in patients’ self-monitoring.  
 
5.4.3. Interactions with the GP  
There was a strong feeling of frustration expressed towards current healthcare structure 
especially towards the GP.  One COPD patient stated: “I rang the GP practice and I could only 
see the nurse as the GP I wanted to see is popular and thus has a 2 week waiting list. The nurse 
called back and said to attend A&E. I commented: You're joking. I'll look like an idiot going 
to A&E. The things you have to go through”. This very angry outburst from one male elderly 
participant perhaps presents the opposite face of published work (Effing et al., 2007) which 
merely measures the number of admissions to A&E without delving more deeply into how far 
patients have attempted to manage their own condition – with support from Primary Care. 
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COPD patients were not complimentary about their care by GP or Community Nursing staff. 
Some COPD patients felt that there was not enough focus on them. “If you see your GP it's for 
5 minutes and they don't even ask how you feel”. However, some COPD patients lacked 
confidence in self-management of their condition and were thus apprehensive: “When I ring 
my GP and I say that I think I have an infection the receptionist tells me to take my rescue 
medication; Sometimes you just want to see the Doctor and not treat myself”. It is possible that 
this type of COPD patient in the community is less likely to start treatment at an appropriate 
time which in turn could lead to an increase in exacerbation severity and additional hospital 
admission (Effing et al., 2007).  
 
5.4.4. All alone 
The final theme identified is “All alone”. During the workshops and the subsequent analysis of 
the reports it became clear that the COPD patients were deriving a strong sense of support from 
both the electronic Wellbeing and Self-Assessment diary and the clinical research team. 
However, this theme of support was likely to be enhanced by a fear of being “all alone”. The 
COPD patients felt that they had been left to “just get on” with self-management of their 
condition and this caused feelings of isolation, apprehension and fear. One COPD patient 
commented “When I finished the trial I felt: “Oh no I don't want to finish”; Another one stated 
sadly, “makes you feel without this there is nothing apart from inhalers and medication”. Such 
responses raise major concerns in a context of the focus on patient well-being reducing the 
probability of COPD-related hospital admissions (Zwerink et al., 2014) and the need to avert 
disability, hospitalisation and even death (Garcia-Aymerich et al., 2011).  
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5.5. Discussion 
In this qualitative study bespoke workshops (with the help of a clinical psychologist and the 
research nurse) were conducted for patients living with COPD, who were part of a pilot 
community-based longitudinal study investigating COPD and health status (Chapter 4, Page 
251). Following thematic analysis within a Framework Method (Gale et al., 2013) conducted 
by a multi-disciplinary team approach the COPD patient comments were positioned within four 
themes: technology, humanity, interactions with the GP and all alone. The results of this 
qualitative study demonstrate a successful model of care to deliver effective self-management 
for patients with COPD. Using the theory of self-management (Ryan & Sawin, 2009) which is 
based in self-efficacy theory (Bandura, 1995) COPD patients were engaged into an intervention 
involving an electronic Wellbeing and Self-Assessment Diary accessed via an iPad (Apple, 
USA), and regular contact with a dedicated clinical team. The electronic Wellbeing and Self-
Assessment diary was well received with an excellent compliance rate for completion of the 
daily diary (98%). This was echoed in the community-based longitudinal study (Chapter 4, 
Page 251) free-text feedback received for all enrolled patients; specifically, comments 
indicated that the COPD patients found the electronic Wellbeing and Self-Assessment Diary 
to be helpful in assisting them in their daily self-management and as a platform to interact with 
myself and a named nurse.  The recording of readings/self-assessments in COPD can provide 
a sense of security by offering an ability to explain symptoms and widen the possibility of 
taking action (Huniche et al., 2013). The electronic Wellbeing and Self-Assessment Diary 
helped to facilitate this by providing a platform to record symptoms and allow healthcare 
professionals to take action based on this information. The recording of daily symptoms helped 
to increase patients' awareness of their own disease and arguably, this has the potential to 
improve self-management for patients living with COPD in the future. The use of education in 
self-management has been shown to reduce urgent healthcare utilisation in COPD (Dickens et 
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al., 2014). The research team helped provide support by creating a safety net for the COPD 
patients.  
 
It could be argued that the key to the electronic Wellbeing and Self-Assessment diary's success 
was the real time support provided by the team. In addition to the regular visits and remote 
surveillance of symptoms the intervention by the team when the COPD patients were unwell 
helped to add to the sense of support. This intervention was not restricted to “office hours” and 
thus meant that an additional level of healthcare input was available “out of hours”. Thus COPD 
patients did not have to rely on traditional modalities that are unfamiliar or time consuming. 
Overall COPD patient confidence in self-management of their condition was improved 
resulting in none of the enrolled study patients Chapter 4, Page 251 requiring hospital-based 
care for an acute exacerbation. Consequently, this had a major (positive) impact on NHS 
resources; besides having a beneficial impact in the wellbeing of the COPD patients. Thus, it 
can be argued that the provision of a well-designed and appropriately supported electronic PRO 
instrument for COPD patients has the potential to allow for a more cost-effective way of 
managing these patients, crucially in the comfort of the patients’ home. 
 
This study demonstrates that COPD patients will engage in a process they are initially 
apprehensive about if there is an appropriate level of specialist support. The study helped to 
improve patient self-efficacy reduce hospital admissions and enhance COPD patient wellbeing.  
It can be argued that all key patient-related elements should be considered when designing self-
management tools for patients with COPD (Wortz et al., 2012). 
 
Workshops were conducted as they provided advantages. They do not discriminate against 
people who cannot read or write, and they encourage people who would find it uncomfortable 
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to be interviewed on their own and/or people who feel they have little to say (Ritchie, 2014). 
The location of the workshops was in a place where the COPD patients held their weekly 
exercise classes (pulmonary rehabilitation) which they all enjoyed attending. This may have 
created a positive feeling going into each workshop; however during the workshops it was 
discovered that these classes were ending which dismayed all the COPD patients. The 
moderator for the workshops was the research nurse who had also visited the COPD patients. 
This might have made some COPD patients reluctant to criticise the community-based 
longitudinal study (Chapter 4, Page 251) especially those that were still active within it. There 
were no audio recordings which may have led to incomplete transcription, although two 
transcribers (myself and a clinical psychologist) were used and the generated reports were 
consistent in data capture. The multi-disciplinary team all engaged with data analysis. 
 
In conclusion the results from this chapter have demonstrated that COPD patients are willing 
to embrace technology to improve the management of their chronic disease. However, one 
modality alone cannot be comprehensive enough to manage the disease. An interactive 
platform between the patients and their healthcare team needs to actively exist. Telehealthcare 
is increasingly being promoted as this platform but an appropriate support system needs to be 
in place for it to be effective and sustainable. A faceless communication technology or 
technologies that cannot be responded to promptly may end up alienating the end-user. This 
could lead to telehealthcare modalities being deemed ineffective and the opportunity to 
enhance chronic disease management being missed/abandoned. 
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6.1. Introduction 
The saliva sampling container (collector) selected for individuals in this thesis was a pre-
marked 15ml centrifuge tube (Nunc, Denmark), (Chapter 2, Page 84). Informal feedback from 
COPD patients involved in the first community-based cohort study (Chapter 3, Page 221) 
highlighted that although this collector was functional it could be end-user refined. Taking this 
into account a process was begun, within the timeframe of this thesis, to develop a prototype 
saliva collector. The design of this collector is intended to be patient-driven but also 
incorporating internal engineering solutions that could substitute pre-analysis saliva sample 
processing such as centrifugation (Chapter 2, Page 92) that presently requires laboratory-based 
instruments. 
 
To understand COPD patients’ needs and preferences in addition to the informal individual 
patient feedback received (Chapter 3, Page 221), a qualitative study utilising workshops was 
conducted; with COPD patients who were either participating or had completed the 
community-based longitudinal study (Chapter 4, Page 251). The methodology for these 
workshops was based on the successful workshop model conducted in Chapter 5, Page 361.  
 
The purpose of these workshops was to explore in detail COPD patients’ experiences of 
providing saliva, its collection into a container and the usefulness of the provided collection 
protocol (Chapter 2, Figure 2.28, Page 209). These workshops also discussed key features that 
patients wished to see incorporated into an “ideal” saliva collector fit for purpose and ease of 
use. Workshop discussions enabled me to produce design concepts of a first saliva collector 
(with integrated filter system) and 3-dimension (3D)-printed proof-of-principle physical 
prototypes for further evaluation in workshops and laboratory testing. This approach provided 
the necessary information for further refinements to be made to the prototype saliva collector. 
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Overall this chapter reflects the start of an iterative research-patient driven interactive process, 
the data from which will eventually lead to the manufacture of a bespoke saliva collector for 
commercial diagnostic application. Thus the objective of this chapter is to further understand 
the practicalities for development of a POC saliva monitoring tool (Chapter 1, Page 78). 
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6.2. Patient experiences on saliva sampling and method of collection 
COPD patients’ attitudes and experiences were explored by setting semi-structured workshops 
12 months after the start of the community-based longitudinal study (Chapter 4, Page 251). 
COPD patients who had completed or were still active within the community-based 
longitudinal study were invited to take part (Figure 6.1). As such, they formed a purposive 
sample (Ritchie, 2014). 
Figure 6.1: Workshop recruitment 
*COPD patients (n = 31): at this time-point in the community-based longitudinal study only 
31 COPD patients had been recruited. **Workshop 3 was conducted with the 3D-printed 
physical saliva collector prototype.  
  
*COPD Patients 
 (n = 40) 
Active 
(n=12) 
Completed 
(n = 28) 
Agreed to 
participate 
(n = 14: active n = 4, 
completed n = 10) 
Workshop 1 
(n = 5, active n = 1, 
completed n = 4) 
Workshop 2 
(n = 5, active n = 1, 
completed n = 4) 
**Workshop 3 
(n = 4, active n = 1, 
completed n = 3) 
Community-based Longitudinal Study Qualitative Study 
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6.2.1 Workshop demographics 
Fourteen COPD patients accepted invitations to the workshops; however, 4 patients developed 
exacerbations at the time of the scheduled workshop so only 10 patients attended (Figure 6.1, 
Table 6.1). Workshops 1 and 2 were conducted using just concept discussions; workshop 3 
demonstrated the 3D-printed prototype collector and filters. 
 
Table 6.1: Workshop demographics. 
 COPD Patient (n = 14) 
 Male Female 
Gender 10 4 
Age, years 72.25 ± 4.56 63.15 ± 2.25 
BMI, (kg/m2)  26.58 ± 2.45 27.84 ± 3.45 
Total Co-morbidities, an 1.56 ± 0.45 1.55 ± 0.25 
FEV1, (% predicted) 59.15 ± 4.55  58.17 ± 4.88 
FVC, (% predicted) 72.15 ± 2.88  74.89 ± 5.45 
 
Data presented as mean ± SD unless stated. 
 
6.2.2. Data collection 
In preparation for the workshops, due consideration was given to the structure of the groups, 
the venue and the required information to elicit. The chosen venue was the location known and 
frequented by all patients for the exercise-based treatment (pulmonary rehabilitation). A series 
of questions was constructed with the help of a clinical psychologist (Dr. Kathyrn Kinmond, 
Manchester Metropolitan University) and refined (Table 6.2) to seek a better understanding of 
the following factors: patient perception of saliva sampling and their views on how it compared 
with venepuncture sampling for their blood tests; the saliva sampling protocol (Chapter 2, 
Figure 2.28, Page 209) and whether the language used was appropriate; their views on an 
“ideal” saliva collector – its shape, size and feel, its markings if any, texture (opaque or 
transparent); and in  workshop 3 only their perceptions of the produced physical prototype 
.  
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Table 6.2: Workshop questions. 
1. How did you initially feel about the idea of giving a sample of saliva? 
2. You were given a set of instructions to follow before giving a saliva sample. 
a. Were the instructions clear? 
b. Were they difficult to stick to? 
c. Do you feel the instructions should be changed in any way? 
3. Was it easy to produce and give a saliva sample? 
a. Could anything have made it easier? 
b. Did anything make it difficult? 
4. Do you think the current tubes are ok for collection the saliva? 
a. Was it easy or difficult to use the tubes? 
5. What would you change about the collection tube? 
6. Usually you are asked to give a blood sample for teste; we are trying to see whether saliva 
can be used as an alternative. 
a. Do you think that this is better than having a blood sample taken? 
b. Would you be happy in the future giving saliva instead of blood? 
Demonstrate the new proto-type saliva collection device and then pass it around the group. 
7. *What are your likes/dislikes of our new saliva catcher? 
8. Are there any other comments you would like to share with us?  
*This question was only included in workshop 3 to obtain feedback of the manufactured 
prototype saliva collector.  
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All 3 workshops were purposefully facilitated by the clinical research nurse (moderator). The 
rationale for this has been explained in Chapter 5, Page 372. No audio-recording took place so 
the conversations were transcribed in “real-time” by myself and the clinical psychologist for 
each workshop. Every session commenced with a general introduction, and then the main 
discussion. During the workshops all patients were encouraged to talk freely about their 
experiences and at the end of the session asked to raise anything that had not already been 
covered. Each workshop lasted two hours. All patients received a copy of the questions (Table 
6.2) to be discussed one week prior to the workshop. In this way it was aimed to offer the 
patients an opportunity to give informed consent to take part, as they were as fully briefed as 
possible, including being made aware of the questions that were going to be asked of them. All 
COPD patients gave consent to their conversation being transcribed and quotes being used. 
 
6.2.3. Data analysis 
Data transcription and analysis proceeded simultaneously utilising the Framework Method 
(Gale et al., 2013). After each workshop there was a team de-brief to discuss the key themes. 
Following which, the clinical psychologist and I prepared individual reports containing a 
transcript of the conversation and key themes to have emerged from the session; reports were 
then exchanged and mapped. Finally, after all three workshops were completed, a face-to-face 
team meeting was held to discuss the overall results and final refinement of the concluding 
report. 
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6.2.4 Results 
Analysis of the transcripts from the workshops produced two main themes on patients’ 
perceptions and feelings about saliva sample collection. 
 
6.2.4.1. Apprehension and embarrassment 
COPD patients described the process of producing and depositing a saliva sample into the 
provided conventional tube collector that was used during the clinical study. They felt the 
collector length was “comfortable” to hold in their hand but had initially felt “anxious” that it 
would be difficult to drool the sample into the tube due to its “narrow” opening (aperture 
diameter: 15mm) without spilling outside of the tube and soiling. This was echoed by most of 
the COPD patients in particular one stated “hit or miss; sometimes hit, sometimes miss” 
although this was not universal as another COPD patient proclaimed “no problem; bigger bottle 
would be better”. Patients initially felt embarrassed on providing the saliva sample at the first 
visit, especially in front of the research nurse, “Strange at first; old fashioned didn't like spitting 
in front of a lady even though they are professionals; now I have got over that; at first I felt a 
little embarrassed then fine”. This was explained by feelings that they were “going against the 
grain” having been brought up not to spit (this term was used synonymously with drool), 
particularly in front of someone. They also felt slightly “under pressure” to fill the pre-set 
volume of saliva (2mls) as requested; this was related to the perceived “time” they felt it would 
take to achieve the goal. They expressed that having to provide a saliva sample over a time 
frame longer than 10 minutes would heighten apprehension and lead to COPD patients not 
embracing saliva for bio-sampling in the future. Their preference for saliva collection was for 
individuals to be given the collectors with a saliva sampling protocol, and then to be left to 
provide the sample in private; they were happy to safeguard the samples as guided until 
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collection. However, they felt that these initial feelings settled over the study period as they got 
used to the technique and concept, as one COPD patient remarked “I found it easier with time.” 
 
6.2.4.2. Empowerment 
All COPD patients stated that they would prefer to provide saliva samples rather than having 
to have venepuncture for blood tests: “Doesn't bother me; Experiment in saliva better than 
blood, no needles; prefer saliva much easier. They also felt that being able to test their saliva 
at home was also advantageous compared to travelling to the GP surgery, a community clinic 
or hospital central pathology to have their samples taken. They would be happy to monitor their 
saliva as part of a self-management protocol if it meant they could monitor their disease better 
and would feel “more in control” if they could “spot” their acute exacerbations earlier. As 
several COPD patients neatly summarised, “Shall I or shan't I; Wait until tomorrow and 
tomorrow comes I think I should have taken them yesterday; When I give blood it takes 1 week 
for the results; when you have a chest infection you give blood then you wait 1 week I'm 100 
times worse; need something there and then that says you have a bad infection take treatment”. 
 
6.2.4.3. Feedback on the provided saliva collection protocol  
The saliva collection protocol (Chapter 2, Figure 2.28, Page 209) asked for fasting for at least 
30 minutes, abstinence from alcohol for 12 hours and tooth brushing avoidance for 1 hour. 
Patients felt that the saliva collection protocol provided for the studies was non-cumbersome. 
They did not feel that the 30-minute fast time was excessive or that abstinence from alcohol 
for 12 hours would make them less likely to embrace saliva-based testing. They felt the protocol 
was clear and easy to follow. They did however suggest replacing the word “dribbling” with 
“drool”. 
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6.2.4.4. Feedback on designs of a bespoke saliva collector. 
Workshop participants provided useful ideas on features they wished to see incorporated in a 
future saliva collection device. These included: 
 
• The length and diameter of a collector. They felt the grip on the provided conventional tube 
was adequate but that the opening should be wider and that the length could be improved 
upon to a maximum of 60mm without compromising the grip. 
• The collector to incorporate an ergonomic lip in order to increase comfort, facilitate ease of 
use and provide reassurance when providing a sample. 
• The collector to be made of a clear material for example: polycarbonate plastic, and to have 
a minimum saliva volume level indicator to inform when an adequate sample had been 
deposited. 
• The indication of saliva passage through any filters incorporated in the collector was not 
seen as important. 
• Patients had no concerns about handling the saliva collector and felt that a lid would not be 
essential. 
• There had to be a clear set of instructions provided with the sampler on how many times it 
could be used as well as its disposal. They suggested that the collector should be single-use 
only packaged in a re-sealable plastic bag. 
• They had no objection to the saliva collector being connected to an assay container 
(cartridge) so that analysis of biomarkers could be performed on the saliva. Patients 
expressed that if possible the collector should be part of the assay cartridge.  If separate, 
there would need to be a clear auditory indication when the collector attached securely to 
the cartridge; the locking needed to be simple: no twisting and “slide and click” would be 
preferred.  
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6.3. Development of a bespoke saliva collector 
Within the time-frame of this thesis, and in response to the COPD patient feedback in the above 
workshops designs were produced for a new saliva collector device. The driving objective for 
the design was to improve and enhance the end-user’s experience with respects to patient 
providing and collecting saliva samples production and their storage. To augment the 
functionality of the collector, designs purposefully included ideas on filtration systems in order 
to produce a clarified sample for protein analysis and to avoid the need for centrifugation in a 
laboratory (Chapter 2, Page 92). This would be an essential requirement for the future POC 
testing. Design concepts and specifications were used to create compute aided design (CAD) 
files (provided in STEP format) in collaboration with Design Reality (St Asaph Business Park, 
Denbighshire). This allowed 3D-printing of physical prototype models for: (1) a series of 
preliminary experiments to test the functionality of individual components; and (2) feedback 
from COPD patients within a further workshop. 
 
6.3.1. Key factors considered in the design process 
Specific design factors considered included the length and width of the collector, engagement 
of the collector with an end-user's lip, internal air displacement to allow for salivary flow and 
total time for saliva to flow through the device. The design elements also addressed issues of 
(1) the inevitable foam (both macroscopic and microscopic) that occurs when saliva samples 
are drooled and (2) the in-situ filtration of saliva to produce a debris-free filtrate suitable for 
target analyte testing. 
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6.3.1.1. Ergonomic lip feature 
A key problem with the use of conventional tube containers, noted both by us and the patients 
during the community-based studies (Chapter 3, Page 213; Chapter 4, Page 251), and the 
workshops, was the lack of lip engagement and risk of spillage. Thus whilst designs of the new 
saliva collector retained its cylindrical shape a profiled area was constructed around the 
aperture at one end, to rest just below the users' lower lip; this ergonomic lip feature would 
increase user comfort during saliva production and prevent spillage (Figure. 6.2). The diameter 
of the aperture was also increased to 20mm to help saliva capture and flow.  
 
 
Figure 6.2: Ergonomic lip feature.  
This figure illustrates the ergonomic lip feature in a number of different vantage points to 
highlight its key novel concepts: A = concave geometry and rolled lip feature; B = elevated 
datum side compared to the opposing side resulting in a height differential, which further 
defined the lip-engaging feature. Additionally, the ergonomic lip feature is designed to guide 
the end-user visually by shape, and physically by touch, on the correct orientation and position 
for the collector during saliva sampling; C = rolled lip feature. 
 
 
 
 
B A 
C 
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6.3.1.2. Body of the collector 
During the workshops (Section 6.2.4, Page 390) the COPD patients did not report a problem 
with grip of the conventional tube collector so a diameter of 15mm was used for the body of 
the prototype saliva collector. However, its length was shortened as in the workshops patients 
had reported, that albeit subconsciously they felt pressurised to fill the container when given 
the sample tube (apprehension theme) (Section 6.2.4.1, Page 391). The workshops revealed 
that 60mm was a maximum acceptable length for a saliva collector that would avoid 
apprehension and maintain a comfortable grip for patients. The set dimensions of a prototype 
saliva collector (diameter: 15mm, length: 60mm) would maximally accommodate 10mls of 
saliva. Although this volume is far in excess of the saliva quantity that would be required for 
target analyte testing, these dimensions would allow for a filter system to be integrated into the 
collector. 
 
6.3.1.3. Saliva sample filtration 
Biomarker analysis requires a “pure” and macroscopically clear sample prior to undertaking 
testing. The reason for this is that any particulate debris, for example, food (Chiappin et al., 
2007) in the sample can interfere with immunoassays (Wong et al., 2008). In this thesis 
centrifugation was employed to clarify saliva (Chapter 2, Page 92); however for POC testing 
this is not practical. Thus for the prototype collector to meet the needs of POC saliva 
diagnostics it would require an internal filtration system to avoid having to send samples to a 
laboratory for sample centrifugation and processing (Chapter 2, Page 92). The filtration system 
within the collector would need to be able to: (1) de-foam, (2) remove macroscopic and (3) 
microscopic debris. A series of designs were produced for a dual filtration system as a possible 
solution. The first filter (conic) (Figure 6.3) was designed to de-foam saliva and remove 
macroscopic debris. The key concepts of the first filter were a conic surface, which allowed for 
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an increase in overall surface area and a stem to retain the second filter. The conic filter 
incorporated a total of 127 pores each with a diameter of 0.80mm arranged in concentric 
circular groups covering 16% of the total surface area. These pores acted to de-foam and 
macroscopically filter a sample of saliva. 
 
  
Figure 6.3: First (Conic) Filter.  
This figure illustrates the first (conic) filter at 3 different vantage points demonstrating the key 
components: A = Conic surface; B = Stem to retain a second (cellulose acetate) filter; C = 
concentric pore arrangement for de-foaming and macroscopic filtration. 
 
The second filter was for additional micro-filtration of saliva; cellulose acetate (Swan, UK) 
(Figure 6.4) was chosen as the composition of the second 'micro' filter. The key concept of the 
second (cellulose acetate) filter was to remove any residual debris (macroscopic and 
microscopic) that had not been removed by the first (conic) filter. Cellulose acetate (Swan, 
UK), chosen for its inert qualities, has been shown not to affect the level of certain proteins in 
B 
A 
C 
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saliva (Chapter 1, Page 53) and is also used in commercially available saliva kits, for example, 
in oral swabs to collect saliva via passive absorbance (Saliva Bio Oral swab; Salimetrics, USA). 
Although the exact minimum pore diameter on the cellulose acetate filter manufactured by 
Swan, UK is not available; it has been demonstrated in one study of cellulose acetate filters 
manufactured by 5 different companies that the most abundant pore diameter is in the range 
(0.013 to 0.016μm) (Sameer, 2010). The mean molecular radius of CRP (the largest of the three 
biomarkers) is 48.8 ANGSTROM (Kushner and Somerville, 1970) which would be trapped in 
a filter with a minimum pore size of less than 0.005μm. 
 
 
Figure 6.4: Cellulose acetate filter 
This figure demonstrates a box of cellulose acetate filters (Swan, UK) which contains 120 
individual cellulose acetate filters organised into cylindrical bundles of 6. 
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6.4. Bespoke saliva collector 
Transferring above concepts and designs incorporated into CAD files enabled 3D-printed 
saliva collector prototypes; these were built on an Object Connex (Stratasys, USA) using a 
VeroClear resin (Objet Inc, USA). The prototype material used was an acrylic monomer, which 
was built in layers, each ultra-violet cured before moving onto the next layer (Figure 6.5). This 
prototype and its individual components were then used in a series of simple experiments 
designed to explore: (1) transit time of saliva through the prototype saliva collector; (2) sample 
clarity post-filtration; (3) levels of the target saliva biomarkers levels in the filtered saliva. 
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Figure 6.5: 3D-printed prototype saliva collector. 
These figures display the prototype saliva collector built on an Object Connex (Stratasys, USA) 
using a VeroClear resin (Objet Inc, USA): A = complete prototype saliva collector; B = 
prototype saliva collector with outer casing removed to highlight the location of the second 
(cellulose acetate filter); C = “bird’s-eye” view of the prototype collector showing the first 
(conic) filter; E = ergonomic lip feature; F = first (conic) filter; S = second (cellulose acetate) 
filter “house”. 
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6.4.1. Salivary flow through the prototype saliva collector 
The overall purpose was to determine the transit time of saliva through the bespoke prototype 
saliva collector under specific conditions: 
 
1. Conic filter in-situ only. 
2. Conic and cellulose acetate filter (length: 14mm) in-situ. 
3. Conic and cellulose acetate filter (length: 7mm) in-situ. 
 
6.4.1.1. Materials and methods 
Unstimulated whole saliva (7mls) from a healthy non-smoker was collected via passive drool 
into a marked centrifuge tube (Nunc, Denmark). The healthy non-smoker subject (aged: 32 
years, BMI: 22.79kg/m2, no known co-morbidities and no regular oral medications) was 
selected from the Directorate of Respiratory Medicine’s research and outpatient clinic database 
(Chapter 2, Page 88). This subject gave informed written consent and adhered to the saliva 
sampling protocol created in Chapter 2 (Figure 2.28, Page 209) prior to providing the saliva 
sample. To assess transit time through the prototype saliva collector, a set volume (2mls) of 
the above saliva was deposited manually at the top aperture of the prototype collector using a 
pastette (alpha labs, UK).  
 
Transit times were separately determined with the first (conic) filter in-situ and also with both 
first (conic) and second (cellulose acetate) filters in-situ. The second (cellulose acetate) filter 
was tested at two lengths: 14mm and 7mm.  
 
Within the said prototype collector, the cellulose acetate filter is “housed” in a plastic sheath 
(Figure 6.5 (S)) with an open aperture at the apex and an aperture at the base which has three 
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struts to provide a bed. This set-up provides a firm but non-compressed grip to hold the 
cellulose acetate in place. This “housing” for the second (cellulose acetate) filter has a diameter 
of 10mm. Thus three cellulose acetate filters were concentrically fixed together using pressure-
sensitive tape (3M, USA) and placed into the second filter (cellulose acetate) “housing” in the 
prototype collector. The rationale for using two filter lengths was to understand effects on 
saliva clarity and transit time through the prototype collector. It was hypothesised that the 
reduction in filter length (14mm to 7mm) would result in an improved salivary transit time. 
The volume of saliva to transit and emerge through the dual filtration process was documented 
at a pre-set time of 10 minutes. Transit time was quantified using the stopwatch function on an 
iPhone (Apple, USA). This time was chosen as the workshop participants had expressed that 
total saliva sampling time should take no longer than 10 minutes as longer times could 
precipitate anxiety and non-compliance (Section 6.2.4.1, Page 391). Throughout these 
experiments clarity was defined by a direct visual comparison to a standard laboratory-
centrifuged sample of saliva (Figure 6.6D).  
 
6.4.1.2. Results  
The transit time for 2mls of saliva through the prototype collector with the first (conic) filter 
only in-situ was 6 minutes and 32 seconds. This saliva sample was completely de-foamed 
although visually it contained debris (Figure 6.6A). The next experiment involved assessment 
of filtered saliva clarity and transit time through the prototype collector with both the first 
(conic) and second (cellulose acetate) filters (length: 14mm) in-situ. After ten minutes no saliva 
had emerged through the dual filtration system and thus the experiment continued to be 
observed. At 55 minutes, 500ul of visually clarified filtered saliva (Figure 6.6B) had emerged, 
by 60 minutes no further filtered saliva emerged. The final experiment assessed transit time 
and filtered saliva clarity through the prototype collector with the first (conic) and second 
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(cellulose acetate) filter (length: 7mm) in-situ. After 10 minutes 100ul of visually clarified 
filtered saliva was produced (Figure 6.6C).  
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Figure 6.6: Saliva post transit through the prototype collector.  
These figures illustrated the clarity of saliva after transit through the prototype collector: A = 
fresh saliva sample with macroscopic debris and a foam head; B = first (conic) filter only; C = 
first (conic) filter and second (cellulose acetate) filter (length: 14mm); D = first (conic) filter 
and second (cellulose acetate) filter (length: 7mm). Figure E illustrates 3 separate saliva 
samples post-centrifugation at 3000rpm for 15 minutes as a visual comparison to the prototype 
filtered samples. It can also be observed that the dual filtered saliva samples (C and D) contain 
non visible cell debris. 
A B C 
D E 
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6.4.1.3. Conclusion 
The developed prototype saliva collector incorporating the dual filtration system (conic and 
cellulose acetate (Swan, UK)) produced a de-foamed, visually clear (comparable to 
centrifugation) sample of saliva that can be tested for target analyte quantification. However, 
the flow of saliva through these filters would be too long for POC testing and thus further 
experiments were conducted in an attempt to reduce this time. 
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6.4.2. Measures to improve transit time of saliva  
Following on the above results there was a need to improve the transit time for saliva through 
the prototype collector to meet POC expectations. In addition, the workshops (Section 6.2.4.1, 
Page 391) had revealed that a sample transit of greater than 10 minutes was likely to result in 
apprehension and non-compliance, with the majority of users not wanting to provide further 
follow-up samples. The above experiments suggested that the delay in saliva transit was 
occurring as a result of the second (cellulose acetate) filter. This filter however was required in 
order to further “cleanse” the saliva. As a solution to increase saliva transit through this system, 
the possibility of applying a pressure gradient across the cellulose acetate was explored. This 
was based on Darcy’s Law which states that if there is a pressure gradient applied across a 
porous material flow will occur from high pressure towards low pressure (Gray and Miller, 
2004). 
 
6.4.2.1. Materials and methods 
Unstimulated whole saliva (2mls) from two healthy non-smokers collected via passive drool 
in a marked collector was obtained. The healthy subjects were selected from the Directorate of 
Respiratory Medicine’s research and outpatient clinic database (Chapter 2, Page 88), (Table 
6.3); gave informed written consent and adhered to the saliva sampling protocol created in 
Chapter 2 (Figure 2.28, Page 209) prior to providing a sample of saliva. Each saliva sample 
was tested in duplicate.  
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Table 6.3: Subject demographics 
 Healthy Subjects 
Demographics 
Non-smokers 
 (n = 2) 
Age, years 33.15 ± 2.20 
Gender, Male, (Female), n 1 (1) 
BMI, (kg/m2) 21.65 ± 1.61 
Total Co–morbidities, n 0 
Total Number of Oral Medications, n 0 
 
Data presented as mean ± SD, unless stated. 
 
To test the concept of a pressure gradient, a modified second (cellulose acetate) filter was built, 
utilising a 1.5ml eppendorf (length: 32mm, diameter 10mm) (alpha labs, UK) as “housing”. 
Firstly, three cellulose acetate filters 7mm in length were fixed, using pressure-sensitive tape 
(3M, USA), around a hollow soft flexible plastic tube. The hollow plastic tube provided a 
channel for air displacement. The overall length and diameter of this construct was 7mm by 
15mm (Figure 6.7). Up to 3mm in length of this construct was then inserted into a 1.5ml 
eppendorf with the other 4mm remaining external (Figure 6.8). The diameter of the eppendorf 
(100mm) was smaller than the modified second (cellulose acetate) filter construct and thus the 
3mm portion housed inside the eppendorf was externally compressed relative to the 4mm 
portion of the modified second (cellulose acetate) filter construct outside the eppendorf. This 
difference in external compression resulted in a pressure gradient (high to low) across the 
modified filter. A volume of saliva (1ml) was first passed through the prototype saliva collector 
with just the first (conic) filter in place; the obtained filtrate was then aliquoted using a pastette 
(alpha labs, UK) through the modified second (cellulose acetate) filter. 
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Figure 6.7: Cellulose acetate filter construct. 
Three cellulose acetate filters were fixed using a pressure sensitive adhesive around a hollow 
plastic tube (V) with dimensions of: length (L) 7mm and diameter (D) 15mm. This drawing is 
not to scale. 
 
Figure 6.8: Modified second (cellulose acetate) filter.  
The cellulose acetate filter construct (C), (length 7mm, diameter 15mm) is inserted (4mm) into 
a 1.5ml eppendorf (E), (length 15mm, diameter 10mm). The discrepancy in diameter between 
the two results in a pressure gradient across the cellulose acetate filter construct. 
L 
D 
C 
E 
V 
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6.4.2.2. Results 
Using the above filtration approach, on two different 1ml saliva samples tested in duplicate, 
volume of 500ul of filtered saliva was retrieved for all 4 tests (50% saliva sample loss). 
Crucially the transit time of saliva through this modified second (cellulose acetate) filter set-
up was only 30 seconds. The experiment continued to be observed for up to 5 minutes; no 
further saliva was obtained perhaps due to saliva saturation of the filter membrane. 
 
6.4.2.3. Conclusion  
This experiment supports the creation of a pressure gradient across the second (cellulose 
acetate) filter as a possible solution to enhancing saliva sample transit time, whilst providing 
an adequate volume of sample recovery for subsequent salivary biomarker analysis. 
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6.4.3. Comparison of target biomarker levels between modified sampler filtration system 
and conventional tube sample centrifugation  
The next set of experiments explored whether there would be method-dependent differences in 
the measured levels of CRP, PCT and NE in saliva retrieved following filtration using the 
modified method (Section 6.4.2, Page 406) and conventional tube centrifugation. 
 
6.4.3.1. Materials and methods 
Six healthy never-smokers provided 7mls of unstimulated whole saliva collected via passive 
drool into an ice-cooled marked centrifuge tube (Nunc, Denmark). The healthy subjects were 
selected from the Directorate of Respiratory Medicine’s research and outpatient clinic database 
(Chapter 2, Page 88), (Table 6.4); gave informed written consent and adhered to the saliva 
sampling protocol created in Chapter 2 (Figure 2.28, Page 209). For each subject 2mls of the 
retrieved saliva were then aliquoted using a pastette into a separate conventional centrifuge 
tube (Nunc, Denmark) and centrifuged at 3000rpm for 15 minutes (Chapter 2, Page 92); whilst 
a separate 2mls were transferred onto the prototype saliva collector complete with filter 1 
(conic) and then a modified second (cellulose acetate) filter 2. Saliva biomarker measurements 
for CRP, PCT and NE were conducted according to the methodology described in Chapter 2 
(Section 2.4, Page 90). Measurements were conducted on 1 microtitre plate for CRP and NE 
and one kit for PCT. All saliva samples were analysed on the day of collection.  
 
Briefly, CRP was measured in 15ul of saliva using a Salivary ELISA kit (Salimetrics Europe, 
UK) (Chapter 2, Page 90), which has a range of quantification of 0.90 to 30ng/ml; Salivary 
PCT and NE were measured using in-house modified commercial serum-based ELISAs. PCT 
was determined in 100ul of saliva diluted 1:2 in PBS-T using VIDAS BRAHMS PCT kit 
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(bioMérieux, France) (Chapter 2, Page 112) which has a range of quantification of 0.10 to 
400ng/ml. NE was measured in 7.0ul of saliva diluted 1:200 in ELISA wash buffer using PMN-
Elastase ELISA kit (Immundiagnostik, Germany), (Chapter 2, Page 149) which has a range of 
quantification of 2.2 to 2000ng/ml. Biomarker levels of salivary CRP utilised one Salivary 
ELISA kit (Salimetrics, USA), salivary PCT utilised one VIDAS® BRAHMS PCT kit 
(bioMérieux, France) and salivary NE utilised two PMN-Elastase ELISA kits 
(Immundiagnostik, Germany). The intra- and inter-assay CV was less than 8% and 12% 
respectively for all 3 assays.  
 
Table 6.4: Subject demographics 
 Healthy Subjects 
Demographics 
Non-smokers 
 (n = 6) 
Age, years 36.2 ± 12.6 
Gender, Male, (Female), n 3 (3) 
BMI, (kg/m2) 21.9 ± 1.2 
Total Co-morbidities 0 
Total Number of Oral Medications, n 0 
 
Data presented as mean ± SD unless stated. 
 
6.4.3.2. Statistical analysis 
The statistical tests employed in this chapter are discussed in Chapter 2, Page 86. 
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6.4.3.3. Results 
6.4.3.3.1. Salivary CRP 
The levels of salivary CRP in the saliva samples of healthy never-smokers were higher in the 
collector filtered samples (2.13, 0.30ng/ml) compared to equivalent centrifuged samples (1.94, 
0.50ng/ml) although this difference was not statistically significant (p=0.36 by Wilcoxon 
Signed Rank Test) (Table 6.5). Interrogation of the individual subjects salivary CRP levels 
revealed higher levels in four out six of the collector filtered samples especially in subject 3 
(Figure 6.9).  
 
Table 6.5: Endogenous salivary CRP Levels: Tube centrifugation compared to modified 
saliva collector in the same subjects. 
Healthy  
Never-smoker 
Subject 
Tube Centrifuged Sample 
(ng/ml) 
Collector Filtered Sample 
(ng/ml) 
1 1.94 2.29 
2 1.92 1.54 
3 6.49 12.98 
4 2.44 2.13 
5 1.14 1.26 
6 0.84 1.00 
Median, IQR 1.94, 0.50 2.13, 0.30 
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Figure 6.9: Salivary CRP levels across different saliva processing methods. 
Bar charts representing the median salivary CRP levels between the collector filtered compared 
to equivalent tube centrifuged samples. There was no statistical significant between the two 
processing methods (ns; p=0.36).  
 
  
ns 
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6.4.3.3.2. Salivary PCT 
As would be expected in samples from healthy subjects, initial analysis demonstrated no 
endogenous salivary PCT (all samples tested below the lower limit of assay quantification 
(0.10ng/ml) for the mini VIDAS (bioMérieux, France)), in both collector filtered and tube 
centrifuged samples of all subjects (n = 6). Thus all saliva samples were spiked with low-range 
PCT control provided inside the VIDAS BRAHMS PCT kit (bioMérieux, France) following 
the methodology described in Chapter 2 (Table 2.12, Page 118) to determine measurable effects 
if any between the two approaches. Overall there appeared to be a significant reduction in 
spiked salivary PCT levels for the collector filtered saliva (0.65, 0.19ng/ml) compared to 
equivalent tube centrifuged saliva (0.88, 0.24ng/ml) (p<0.01) (Table 6.6, Figure 6.10) The 
results were consistent across all six healthy never-smokers with all collector filtered samples 
demonstrating consistently reduced levels of spiked salivary PCT.  
 
Table 6.6: Spiked salivary PCT levels: Tube centrifugation compared to modified saliva 
collector in all healthy subjects. 
Healthy  
Never-smoker 
Subject 
Tube Centrifuged Sample 
(ng/ml) 
Collector Filtered Sample 
(ng/ml) 
1 0.62 0.48 
2 0.77 0.47 
3 0.88 0.65 
4 0.97 0.85 
5 1.00 0.67 
6 0.14 0.12 
median, IQR 0.88, 0.24 0.65, 0.19 
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Figure 6.10: Salivary PCT levels across different saliva processing methods. 
Bar charts representing the median salivary PCT levels between the collector filtered samples 
compared to equivalent tube centrifuged samples. There is statistical significant difference 
between the two processing methods (*p<0.01) with lower levels of salivary PCT observed in 
collector filtered saliva.   
* 
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6.4.3.3.3. Salivary NE 
The levels of salivary NE in the saliva samples of healthy never-smokers were lower in the 
collector filtered samples (125, 163ng/ml) compared to equivalent tube centrifuged samples 
(267, 471ng/ml); however, this difference was not statistically significant (p=0.07) (Table 6.7, 
Figure 6.11). Of the 3 biomarkers results for recovered salivary NE levels were the most 
variable. In particular, healthy subjects 2 and 5 demonstrated a large reduction in salivary NE 
levels for the collector filtered samples. Interestingly, a reduced level for both salivary CRP 
and PCT is also observed for subject 5, whilst subject 2 also demonstrates a reduced level of 
salivary PCT in collector filtered samples.  
 
Table 6.7: Endogenous salivary NE Levels: Tube centrifugation compared to modified 
saliva collector in the same healthy subjects. 
Healthy  
Never-Smoker Subject 
Tube Centrifuged Sample 
(ng/ml) 
Collector Filtered Sample 
(ng/ml) 
1 167 76 
2 751 323 
3 69 93 
4 159 155 
5 718 95 
6 373 290 
Median, IQR 269, 471 125, 163 
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Figure 6.11: Salivary NE levels across different saliva processing methods. 
Bar charts representing the median salivary NE levels between the collector filtered samples 
compared to equivalent tube centrifuged samples. Whilst there was no statistically significant 
difference between the two processing methods (ns: p=0.07), lower levels of NE were observed 
in the collector filtered saliva samples.  
 
In an attempt to further investigate the observed variability in endogenous salivary NE levels 
between the collector filtered samples and tube centrifuged samples, a further experiment was 
conducted using fixed concentrations of NE that are supplied in the PMN Elastase ELISA kit 
(Immundiagnostik, Germany) (Chapter 2, Page 149) and used to generate the “curve-of-best-
fit” (Chapter 2, Figure 2.18, Page 153).  
ns 
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6.4.4. Comparison of “standard” fixed concentration NE levels between modified 
collector filtration and conventional tube centrifugation 
As the levels of endogenous NE demonstrated a variable difference between the collector 
filtered and tube centrifuged saliva samples, the effects of both sample processing methods 
were investigated on a fixed concentration of NE whilst eliminating the possible matrix effect 
of saliva. To achieve this the fixed concentration “standards” provided by the manufacturer in 
the PMN Elastase ELISA kit (Immundiagnostik, Germany) (Chapter 2, Page 149) were 
utilised.  
 
6.4.4.1. Materials and methods 
The PMN Elastase ELISA kit (Immundiagnostik, Germany) used in this thesis provides four 
sets of lyophilised “standard” at five fixed concentrations of NE: 0, 0.37, 1.1, 3.3 and 10ng/ml. 
Each fixed concentration standard is reconstituted in 500ul of dH2O and the OD generated by 
these standards on the ELISA microtitre plate when read on a plate reader generates a standard 
“curve-of-best-fit” which permits calculation of the target sample NE levels (Chapter 2, Figure 
2.18, Page 153).  
 
To conduct the experiment, 4 sets of standards were reconstituted a total of 750ul of each 
standard concentration (0, 0.37, 1.1, 3.3, 10ng/ml) were aliquoted into five separate collectors 
for centrifugation (3000rpm for 15 minutes) and 750ul into the 5 separate collectors for 
filtration. The samples in the collectors were then aliquoted using an air-pipette onto the 
modified prototype saliva collector with a modified second (cellulose) acetate filter. The 
processed samples were then analysed in duplicate on one PMN Elastase ELISA kit 
(Immundiagnostik, Germany) using the methodology as described in Chapter 2, Page 149.  
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6.4.4.2. Statistical analysis 
The statistical tests employed are discussed in Section 2.2, Page 86. Specifically, recovery of 
NE was calculated by assigning the manufacturer’s documented concentrations of each 
reconstituted standard as 100% and then comparing the quantified NE levels processed either 
by tube centrifugation or modified collector filtration. The formula: 
𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 = 100 (
𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑙𝑒𝑣𝑒𝑙 𝑜𝑓𝑁𝐸 𝑖𝑛 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑝𝑟𝑜𝑐𝑒𝑠𝑠𝑒𝑑 𝑏𝑦 𝑎
𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑙𝑒𝑣𝑒𝑙 𝑜𝑓 𝑁𝐸 𝑖𝑛 𝑟𝑒𝑐𝑜𝑛𝑠𝑡𝑖𝑡𝑢𝑡𝑒𝑑 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑏
) 
where “a” is the method of saliva processing (filtration or centrifugation). The intra-assay CV 
was 4.7%. 
 
6.4.4.3. Results 
There was no significant difference in standard NE recovery between the collector filtered and 
tube centrifuged samples (p=0.897 by paired t-test) (Table 6.8) accounting for the small sample 
size. The NE recovery in the collector filtered samples demonstrated a high degree of 
variability with a “super” recovery in the 1.1 and 10ng/ml standards. This result is unusual, as 
one would not expect an enhanced recovery of NE from a fixed concentration standard. It is 
difficult to draw conclusions from these findings in the collector filtered samples; however, the 
tube centrifuged samples do demonstrate less variable recovery of NE with levels greater than 
90% when compared to the unadulterated standard. Although the 3.3ng/ml standard 
demonstrates a “super” recovery, this is perhaps due to the inherent variability of the ELISA 
microtitre plate. 
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Table 6.8: Recovery of “standard” NE using two saliva sample processing methods.  
Target NE 
Standard level 
 
(ng/ml) 
*Unadulterated 
sample 
 
ng/ml (% recovery) 
Tube Centrifuged 
Sample 
 
ng/ml (% recovery) 
Collector Filtered 
Sample 
 
ng/ml (% recovery) 
10 9.99 (99.9%) 9.89 (98.9%) 16.07 (160%) 
3.3 3.33 (101%) 3.83 (116%) 2.72 (82.4%) 
1.1 1.04 (95%) 1.06 (96.4%) 1.70 (155%) 
0.37 0.43 (116%) 0.36 (97.3%) 0.07 (18.9%) 
0 0.00 0.01 0.00 
Mean ± SD 103 ± 9% 104 ± 13% 106 ± 71% 
 
Data presented as mean ± SD. *Unadulterated sample refers to the levels of the unadulterated 
reconstituted standard processed on a PMN Elastase ELISA kit (Immundiagnostik, Germany). 
 
To better understand the results obtained with the collector filtered samples sub-analysis was 
performed to determine whether the actual levels in the collector filtered standard, as compared 
to the target standard level, would generate an appropriate standard curve-of-best-fit (Figure 
6.12). 
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Figure 6.12: Unadulterated compared to collector filtered standard NE levels. 
A scatter plot with “curve-of-best-fit” plotted on a Log10 abscissa (r2=0.97) for the 
unadulterated standard NE and collector filtered standard NE quantified on the PMN Elastase 
ELISA kit (Immundiagnostik, Germany). The r2 value indicates a 97% agreement between the 
curve-of-best fit and the observed NE levels. 
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6.5. End-user views on the developed saliva collector  
As described in Section 6.2, Page 387 two workshops were conducted to understand COPD 
patients’ views on saliva sampling, collection, sampling protocols and key features in a 
“perfect” saliva collector. The third workshop was conducted using the same approach as the 
previous two workshops with the inclusion of one extra question (Table 6.2, Page 389) and 
demonstration of the prototype saliva collector which incorporated design features discussed 
in the first two workshops. 
 
COPD patients felt the bespoke prototype saliva collector provided an excellent grip and that 
its look, feel and dimensions would alleviate the feelings of apprehension noted with the bland 
conventional tube. They particularly embraced the ergonomic lip feature and felt this would 
aid collection and provide “comfort” whilst drooling and reduce any anxiety/embarrassment 
about spilling/miss-directing the sample. They felt that the new collector was a “step-in-the-
right-direction” and would be an important component of any saliva based POC testing system.  
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6.6. Discussion 
Currently there are numerous manufacturers of saliva-based testing kits and unstimulated 
whole saliva collection aids (Chapter 2, Page 81); however, they all require a saliva sample to 
be transported back to the particular manufacturer’s laboratory for processing. Thus the saliva 
collectors within these kits merely function as sample retrieval and storage devices. The aim, 
within the permitted time-frame of this thesis, was to commence the design and development 
of a saliva collector prototype that would function as both a device for collection and filtration 
of the saliva, thereby avoiding the need for laboratory-based processing and centrifugation. 
This would be a first step in enhancing near-patient salivary diagnostic testing.  
 
In this chapter it has been established that COPD patients would welcome saliva-based home 
testing, which provides a minimally invasive alternative to serum or plasma testing, provided 
that the required volume of saliva is small and that processing would occur in as short period 
as possible. Patient feedback on the basic design requirements of a bespoke collector for saliva 
proved invaluable, most notably the construction of a lip-engaging feature to make saliva 
retrieval more comfortable. The introduction of a pressure gradient within the collector 
appeared to address the need for enhanced saliva passage through the system reducing sample 
transit times of the saliva to an end user acceptable level. 
 
To by-pass the need for saliva samples to be sent to a central laboratory for processing, the 
ability of the collector system needed to incorporate capability to de-foam and purify a sample 
of saliva ready for biomarker testing. This was addressed through the insertion of a 
combinatorial filter system composed of a multi-pored conic-surfaced first filter and a cellulose 
acetate-based second filter. This arrangement provided macroscopically clear saliva. Results 
from initial experiments exploring the recovery of target biomarkers in samples processed 
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through this newly developed filtration system, as compared to conventional laboratory 
centrifugation, demonstrated no statistically significant difference in the endogenous levels of 
salivary CRP and NE, although CRP levels following collector filtration were higher. 
Interestingly salivary CRP has been found to be reduced in centrifuged saliva compared to 
unprocessed saliva samples (Mohamed et al., 2012). Saliva spiked with PCT (as no endogenous 
PCT was quantified in the healthy saliva samples) was significantly reduced in the collector 
filtered samples compared to tube centrifuged samples by a magnitude of 25%. This was 
consistent for all tested samples and will need to be investigated further so as to avoid losing 
important subtle changes in this biomarker. PCT (13kDa) has the lowest molecular weight of 
the 3 proteins in this thesis compared to CRP (110kDa) and NE (29.5 kilodaltons (kDa)). The 
minimum pore size of the filters is such that it should not trap any of the 3 target proteins 
(Section 6.3.1.3, Page 396); however, it is possible that PCT forms protein complexes with 
other larger salivary proteins and thus is retained in the filter. The same effect has been 
observed for myoglobin, a protein with a similar molecular weight (16.7kDa) to PCT (Lipps, 
2008).  
 
The quantification of endogenous NE was higher in the tube centrifuged samples compared to 
collector filtered samples except for subject 3; both subjects 2 and 5 there was a large difference 
in endogenous NE levels between collector filtered and tube centrifuged samples, with the 
latter having higher levels (Table 6.7, Page 416). A possible explanation for this may have been 
the effect of centrifugation on saliva neutrophils causing increased NE release from the 
azophilic granules due to trauma or possibly the intrinsic breakdown of NE during 
centrifugation. Indeed the used rate of 3000prm equates to approximately 1500g; it has been 
hypothesised that a centrifuge speed above 600g may generate sufficient sheer stress to damage 
the interior structure of the neutrophil and thus release NE (Fukuda and Schmid-Schönbein, 
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2002). It is unclear however whether these sheer forces are sufficient to disrupt the exterior 
structure (cell membrane). Indeed, another study has demonstrated that centrifugation at 1550g, 
albeit for only 3 minutes, did not result in liberation of elastase from neutrophils (Fischer et al., 
1998).  
 
The experiment in Section 6.4.4, Page 418 using reconstituted lyophilised manufacturer-
provided NE “standards” demonstrated a consistent recovery in sample-centrifuged “standard” 
NE. This supports the hypothesis that centrifugation of a sample containing NE at 3000rpm for 
15 minutes will not result in an intrinsic breakdown of exposed NE. The recovery of collector 
“standard” NE was variable with both the 10 and 1.1 ng/ml demonstrating a “super” recovery. 
An explanation for this is not immediately forthcoming. Overall there is no statistically 
significant difference in NE recovery between the 2 methods. It is also important to note that 
the actual NE levels across the 5 “standard” concentration ranges processed through the 
developed collector, as compared to the expected NE levels followed the curve-of-best-fit with 
a r2 value of 0.97 (Figure 6.12, Page 421). 
 
Within the limited time-frame of this thesis a bespoke end-user tailored saliva collector has 
been created as a proof-of-principle and tested. Importantly throughout the design-
development process, COPD patients were able to provide ideas and refinements. This 
approach in diagnostics development brings invaluable details to improve the fit between the 
user, the particular technology and the organisation of care, which is key for the usability and 
acceptability of a new tool (van der Weegen et al., 2013) 
 
Further detailed work is now required to optimise the filtration system and recovery times for 
all target biomarkers and to ensure close fit with a biomarker-specific assay consumable. 
Chapter 7:  General Discussion and Conclusion 
 426  
 
 
 
 
 
 
 
 
 
 
 
Chapter 7: 
 
General Discussion and Future Directions 
  
Chapter 7:  General Discussion and Conclusion 
 427  
7.1. Introduction 
COPD is a complex and heterogeneous disease, which is not accurately defined by current 
diagnostic and severity criteria based on post-bronchodilator FEV1 (Vestbo et al., 2013). 
Progress is being made to identify phenotypes of the disease for targeted treatment and long-
term disease trajectory (Pinto et al., 2015). Within the natural course of COPD, acute episodes 
of deterioration (exacerbations) arise which may lead to periods of extended disability, 
hospitalisation, reduced quality of life and even death (Toy et al., 2010). An increased 
frequency of exacerbations accelerates lung function decline; furthermore, the more severe the 
disease status the increased frequency of exacerbations (Seemungal and Wedzicha, 2014). 
Prevention, early exacerbation detection and prompt treatment would all have an important 
impact on clinical outcome and quality of life in patients (Wilkinson et al., 2004).  
 
However, this requires practical yet sensitive tool/s for patient surveillance and/or self-
management. COPD currently ranks 3rd on the global mortality statistics (Lozano et al., 2012). 
It is one of the costliest in-patient conditions treated by the NHS, accounting for approximately 
12% of all hospital attendances and nearly 2% of total NHS capacity in the UK (Halpin and 
Miravitlles, 2006). The rate of mortality for COPD in the UK is one of the highest in the EU 
(Network, 2011). In an effort to address this, the Department of Health published a policy paper 
setting out six objectives, five of which are relevant to COPD; these need to be achieved to 
deliver on the Government’s commitment to improve health outcomes and reduce inequalities 
in chronic long term conditions (Health, 2011). Therein key elements are highlighted that could 
improve overall life quality and outcomes for COPD patients: 
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1.  Individual stratification; risk profiling,  
2. Integrated care team approach moving away from reactive to proactive models of care, 
3. Self-care that recognises the need for a partnership between healthcare professionals and 
patients. 
 
The ideal is that management of COPD should actively [rather than just “lip-service”] involve 
the actual patients in their own care, using generic long-term conditions models, good practice 
in disease pathways and wherever possible incorporating non-intrusive assistive technologies. 
There still remains an unmet need to improve COPD self-management, by better understanding 
disease phenotypes and by defining the role of objective and subjective health measures in 
disease surveillance and self-care strategies. a series of objectives (Chapter 1, Page 76) were 
set out to provide a structured approach in this thesis to provide some solutions towards 
achieving these goals. This thesis has identified the “best” type of saliva (unstimulated whole 
collected via passive drool) and determined a group of factors required for near patient 
sampling including standardisation of pre-analysis protocols for saliva sampling (Chapter 2, 
Page 80). Preparatory work on saliva and modified non-saliva assays demonstrated precision, 
linearity and recovery of the target biomarkers although further work will need to be 
undertaken to ensure the assays are commercial market ready (Section 7.5, Page 443). A simple 
reproducible PRO score was created (Chapter 2, Page 209) and utilised in two clinical studies 
where its reproducibility and ease of completion were identified (Chapter 3, Page 213 and 
Chapter 4, Page 251). Further work is required to ensure the PRO is commercial market ready 
(Section 7.5, Page 443). The clinical studies (Chapter 3, Page 213 and Chapter 4, Page 251) 
demonstrated that  
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the saliva biomarkers could distinguish between health and COPD and importantly could be 
used to monitor disease status in COPD patients to provide the foundation for predictive health 
status change in synergy with PROs.  
  
Chapter 7:  General Discussion and Conclusion 
 430  
7.2. Saliva sampling: its role in clinical monitoring  
The first facet of this thesis involved the evaluation of saliva as a feasible sample fluid for 
collection in COPD patients. Saliva is a body-fluid that can be non-invasively sampled and 
provides a window into the health of a patient (Wong, 2008, Denny et al., 2008). It requires 
minimal training for sample collection compared to phlebotomy (Koh and Koh, 2007) and 
therefore an individual could provide a self-directed sample at a time and location that is 
convenient to themselves. The primary challenges of saliva sampling that were addressed in 
this thesis were sample collection and processing protocols including effects of fasting and 
salivary flow, modification of commercially available non-saliva-based assays (PCT and NE) 
and blood contamination bias.  
 
A non-intrusive method for was chosen for saliva collection (unstimulated whole via passive 
drool) that is arguably harder to standardise requiring a series of pre-sampling protocols, but is 
more practical, expeditious and simpler to provide (Nunes et al., 2015). Unstimulated whole 
saliva is a heterogeneous sample (Chapter 1, Page 49) and a sampling collection and processing 
protocol helps to ensure sample consistency (Henson and Wong, 2010).  The first challenge 
was to design a bespoke COPD patient-orientated saliva sampling protocol to reduce the 
likelihood of sampling bias and to improve patient compliance (Kudielka et al., 2003). This 
required consideration of factors that could be refined to help the process of saliva production 
for the end-user (Chapter 2, Page 169). Outside a laboratory environment, ambulatory and near-
patient saliva sampling for analyte measurements still require strict guidelines to follow and 
accurate timing of collections. However sampling protocols have been shown to have poor 
adherence by patients (Kudielka et al., 2003). Thus key to achieving reliable collections and 
compliance with set instructions, was my interaction with COPD patient workshops (Chapter 
6, Page 382). This enabled the creation of a saliva collection protocol written in plain language 
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with a clear set of simple “do’s and don’ts” (Chapter 2, Figure 2.28, Page 209) that was user-
friendly. In addition, COPD patients particularly welcomed their involvement in establishing a 
method for repeated non-invasive testing over other modalities such as phlebotomy. These 
workshops also highlighted the importance of patient-research co-design when introducing 
potentially disruptive interventions into disease management pathways. COPD patients 
provided refinements and patient “know-how”, bringing in valuable details to improve the fit 
between the user, the technology and the organisation of care, which is important for the 
usability and acceptability of a tool (van der Weegen et al., 2013). This process was not solely 
confined to the saliva sampling protocol but also used to develop a prototype saliva collector.  
 
This thesis is the first to establish that COPD patients’ salivary flow rate is comparable to 
healthy non-smoker subjects (Fenoll-Palomares et al., 2004) albeit in a small sample size. A 
crucial finding which reassured me that saliva sampling in COPD patients would be practically 
feasible and that patients would be able to effortlessly produce an adequate set volume for 
target analyte testing. Next to consider was the potential for sample contamination with blood 
(Chapter 2, Page 172). Presently within the literature the methodology for blood contamination 
detection is varied. The consensus is that significant blood contamination is rare and that 
samples contaminated with significant amounts of blood are visually discoloured and thus can 
be discarded without the need for formal testing (Kamodyova et al., 2015). Approximately a 
quarter of the pilot study samples tested positive for blood contamination; however there was 
no effect on target analyte quantification when accounting for co-variates such as gum disease. 
Despite this information, knowing that blood contamination could cause interference with 
immunoassays (Chiappin et al., 2007) random testing of saliva samples continued throughout 
the community-based studies to ensure the highest level of immunoassay accuracy and as a 
basis of quality control. This was important in view of the modified non-saliva based assays 
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for PCT and NE. Furthermore, saliva sampling instructions included the requirement for 
patients to avoid tooth brushing prior to collection with assessment of gum disease carried out 
regularly by the clinical team. Gum disease was important to account for as Kamodyova et al. 
(2015) observed that saliva contaminated with blood is more common in individuals with poor 
oral health and history of gingivitis or periodontitis. This thesis is the first to account for blood 
contamination in the quantification of salivary CRP, PCT and NE. The common use of a 
modified urine reagent stick to detect for presence of blood in saliva could be a potential 
limitation (Chapter 2, Page 200). However as discussed previously, this approach generated a 
high amount of false positives but was effective in identifying samples with nil contamination.  
 
Presently, only CRP has a saliva-based immunoassay for target analyte quantification albeit 
labelled as a “for research use only”. The quantification of PCT and NE required modification 
of “for diagnostic use” (Chapter 2, Page 91) serum-based immunoassays. As discussed saliva 
is a heterogeneous fluid and whole saliva sampling can introduce contaminants that affect 
immunoassay function. The sampling protocol addressed these issues however it is important 
to validate all 3 assays in the “hands of the user” to ensure that the levels of the target analytes 
are quantified accurately and reproducibly. My experiments demonstrated that modification of 
these said immunoassays for saliva resulted in reliable and reproducible results (Reed et al., 
2002). This was also undoubtedly helped by having a clear sampling protocol. A potential 
limitation however was the modification of the serum-based PCT assay. PCT is undetectable 
in patients who are clinically stable (Chapter 1, Page 69) with the VIDAS B.R.A.H.M.S PCT 
(bioMérieux, France) lower limit of detection being set at 0.10ng/ml. This resulted, as would 
be expected, in a significant proportion of the saliva samples testing “negative” for PCT. A 
more sensitive assay that could quantify salivary PCT below this lower limit of assay 
quantification would perhaps provide additional data in stable phase COPD patients that could 
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be used for corollary analysis with the 2 other saliva biomarkers. Overall all 3 immunoassays 
reliably and reproducibly detect CRP, PCT and NE in the saliva of COPD patients and healthy 
subjects. 
 
The range of quantification for an immunoassay however remains crucial for potential point-
of-care applications. For example, salivary PCT using the BRAHMS VIDAS PCT kit 
(bioMérieux, France) on the mini-VIDAS instrument (bioMérieux, France) has a range of 
quantification: 0.10 to 400ng/ml. Thus samples of saliva tested for PCT using this instrument 
that are below the lower limit of assay quantification (0.10ng/ml) are quantified as “less than 
0.10ng/ml”. This has important implications for statistical analysis. These saliva samples that 
have tested below the lower limit of assay quantification (negative) need to be included in 
statistical analysis; however using the term “less than 0.10” is not possible as would be in a 
laboratory-generated report. A number needs to be chosen to represent these “negative” 
samples especially when the analyte is being tested in a bio-fluid known to have much lower 
concentrations of said biomarker than in blood/serum. This number can in this example for 
PCT range from 0 to 0.099ng/ml. The selection of this “negative” value is important. Saliva 
samples below the lower limit of assay quantification for PCT were assigned as 0.09ng/ml. 
This approach enhanced statistical robustness by maintaining the number difference between 
each quantifiable level of PCT above 0.10ng/ml i.e. the mini-VIDAS output for PCT is up to 2 
decimal places.  Accordingly, the same methodology as used for assigning numerical values to 
the “negative value” for salivary CRP and NE. Overall this approach is more stringent than 
using a value of zero or half the lower limit of quantification which would produce a downward 
bias on the data (Muir K, 2004) and thus increase the difference between negative and 
quantifiable concentrations of the target analytes. Published studies for these 3 biomarkers in 
serum and sputum of COPD patients do not always define the number of individuals who have 
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target biomarkers below the lower limit OD detection of the immunoassays used to detect the 
target analytes; and more importantly the subsequent mathematical approach to these subjects 
(de Torres et al., 2006, Ishikawa et al., 2015, Pinto-Plata et al., 2006) Other studies just revert 
to using a value of half the lower limit of assay quantification for analyte results that were 
below the lower limit of assay quantification (Dickens et al., 2011). This approach enhances 
the accuracy of the statistical analyses for target analyte salivary biomarker levels for all 
calculations in this thesis. 
 
There is increasing evidence that saliva sampling of target analytes could be used as a mirror 
to reflect systemic profiles of an individual akin to blood sampling of the same target analytes 
(Lima et al., 2010). This thesis has established that saliva CRP and PCT reflect serum levels 
(Chapter 3, Page 242), and thus for these biomarkers saliva could be considered as providing 
an accurate substitute for serum testing. The correlations for saliva-serum CRP has been 
extensively investigated and established in the wider literature (Ouellet-Morin et al., 2011, 
Punyadeera et al., 2011). Presently the establishment that salivary PCT is a reflection of serum 
is a first. Salivary NE did not correlate with serum levels; a potential explanation for the discord 
may be the endogenous levels in the oral cavity, the counter-argument however is the observed 
significant correlations between salivary NE and both salivary CRP and PCT. This adds 
support that salivary NE is reflecting systemic, rather than an oral cavity, based processes. 
There also exists the possibility of rapid in-activation of NE in-vivo (Carter et al., 2013). It 
could be hypothesised that salivary NE testing is reflective of systemic inflammation that 
cannot be identified with serum-based NE testing. These results perhaps highlight an added 
benefit of saliva compared to serum testing for certain analytes. Overall the conclusion is that 
saliva-based testing of CRP and PCT is reflective of serum-equivalent findings and that 
salivary NE is also potentially reflective of serum-based indicators of inflammation. These 
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results support a saliva-based approach for the routine measurement of the 3 target analytes at 
point-of-care (POC) as a surrogate for serum-based testing.  
 
Having established the correct saliva sampling protocol and validated the quantification of a 
panel of COPD-relevant biomarkers in saliva, there remains the challenge of having the correct 
collector that appeals to patients, reduces errors with sampling and does not interfere with 
analyte analysis. Interestingly throughout saliva sampling in the community-based studies it 
was observed that although the chosen saliva tube collector (Chapter 2, Page 84) was 
functional, it lacked engagement and appeared daunting to patients due to its length with a 
“pressure to fill” (Chapter 6, Page 391). Thus a bespoke prototype saliva collector was 
developed within the time-frame of this thesis. 
 
Saliva has the potential to be used frequently in POC testing and by patients themselves in their 
homes. COPD patients as discussed earlier are willing to embrace saliva testing provided there 
is a clear instruction protocol and that collection times are less than 10 minutes. Accordingly, 
in designing the specifications of a near-patient saliva collector prototype, it was determined 
that it had to incorporate features to enhance patient comfort and compliance (Chapter 6, Page 
393) with saliva sampling as well as components that would substitute the laborious laboratory-
based sample purification procedures (Chapter 2, Page 92). A series of potential engineering 
solutions were evaluated, that would process and deliver a “filtered” sample of saliva which 
would not require first-step laboratory centrifugation for sample purification. Preliminary 
experiments confirmed the merits of the designed saliva collector; however there are 
limitations in the recovered levels of PCT and variability in NE levels. Further testing and end-
user led design refinement of these concepts will be required in the future.  
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7.3. Salivary biomarkers and spirometry: their potential to predict COPD 
exacerbations 
One of the ambitions of my thesis was to determine whether saliva could be used to detect 
health status change in COPD, and its potential role for the management of COPD 
exacerbations. To address this, 2 community-based studies were conducted (Chapter 3, Page 
213 and Chapter 4, Page 251). Individual risk profiling in COPD patients was also explored, 
based on the trajectories of spirometry and these biomarkers over time (Chapter 4, Page 299 
and 313). The driving concept was an attempt to characterise COPD patients based on the 
temporal variability of their disease and not just a “snap-shot” of status as is commonly found 
in the current risk profiles for example BODE (Chapter 1, Page 27). This approach appeared 
sensible in light of established findings that COPD patients have a non-uniform decline in 
objective measurables, for example FEV1, over the course of their disease (Casanova et al., 
2014).  
 
The methodology of the first study (Chapter 3, Page 213) has been established as essential for 
comparison of all pulmonary biomarkers in patients with COPD (Barnes et al., 2006). Within 
that study stable phase level for all 3 biomarkers were established and reproducibility of these 
levels, which demonstrated a consistent agreement (low variability) in repeated saliva 
biomarker levels in the same COPD patients across the same status of their disease. This is 
important if saliva is to be utilised as a replacement for serum-based testing and indeed has 
been a major challenge for other novel monitoring approaches, for example electronic nose 
breath analysis (Chapter 1, Page 41). 
 
All 3 target salivary biomarkers demonstrated a significant rise during a patient-defined 
exacerbation event in both clinical studies with the community-based longitudinal study 
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(Chapter 4, Page 251) statistically powered to establish this effect. The longitudinal study 
allowed for an understanding in exacerbation prediction with CRP and NE levels, both 
demonstrating early change (up to 7 days prior to exacerbation onset) within a defined 
prodromal phase (Table 4.1, Page 275). Additionally, the ability to identify COPD patients at 
risk of re-exacerbation within 2 weeks of completing an index exacerbation was demonstrated 
based on both spirometry (Chapter 4, Page 312) and salivary biomarker levels (Chapter 4, 
Pages 344). A potential limitation to these results is the significant but moderate ROC curve 
accuracy for exacerbation diagnosis for salivary CRP (Chapter 4, Page 318) and PCT (Chapter 
4, Page 331) (Fischer et al., 2003). The result for salivary NE (Chapter 4, Page 341) was not 
significant perhaps highlighting that clinical cut-offs cannot be set for this variable but that 
instead comparison and establishment of an individual’s baseline status is crucial. However, 
this would only be an issue if one is advocating that each salivary biomarker be used in 
isolation; rather the approach used in this thesis calls for a panel of biomarkers to be 
simultaneously tested for disease status monitoring (Agustí et al., 2012).  Indeed, a rise in 2 or 
more salivary biomarkers during an index exacerbation (Chapter 4, Page 348) predicted the 
risk of re-exacerbation.  It is proposed that these results could be incorporated in a diagnostic 
monitoring algorithm which might enable a disruptive shift change in COPD exacerbation 
management, away from a reactive towards a proactive model of care, adding power of effect 
by using in conjunction with PROs discussed later in this chapter (Section 7.4, Page 440).  
 
LCGA was used to interrogate the study-generated real-life datasets to understand the temporal 
variability of both salivary biomarkers and spirometry and whether they, in conjunction with 
other established COPD metrics, could generate individual patient risk profiles (Chapter 4, 
Page 350).  This analytical technique clusters patients into discrete sub-populations based on 
the variability of a target parameter over time. This analysis was not only conducted for salivary 
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biomarkers but also spirometry in an attempt to create a multidimensional composite 
score/cluster based on multiple metrics. This novel score will form part of my concepts for 
future work arising from this thesis (Section 7.5, Page 443). This approach is supported by the 
findings that COPD patients may manifest multiple phenotypes/clusters (Han et al., 2010a). 
Although discrete sub-population clusters were identified for each salivary biomarker there 
was no statistical significance in the COPD patient composition for each cluster and overall re-
exacerbation risk, except for salivary NE. The role of these individual clusters at present 
remains elusive; the COPD patients who compose these individual clusters need to be 
followed-up over a longer time-frame to understand what additional information on COPD 
disease status can be provided. Salivary NE clusters however did show the importance of co-
morbidity (Pinto et al., 2015) and interestingly for FEV1 the separate sub-population clusters 
appeared to predict the risk of re-exacerbation (Chapter 4, Page 307). Overall, my thesis 
provided seminal data evaluations utilising LCGA to cluster sub-populations of COPD patients 
from observations derived in the stable-prodromal period of their disease; however limitations 
do need to be addressed. Although COPD patients were deemed to be clinically stable on 
enrolment into the longitudinal study, they could exacerbate at any time-point and, by virtue 
of the study design, exit from the study as soon as their post-exacerbation-recovery period was 
completed. As study participants were also frequent exacerbators, some had their first acute 
episode quite close to their point of entry into the study; thus reducing the length of stable-
prodromal phase data to analyse (Table 4.4, Page 277). Importantly LCGA is robust to missing 
data sets as long as the data is missing at random (Chen et al., 2009). 
 
This thesis perhaps for the first time also provides the ability to better define a COPD 
exacerbation based on a mixed model of subjective and objective markers of health. This is 
possible because saliva-based biomarkers can be frequently sampled and accurately quantified. 
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The aetiology of an exacerbation is not just simply pathogen-dependent but phenotypes based 
on low inflammatory and eosinophilic processes are now emerging (Bafadhel et al., 2011). 
Interestingly peripheral (blood) eosinophilia has been shown to be predictive of corticosteroid 
responsiveness during an acute exacerbation of COPD (Singh et al., 2014) and not just 
pathogen specific (Rohde et al., 2008). Recent studies have also begun to establish that a certain 
sub-group of COPD patients are at an increased risk of pneumonia when receiving inhaled 
corticosteroids as part of their maintenance treatment (Janson et al., 2013). This reinforces the 
argument that stable-prodromal phase and exacerbation phase clusters need to better defined 
and characterised; and that reliance on an exacerbation definition based solely on symptoms, 
whilst practical, needs to be improved to be more phenotypically focused which in turn could 
lead to better treatment stratification.  
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7.4. Patient-reported outcomes: their value in self-management protocols 
A major component of my thesis work also involved PROs, which have been recognised as 
important in monitoring health status in COPD (Vestbo et al., 2013). Although a wide-array of 
PROs are available in the literature (Chapter 1, Page 27) none at present have been established 
as a reliable and practical monitor of COPD health status at point-of-care (Chapter 2, Page 
210). Questionnaires such as SGRQ and CRQ are considered too long and complex to be used 
in routine everyday self-management protocols (Celli, 2003). A novel simple symptom score 
(COPD Wellbeing Score) was developed based on clinically-relevant metrics for COPD 
identified in the wider literature (Walters et al., 2012). Content-validity was established with 
correlations to MRC score, salivary biomarkers and changes during an acute exacerbation of 
COPD (Chapter 3, Page 232) (Jones et al., 2009), alongside COPD patient feedback in 
workshops (Chapter 5, Page 361) (Howard et al., 2012). Additionally, absence of significant 
changes in the trajectory of COPD Wellbeing Score during stable-prodromal phases adds to a 
high test re-test reliability (Chapter 4, Page 289). A further method of validation with respects 
to utilising the wellbeing score as a daily monitoring tool was to create a bespoke electronic 
diary (COPD Wellbeing and Self-Assessment diary). This was in recognition of the limitations 
of paper-based diaries and the arguments about the validity of daily symptom monitoring in 
studies using these diaries (Chapter 4, Page 254). This newly designed electronic diary also 
contained a HRO section to enable cross-reference to the PROs. The inclusion of HRO section 
takes this electronic diary one step further than currently available electronic diaries by 
capturing and correlating the two metrics with each other and providing a genuine interactive 
platform for patients and healthcare professionals alike.  
 
The electronic Wellbeing and Self-Assessment diary demonstrated excellent compliance, 
usability and functionality which were confirmed in end-user led workshops (Chapter 5, Page 
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361). In conjunction with this, COPD patients felt the electronic Wellbeing and Self-
Assessment diary enhanced education about their condition; patients provided feedback on how 
the diary was comprehensive but could be more encompassing for example: lack of appetite. 
This process as described above demonstrates content-validity for the COPD Wellbeing score 
and also provides patient-directed ideas for refinement, thus contributing to an overall 
enhanced level of participation and compliance (Morren et al., 2009). The electronic diary was 
seen to create an environment of partnership between the research team (healthcare 
professionals) and the patients, who remained central to all the decision-making. This was due 
to a proactive self-management care model with “real-time” COPD Wellbeing Score 
surveillance and proactive actions based on deteriorations of said score. It helped facilitate self-
management by providing an enhanced feeling of security and safety. In effect, COPD patients 
were compelled to self-manage their disease with the knowledge that a care provider was 
monitoring, incentivising them into entering regular and accurate information as they were 
aware that without this they could not be remotely monitored. Such compliance is also 
important as it is recognised that COPD patients fail to report an acute exacerbation in a third 
of events (Langsetmo et al., 2008). It could be postulated that the methods in Chapter 4, Page 
270 provided for a successful integrated self-management ecosystem, the framework of which 
still requires to be compared to current practices to better understand its overall benefit on 
disease outcome. A potential limitation that needs to be addressed was the single daily score 
entry which potentially misses intra-day fluctuations; however this feature can easily be 
accommodated in future software updates to the diary. 
 
Analysis of the generated datasets of COPD Wellbeing scores from the whole cohort and per 
individual utilised a novel analytical technique (Chapter 4, Page 274) with added sensitivity 
compared to methodologies currently used in the literature for symptom score analysis 
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(Alahmari et al., 2014). Thus the scores were shown to be able to identify an early onset change 
in symptom trajectory prior to the onset of an acute exacerbation of COPD and also highlighted 
symptom trajectories during treatment. Furthermore, this approach also identified potential 
changes around a re-exacerbation post-treatment completion. Such information is of huge 
clinical relevance and demonstrates how patient-derived symptoms can be made to be effective 
in practical everyday monitoring tools; specifically, how they could be key determinants of 
COPD health status monitoring algorithms alongside other viable metrics such as salivary 
biomarkers and spirometry (Section 7.3, Page 436). 
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7.5. Conclusion and Future Directions 
This thesis has sought to develop a holistic approach to the near-patient management of a 
chronic condition. A key factor has been the research-patient partnership in guiding the design 
of key instruments and understanding COPD patients’ “needs and wants”. Consideration has 
been given to the most ideal body-fluid to sample and methods involved in sample 
reproducibility. A content-valid reproducible PRO has been developed that was successfully 
incorporated into a proactive self-management model and conducted exploratory analysis to 
define clusters in COPD patients that could be used to monitor disease state over time. 
 
Further work to the modified immunoassays to prepare them for commercial availability would 
involve several additional validation steps: (1) robustness of the method to small variations in 
method parameters for example, incubation time, working assay temperature; (2) sample 
stability based on different storage conditions, freeze-thaw cycles and testing the same sample 
at repeated time interval and further experiments involving parallelism for biomarker spiked 
saliva tested against a spiked substitute matrix (Andreasson et al. 2015) 
 
Additional work to enable the PRO to be commercially ready would involve a further clinical 
trial involving a larger cohort of COPD patients and observation of the COPD Wellbeing score 
over 1 year. This will confirm content validity and test-retest reproducibility during stable 
disease phase. Qualitative research methods can then be employed to confirm overall content 
validity of the score. 
 
The next aspect of this thesis that could be exploited in future are the use of the parameter 
datasets to generate predictive/diagnostic algorithms based on a combination of inputs from 
wellbeing scores, FEV1 and salivary biomarker panel levels. Their usefulness for COPD patient 
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health status surveillance could then be explored longitudinally in community-based studies to 
determine whether they could reduce hospitalisations and improve patient outcomes when 
compared to best supportive care. 
 
Characterisation of the observed stable-prodromal phase clusters for both spirometry and 
biomarkers requires a longer longitudinal study of perhaps over at least one year. For the 
baseline clusters that have been identified as possible “candidate” phenotypes an iterative 
validation process will need to take place (Han et al., 2010b). This would provide further 
information on whether these clusters can identify differences in disease progression, re-
exacerbation and whether COPD patients remain in the same cluster over a protracted time-
frame (1 to 5 years). This study could also incorporate the multidimensional score/clusters that 
have been generated in this thesis (Table 4.36, Page 351) to understand whether they can 
provide additional information than each component in isolation. 
 
The second aspect for exploitation would be to expand the repertoire of the salivary panel of 
biomarkers for COPD, for example eosinophilic cationic protein which acts as a biomarker for 
eosinophilic inflammation (Saha and Brightling, 2006) in saliva.  Exacerbations as previously 
discussed do not appear to be simply defined by pathogen or air pollution but that distinctive 
phenotypes/clusters do exist. Factor analysis (Chapter 4, Page 352) was utilised in an attempt 
to understand the key components when assessing acute exacerbations of COPD; however, this 
needs to be further explored to understand the relationship to the recently described COPD 
exacerbation phenotypes. In addition, direct markers of bacterial load, the commonest cause of 
an acute exacerbation (Butorac-Petanjek et al., 2010), and the role of specific pathogens during 
acute exacerbations warrant further attention. New technologies are emerging (such as the new 
biomarker assays from Aseptika Limited, Cambridge (Activ8rlives)) for the quantification of 
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specific bacteria (for example, Pseudomonas aeruginosa, Haemophilus influenzae) which are 
present in the sputum of patients with COPD (Bafadhel et al., 2015, Millares et al., 2014). 
Bronchial colonisation by Haemophilus is associated with an increased systemic inflammatory 
response in stable COPD subjects (Marin et al., 2012). Both Haemophilus and pseudomonas 
constitute approximately 30-40% of the bacterial aetiology in acute exacerbations of COPD. 
Isolation of these organisms is also more prevalent in acute exacerbations of COPD patients 
with severe disease (Ko et al., 2005, Miravitlles et al., 1999). I would look to calibrate these 
non-saliva-based assays and understand the reflection of saliva, to sputum-based biomarkers. 
Colonisation by bacterial pathogens has been associated with a clinically significant moderate 
increase in daily symptoms (Desai et al., 2014). Direct knowledge of bacterial levels may also 
provide an additional aspect to exacerbation prediction, by identifying a non-pathogenic rise 
from baseline bacterial load. This could act as a direct predictor of bacterial-driven acute 
exacerbations. Questions that need addressing would include: (1) does a non-pathogenic rise 
from baseline bacterial load immediately translate into a pathogenic rise? (2) does total baseline 
bacterial load equate to accelerated lung function decline? The need for an improved 
understanding of the direct role of respiratory pathogens in COPD is being recognised; 
specifically, in longitudinal monitoring to assess how changes in the COPD airway microbiome 
may contribute to the incidence and severity of COPD (Bourne et al., 2014). 
 
The third aspect for further exploitation would be the further development of a bespoke 
prototype saliva collector (Chapter 6, Page 394), specifically in regards of an appropriate 
filtration system that would by-pass the need of centrifugation yet not compromise recovery 
and measurement of the 3 target biomarkers studied in this thesis. Ultimately if the bespoke 
saliva collector is to be used at POC with a near-patient saliva analyser, a docking interface 
will need to be developed.  
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Improvements to the electronic Wellbeing and Self-Assessment diary have already been 
suggested based on the workshops in Chapter 5, Page 361. Further updates to the diary could 
consider incorporating features for multiple daily entries.  An enhanced electronic COPD 
Wellbeing and Self-Assessment diary could also be part of a virtual care suite that could also 
connect to a future developed near-patient saliva analyser. 
 
In conclusion, COPD is a complex heterogeneous disease that requires improved classification, 
disease monitoring and tailored interventions for better self-management of acute 
exacerbations. This thesis has created the tools to improve the classification and monitoring of 
COPD and opens new avenues for future research which have already been recognised as 
innovative (Horizon, 2015). The ultimate goal would be to have COPD patients accurately 
clustered/phenotyped with personalised treatment plans and actively engaged in self-
management utilising a composite suite of POC tools (saliva-based testing, spirometry and 
PROs). This ideal eco-system would in turn help reduce the burden of disease for COPD 
patients and hopefully increase both the quality and quantity of their life.  
 
  
  
Chapter 7:  General Discussion and Conclusion 
 447  
 
 
 
 
 
 
 
 
“We chose to go to the moon in this decade and do other things, not because they are easy, but 
because they are hard” 
         John F Kennedy. 
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Appendix 1:  
Please tick the most appropriate answer 
Week Commencing: .................................................................................................................. 
 
1. How is your breathing today? 
 
2. How is your breathing affecting your ability to perform? 
a. Activities of daily living. e.g. Self-wash/Dress; cooking, housework 
 
b. Physical Activities. e.g. Walking, shopping, gardening 
  
 
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Excellent 
 
       
Good 
 
       
Fair 
 
       
Bad 
 
       
Very 
Bad 
       
 
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Not at 
all 
       
Little 
 
       
 Fair 
Amount 
       
Much  
 
       
Very 
Much 
       
 
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Not at 
all 
 
       
Little 
 
       
 Fair 
Amount 
       
Much 
  
       
Very 
Much 
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3. Do you have a cough? 
 
4. How much sputum do you produce daily? 
 
5. What is the colour? 
 
  
 
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
No        
        
 Yes        
Much 
Better 
       
Better 
 
       
Usual 
 
       
Worse 
 
       
Much 
Worse 
       
 
Monday 
Tuesda
y 
Wednesday Thursday Friday Saturday Sunday 
None 
 
       
5mls  
(1 teaspoon) 
       
15mls 
(1 tablespoon)  
       
30mls 
(1 egg cup) 
       
50mls or more 
(1 cup or 
more) 
       
 
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Watery, clear, 
transparent 
       
Watery, cloudy, 
colourless 
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Figure S1.1: Paper-based version of the electronic COPD Wellbeing and Self-Assessment 
Diary.  
This paper-based version of the COPD Wellbeing Score on the electronic Wellbeing and Self-
Assessment diary was available to COPD patients in the community-based study (Chapter 4, 
Page 251) in lieu of the electronic Wellbeing and Self-Assessment diary. 
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Appendix 2:  
 
Figure S1.2: Salimetrics: salivary C-reactive protein ELISA kit manual.  
This figure represents page 19 of the manual, documenting the manufacturer’s recovery 
experiment results. 
